2014 AES Annual Meeting, Seattle, Wash.
Transcription
2014 AES Annual Meeting, Seattle, Wash.
ANNUAL MEETING PROGRAM BOOK 2014 DECEMBER 5 - 9 Washington State Convention Center | Seattle, WA Biennial North American Regional Epilepsy Congress 5th Visit BOOTH #405 to learn more t h g i F o t y d a e R Bobby, age 47, diagnosed with LGS. ONFI® (clobazam) is FIERCELY DEDICATED to helping Bobby & Julian fight their seizures. ONFI is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Julian, age 6, diagnosed with LGS. Important Safety Information • ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system (CNS) depressants. Prescribers should caution patients against engaging in hazardous activities that require mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known. • ONFI has a CNS depressant effect. Patients should be cautioned against the simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated. • As with all antiepileptic drugs (AEDs), ONFI should be gradually withdrawn to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses. • Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. • Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment. • AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to the AED or illness, because epilepsy itself can increase these risks. • The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group clinical trial who received clobazam as adjunctive therapy (≥10% in any treatment group and at least 5% greater than placebo, respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%), drooling (14% vs. 3%), aggression (14% vs. 5%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%). Please see Brief Summary of Prescribing Information on the following pages. For full Prescribing Information, Medication Guide, and Instructions for Use, go to www.ONFI.com. ©2014 Lundbeck. All rights reserved. ONFI is a registered trademark of Lundbeck CLB-B-00123 09/2014 1 ONFI® (clobazam) tablets, for oral use, ONFI® (clobazam) oral suspension, Brief Summary of Prescribing Information (See package insert for full Prescribing Information or visit www.ONFI.com) Rx Only INDICATIONS AND USAGE – ONFI® (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. CONTRAINDICATIONS – None [see Contraindications]. WARNINGS AND PRECAUTIONS – Somnolence or Sedation: ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants. Prescribers should caution patients against engaging in hazardous activities requiring mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known [see Warnings and Precautions]. Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants: Since ONFI has a central nervous system (CNS) depressant effect, patients or their caregivers should be cautioned against simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated [see Warnings and Precautions]. Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided. ONFI should be tapered by decreasing the dose every week by 5-10 mg/day until discontinuation [see Dosage and Administration]. As with all antiepileptic drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to patients who received excessive doses over an extended period of time, followed by an abrupt discontinuation. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic doses for several months [see Warnings and Precautions]. Serious Dermatological Reactions: Serious skin reactions, including StevensJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment initiation or when re-introducing therapy. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered [see Warnings and Precautions]. Physical and Psychological Dependence: Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence [see Drug Abuse and Dependence]. Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing ONFI or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers [see Warnings and Precautions]. ADVERSE REACTIONS – Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug 2 and may not reflect the rates observed in practice. During its development for the adjunctive treatment of seizures associated with LGS, ONFI was administered to 333 healthy volunteers and 300 patients with a current or prior diagnosis of LGS, including 197 patients treated for 12 months or more. The conditions and duration of exposure varied greatly and included single- and multiple-dose clinical pharmacology studies in healthy volunteers and two double-blind studies in patients with LGS (Study 1 and 2) [see Clinical Studies]. Only Study 1 included a placebo group, allowing comparison of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1): The adverse reactions associated with ONFI treatment discontinuation in ≥1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 in the full Prescribing Information lists the adverse reactions that occurred in ≥5% of ONFI treated patients (at any dose), and at a rate greater than placebo treated patients, in the randomized, double-blind, placebo-controlled, parallel group clinical study of adjunctive AED therapy for 15 weeks (Study 1). Table 3. Adverse Reactions Reported for ≥5% of Patients and More Frequently than Placebo in Any Treatment Group ONFI Dose Level Placebo Lowa Mediumb Highc All ONFI N=59 N=58 N=62 N=59 N=179 % % % % % Gastrointestinal Disorders Vomiting 5 9 5 7 7 Constipation 0 2 2 10 5 Dysphagia 0 0 0 5 2 General Disorders and Administration Site Conditions Pyrexia 3 17 10 12 13 Irritability 5 3 11 5 7 Fatigue 2 5 5 3 5 Infections and Infestations Upper respiratory 10 10 13 14 12 tract infection Pneumonia 2 3 3 7 4 Urinary tract infection 0 2 5 5 4 Bronchitis 0 2 0 5 2 Metabolism and Nutrition Disorders Decreased appetite 3 3 0 7 3 Increased appetite 0 2 3 5 3 Nervous System Disorders Somnolence or Sedation 15 17 27 32 26 Somnolence 12 16 24 25 22 Sedation 3 2 3 9 5 Lethargy 5 10 5 15 10 Drooling 3 0 13 14 9 Ataxia 3 3 2 10 5 Psychomotor hyperactivity 3 3 3 5 4 Dysarthria 0 2 2 5 3 Psychiatric Disorders Aggression 5 3 8 14 8 Insomnia 2 2 5 7 5 Respiratory Disorders Cough 0 3 5 7 5 a Maximum daily dose of 5 mg for ≤30 kg body weight; 10 mg for >30 kg body weight b Maximum daily dose of 10 mg for ≤30 kg body weight; 20 mg for >30 kg body weight c Maximum daily dose of 20 mg for ≤30 kg body weight; 40 mg for >30 kg body weight Post Marketing Experience: These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class. Blood Disorders: Anemia, eosinophilia, leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred; Gastrointestinal Disorders: Abdominal distention; Investigations: Hepatic enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders: Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination; Respiratory Disorders: Aspiration, respiratory depression; Skin and Subcutaneous Tissue Disorders: Rash, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), urticaria. DRUG INTERACTIONS – Effect of ONFI on Other Drugs: ONFI is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, their effectiveness may be diminished when given with ONFI. Additional non-hormonal forms of contraception are recommended when using ONFI [see Clinical Pharmacology, Patient Counseling Information]. ONFI inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary [see Clinical Pharmacology]. Effect of Other Drugs on ONFI: Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of ONFI may be necessary when coadministered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) [see Clinical Pharmacology]. CNS Depressants and Alcohol: Concomitant use of ONFI with other CNS depressants may increase the risk of sedation and somnolence [see Warnings and Precautions]. USE IN SPECIFIC POPULATIONS – Pregnancy - Pregnancy Registry: To provide information regarding the effects of in utero exposure to ONFI, physicians are advised to recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves or their caregiver. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. Pregnancy Category C: There are no adequate and well-controlled studies of ONFI in pregnant women and no adequate developmental toxicity studies of clobazam in animals. Although limited, the available animal data suggest developmental toxicity, including an increased incidence of fetal abnormalities following oral administration of clobazam to pregnant animals at doses similar to those used clinically. Data for other benzodiazepines suggest the possibility of adverse effects in animals and humans. Long-term effects on neurobehavioral and immunological function have been reported in rodents following prenatal exposure to benzodiazepines. Neonatal flaccidity, respiratory and feeding difficulties, hypothermia, and withdrawal symptoms have been reported in infants born to mothers who received benzodiazepines, including clobazam, late in pregnancy. Therefore, ONFI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [see Use in Specific Populations]. Nursing Mothers: ONFI is excreted in human milk. The effects of this exposure on infants are unknown [see Use in Specific Populations]. Pediatric Use: The safety and effectiveness in patients less than 2 years of age have not been established. In a study in which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days 14 to 48), adverse effects on growth (decreased bone density and bone length) and behavior (altered motor activity and auditory startle response; learning deficit) were observed at the high dose. The effect on bone density, but not on behavior, was reversible when drug was discontinued. The no-effect level for juvenile toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to clobazam and its major active metabolite, N-desmethylclobazam, less than those expected at therapeutic doses in pediatric patients. Geriatric Use: Clinical studies of ONFI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly subjects appear to eliminate clobazam more slowly than younger subjects based on population pharmacokinetic analysis. For these reasons, the initial dose in elderly patients should be 5 mg/day. Patients should be titrated initially to 10-20 mg/day. Patients may be titrated further to a maximum daily dose of 40 mg if tolerated [see Dosage and Administration, Clinical Pharmacology]. CYP2C19 Poor Metabolizers: Concentrations of clobazam’s active metabolite, N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in extensive metabolizers. For this reason, the initial dose in patients known to be CYP2C19 poor metabolizers should be 5 mg/day. Dose titration should proceed slowly according to weight to 10-20 mg/day, and may be titrated further to a maximum daily dose of 40 mg on day 21 based upon clinical response [see Dosage and Administration, Clinical Pharmacology]. Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with mild and moderate renal impairment. There were no significant differences in systemic exposure (AUC and Cmax) between patients with mild or moderate renal impairment and healthy subjects. No dose adjustment is required for patients with mild and moderate renal impairment. There is essentially no experience with ONFI in patients with severe renal impairment or ESRD. It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable [see Dosage and Administration, Clinical Pharmacology]. Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of ONFI. For this reason, the initial dose in patients with mild to moderate hepatic impairment (Child-Pugh score 5-9) should be 5 mg/day. These patients should be titrated according to weight to 10 to 20 mg/day, and may be titrated further to a maximum daily dose of 40 mg on day 21 based upon clinical response. There is inadequate information about metabolism of ONFI in patients with severe hepatic impairment. Therefore no dosing recommendation in those patients can be given [see Dosage and Administration, Clinical Pharmacology]. DRUG ABUSE AND DEPENDENCE – Controlled Substance: ONFI contains clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be abused in a similar manner as other benzodiazepines, such as diazepam. The pharmacological profile of ONFI is similar to that of other benzodiazepines listed in Schedule IV of the Controlled Substance Act, particularly in its potentiation of GABAergic transmission through its action on GABAA receptors, which leads to sedation and somnolence. The World Health Organization epidemiology database contains reports of drug abuse, misuse, and overdoses associated with clobazam [see Drug Abuse and Dependence]. Dependence: In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence is present even with use of ONFI at the recommended dose range over periods of only a few weeks. The risk of dependence increases with increasing dose and duration of treatment. The risk of dependence is increased in patients with a history of alcohol or drug abuse. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal symptoms. As with other benzodiazepines, ONFI should be withdrawn gradually [see Dosage and Administration, Warnings and Precautions]. In ONFI clinical pharmacology trials in healthy volunteers, the most common withdrawal symptoms after abrupt discontinuation were headache, tremor, insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea [see Warnings and Precautions]. Other withdrawal reactions to clobazam reported in the literature include restlessness, panic attacks, profuse sweating, difficulty in concentrating, nausea and dry retching, weight loss, blurred vision, photophobia, and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause seizures, psychosis, and hallucinations [see Warnings and Precautions]. OVERDOSAGE – Signs and Symptoms of Overdosage: Overdose and intoxication with benzodiazepines, including ONFI, may lead to CNS depression, associated with drowsiness, confusion and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and, rarely, coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol [see Overdosage]. Management of Overdosage: The management of ONFI overdose may include gastric lavage and/or administration of activated charcoal, intravenous fluid replenishment, early control of airway and general supportive measures, in addition to monitoring level of consciousness and vital signs. Hypotension can be treated by replenishment with plasma substitutes and, if necessary, with sympathomimetic agents. The efficacy of supplementary administration of physostigmine (a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI overdose has not been assessed. The administration of flumazenil in cases of benzodiazepine overdose can lead to withdrawal and adverse reactions. Its use in patients with epilepsy is typically not recommended [see Management of Overdosage]. Lundbeck Deerfield, IL 60015, U.S.A. ONFI is a registered trademark of Lundbeck November 2013 CLB-L-00001a 3 4 Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369 | 1-800-654-2299 © 2014 Upsher-Smith Laboratories, Inc. 109864.01 Booth 823 5 FRIDAY November 30, 2007 UCB welcomes you to AES Visit us at booth 205 for exciting new information on VIMPAT® for your patients. VIMPAT is a registered trademark under license from Harris FRC Corporation. ©2014, UCB, Inc., Smyrna, GA 30080. All rights reserved. LCM-PRM-035038-0914 ® 6 Visit the AES Booth to… 1 in 3 readers take action as a result of reading AES Connections in their inbox every other Friday Socialize n Watch Video Interviews n Review Publications n See Live Demos n Learn More About AES n See You at Booth #125 in the Exhibit Hall AES Career Center Your hub for hundreds of jobs, maximum exposure to top opportunities, and highly qualified applicants • Clinical and research positions for epilepsy and neurology professionals • Easy-to-use and highly targeted resources for online employment connections • Access to the National Healthcare Career Network (NHCN), connecting you to the career centers of over 290 top healthcare associations and professional organizations. AES Connections Become an Engaged Member ...Great Conversation ...Connected Community ...Different Perspectives Share Yours Today AES Connect connect.aesnet.org careers.aesnet.org 7 WELCOME MESSAGE Welcome to Seattle and our 68th AES Annual Meeting! To previous attendees, we are thrilled to have you back. To first time attendees, it is a pleasure to welcome you into the AES Community. As you settle in and start off your week, I encourage you to take notice of the energy within the convention center. I like to refer to the Annual Meeting as the Annual “Reunion,” a time when colleagues, friends and even family, reunite under the common goal to cure the epilepsies. I assure you that your time in Seattle will be filled with learning, networking and fun. Don’t forget to connect with the larger AES Community on Twitter #aesmtg14. Within this program book you will find a broad schedule of programs, exhibits, social events and networking opportunities that invite your participation. Quality educational sessions have been organized by your AES Annual Meeting and Scientific Program Committees targeted to the professional needs and wide interests of meeting attendees. This year’s lineup of programs was carefully selected based on your feedback: n Poster Walking Tours – Take a stroll through the Exhibit Hall and experience an enhanced learning opportunity as authors present their posters throughout the week. Enjoy this feature of the AES meeting by joining one of the popular Poster Walking Tours led by thought leaders. See page 15 for the schedule. n Fellows Program – We are proud to continue the AES Epilepsy Fellows Program, which supports 95 trainees in epilepsy fellowships, and 10 Ph.D.s doing epilepsy research. Fellows are paired with mentors for career guidance and support, giving them the opportunity to learn and connect with others throughout the meeting. n Social Networking Groups – SIG, Investigators’ Workshops and symposium participants have a greater opportunity to meet and continue group discussions during social networking hours on Sunday from 8:00 p.m. to 10:00 p.m. n Annual Meeting Mobile App – Access meeting information. Network with fellow attendees. Even organize your schedule at your fingertips! If you have not done so already, download the AES Annual Meeting App to your smartphone. I invite you to join me at that this year’s Presidential Symposium, The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction, taking place on Saturday, December 6 from 8:30 a.m. to 11:45 a.m. Together we will find out who the winners are and their novel solutions in seizure detection and prediction. This session is a must see, I guarantee it! Have a great meeting! Elson So, M.D. President, American Epilepsy Society 2014 AES BOARD OF DIRECTORS PRESIDENT Elson L. So, M.D. FIRST VICE PRESIDENT Amy Brooks-Kayal, M.D. SECOND VICE PRESIDENT Michael D. Privitera, M.D. BOARD MEMBERS Bruce E. Hermann, Ph.D. EX-OFFICIO Eileen M. Murray, MM, CAE, AES Executive Director David M. Labiner, M.D. Brandy Fureman, Ph.D. (NIH/NINDS) Jack M. Parent, M.D., Ph.D. Philip Gattone (Epilepsy Foundation) Helen E. Scharfman, Ph.D. Sheryl Haut, M.D. (North American Commission / ILAE) Shlomo Shinnar, M.D., Ph.D. Karen S. Wilcox, Ph.D. Robert E. Hogan , M.D. (Education) Jaideep Kapur, M.D., Ph.D. (Development) TREASURER William D. Gaillard, M.D. Kimford J. Meador, M.D. (Research) PAST PRESIDENT Jacqueline A. French, M.D. Carl E. Stafstrom, M.D., Ph.D. (Epilepsy Currents) Joseph I. Sirven, M.D. (Epilepsy Foundation PAB) William H. Theodore, M.D. (Communications & MOC Liaison) James W. Wheless, M.D. (Clinical Council & AAN Liaison) 8 TABLE OF CONTENTS FRIDAY SATURDAY SUNDAY MONDAY TUESDAY Epilepsy Specialist Symposium ......................................................28 Annual Fundamentals of Epilepsy Symposium .................28 28th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic .................................................29 Professional Development in AES ...............................................29 Special Interest Group Meetings ................................................29 Hoyer Lecture ................................................................................................30 Spanish Symposium ..................................................................................30 Special Interest Group Meetings ................................................30 Mentoring Session for Junior Investigators .....................32 Special Interest Group Meetings ................................................32 Presidential Symposium........................................................................33 Antiepileptic Therapy Symposium ................................................33 Investigators’ Workshop ......................................................................34 Professionals in Epilepsy Care Symposium ........................34 North American Commission Symposium ............................35 Poster Session 1 ........................................................................................36 Investigators’ Workshops ...................................................................47 Annual Course ................................................................................................49 Special Interest Group Meetings ................................................50 Social Networking Groups ..................................................................50 Poster Session 2 ........................................................................................51 TABLE OF CONTENTS Meeting Information Schedule-at-a-Glance ..............................................................................12 Poster Walking Tours ...............................................................................15 Poster Schedule .........................................................................................17 AES Special Recognition ......................................................................18 Berry, Grass and Nurse Awardees ............................................20 Young Investigator Awardees ..........................................................21 Special Interest Group Schedule .................................................22 Scientific Exhibit Schedule .................................................................23 Exhibitor Locations ...................................................................................82 Abstract Author Index ...........................................................................93 General Information ...............................................................................120 Faculty Ready Room and Photos ..............................................122 Watch for these 2015 dates! Annual Meeting Call for Abstracts Available March 1, 2015 AES Research Recognition and Distinguished Achievement Awards Nominations August 1, 2015 AES 2015 Annual Meeting December 4 - 8 Philadelphia, PA Pennsylvania Convention Center Special Interest Group Meetings ................................................61 Merritt-Putnam Symposium .............................................................61 Special Interest Group Meetings ................................................62 Lennox and Lombroso Lecture .......................................................62 Investigators’ Workshop ......................................................................63 FDA Town Hall Update ............................................................................63 Pediatric Epilepsy Highlights Session......................................63 Pediatric State of the Art Symposium ..................................64 Platform Sessions ......................................................................................65 Poster Session 3 ........................................................................................66 Special Interest Group Meetings ................................................77 Hot Topics Symposium ...........................................................................78 Scientific Symposium ..............................................................................78 AES is an ACCME accredited provider. 9 Lighten your load and receive session handouts and important meeting information electronically! Accounts have been pre-created for all pre-registered attendees. On-site registrants may sign up online. For instructions: Please refer to the flyer provided in your meeting bag or for further details go to www.aesnet.org/meetings_events/ annual_meeting/general_info Questions virtualTotebag Support Desk: 410.402.1062 email: [email protected] Go here: www.aesnet.org/meetings_events/ annual_meeting/meeting_app The AES Annual Meeting is at your fingertips! Stay up to the minute about sessions, schedules, conversations and activities at the 68th Annual Meeting. #AESMTG14 – official meeting hashtag Wi-Fi available throughout Convention Center (except in the Exhibit Hall and Poster Sessions) American Epilepsy Society 10 is proud to recognize the following supporters of the 2014 Annual Meeting. Benefactor Level $500,000 + Sunovion Pharmaceuticals, Inc. Leader Level $250,000 – $499,999 Eisai, Inc. UCB, Inc. Partner Level $100,000 – $249,999 Lundbeck Pharmaceuticals, Inc. Upsher-Smith Laboratories, Inc. Supporter Level $50,000 – $99,999 Cyberonics, Inc. Natus Neurology Incorporated Supernus Pharmaceuticals, Inc. Mallinckrodt Pharmaceuticals Acorda Therapeutics Contributor Level $25,000 – $49,999 Nihon Kohden America, Inc. Cadwell Laboratories, Inc Compumedics Limited Pfizer Inc. Advocate Level $10,000 – $24,999 Neuropace, Inc. ELEKTA Electrical Geodesics, Inc. GW Pharmaceuticals Medtronic, Inc. Blackrock Microsystems, LLC Patron Level $5,000 – $9,999 Rhythm Link Ad-Tech Medical Instrument Corp. Monteris Medical, Inc. Medical Neurogenetics, LLC Nexstim, Inc. Neurolynx, Inc. PMT Corporation Ripple LLC Lifelines Neurodiagnostics Systems, Inc. The Jack Pribaz Foundation Listing is in order of support level as of October XX, 2014 Listing is in order of support level as of October 21, 2014 11 SCHEDULE-AT-A-GLANCE THURSDAY 5:00 p.m. - 7:00 p.m. December 4 Registration Convention Center – South Lobby, Level 4 FRIDAY 7:00 a.m. - 6:00 p.m. December 5 Registration 3:30 p.m. - 5:30 p.m. Convention Center – South Lobby, Level 4 8:30 a.m. - 11:30 a.m. Epilepsy Specialist Symposium: The Generalized Epilepsies 3:30 p.m. - 6:00 p.m. Convention Center – Ballroom 6E, Level 6 12:30 p.m. - 3:00 p.m. 1:30 p.m. - 3:00 p.m. Hoyer Lecture Convention Center – Ballroom 6E, Level 6 Spanish Symposium: Complementary and Alternative Approaches to Epilepsy Treatments Convention Center – Room 612, Level 6 Annual Fundamentals of Epilepsy Symposium: The Side Effects of Epilepsy Treatment 5:30 p.m. - 6:15 p.m. Convention Center – Ballroom 6E, Level 6 6:00 p.m. - 7:30 p.m. Symposia Break Convention Center – Level 6 Professional Development in AES: A Program for Junior Members and Those in Transition Special Interest Group Meetings See page 30 Convention Center – Room 603, Level 6 Special Interest Group Meetings See page 29 SATURDAY 6:30 a.m. - 6:00 p.m. Registration December 6 2:15 p.m. - 5:00 p.m. Convention Center – South Lobby, Level 4 6:30 a.m. - 7:00 a.m. Continental Breakfast Convention Center – Level 6 7:00 a.m. - 8:30 a.m. Mentoring Session for Junior Investigators Convention Center – Room 307 / 308, Level 3 7:00 a.m. - 8:30 a.m. 5:00 p.m. - 6:00 p.m. 5:15 p.m. - 7:45 p.m. SUNDAY Registration 7:00 p.m. - 10:00 p.m. December 7 8:45 a.m. - 5:15 p.m. Poster Session 2 (includes late-breaking abstracts) Continental Breakfast 10:00 a.m. - 6:00 p.m. See page 47 12 Exhibit Hall Reception: Suds for Science 5:00 p.m. - 6:00 p.m. Convention Center – Hall 4B, Level 4 6:00 p.m. - 7:30 p.m. Convention Center – Hall 4B, Level 4 Investigators’ Workshops IW Posters / Boxed Lunch: Noon - 1:30 p.m. Annual Course: Seizures and EEG in the Critically Ill Patient Convention Center – Ballroom 6C, Level 6 Scientific Exhibits See page 23 Third Annual Wine Tasting and Silent Auction See page 27 Convention Center – South Lobby, Level 4 8:45 a.m. - 4:45 p.m. North American Commission Symposium: Pediatric Epilepsy Surgery: Update on Current Practice Convention Center – Ballroom 6E, Level 6 Convention Center – Hall 4B, Level 4 Lunch: Noon - 1:00 p.m. 8:00 a.m. - 6:00 p.m. Professionals in Epilepsy Care Symposium: Practical Applications for the Comprehensive Treatment of Epilepsy Convention Center – Ballroom 6C, Level 6 5:30 p.m. - 7:30 p.m. Exhibit Hall – Grand Opening Poster Session 1 8:00 a.m. - 5:00 p.m. Symposium Break Convention Center – Hall 4B, Level 4 Convention Center – Hall 4B, Level 4 7:30 a.m. - 6:00 p.m. Investigators’ Workshop Convention Center – Ballroom 6E, Level 6 Presidential Symposium: The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction Convention Center – Ballroom 6C, Level 6 Noon - 6:00 p.m. Convention Center – Ballroom 6C, Level 6 2:30 p.m. - 4:00 p.m. Special Interest Group Meetings See page 32 8:30 a.m. - 11:45 a.m. Antiepileptic Therapy Symposium: The New AEDs: Where Do They Belong in Your Armamentarium? Special Interest Group Meetings See page 50 8:00 p.m. - 10:00 p.m. Social Networking Groups Sheraton – Madrona, Second Floor SCHEDULE-AT-A-GLANCE MONDAY Registration 2:15 p.m. - 3:00 p.m. Convention Center – South Lobby, Level 4 6:30 a.m. - 7:00 a.m. Continental Breakfast 3:00 p.m. - 4:30 p.m. Convention Center – Level 6 7:00 a.m. - 8:30 a.m. Special Interest Group Meetings 8:00 a.m. - 5:00 p.m. 8:45 a.m. - Noon Poster Session 3 Continental Breakfast 3:00 p.m. - 5:00 p.m. FDA Town Hall Update: SUDEP and Clinical Trials Convention Center – Room 612, Level 6 3:00 p.m. - 5:15 p.m. Pediatric Epilepsy Highlights Session Convention Center – Hall 4B, Level 4 Convention Center – Ballroom 6E, Level 6 Scientific Exhibits Platform Sessions (3 Concurrent) See page 23 See page 65 Merritt-Putnam Symposium: Stress, Cannabinoids and Epilepsy: The Science Behind the Buzz Convention Center – Ballroom 6C, Level 6 9:00 a.m. - 10:30 a.m. Investigators’ Workshop Convention Center – Room 607, Level 6 See page 61 8:00 a.m. - 3:00 p.m. Lennox and Lombroso Lecture Convention Center – Ballroom 6C, Level 6 5:00 p.m. - 5:30 p.m. Symposia Break Convention Center – Level 6 5:30 p.m. - 8:00 p.m. Special Interest Group Meetings Pediatric State of the Art Symposium: Long-term Outcomes of Neonatal Seizures SCHEDULE-AT-A-GLANCE 6:30 a.m. - 6:00 p.m. December 8 Convention Center – Ballroom 6C, Level 6 See page 62 10:00 a.m. - 3:00 p.m. Exhibit Hall Convention Center – Hall 4B, Level 4 TUESDAY 6:30 a.m. - 11:00 a.m. 6:30 a.m. - 7:00 a.m. 7:00 a.m. - 8:30 a.m. Registration December 9 8:45 a.m. - 10:45 a.m. Hot Topics Symposium: Epilepsy Updates Convention Center – South Lobby, Level 4 Convention Center – Ballroom 6C, Level 6 Continental Breakfast Convention Center – Level 6 Scientific Symposium: The Epidemiology, Pathophysiology & Prevention of SUDEP Special Interest Group Meetings Convention Center – Ballroom 6E, Level 6 See page 77 Suds for Science and Exhibit Hall Reception Sunday, December 7 5:00 p.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 Network with attendees from around the world at the general reception in the Exhibit Hall. Join us for appetizers and visit Sunovion Pharmaceuticals at Booth #105 to receive your complimentary drink tickets. A portion of the funds received from support and beverage sales will benefit the Lennox and Lombroso Trust. EQUIPMENT AUCTION TO BENEFIT: The Lennox and Lombroso Trust for Research & Training and The Susan S. Spencer Fund for Clinical Education and Research AES thanks Natus for participating in the equipment auction. Supported by Sunovion Pharmaceuticals, Inc. 13 EQUIPMENT AUCTION TO BENEFIT: The Lennox and Lombroso Trust for Research & Training and The Susan S. Spencer Fund for Clinical Education and Research EEG Machine Becomes Research Dollars for AES For six years, Nihon Kohden has pioneered a unique giving program by auctioning off its EEG-1200 machine and donating 100 percent of the proceeds to the Lennox and Lombroso Trust for Research & Training and the Susan S. Spencer Fund for Education and Research. This year, Dignity Health Neurological Institute of Northern California (Sacramento) is the EEG-1200 Auction winner at $23,263.75. Nihon Kohden executives will present a check to the American Epilepsy Society on Saturday, December 6 at 1:00 p.m. on the floor of the Exhibit Hall. AES thanks Nihon Kohden Booth #617 for their continued support and for again participating in the annual equipment auction. We also thank those that participated in the bidding. The American Epilepsy Society is pleased to announce INNOVATION PAVILIONS located inside the Exhibit Hall Convention Center – Hall 4B, Level 4 These pavilions offer companies an opportunity to provide education and training to Annual Meeting attendees in a convenient and more personal environment. The Innovation Pavilions will be open on the following days: Saturday, December 6: Noon – 6:00 p.m. Sunovion Pharmaceuticals, Inc. (A) • Lundbeck Pharmaceuticals, Inc. (B) NeuroPace, Inc. (C) • Cyberonics, Inc. (D) Sunday, December 7: 10:00 a.m. – 6:00 p.m. Sunovion Pharmaceuticals, Inc. (A) • Lundbeck Pharmaceuticals, Inc. (B) NeuroPace, Inc. (C) • Cyberonics, Inc. (D) Monday, December 8: 10:00 a.m. – 3:00 p.m. Eisai, Inc. (C) 14 Poster Walking Tours Convention Center – Exhibit Hall 4B, Level 4 The Poster Walking Tours will take place on the days noted below, beginning at 12:15 p.m. each day, and tours will depart every 10 minutes. Join AES leaders and visit interesting, compelling or novel posters and discuss perspectives on how the presented data is meaningful. Leaders and participants will meet and gather at the Poster Information table near the front of the Poster Hall. Announcements will be made in the Poster Hall prior to each tour departure. A schedule of topics and tour leaders will be available at the Poster Information Table. POSTER SESSION 1: Saturday, December 6 Poster tour leaders: David Prince, Andres Kanner, Jean Gotman, Bruce Hermann, Karen Wilcox POSTER SESSION 2: Sunday, December 7 Poster tour leaders: Jackie French, Ilo Leppik, Steve Roper, Joseph Sirven, Andrew Cole POSTER SESSION 3: Monday, December 8 Poster tour leaders: Anne Anderson, Greg Bergey, Dennis Spencer, Kimford Meador, Eric Kossoff Poster tour leaders are subject to change Participate in the AES PASSPORT TO PRIZES PROGRAM Join us in the Epilepsy Resource Center (located in the Exhibit Hall) for daily prize drawings and a grand prize drawing on Monday, December 8. Prize Drawing Schedule: SATURDAY, DECEMBER 6 Prize Drawing – 5:30 p.m. SUNDAY, DECEMBER 7 Prize Drawing – 5:30 p.m. MONDAY, DECEMBER 8 Prize Drawing & Grand Prize Drawing – 2:30 p.m. In your AES Annual Meeting bag, as well as the virtualTotebag, you will find a Passport brochure. To be included in the drawing to win a variety of great prizes, visit the booths of participating exhibitors to get your Passport validated. The more exhibitors you visit, the better your chances. Please complete your contact information and drop the passport in the raffle drum located in the Epilepsy Resource Center. Participants must be present to win. See your Passport for a list of participating exhibitors. 15 colleague COMMUNITYfriend fellow inspire innovation THANKYOU COLLABORATION applause insight catalyst mentee admiration GRATITUDE mentor appreciation CARING Show your appreciation to Someone Who..... è Has influenced your career or your work in epilepsy è Is someone you admire è Has been a great colleague or collaborator è Is celebrating a personal or professional milestone The Community of Caring pin symbolizes the collaborative energy, the community spirit and the supportive professional exchange among AES members. Pins are available for sale at the AES Booth #125 in the Exhibit Hall. All proceeds will benefit the AES New Initiatives Fund, supporting research and education to advance the prevention, treatment and cure of epilepsy. Those who purchase and receive pins will be recognized in a special way during the Annual Meeting. Community of Caring Pin 16 POSTER SCHEDULE Detailed map of the Poster Hall is available in the virtualTotebag and at the Poster Information Table Saturday, December 6 Translational Research Behavior / Neuropsychology / Language Genetics Neuropathology of Epilepsy Neurophysiology Clinical Epilepsy Neuroimaging Comorbidity (Somatic and Psychiatric) Antiepileptic Drugs Surgery 1.001 – 1.078 1.079 – 1.101 1.102 – 1.121 1.122 1.123 – 1.180 1.181 – 1.232 1.233 - 1.269 1.270 – 1.293 1.294 – 1.345 1.346 – 1.377 POSTER SCHEDULE Poster Session 1: Noon – 6:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 36-46) Authors Present: Noon – 2:00 p.m. Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15) Sunday, December 7 Poster Session 2: 8:00 a.m. – 6:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 51-60) Authors Present: Noon – 2:00 p.m. Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15) Behavior / Neuropsychology / Language Health Services Practice Resources Epidemiology Public Health History of Epilepsy Case Studies Professionals in Epilepsy Care Neurophysiology Clinical Epilepsy Neuroimaging Comorbidity (Somatic and Psychiatric) Antiepileptic Drugs Surgery 2.001 – 2.031 – 2.060, 2.061 – 2.067 – 2.084 – 2.098 – 2.101 – 2.131 – 2.144 – 2.164 – 2.235 – 2.257 – 2.276 – 2.334 – 2.030 2.366 2.066 2.083 2.097 2.100 2.130 2.143 2.163 2.234 2.256 2.275 2.333 2.365 Investigators’ Workshop Lunch Poster Session Noon – 1:30 p.m. Convention Center – Room 6F, Level 6 (see pages 47-48) Monday, December 8 Poster Session 3: 8:00 a.m. – 3:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 66-75) Authors Present: Noon – 2:00 p.m. Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15) Translational Research Behavior / Neuropsychology / Language Genetics Neuropathology of Epilepsy Epidemiology Neurophysiology Clinical Epilepsy Neuroimaging Antiepileptic Drugs Non-AED / Non-Surgical Treatments Surgery 3.001 3.075 3.086 3.108 3.126 3.146 3.196 3.254 3.288 3.318 3.343 – – – – – – – – – – – 3.074 3.085 3.107 3.125 3.145 3.195 3.253 3.287 3.317 3.342 3.375 Abstract Author Index – see pages 93-108 17 AES SPECIAL RECOGNITION AES Service Award Co-Recipients AES Service Award Co-Recipients Friday, December 5 – 3:30 p.m. Convention Center – Ballroom 6E, Level 6 (Immediately preceding the Hoyer Lecture) Friday, December 5 – 3:30 p.m. Convention Center – Ballroom 6E, Level 6 (Immediately preceding the Hoyer Lecture) Robert L. Ruff, M.D., Ph.D. Dr. Robert Ruff is a Professor of Neurology and Neurosciences at Case Western Reserve University. He has been the VA’s National Director for Neurology for eight years. Dr. Ruff received his M.D. and Ph.D. in Physiology and Biophysics from the University of Washington. He did his Neurology Residency at New York Hospital Cornell Medical Center. Served as Chief of Neurology at the Cleveland VAMC, Chairman of the Neurology Field Advisory Committee, and oversaw the operations of the six Parkinson’s Disease Research, Educational, and Clinical Centers (PADRECC), four Epilepsy Centers of Excellence (ECoE), and the two Multiple Sclerosis Centers of Excellence (MSCoE). Under his direction, the ECoEs, PADRECC and MSCoE developed into national neurology care networks with more than 50 sites in each of the networks. Dr. Ruff developed the ECoE program in response to a request from Congress. Under his leadership, the ECoE program passed through a trail period which demonstrated its value to veterans and the ECoE program will be continuously funded. In addition, Dr. Ruff served as the VA’s Acting Director, Rehabilitation Research and Development Service. Dr. Ruff is Medical Director of the Functional Stimulation Center at Case Western Reserve University School of Medicine. He also serves as the Deputy Editor, Journal of Rehabilitation Research and Development. Karen L. Parko, M.D. Dr. Karen Parko is a Professor of Neurology at the University of California, San Francisco (UCSF), and the National Director of the Veterans Affairs Epilepsy Centers of Excellence. She is a retired Commissioned Officer from the United States Public Health Service (USPHS). Dr. Parko received a B.A. degree in Psychobiology from New York University and an M.D. degree from the F. Edward Hebert School of Medicine at the Uniformed Services University in Bethesda, M.D. Following an internship in Internal Medicine at the Washington Hospital Center in Washington, D.C., she completed a residency in Neurology at UCSF. After residency she worked in the Indian Health Service as a solo neurologist for ten years on the Navajo reservation, where she established the reservation’s first neurology clinic, providing adult and pediatric neurology services and neurodiagnostic testing to this population of nearly 300,000. Dr. Parko has been involved in disaster and humanitarian relief medicine and served as a medical officer aboard NOAA vessel McArthur during its Stenella Mission in the Eastern Pacific. Dr. Parko serves on the National Professional Advisory Board of the Epilepsy Foundation and previously chaired the Professional Advisory Board of the Northern California Chapter. She has received many awards for her work including being named the Public Health Service Clinical Physician of the Year in 2001, was a finalist for The Frank Brown Berry Prize in Federal Healthcare in 2003, and she received the Epilepsy Foundation of Northern California’s Commitment to Progress Award in 2011. The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for the improved understanding and treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program. Award for Basic Science Award for Clinical Science (Immediately preceding the Presidential Symposium) (Immediately preceding the Presidential Symposium) Saturday, December 6 – 8:30 a.m. Convention Center – Ballroom 6C, Level 6 Carolyn R. Houser, Ph.D. Dr. Carolyn Houser is Professor of Neurobiology in the David Geffen School of Medicine at the University of California, Los Angeles. She received her Doctoral degree in Anatomy from UCLA, and completed postdoctoral training in the Division of Neuroscience at the City of Hope Research Institute, Duarte, CA. Dr. Houser then joined the Comprehensive Epilepsy Program at the VA Greater Los Angeles Healthcare System and the faculty of the Department of Neurobiology at UCLA. Dr. Houser’s research has focused on neuroanatomical alterations and plasticity in epilepsy. Her studies provided the first descriptions of granule cell dispersion in patients with temporal lobe epilepsy and contributed to the early descriptions of mossy fiber sprouting in humans with epilepsy. Dr. Houser’s studies have been published in leading journals of neuroscience, neurology and epilepsy, and have provided a neuroanatomical foundation for numerous electrophysiological and neurochemical studies in the field. Dr. Houser is strongly committed to education in neuroscience and has received numerous teaching awards. Her service to the profession has includes AES Committees boards and Committees of the Epilepsy Foundation, NIH and other epilepsy-related organizations, and Chair of a recent Gordon Research Conference. 18 Saturday, December 6 – 8:30 a.m. Convention Center – Ballroom 6C, Level 6 Ruth Ottman, Ph.D. Dr. Ruth Ottman is Professor of Epidemiology (in Neurology and the Sergievsky Center), Deputy Director for Research, Gertrude H. Sergievsky Center, Columbia University, and Research Scientist, Division of Epidemiology, New York State Psychiatric Institute. She is also Deputy Director of the Columbia Center for Research on Ethical, Legal, and Social Implications of Psychiatric, Neurologic, and Behavioral Genetics. She received her B.A. in zoology and Ph.D. in genetics from the University of California at Berkeley, and has been at Columbia University throughout her career. Dr. Ottman is a genetic epidemiologist whose research addresses the role of inherited factors in susceptibility to neurologic disorders, primarily focusing on epilepsy. Her research group was the first to recognize the epilepsy syndrome autosomal dominant epilepsy with auditory features and to identify LGI1 as a major susceptibility gene for the disorder. She developed and validated several research instruments for standardized data collection on epilepsy in large-scale studies. She has recently begun to focus on the clinical and psychosocial impact of genetic information on individuals with epilepsy and their family. She is a major collaborator in the Epilepsy Phenome / Genome Project and in the Epi4K Center without Walls for Collaborative Research in the Epilepsies. AES SPECIAL RECOGNITION J. Kiffin Penry Excellence in Epilepsy Care Award Joyce A. Cramer, B.S. Joyce A. Cramer is now a consultant after a career in basic and clinical research at Yale University School of Medicine. She also served as President and Chief Scientific Officer of Epilepsy Therapy Project, a non-profit organization providing grants and investments for new epilepsy therapies. Joyce worked in pre-clinical research before initiating several decades of work in clinical trials. She developed methods for the evaluation of drug efficacy and adverse effects, study design and management, and enhancement of medication compliance and persistence, as well as instruments to assess quality of life, treatment satisfaction and other patientreported outcomes for various medical disorders. The QOLIE quality of life instruments, Seizure Severity Questionnaire (SSQ), and Systemic and Neurotoxicity Scales are widely used in research around the world. A current focus is on development of the Personal Impact of Epilepsy Scale (PIES). Her publications include five books, more than 200 peer-reviewed papers, and numerous book chapters covering a variety of topics. She is a frequent lecturer and consultant on these topics. Joyce served as AES Treasurer and on the AES Board of Directors. She was Chair of the Board of Trustees of the Lennox Trust Fund. She has served on the Boards of Directors of the International Society for Pharmacoeconomics and Outcomes Research and the Society for Clinical Trials, as well as the Editorial Boards of Epilepsia and Epilepsy & Behavior and currently of Acta Neurologica Scandinavica. She has received the ILAE International Ambassador Award and the AES Service Award. William G. Lennox Award Monday, December 8 – 8:45 a.m. Convention Center – Ballroom 6C, Level 6 (Immediately preceding the Merritt-Putnam Symposium) Monday, December 8 – 2:15 p.m. Convention Center – Ballroom 6C, Level 6 (Immediately preceding the Lennox and Lombroso Lecture) Karen Gale, Ph.D. Awarded posthumously The AES community was saddened by the recent passing of, Karen Gale, Ph.D., Professor in the Department of Pharmacology & Physiology at Georgetown University. During her more than 35 years at Georgetown, Dr. Gale left an indelible mark as a researcher, educator and stalwart advocate for faculty, students and staff. Dr. Gale was a widely recognized expert in seizure circuitry, and the mechanisms of seizure-induced brain damage and neuroprotection. She was an NIH-funded researcher for more than 20 years, and the founding director of Georgetown’s Interdisciplinary Program in Neuroscience (IPN) that has 50 faculty members from 11 departments campus-wide. AES selected Dr. Gale for her pioneering research on the critical roles of subcortical structures, including the substantia nigra, and on seizure control and propagation that has been seminal in shaping the understanding about the distributed nature of seizures and how they might be controlled, and her recent work on comorbidities of epilepsy including deleterious effects of antiepileptic compounds on neural development. Dr Gale was also recognized for her tireless commitment to the development of early career investigators, women and minority scientists in the epilepsy community through mentorship and advocacy. AWARDEES Saturday, December 6 – 2:15 p.m. Convention Center – Ballroom 6C, Level 6 (Immediately preceding the AET Symposium) Extraordinary Contributions Award Lennox and Lombroso Lecturer Monday, December 8 – 2:15 p.m. Convention Center – Ballroom 6C, Level 6 A $10,000 award is provided by the Lennox and Lombroso Trust Fund Hans O. Lüders, M.D., Ph.D. Dr. Hans O. Lüders is Professor of Neurology and staff at the Epilepsy Center, Case Medical School, Cleveland, OH. He received his degree in medicine from the Catholic University, Santiago, Chile and trained in neurology at the Neurological Institute, Kyushu University, Fukuoka, Japan. He joined the Mayo Clinic as a clinical fellow in Electroencephalography and received a Ph.D. in Neurophysiology from the University of Minnesota. He trained under Prof. Eli Goldensohn at the Neurological Institute in New York. He became head of the Epilepsy Center at the Department of Neurology, Cleveland Clinic Foundation where he served as Chairman of Neurology until he moved to University Hospital, Case Medical Center, to lead and develop the epilepsy program. Dr. Lüders established the intensive course in Epilepsy and Clinical Neurophysiology and developed the highly specialized Epilepsy Surgery Program which are now offered at the Cleveland Clinic and at University Hospitals. He has edited of more than 19 books including the most advanced “Textbook of Epilepsy Surgery”. Dr. Lüders established the “Cleveland Clinic International Epilepsy Symposia” and the “International Epilepsy Colloquia” sponsored by France, Germany, England and Cleveland, OH. He developed an original, strictly semiological classification of epileptic seizures and the original description of several semiological seizure types as well as identified several cortical ”centers” by electrical stimulation of the human brain. Dr. Lüders pioneered the use of subdural electrodes in the presurgical evaluation of epilepsy surgery in the 1980s and is supporting the introduction from Europe of depth electrodes in the U.S. Anne Berg, Ph.D. Dr. Anne Berg received her Ph.D. from Yale University in 1986. The focus of her research for over 25 years has been in the area of pediatric seizures and epilepsy with a specific emphasis on seizure outcomes, developmental and cognitive consequences, the impact on quality of life and the implications of all of these considerations for care and care-models. She is the lead investigator of the NINDS-funded Connecticut Study of Epilepsy which spanned two decades and is providing an unprecedented understanding of the impact of childhood epilepsy later in early adulthood. In 2007, she played a key role in focusing NINDS research priorities on the cognitive, developmental, and behavioral comorbidities of epilepsy and has organized sessions at American Epilepsy Society meetings to investigate these areas and identify research opportunities for improving patients’ outcomes. Dr. Berg was Co-Chair of the 2013 NINDS-sponsored Curing Epilepsies conference and also organized and led the workshop, “Priorities in Pediatric Epilepsy Research: Improving Children’s Futures Today” held in Chicago, November 2013. She helped spearhead the formation of the Pediatric Epilepsy Research Consortium (PERC) which has grown to 37 centers nationwide and is laying the foundation and creating the infrastructure for practice-changing clinical research to improve the diagnosis, treatment, and outcomes of children with pediatric epilepsies. Dr. Berg received a Jacob K. Javits Neuroscience Investigator Award from NINDS in 2007 and the American Epilepsy Society Research Recognition Award for Clinical Research, 2008. 19 SUZANNE AND PETER BERRY INTERNATIONAL TRAVEL AWARDEES This award is given to recognize and honor two young investigators doing research in clinical neuroscience related to epilepsy in Asia, Africa, Oceania, Middle East or Latin America by supporting travel to present research at the AES Annual Meeting. Contact Author Abstract Title Poster Leyla Baysal Kirac, M.D. Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies: Possible Prediction of Patients at Risk For SUDEP 1.128 Rie Sakuraba, M.H.Sc. High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity 3.159 GRASS YOUNG INVESTIGATOR AWARDEES This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy. Awardees are selected from young investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer Lecture on Friday, December 5. Congratulations to the following awardees: Contact Author Abstract Title Poster / Platform Chad R. Frasier, Ph.D. Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes Have Increased Sodium Current Density And Increased Beating Rate C.02 Ethan M. Goldberg, M.D., Ph.D. A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy And Cortical Circuit Dysfunction C.06 SeokJun Hong, M.Sc. Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy: Class II Diagnostic Evidence B.04 Lawrence Hsieh, Ph.D. New Model Of Focal Cortical Dysplasia Associated Epilepsy 3.030 Esther Krook-Magnuson, Ph.D. Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy C.03 Lena H. Nguyen, B.S. Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia 3.050 Vineet Punia, M.D., M.S. Factors Influencing Driving Impairment In Persons With Refractory Epilepsy A.02 Jacy Wagnon, Ph.D. Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy C.09 NURSE AWARDEES Contact Author Abstract Title Rachael Mealey, M.S.N., CRNP Improving Quality Of Care Following EMU Discharge 2.135 Kimberly Orton, RN To Coordinate Or Not To Coordinate? 2.134 Guinevere T. Que, NP Pregnancy And Seizures: Review Of Practice At George Washington University In The Past 5 Years 2.066 Patsy Ramey, MSN, RN Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear Elimination Kinetics In Some Individuals 1.338 Acknowledgment: Nurse awards are supported by Eisai Inc. 20 Poster YOUNG INVESTIGATOR AWARDEES Poster / Platform Abstract Title Karlene T. Barrett, Ph.D. TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice 1.025 Monica Dhakar, M.D. Broadband Intracranial Ictal EEG Analysis In Lesional And Non-lesional Pharmacoresistant Epilepsy 3.174 Dario J. Englot, M.D., Ph.D. Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery 1.369 Alejandra M. Fernandez, B.S. A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures In Pilocarpine-Induced Epileptic Mice 3.342 Federica Frigerio, Ph.D. Pro-Resolving Receptors ChemR23 and ALXR Expression During Epileptogenesis In Mice 1.020 Stephen Gliske, Ph.D. Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone 3.067 Abhijeet Gummadavelli, B.A. Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures 1.044 Se Hee Kim, M.D. Adaptive Function In Dravet Syndrome 3.244 Seongtaek Lee, M.S, B.S. Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures 1.236 Tiffani L. McDonough, M.D. Prediction Of Future Epilepsy In Neonates Who Received Selective Head Cooling For HIE 2.221 Rawad Obeid, M.D. The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic Ischemic Encephalopathy Undergoing Hypothermia 2.159 Reesha R. Patel, B.S. Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol 1.294 Sandra Petty, M.B.B.S, FRACP Ph.D. Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts 1.291 Craig A. Press, M.D., Ph.D. Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For Medically Refractory Epilepsy 1.326 Rajsekar R. Rajaraman, M.D. Predictive Model For Early Posttraumatic Seizures In The PICU A.09 Udaya K. Seneviratne, FRACP Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies 1.227 Kyle Thomson, Ph.D. Use Of An Automated-Feeding System For The Testing Of Potential Anticonvulsant Compounds In Chronic Epileptic Rats 1.050 Ebru Nur Vanli-Yavuz, M.D. How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones? 2.224 Matthew Weston, Ph.D. Hyperactivation Of mTOR Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of Synaptic Transmission 1.013 Jennifer Wong, Ph.D. Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models Of Refractory Epilepsy 3.106 AWARDEES Contact Author Ackowledgment: Young Investigator Awards are supported by Eisai Inc. and Medtronic, Inc. 21 SPECIAL INTEREST GROUP SCHEDULE Friday, December 5: 1:30 p.m. – 3:00 p.m. n Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal and Dendritic Homeostasis (Convention Center – Room 620, Level 6) n Neuroimaging: MRI Normalcy – A Moving Target! (Convention Center – Room 607, Level 6) n Quality, Value and Safety: Improving the Epilepsy Monitoring Unit (Convention Center – Room 617, Level 6) Friday, December 5: 6:00 p.m. – 7:30 p.m. n Cognitive and Behavioral Interventions for Epilepsy: PNES Case Reports and Underlying Mechanisms (Convention Center – Room 607, Level 6) n EEG: Dense Array EEG and EEG Source Localization in Clinical Practice (Convention Center – Room 609, Level 6) n Head Trauma and Military Epilepsy Care: Practical Guide to Caring for Epilepsy Patients in the VA System (Convention Center – Room 620, Level 2) n Junior Investigators: Mentorship (Convention Center – Room 615, Level 6) n Neuropharmacology: Medication Discontinuation Post Surgery: To Do or Not to Do? (Convention Center – Room 617, Level 6) n SUDEP: Hot Topics in SUDEP (Convention Center – Room 603, Level 6) Saturday, December 6: 7:00 a.m. – 8:30 a.m. n Basic Neuroscience: Brain Mosaicism in Epilepsy (Convention Center – Room 607, Level 6) n Children’s Hour: Dravet Syndrome in 2014 (Convention Center – Room 609, Level 6) n Ictal Semiology Cases: How Semiology Helps to Localize the Seizure Onset Zone and Elucidate the Propagation Pattern (Convention Center – Room 612, Level 6) n Neurostimulation and Neuroengineering: New Developments (Convention Center – Room 603, Level 6) n Private Practice: How to Survive with Private Epilepsy Centers in the Changing Health Care Environment (Convention Center – Room 617, Level 6) n Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis and Treatment Issues (Convention Center – Room 615, Level 6) Sunday, December 7: 6:00 p.m. – 7:30 p.m. n Drug Resistant Epilepsy – Definition, Epidemiology, Predictors, Using Big Data for Epidemiological Research (Convention Center – Room 617, Level 6) n Frontal Lobe Epilepsy: Semiology and Cognitive Aspects (Convention Center – Room 608, Level 6) n MEG / MSI Source Imaging (MSI) Source Localization Results: Blind Faith, Black Art, or Scientific Method? (Convention Center – Room 620, Level 6) n Neonatal Seizures: Should We Pursue Comparative Effectiveness Studies for the Treatment of Neonatal Seizures? (Convention Center – Room 609, Level 6) 22 n Neuroendocrinology: Sex Differences in Epileptogenesis (Convention Center – Room 613, Level 6) n Pediatric Case Discussions (Convention Center – Room 612, Level 6) n Psychogenic Nonepileptic Seizures: What Can We Learn From PNES Semiology? (Convention Center – Room 615, Level 6) Monday, December 8: 7:00 a.m. – 8:30 a.m. n Ketogenic Diet: Does the Ketogenic Diet Offer a “Cure” for Epilepsy? (Convention Center – Room 613, Level 6) n Neuropsychology: Can We Spare Memory With Newer Surgical Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data from Laser Ablation, Multiple Hippocampal Transection, and Fornix DBS (Convention Center – Room 609, Level 6) n NINDS and Non-Profit Research Resources (Convention Center – Room 620, Level 6) n Nursing (Convention Center – Room 608, Level 6) n Status Epilepticus – Are We Over-Treating Status Epilepticus, and Especially, Nonconvulsive Status Epilepticus? (Convention Center – Room 612, Level 6) Monday, December 8: 9:00 a.m. – 10:30 a.m. n NEW – Epilepsy and Aging (Convention Center – Room 620, Level 6) n Surgery: Surgical Failure in Pediatric and Adult Epilepsy: ‘The Slam Dunk Case that Wasn’t!’ (Convention Center – Room 609, Level 6) n Tuberous Sclerosis: Thinking Outside the Tuber in TSC (Convention Center – Room 612, Level 6) Tuesday, December 9: 7:00 a.m. – 8:30 a.m. n Critical Care (ICU EEG Monitoring): Controversies in ICU EEG Interpretation and Management (Convention Center – Room 612, Level 6) n Genetics: Personalized Epilepsy Diagnosis and Treatment (Convention Center – Room 613, Level 6) n NEW – Global Health in Epilepsy: How Can You Get Involved? (Convention Center – Room 603, Level 6) n Practice Management (Convention Center – Room 618, Level 6) n Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We Missing A Diagnostic / Therapeutic Opportunity? (Convention Center – Room 606, Level 6) n Temporal Lobe Club: The Thalamus in Epilepsy – Player or Bystander? (Convention Center – Room 620, Level 6) n Tumor Induced Epilepsy – Meningiomas (Convention Center – Room 604, Level 6) n Women’s Issues: Controversies in Caring for Women with Epilepsy (Convention Center – Room 615, Level 6) SCIENTIFIC EXHIBIT SCHEDULE Scientific exhibits will be on display at this year’s annual meeting and will be located in Rooms 603, 604, 607, 612 and 615 on Level 6 of the Washington State Convention Center. These exhibits will provide meeting attendees an opportunity to update themselves on the latest research. Authors will be present throughout the exhibit. Sunday, December 7 • 8:00 a.m. – 11:00 a.m. Cyberonics, Inc. VNS Therapy®: Foundational Treatment for Drug-Resistant Epilepsy Room 603 Lundbeck Pharmaceuticals, Inc. Research Updates for Antiepileptic Therapies Clobazam, Vigabatrin, and IV Carbamazepine 607 UCB, Inc. Continuing UCB’s Long-Term Commitment to Epilepsy Management 612 Sunday, December 7 • 8:00 a.m. – 5:00 p.m. EQUIGEN 604 Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation Monday, December 8 • 8:00 a.m. – 11:00 a.m. Upsher-Smith Laboratories, Inc. Upsher-Smith CNS Update 603 Sunovion Pharmaceuticals, Inc. Aptiom® (eslicarbazepine acetate) Scientific Exhibit Room 607 Sage Therapeutics Clinical Progress of SAGE-547 in Status Epilepticus and Advances in Next-Generation Neurosteroids 615 Monday, December 8 • 8:00 p.m. – 5:00 p.m. EQUIGEN 604 Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation 23 S! R E T C A R A H C F O T S A C R U O JOIN WALK FOR AES RESEARCH & TRAINING RAISE FUNDS FOR EPILEPSY RESEARCH & TRAINING The National Walk for Epilepsy Washington, D.C. – April 11, 2015 Walk with your colleagues! Join Lorna Myers, Nathan Fountain, Patrice Jackson-Ayotunde, Dennis Spencer, Martin Penry, Elson So, Jaideep Kapur, Mike Privitera, Jacqueline French, Patty Shafer, and many others for the 2015 National Walk for Epilepsy. All funds raised by AES Teams Support AES Research and Training efforts – even virtual teams can participate! Teams can support any AES fund: Spencer, Lennox and Lombroso, Dreifuss, Penry, Goldberg-Kaufman and New Initiatives Fund. Raise the most money and win the AES trophy! Sign up or get more information today! Contact Kathy Hucks at 860-586-7505 x512 or [email protected]. 24 Your place for ongoing professional education in epilepsy. ELI is the new AES online tool offering quick access to: n n n n n Relevant CME-based programs for epilepsy Tailored Self-Assessments in Epilepsy (SAEs) Rich archived educational content Easy portal to AES partner projects for epilepsy Organized records for self-directed learning It’s all here at: aesnet.org/professional_education AES is an ACCME accredited provider. 25 n ! i Jo day o T WHY JOIN THE AMERICAN EPILEPSY SOCIETY? The American Epilepsy Society serves as a resource for its membership and the epilepsy community by providing access to data on the latest breakthroughs, technologies and methodologies in epilepsy research. The American Epilepsy Society promotes interdisciplinary communication, scientific investigation and exchange of clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and knowledge-sharing among its members and Annual Meeting attendees. Become a member today by going to www.AESnet.org or visit the AES Booth #125 at the AES Annual Meeting located in the Exhibit Hall. AES MEMBERS ARE: n n n n n n n n n n n Adult Neurologists Advanced Practice Nurses Basic Science Researchers Clinical Researchers Consultants Doctors of Osteopathic Medicine Doctors of Veterinary Medicine Emergency Room Physicians Epileptologists Fellows Government/Regulatory n n n n n n n n n n n Internists Licensed Practical Nurses Neurosurgeons Non-Profit Staff Nutritionists Office Managers Pediatric Neurologists Pharmacists Pharmacologists Presidents/CEOs in Industry Industry/Marketing Professionals n n n n n n n n n Psychiatrists Psychologists Physicians Assistants Registered Nurses Residents Social Workers Students Technologists and Others AES MEMBERS RECEIVE: n n n n n n n n n n n 26 Epilepsy Currents, the official journal of AES Epilepsia, the official journal of ILAE Reduced annual meeting registration fees Discounted subscriptions to scientific journals Listing in Find-A-Doctor online directory Network with members through AES Connect Members-only discussion blogs Research funding opportunities Distinguished Achievement and Research Recognition Awards Weekly e-newsletters with relevant, timely news Full service career center Raise Your Glass for the... Third Annual Wine Tasting & Silent Auction Join your friends, colleagues and hosts – Mike Privitera, Greg Bergey and Dennis Spencer in an evening to benefit the Susan S. Spencer Fund and Lennox and Lombroso Trust Featuring locally sourced cuisine and hand-selected regional wines for your enjoyment. Saturday, December 6th 7:00 PM to 10:00 PM Where: 1927 EVENTS n 1927 3rd Avenue, Seattle, WA — a short stroll from the Convention Center! Purchase your tickets today at the “solutions” counter at the registration desk, Convention Center, South Lobby, Level 4. More than 12,000 people visit the AES website each month -- are you one of them? The NEW AES website features: • • • • • Fresh news and daily updates Dynamic content Online community forum for AES members Mobile friendly content Learning and research opportunities www.AESNET.org JOIN US ON THE AES SITE TODAY! 27 AES Fellows Program • Friday, December 5, 2014 The goal of the AES Fellows program is to encourage and support epilepsy fellows in training to attend the AES Annual Meeting where they will receive the latest updates in clinical and basic science research. A breakfast and lunch will be provided to allow fellows the opportunity to meet and pair with mentors who will provide guidance regarding career planning, potential research paths, and clinical endeavors. Following the breakfast the fellows will attend the Epilepsy Specialist Symposium and the Annual Fundamentals of Epilepsy Symposium, as well as the Hoyer Lecture. A panel of experts will present and discuss their experiences in the fields of research, and clinical and private practice. This program is supported by UCB, Inc., Eisai, Inc., Supernus Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc. and Acorda Therapeutics. 8:30 a.m. – 11:30 a.m. Annual Fundamentals of Epilepsy Symposium: The Side Effects of Epilepsy Treatment (3.0 CME Credits) •Convention Center – Ballroom 6E, Level 6 (2.5 CME Credits) •Convention Center – Ballroom 6E, Level 6 Overview This symposium will address current knowledge regarding generalized epilepsies including idiopathic, symptomatic and progressive generalized epilepsies. Faculty will address current understanding of their pathophysiology, review data regarding prognosis and criteria for diagnosis, and discuss management options for patients with generalized epilepsies. Learning Objectives u u u 12:30 p.m. – 3:00 p.m. Epilepsy Specialist Symposium: The Generalized Epilepsies Develop treatment plans and provide counseling based on current understanding of the pathophysiology of generalized epilepsies and their prognosis Apply current criteria in diagnosing generalized epilepsies Recognize behavioral and cognitive comorbidities of generalized epilepsies and provides appropriate interventions. Target Audience Basic and Intermediate (see page 120 for details) Program Chair: Michael R. Sperling, M.D. Overview This activity will provide comprehensive information about the potential side effects of different epilepsy therapies, not limited to the usual side effects of antiepileptic drugs. Included will be a synopsis of the adverse effects that can be encountered from treatment of seizures and epilepsy providing a comprehensive overview that will assist in tailoring treatment to individual patients. The speakers will discuss antiepileptic drug side effects; side effects of acute treatments for epilepsy (especially status epilepticus); side effects of devices that provide neuromodulation (VNS, RNS, DBS); side effects of epilepsy surgery evaluation and epilepsy surgery; and side effects of other treatments (diet, hormones, cannabinoids, herbal medications). Learning Objectives u u u u Implement appropriate medical treatment based on improved understanding of potential adverse effects of treatment options Refer patients earlier in course of treatment for consideration of surgery or for use of a device for seizure control Counsel patients more knowledgeably about the potential adverse effects of their treatment and helps identify potential hazards arising from treatment Help patients communicate effectively about their care, including identifying previously unrecognized adverse effects of their treatment Identify treatment-related cognitive and emotional adverse effects of newly emergent and alternative treatments. 8:30 a.m. Introduction Michael R. Sperling, M.D. u 8:45 a.m. Pathophysiology of the Generalized Epilepsies Solomon L. Moshé, M.D. Target Audience 9:15 a.m. Seizure Types and Syndromes in the Generalized Epilepsies Prakash Kotagal, M.D. Program 9:45 a.m. Prognosis of the Generalized Epilepsies Katherine Nickels, M.D. 10:15 a.m. Treatment of the Idiopathic Generalized Epilepsies Michael S. Duchowny, M.D. 10:45 a.m. Treatment of Symptomatic and Progressive Generalized Epilepsies Sandra L. Helmers, M.D., M.P.H. 11:15 a.m. Case Studies and Conclusions Michael R. Sperling, M.D. Basic and Intermediate (see page 120 for details) Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and Tracy A. Glauser, M.D. 12:30 p.m. Introduction Tracy A. Glauser, M.D. 12:40 p.m. Antiepileptic Drug Side Effects Eugen Trinka, M.D., M.Sc. 1:05 p.m. Side Effects of Acute Treatments for Epilepsy David M. Treiman, M.D. 1:30 p.m. Side Effects of Devices (VNS, RNS, DBS) Robert S. Fisher, M.D., Ph.D. 1:55 p.m. Side Effects of Epilepsy Surgery Evaluation and Epilepsy Resective Surgery Mary L. Zupanc, M.D. 2:20 p.m. Side Effects of Other Treatments (Diet, Hormones, Cannabinoids, Herbal Medications) Kristen Park, M.D. 2:45 p.m. Conclusions Elinor Ben-Menachem, M.D., Ph.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 3.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-028-L01-P. Initial Release Date: 12/5/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Epilepsy Specialist Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Practice-based Learning and Improvement, and Medical Knowledge Acknowledgment This program is supported by an educational grant from Eisai, Inc. 28 Continued on page 29 FRIDAY December 5, 2014 Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-029-L01-P. Initial Release Date: 12/5/2014. Special Interest Group Meetings ABPN Core Competencies Location listed under each session 1:30 p.m. – 3:00 p.m. The American Board of Psychiatry and Neurology has reviewed the Annual Fundamentals of Epilepsy Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal and Dendritic Homeostasis Core Competencies: Patient Care, Medical Knowledge and System-based Practice Coordinators: Amy L. Brewster, Ph.D., Dane M. Chetkovich, M.D., Ph.D. Speakers: Sookyong Koh, M.D., Ph.D., Robert S. Fujinami, Ph.D., Viji Santhakumar, Ph.D. Acknowledgment This program is supported by an educational grant from UCB, Inc., Eisai, Inc. and Lundbeck Pharmaceuticals, Inc. with additional support from Supernus Pharmaceuticals, Inc. and Cyberonics, Inc. separate registration required — see below for instructions 9:00 a.m. – 3:15 p.m. 28th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic Sheraton – Metropolitan Ballroom A, Level 3 This intensive, one-day conference is designed for those professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Department of Neurology of Wake Forest University School of Medicine, Winston-Salem, North Carolina, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families. Registration for this program is done separately from the AES Annual Meeting and begins on September 1, 2014. You may register by calling Wake Forest School of Medicine at 800.642.0500. Convention Center – Room 620, Level 6 Activation of inflammatory mechanisms that include recruitment of reactive microglia and associated signaling molecules such as cytokines and complement cascade activation, among others, are often seen in surgical resections from individuals with epilepsy and have been widely described before, during, and after seizures in experimental models. The goal of this session is to discuss potential mechanisms by which inflammatory mediators may contribute to pathological epileptogenic changes in the brain. Neuroimaging: MRI Normalcy – A Moving Target! Convention Center – Room 607, Level 6 Coordinators: Matthias J. Koepp, M.D., Ph.D., Neda Bernasconi, M.D., Ph.D. Speakers: Boris Bernhardt, M.D., R. Edward Hogan, M.D., William D. Gaillard, M.D. About 30% of patients with electrographic evidence of temporal lobe epilepsy (TLE) have normal MRI scans. The location of the seizure focus is unclear in this patient population. Possibilities include (i) a subtle form of hippocampal sclerosis that is not apparent on MRI; (ii) alterations in synaptic or receptor physiology not visible on MRI; or (iii) pathology not detected by MRI, such as certain forms of cortical dysplasia. Patients with MRI-“negative” TLE may be candidates for additional neuroimaging techniques including advanced MR imaging with novel acquisition or post-processing techniques, MRS, PET, and SPECT. Peri-ictal imaging may increase the yield to detect abnormalities. This SIG will focus on the management of MRI-normal TLE, emphasizing the neuroimaging perspective. Up to 5.0 AMA Category 1 CME credit will be given. Quality, Value and Safety: Improving the Epilepsy Monitoring Unit 1:30 p.m. – 3:00 p.m. Coordinator: Katherine Noe, M.D., Ph.D. Speakers: Gabriel U. Martz, M.D., Nathalie Jetté, M.D., Khara M. Sauro, Ph.D., Janice Walbert, R.EEG/EPT Professional Development in AES: A Program for Junior Members and Those in Transition Convention Center – Room 603, Level 6 The American Epilepsy Society invites all interested meeting attendees to come to a special session on volunteer and leadership opportunities within the Society. AES has a variety of programs year round to improve the care and treatment of patients with epilepsy. These efforts include education for basic scientists and clinicians, research grant programs, leadership and organizational activities, community outreach and advocacy. Greater participation in the Society offers members extensive career development opportunities by providing a chance to hone leadership skills, to network with other AES members and outside funding organizations, and most importantly, to make significant contributions to improve the lives of patients with epilepsy. FRIDAY Nurse Practitioners may claim 1.5 hours of pharmacology for this session. This session will be useful to trainees, basic scientists, clinicians and other allied health professionals (nurses, psychologists, Pharm.D.s) who want to know more about AES organizational structure or who want to become more involved. The session will provide an overview of the professional development and volunteering opportunities within the Society, followed by short presentations by members active in AES leadership. The session will end with a chance to meet with AES staff and committee leaders to learn more about available opportunities. Convention Center – Room 617, Level 6 This year’s SIG will focus on current efforts to improve the quality, safety, and value of care provided in epilepsy monitoring units. Reduction in 30-day readmission rates is an ongoing focus of quality improvement efforts for all hospitalized patients, and influences payments to hospitals from the Centers for Medicare and Medicaid Services. Dr. Gabriel Martz, from the Medical University of South Carolina will present his research into EMU readmissions. Continuing prior discussions on ways to improve the patient experience in the EMU, Dr. Nathalie Jetté and colleague Dr. Khara Sauro will discuss their unique experience with a multidisciplinary EMU Quality Improvement Team at the University of Calgary. Finally, Janice Walbert, Executive Director of ABRET, will describe their challenges / successes to date in developing and implementing certification of EEG laboratories. Time will be available for audience questions and discussion. 29 FRIDAY December 5, 2014 3:30 p.m. – 5:30 p.m. 4:10 p.m. Dietary Measures, Vitamins and Other Supplements, Herbal Therapies Carlos Medina-Malo, M.D. 4:40 p.m. Non-conventional Medical Treatments, Mind-body Therapies Blanca Vazquez, M.D. Presentation: Robert L. Ruff, M.D., Ph.D. and Karen L. Parko, M.D., AES Service Awards, NINDS Update 5:10 p.m. Round Table Mario A. Alonso-Vanegas, M.D., Patricio Abad, M.D. Lecturer: Frances Jensen, M.D. 5:50 p.m. Conclusions Mario A. Alonso-Vanegas, M.D. The 12th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer Dr. Frances Jensen, is sponsored by the National Institute of Neurological Disorders and Stroke. Dr. Jensen’s presentation is the twelfth in a series of lectures highlighting the promise of epilepsy research. This series is held in memory of Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy and promoting research into a cure and a better quality of life for those with the disorder. The purpose of the lecture is to raise awareness of epilepsy among researchers and the public and provide intellectual stimulation that will encourage continuing progress toward finding a cure for epilepsy. Credit Designation Supported in part by Upsher-Smith Laboratories, Inc. and NINDS. The American Board of Psychiatry and Neurology has reviewed the Spanish Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. 12th Judith Hoyer Lecture in Epilepsy: Reshaping Epilepsy As a Spectrum Disorder: Implications for Clinical Care, Research and Education Convention Center – Ballroom 6E, Level 6 3:30 p.m. – 6:00 p.m. Spanish Symposium: Complementary and Alternative Approaches to Epilepsy Treatments The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-030-L01-P. Initial Release Date: 12/5/2014. ABPN Core Competencies Core Competencies: Patient Care, Medical Knowledge, Practice-based Learning and System-based Practice (2.5 CME Credits) Convention Center – Room 612, Level 6 Overview This symposium will present an overview on the role of neurostimulation, diet, vitamins and other supplements, herbal therapies, non-conventional medical treatments (acupuncture, cannabis, others), and psychological and Mind-body therapies (biofeedback, meditation, yoga, relaxation techniques) in the treatment of epilepsy. Treatment paradigms and evidence-based approach will be addressed. As a result of attending this symposium, the attendee will recognize alternative treatments when managing patients with medically refractory epilepsy and become familiar with current evidence and rationale for their use, allowing for consideration of neurostimulation and other available alternative treatment options. Learning Objectives u Utilize newer as well as established treatments such as neurostimulation, dietary therapy and other alternative methods as therapeutic options in refractory epilepsy u Counsel families regarding neurostimulation and alternative therapies based on currently defined indications u Treat patients with refractory epilepsy through use of alternative treatments not previously considered u Recognize the value of treating refractory epilepsy through use of new techniques such as mind-body techniques and psychological therapy. Target Audience Basic and Intermediate (see page 120 for details) Program Co-Chairs: Patricio E. Abad, M.D. and Mario A. Alonso-Vanegas, M.D. 30 3:30 p.m. Introduction Patricio E. Abad, M.D. 3:40 p.m. Neurostimulation for Epilepsy David King-Stephens, M.D. 6:00 p.m. – 7:30 p.m. Special Interest Group Meetings Location listed under each session Cognitive and Behavioral Interventions for Epilepsy: PNES Case Reports and Underlying Mechanisms Convention Center – Room 607, Level 6 Coordinators: Lauren Frey, M.D., Marcio Sotero de Menezes, M.D., Rosa Michaelis, M.D., Steven C. Schachter, M.D., Siegward M. Elsas, M.D. Speakers: Ivan Osorio, M.D., W. Curt LaFrance, Jr., M.D., M.P.H., Janelle Wagner, Ph.D. Cognitive–behavioral therapy, mind–body approaches, and multimodal educational interventions have consistently demonstrated positive effects on patient well-being. Nevertheless, the evidence for their effects on seizure control remains inconsistent, which is partly attributable to the methodological difficulties inherent in rigorously testing these interventions. In the first part of this SIG, Dr. Osorio will present observations from invasive EEG monitoring that inform the hypothesis for a possible physiological antiseizure mechanism of cognitive tasks. In the second part, we will review case-based tools that may help SIG participants identify suitable candidates for behavioral interventions, select appropriate interventions and monitor intervention outcomes. A number of experienced therapists will demonstrate how their therapeutic approaches would work in practice. Dense Array EEG and EEG Source Localization in Clinical Practice Convention Center – Room 609, Level 6 Coordinators: Kitti Kaiboriboon, M.D., Susan T. Herman, M.D. Speakers: Susan T. Herman, M.D., Kitti Kaiboriboon, M.D., Serge Vulliemoz, M.D. This SIG will review the use of dense array (64 or more channels) EEG and EEG source localization for routine EEG and epilepsy monitoring. Routine EEG using 21 scalp electrodes has excellent temporal but relatively poor spatial resolution, FRIDAY December 5, 2014 Head Trauma and Military Epilepsy Care: Practical Guide to Caring for Epilepsy Patients in the VA System Convention Center – Room 620, Level 6 Neuropharmacology: Medication Discontinuation Post Surgery: To Do or Not to Do? Convention Center – Room 617, Level 6 Coordinators: Jeannine Conway, Pharm.D., M.D. and Laura Strom, M.D. Speakers: Laura Strom, M.D. and Pei Shieen Wang, Pharm.D. This SIG brings together individuals in a debate format with an interest in anticonvulsants and optimizing their use. This year’s session will address the decision to discontinue anticonvulsants post surgery; encouraging audience participation. We will also discuss the practical challenges that can occur as medication is being withdrawn, including adverse reactions and medication interactions. Upon completion of the session, the participant should be able to present reasonable options to their patients about making a decision about medication discontinuation. FRIDAY limiting its utility in localization of epileptiform activity and seizures. Recent advances in amplifier technology and electrode technology now allow recording of 128-256 channels of EEG. EEG source imaging (ESI) is a model-based imaging technique that determines the “inverse EEG solution,” or the generating source of electrical potentials recorded on the scalp. Improved ESI software can now build realistic head models based on individual patients’ MRIs, perform source localization, and co-register results to imaging studies in less time and without need for programming skills. These advances now put dense array EEG and ESI tools in the hands of clinical electroencephalographers, but the clinical utility of these techniques has not yet been fully explored. Speakers will debate the pros and cons of dense array EEG in comparison to other techniques used for epilepsy diagnosis and localization. SUDEP: Hot Topics in SUDEP Coordinators: Tung Tran, M.D., Jonathan Halford, M.D., Enrique A. Feoli, M.D., Joseph Drazkowski, M.D. Speakers: Tung Tran, M.D. and Kenneth R. Perrine, Ph.D. Convention Center – Room 603, Level 6 We will discuss how epilepsy care in the VA system is different from epilepsy care outside of a Veterans Affairs Medical Center (VAMC). Specifically, we will discuss (1) how the VA medication formulary system works on a local VAMC and national level and changes to the formulary for 2014 (2) technical challenges to setting up a neurophysiology lab in a VAMC (3) the structure of VA administration and how to request expansion of services for epilepsy care at your VAMC and (4) an update on progress to develop the VA Epilepsy Centers of Excellence (ECoEs) and what services they can provide non-ECoE VAMCs. This SIG is designed to dovetail with a book, “VA Epilepsy Manual” that is being prepared now (editor Aatif Husain, M.D.) and will be published a few months before this SIG and will be handed out at this SIG meeting. Our understanding of SUDEP is moving forward thanks to a broad range of research including animal models, the search for clinical biomarkers, and collaborative work with coroners, medical examiners and device developers. This year, we will delve into hot topics with experts in the field. Speakers and topics will be selected based on cutting-edge SUDEP-related research presented at this AES meeting and at the recent Partners Against Mortality in Epilepsy (PAME) conference. Ample time will be allowed for discussion with audience members. Coordinators: Elizabeth J. Donner, M.D. and Lawrence J. Hirsch, M.D. Speakers: TBA Supported by Sunovion Pharmaceuticals, Inc. Junior Investigators: Mentorship Convention Center – Room 615, Level 6 Coordinators: William Stacey, M.D., Ph.D. and Mackenzie Cervenka, M.D. Speakers: Kevin J. Staley, M.D., Gregory K Bergey, M.D., Frances E. Jensen, M.D. Whether you are a clinician, a researcher, or both, effective mentorship is critical to your academic success. Our interactive panel will discuss and answer questions about finding and utilizing mentors at this early stage in your career. Topics will include the importance of mentorship in grant proposals, finding faculty positions, and collaborations. This panel discussion is independent of the AES mentoring program, which attendees are also encouraged to attend. Get Your Annual Meeting CME / CE Credit Online Go to www.AESnet.org See page 120 for details 31 • AES 68TH ANNUAL MEETING Seattle, WA • SATURDAY December 6, 2014 www.AESnet.org 7:00 a.m. – 8:30 a.m. Mentoring Session for Junior Investigators Convention Center – Room 307 / 308, Level 3 Pre-application required This program is targeted to fellows, postdoctoral researchers, instructors and assistant professor level junior faculty. Epilepsy professionals at the Associate Professor level will volunteer to serve as mentors. Accepted applicants will meet with their assigned mentors during this time. 7:00 a.m. – 8:30 a.m. Special Interest Group Meetings Location listed under each session Basic Neuroscience: Brain Mosaicism in Epilepsy Convention Center – Room 607, Level 6 Coordinators: Martin Gallagher, M.D., Ph.D., Laura A. Jansen, M.D., Ph.D. Speakers: Annapurna Poduri, M.D., Laura A. Jansen, M.D., Ph.D., Kathleen Millen, Ph.D., Franck K. Kalume, Ph.D. The speakers will present an overview of genetic mosaicism in the brain, studies of mosaic PI3K/AKT pathway mutations in human brain malformations, and animal models of PI3K/AKT pathway activation. Implications for the diagnosis and treatment of epilepsy in patients with malformations of cortical development will be highlighted, and plenty of time will be available for audience questions and discussion. Children’s Hour: Dravet Syndrome in 2014 Convention Center – Room 609, Level 6 Coordinators: Elaine C. Wirrell M.D., Lieven Lagae, M.D., Ph.D. Speakers: Joseph Sullivan, M.D., Sarah Weckhuysen, M.D., Rima Nabbout, M.D., Ph.D. In recent years, considerable progress has been made in the diagnosis and treatment of Dravet syndrome. The speakers will focus on these clinically relevant new achievements and present the key clinical features, guide us through the complex genetic background and discuss the newer treatment options in this drug-resistant childhood epilepsy syndrome. The goal of this SIG is to be able to recognize a young child with Dravet Syndrome, to order the right genetic testing and to apply standard and newer treatment options. Supported by Acorda Therapeutics and GW Pharmaceuticals. Ictal Semiology Cases – How Semilogy Helps to Localize the Seizure Onset Zone and Elucidate the Propagation Pattern Convention Center – Room 612, Level 6 Coordinators: Phillipe Kahane, M.D., Ph.D., Charles A. Szabo, M.D. Speakers: Charles A. Szabo, M.D., Philippe Kahane, M.D., Ph.D., Hans O. Lüders, M.D., Ph.D., Andrew Bleasel, M.D. We will be presenting 4-8 cases of patients undergoing epilepsy surgery. The cases will be primarily discussed in strong interaction with the audience based on seizure semiology, to show how the careful analysis of subjective and observable clinical elements help to localize the seizure onset zone and to reconstruct the propagation pattern. The final explanation will be briefly given at the end of each case presentation, based on intracranial EEG and / or surgical result. 32 Neurostimulation and Neuroengineering: New Directions Convention Center – Room 603, Level 6 Coordinators: Christopher DeGiorgio, M.D., Catherine Schevon, M.D., Ph.D., Steven J. Schiff, M.D., Ph.D. Speakers: Marom Bikson, Ph.D., Robert Fisher, M.D., Ph.D., Selim Benbadis, M.D. The SIG will focus on the following topics: Transcranial Magnetic Stimulation for the Treatment of Epilepsy Seizure Detection Devices: Detection Strategies, Sensitivity, and Clinical Impact; Controversies in Neurostimulation 2014-2015: An Interactive Debate with Audience Participation. The topics will be followed by a period of interactive discussion. Private Practice: How to Survive with Private Epilepsy Centers in the Changing Health Care Environment Convention Center – Room 617, Level 6 Coordinators: Marcelo E. Lancman, M.D., Pavel Klein, M.D. Speakers: John S. Ebersole, M.D., David J. Anschel, M.D., Thomas H. Swanson, M.D. We will discuss several topics related to the ability of private practice centers to survive and thrive in the fast-changing healthcare environment. First, we will discuss the dramatic changes underway in many communities of large academic institutions and hospital chains buying out private practice physicians and how this may impact private epilepsy centers in terms of competition, referral patterns, hospital access, and hospital and insurance contract negotiations. Second, we will discuss the impact of ACA on the practice of epilepsy at private centers — the competing forces of decreased utilizations (increased co-pays and physician access restriction vs. potential increased coverage of previously uninsured patients with epilepsy); and the flux/chaos (changes in insurance policies and insurance among insured patients). Third, we will address the increased burden on time and resources of both insurance and governmental requirements of medication and procedure authorizations and denials, which have accelerated remarkably in the last 12-24 months. Fourth, to end on a positive note, we will highlight possibilities for how to compete in this changing environment, e.g. by offering highly specialized services such as MEG by virtue of greater control over resources, and of routine services at better access by virtue of flexibility and responsiveness; and how in in both areas, super-specialized epilepsy care and the routine epilepsy care private centers can have a competitive advantage over large academic centers and hospital chains. Supported by Acorda Therapeutics. Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis and Treatment Issues Convention Center – Room 615, Level 6 Coordinators: John J. Barry, M.D., Rochelle Caplan, M.D. Speakers: Mary Wojnaroski, Ph.D., Michael Kerr, M.B.ChB., FRCPSYCH Aggressive behaviors in individuals with epilepsy have been a controversial topic. The association of aggression or violence with epilepsy has been debated despite being reproduced in some animal models and may have significant psychological and environmental consequences. The Psychiatric SIG will focus on 1) Evidence-based diagnostic and treatment options for aggressive behaviors in children and adolescents and 2) Aggression in adults appearing in the post-ictal state, especially affiliated with comorbid psychosis and finally 3) Aggression seen in individuals with developmental delay. The format of the SIG will utilize cases for both children and adults as a nidus for group discussion. Supported by Sunovion Pharmaceuticals, Inc. SATURDAY December 6, 2014 8:30 a.m. – 11:45 a.m. Presidential Symposium: The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction (2.25 CME Credits) Convention Center – Ballroom 6C, Level 6 Presentation: Carolyn R. Houser, Ph.D. and Ruth Ottman, Ph.D., Research Awards, ILAE Update Overview Learning Objectives u Recognize the role of the International EEG Database in developing spatial and temporal prediction of epilepsy and seizures u Understand the physiologic basis of epileptogenesis, understand impact of localization on surgery outcomes and appreciate issues related to research into seizure prediction u Researchers will utilize described approaches with quantitative analysis using large NIH database for developing new research questions and methodology. Target Audience Advanced (see page 120 for details) Program Co-Chairs: Brian Litt, M.D. and Gregory A. Worrell, M.D., Ph.D. 9:30 a.m. Introduction Elson So, M.D. 9:35 a.m. Review Current State of the Art of Electrophysiological Biomarkers Gregory A. Worrell, M.D., Ph.D. 10:05 a.m. Review Current State of the Art of Seizure: Detection and Devices Kathryn Davis, M.D. 10:30 a.m. Review Current State of the Art: Prediction and Devices Mark J. Cook, M.D. 10:55 a.m. NIH International Electrophysiology Database and the Competition Brian Litt, M.D. 11:20 a.m. The Seizure Detection & Prediction Contest Benjamin Brinkmann, Ph.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.25 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.25 contact hours (0.25 CEUs). UAN 0077-9999-14-031-L01-P. Initial Release Date: 12/6/2014. Acknowledgment The International Competition is co-sponsored by the American Epilepsy Society, National Institute of Neurological Disorders and Stroke and the Epilepsy Foundation. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Presidential Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. SATURDAY This symposium will address the role of electrophysiological biomarkers in diagnosis, localization, and prediction of focal seizures and epilepsy. We review the current state of the art of electrophysiological biomarkers in epilepsy. Utilizing a large electrophysiology database (NIH-sponsored International EEG Database) the concepts of data-sharing, large-scale computation, and reproducible research will be introduced. Specific applications using electrophysiological biomarkers to predict epilepsy (epileptogenesis), predict seizures (ictogenesis), and map the epileptogenic zone will be presented. Algorithms for detection and spatiotemporal mapping of electrophysiological biomarkers from multiple research groups will be presented. The performance of these algorithms will be rigorously evaluated in an open competition applied to large-scale clinical and basic research datasets: 1) Prediction of epilepsy in animal models, 2) Seizure forecasting in dogs and humans, and 3) Localization of epileptogenic zone in humans. The results of the competition between multiple international research groups will be reviewed and awards presented for the best performance for predicting epilepsy, predicting seizures, and mapping the epileptogenic zone. 11:40 a.m. Conclusions Brian Litt, M.D., Gregory A. Worrell, M.D., Elson So, M.D. Core Competencies: Medical Knowledge 2:15 p.m. – 5:00 p.m. Antiepileptic Therapy Symposium: The New AEDs: Where Do They Belong in Your Armamentarium? (2.5 CME Credits) Convention Center – Ballroom 6C, Level 6 Presentation: Joyce A. Cramer, J. Kiffin Penry Award Overview This symposium will present an overview of the 8 newest antiepileptic drugs (AEDs) that include clobazam, eslicarbazepine, ezogabine, lacosamide, perampanel, rufinamide, stiripentol, and vigabatrin. Discussion will cover the developmental history of the drug, mechanisms of action, indications for use, efficacy, safety issues, tolerability and ease of use to include drug interactions, formulations and dosing. Treatment paradigms that demonstrate the differential role of the medications will be presented. As a result of attending this symposium, the attendee will have an understanding of how to incorporate the newest AEDs into an integrative treatment algorithm for their clinical practice and will be able to counsel patients and their families regarding risks, benefits and alternatives. Learning Objectives u Recognize opportunities in their clinical practice to use one or more of the eight newest AEDs and appropriately counsel patients regarding risks, benefits and alternatives u Participate in counseling patients and their families regarding use of one or more of the eight newest AEDs u Assist clinicians in their prescribing of one or more of the eight newest AEDs through an understanding of pharmacology and drug-to-drug interactions u Assist in identifying tolerability of adverse effects in the use of one or more of the eight newest AEDs, particularly in reference to cognitive and behavioral outcomes. 33 SATURDAY December 6, 2014 Target Audience 5:15 p.m. – 7:45 p.m. Programs Co-Chairs: Angus A. Wilfong, M.D. and Jerry J. Shih, M.D. Professionals in Epilepsy Care Symposium: Practical Applications for the Comprehensive Treatment of Epilepsy 2:30 p.m. Introduction Angus A. Wilfong, M.D. (2.5 CME Credits) 2:45 p.m. Ezogabine / Eslicarbazepine Martin J. Brodie, M.D. 3:10 p.m. Stiripentol / Vigabatrin Elinor Ben-Menachem, M.D., Ph.D. 3:35 p.m. Lacosamide / Perampanel John Pollard, M.D. 4:00 p.m. Clobazam / Rufinamide Joan A. Conry, M.D. 4:25 p.m. Integration of New AEDs Into Clinical Practice William E. Rosenfeld, M.D. 4:50 p.m. Conclusions Jerry J. Shih, M.D. Basic and Intermediate (see page 120 for details) Convention Center – Ballroom 6C, Level 6 Overview Learning Objectives u Recognize when to screen for comorbid epilepsy conditions, initiate appropriate treatment, and refer to the appropriate health care professional u Participate in providing education, resources, and counseling to persons with epilepsy and their families regarding the comprehensive treatment needs of persons with epilepsy u Assist the epilepsy care team / provider in identifying and treating the comorbid conditions and identifying antiepileptic medication issues for children, men, women, and the elderly u Assist the epilepsy care team / provider in identifying and using best screening instruments regarding epilepsy psychiatric / psychological / neurodevelopmental comorbid conditions for persons with epilepsy and their families. Learner will also assist in the practical provision of or access to behavioral treatment of such comorbid conditions. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Nurse Practitioners may claim 2.5 hours of pharmacology for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-032-L01-P. Initial Release Date: 12/6/2014. Target Audience Basic and Intermediate (see page 120 for details) ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Antiepileptic Therapy Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Program Co-Chairs: Georgette Smith, Ph.D., APRN, CPNP and Janelle Wagner, Ph.D. 5:15 p.m. Introduction and Case Presentation Georgette Smith, Ph.D., APRN, CPNP 5:30 p.m. Behavioral Health and Cognitive Screening as Part of the Epilepsy Clinic Visit Bruce P. Hermann, Ph.D. 5:50 p.m. Finding Resources and Practical Solutions for Behavioral Interventions Loretta Carbone, M.S.W. 6:10 p.m. Antiepileptic Therapy: Pediatric, Elderly, Women’s and Men’s Issues Jeannine Conway, Pharm.D. 6:30 p.m. Moderator: Kamil Detyniecki, M.D. Speakers: Charlotte Hill, Ph.D., Benjamin J. Whalley, BPharm, Ph.D., Orrin Devinsky, M.D. Special Populations Mary Jo Pugh, Ph.D., RN (Veterans) Jonathan Edwards, M.D. (Adolescents) 7:10 p.m. Review of Cases: Panel Discussion Sandra Cushner Weinstein, M.S.W. This Investigator Workshop is supported in part by GW Pharmaceuticals. 7:30 p.m. Conclusions Janelle Wagner, Ph.D. Core Competencies: Patient Care and Medical Knowledge Acknowledgment This program is supported by an educational grant from Eisai, Inc., UCB, Inc., Lundbeck Pharmaceuticals Inc. and Sunovion Pharmaceuticals, Inc. 2:30 p.m. – 4:00 p.m. Investigators’ Workshop Convention Center – Ballroom 6E, Level 6 Cannabinoids in Epilepsy: Do They Work? If So, How? 34 SATURDAY Recent research and practice recommendations include the comprehensive care of persons with epilepsy and their families. Despite this recommendation no guideline exists for comprehensive epilepsy care. This symposium will present recent research and practice evidence to assist interdisciplinary providers about practical ways to provide comprehensive care for persons with epilepsy and their families through the lifespan. Cases will be used to apply interventions to improve health outcomes through early comorbidity screening and health outcomes including: behavioral health screening, behavioral interventions and resources, antiepileptic medication through the lifespan, as well as care of special populations such as veterans and adolescents. SATURDAY December 6, 2014 Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Programs Chair: Gary W. Mathern, M.D. Introduction Gary W. Mathern, M.D. 5:40 p.m. AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-033-L01-P. Initial Release Date: 12/6/2014. What Is Pediatric Epilepsy Surgery? Gary W. Mathern, M.D. 6:05 p.m. What Is So Special About Children? J. Helen Cross, M.D. ABPN Core Competencies 6:30 p.m. Pediatric Epilepsy Surgery: Is it Only Rare Syndromes? William D. Gaillard, M.D. 6:55 p.m. What is the Role of Social Media and Nonprofits? Adam Hartman, M.D. 7:20 p.m. Conclusions Gary W. Mathern, M.D. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit The American Board of Psychiatry and Neurology has reviewed the Professionals in Epilepsy Care Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Practice-based Learning, Interpersonal and Communication Skills and System-based Practice Acknowledgment This program is supported by an educational grant from Eisai, Inc., and UCB, Inc. 5:30 p.m. – 7:30 p.m. North American Commission Symposium: Pediatric Epilepsy Surgery: Update on Current Practice (2.0 CME Credits) Convention Center – Ballroom 6E, Level 6 Overview This symposium will present an overview of pediatric epilepsy surgery presenting, in part, data from the ILAE Pediatric Epilelpsy Surgery Task Force. This symposium will address criteria for when to refer, what constitutes pediatric epilepsy surgery, what are effective outcome measures, the social impact and co-morbities of pediatric epilepsy surgery syndromes, and the emergence of non-profit parent groups to influence care and practice in the field. Learners will be provided with established criteria for diagnosis of intractable pediatric epilepsy. Learning Objectives u Determine which pediatric patients are candidates for epilepsy surgery based on international standards suggested by the ILAE Pediatric Epilepsy Surgery Task Force u Refer pediatric patients for epilepsy surgery based on international experience u Counsel family regarding diagnosis of intractable epilepsy as currently defined u Explain the process of evaluating a child for epilepsy surgery in view of international experience u Assess children with intractable epilepsy in anticipation of referral for surgical evaluation using current criteria, defining current psychological and neuropsychological status. Target Audience Basic, Intermediate, and Advanced (see page 120 for details) Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. SATURDAY 5:30 p.m. Nurses may claim up to 2.0 contact hours for this session. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the North American Commission Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Patient Care, Practice-based Learning, Systems-based Practice AES ANNUAL BUSINESS MEETING All AES members are encouraged to attend this yearly meeting. You’re invited to attend Sunday, December 7 8:00 a.m. – 8:30 a.m. Sheraton Seattle Hotel Metropolitan Ballroom B, Third Floor Coffee will be available 35 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 Authors Present: Noon – 2:00 p.m. Poster Walking Tours begin at 12:15 (see page 15 for details) Translational Research Mechanisms 1.001 Enhanced Histamine Release During The Pilocarpine-Induced Status Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats: Effects Of Sodium Cromoglycate/ L. Rocha, M. Valle-Dorado, C. Santana-Gomez, S. Orozco-Suarez 1.002 PET Imaging Of Translocator Protein In Temporal Lobe Epilepsy/ L. Dickstein, P. Zanotti-Fregonara, I. Dustin, J. Liow, J. Hirvonen, W. Kreisl, K. Jenko, S. Inati, M. Fujita, C. Morse, J. Hong, V. Pike, S. Zoghbi, R. Innis, W. Theodore 1.003 Time- And Region-Specific Alterations In Cyclin D1 Expression Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/ Y. Cruz Del Angel, D. Strode, A. Brooks-Kayal, H. L. Grabenstatter 1.004 Basic Mechanisms Of Acute And Chronic Neocortical Epilepsy Revealed By Multi-Electrodes Extracellular Field Recordings In Brain Slices/R. Serafini, J. Loeb 1.005 Adenosine Kinase Expression In Cortical Dysplasia With Balloon Cells: A Developmental Lineage Of Cell Types Analysis Epilepsy Center, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China/ T. Li, G. Luan 1.006 Proteomic Analysis Of TrkBMediated Synaptic Changes Following Status Epilepticus/E. B. Ludmir, Y. Huang, B. Gu, E. J. Soderblom, M. Moseley, J. O. McNamara 1.007 Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability In The Normal And Injured Brain/ A. A. Korgaonkar, Y. Li, V. Santhakumar 1.008 T Cells Rapidly Relocate From Spleen And Accumulate During Epileptogenesis In A Rat Brain Of Cortical Dysplasia Following A Second Hit/K. Ayasoufi, A. Nemes, A. Valujskikh, Z. Ying, I. Najm 1.009 Developmental Plasticity Of Dentate Gyrus Granule Cells Following Epileptiform Activity In Vitro/ K. P. Patterson, Y. Chen, G. P. Brennan, C. Ly, T. Baram 1.010 New Animal Model Of SUDEP: Brainstem Ictal EEG Is Associated With Respiratory Arrest/T. Salam, G. Montandon, R. Genov, J. Perez Velazquez, P. Carlen 1.011 Mechanisms Underlying Transitions Between Bursting And Seizing In A Computational Network Model/W. Swiercz, K. Lillis, K. Staley 1.012 Increased Expression Of Growth Associated Protein 43 After Seizures In Rodent Model Of Irradiation-Induced Cortical Dysplasia/A. Nemes, Z. Ying, I. Najm 36 1.013 Hyperactivation Of mTOR Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of Synaptic Transmission/M. Weston, H. Chen, J. Swann 1.014 Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of Temporal Lobe Epilepsy/ P. Buckmaster, I. Toyoda, S. Fujita, A. Thamattoor 1.015 GABAB Receptors Regulate Trafficking Of Extrasynaptic GABAA Receptors In Dentate Gyrus Granule Cells Via PKA- And PKC-Dependent Signaling Pathways/W. Tao, W. Spain, C. Ransom 1.016 Potassium Concentration Bidirectionally Modulates Seizure-Like Events In The 4-AP Epilepsy Model In Vitro And In Vivo/P. Bazzigaluppi, L. Wang, S. Dufour, T. Valiante, P. Carlen 1.017 Onset Of Spontaneous Limbic Seizures Is Associated With Changes In Firing Dynamics Of Neuronal Ensembles In Hippocampus And Parietal Association Cortex/ A. Neumann, A. Luczak, M. Sprengers, H. Steenland, K. Bzymek, J. Xie, V. Lapointe, Z. Navratilova, F. Kloosterman, K. Vonck, P. Boon, B. L. McNaughton, R. Raedt 1.018 Human Single Neuron Correlates Of High Frequency Oscillations During Seizures/ O. J. Ahmed, E. N. Eskandar, L. R. Hochberg, S. S. Cash 1.019 Invited Speaker Abstract Submission 1.020 Pro-Resolving Receptors ChemR23 And ALXR Expression During Epileptogenesis In Mice/ F. Frigerio, A. Torello, M. Neveux, K. Leclercq, A. del Prete, S. Sozzani, R. Kaminski, A. Vezzani 1.021 Impermeant Anions Are Involved In Setting The Neuronal Chloride Concentration, Implications For Seizure Treatment/J. Glykys, V. Dzhala, K. Egawa, T. Balena, Y. Saponjian, K. Kuchibhotla, B. Bacskai, K. T. Kahle, T. Zeuthen, K. Staley 1.022 Adenosinergic Pathway Involvement In Protective Effect Of Atorvastatin In PentylenetetrazolInduced Seizures In Rats/A. Goyal, R. Kumar, Y. K. Gupta 1.023 Does Enhancement Of Ventilation Reduce Respiratory Arrest In DBA/1 Mice?/C. Zeng, X. Long, J. Cotten, S. Forman, K. Solt, C. Faingold, H. Feng 1.024 The mTOR Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced Dendritic Injury In Mice/D. Guo, N. Rensing, M. Wong 1.025 TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice/K. Barrett, L. Scott, S. Mandadi, P. Whelan, M. Scantlebury 1.026 Hypothermia Prevents The Development Of The Calcium Plateau Following Status Epilepticus/ K. Phillips, L. Deshpande, R. DeLorenzo Models 1.027 Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In Mice Following Controlled Cortical Impact/J. Boychuk, C. Butler, B. Smith 1.028 The Action Potential Firing Frequency Of Fast-Spiking Basket Cells Is Reduced After Status Epilepticus/H. Sun, H. Goodkin 1.029 Benzodiazepine Resistant Status Epilepticus And Brain Injury In DFP Model Of OP Intoxication/ R. Kuruba, X. Wu, D. Reddy 1.030 Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces Hippocampal Structural Pathology And Spontaneous Recurrent Seizures/ C. Gavrilovici, Y. Jiang, M. Chansard, R. Liu, K. Parsons, S. Park, M. Scantlebury, G. Teskey, J. M. Rho, M. Nguyen 1.031 Midazolam Refractory Seizures And Brain Injury Following Acute Organophosphate Intoxication/X. Wu, R. Kuruba, D. Reddy 1.032 Diminished Antiepileptogenic Effects Of Neurosteroids In Mice Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/B. Clossen, D. Reddy 1.033 Perimenstrual Upregulation Of Delta-Subunit Extrasynaptic GABA-A Receptors Mediating Tonic Inhibition And Neurosteroid Sensitivity/ C. Carver, X. Wu, O. Gangisetty, D. Reddy 1.034 Alcohol And SUDEP In Genetically Epilepsy Prone Rats (GEPR-9s)/C. Faingold, M. Randall, S. P. Kommajosyula 1.035 Hyperthermic Seizures And Seizure Susceptibility: A Novel Approach Using Zebrafish/J. Ullmann, G. Leanage, D. Reutens 1.036 Alterations Of Neurometabolites And Fear Responses After NMDA-Induced Spasms In Infant Rats/M. Lee, M. Yum, D. Woo, T. Ko 1.037 Progesterone Increases AMPA Receptor Cell Surface Expression Via Mechanisms Involving Progesterone Receptors/J. Kapur, S. Joshi, C. Passmore, J. Williamson 1.038 Antiseizure Effects Of TrkB Kinase Inhibition/R. Kotloski, G. Liu, J. McNamara Saturday December 6, 2014 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.052 Early-Life Clonazepam Exposure Leads To Persistent Alteration Of Seizure Susceptibility/ H. Kubova, G. Tsenov, J. Virta, P. Mares 1.053 Blood-Brain Barrier Integrity In Epileptic WAG/Rij rats with rotational movements/C. Gurses, D. Sahin, C. Ugur Yilmaz, N. Orhan, B. Ahishali, M. Kucuk, N. Arican, N. Ates, M. Kaya 1.054 Treatment Of Convulsive Status Epilepticus In An Animal Model Of Glucose Transporter Type 1 Deficiency (G1D) Syndrome/C. Trent, L. Good, D. Kelly, S. Kayani, J. Pascual, K. Rajasekaran 1.055 Minocycline Reverses ProEpileptogenic Effect Of Viral-Like Brain Inflammation In The Mature And Immature Rat Brain/N. Dupuis, A. Mazarati, B. Desnous, S. Auvin 1.056 Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat Pups But Does Not Affect The Adult Rats/B. Desnous, A. Mazarati, N. Dupuis, S. Auvin Human Studies 1.057 Improving Seizure Outcomes In Patients With Neocortical Epilepsy By Resecting Brain Regions Generating Ictal Phase Locked High-Frequency Oscillations (HFOs)/S. A. Weiss, R. Connors, G. Banks, E. Smith, A. Lemesiou, B. Zhao, C. Filippi, R. Emerson, L. Bateman, M. Nowell, R. Rudoinov, B. Diehl, M. Walker, C. Schevon 1.058 The Gamma Band Effect For Episodic Memory Encoding Is Absent In Epileptogenic Hippocampi/B. Lega, A. Dionisio, W. Bingaman, I. Najm, J. Gonzalez-Martinez 1.059 Structure And Risk Factors of Epileptic Seizures At Patients With Severe Head Injury/I. Trifonov, V. Krylov, A. Talypov 1.060 Alternation Of Cross Frequency Coupling In The Pre-Ictal iEEG Of Epileptic Patients/K. Edakawa, H. Kishima, T. Yanagisawa, S. Oshino, Y. Inoue, H. Khoo, T. Maruo, M. Kobayashi, M. Hirata, T. Yoshimine 1.061 Brain State Dynamics And The Role Of The Epileptogenic Zone/ S. Burns, S. Santaniello, W. Anderson, S. V. Sarma 1.062 Prospective Evaluation Of The Effects Of Clinical And Subclinical Epileptoform Discharges On Driving Safety/Y. Si, E. Gudbranson, W. Chen, M. Midura, R. Wu, B. Geng, P. Vitkovskiy, A. Sivaraju, R. Sainju, A. Fernandez, A. Alareddy, I. Quraishi, R. Duckrow, L. Hirsch, H. Blumenfeld 1.063 The Frontal And Insular Network: A Corticocortical Evoked Potentials Study/R. Enatsu, J. Gonzalez-Martinez, J. Bulacio, Y. Kubota, J. Mosher, R. Burgess, I. Najm, D. Nair 1.064 Seizure Propagation Across Micro Domains In Epileptic Patients Undergoing Intracranial Monitoring/ I. Basu, W. S. Anderson 1.065 Why Do Placebos Decrease Seizures In Clinical Trials?/ D. Goldenholz, R. Moss, W. Theodore Devices, Technologies, Stem Cells 1.066 Commercial Development Of Advanced Wireless Technologies In Implantable Neurostimulators For The Treatment Of Epilepsy/E. Chow, C. Warren, A. Shen, K. Venkatraman, A. Jones, A. Adkins, O. Abdel-Latief, D. Thompson, B. Byerman 1.067 Cardiac-Based Seizure Detection: Long-Term Patient FollowUp From The AspireSR E-36 Trial/ P. Boon, K. van Rijckevorsel, R. El Tahry, C. Elger, N. Mullatti, A. Schulze-Bonhage, K. Vonck, G. Wagner, W. Van Grunderbeek, R. McGuire 1.068 VNS Therapy Automatic Magnet Mode Outcomes Study In Epilepsy Patients Exhibiting Ictal Tachycardia/R. Fisher, J. Harvey, P. Afra, B. Najimipour 1.069 Immunomodulation For LongLasting Anticonvulsant Effects After Neural Xenografting In Rats – Neonatal Induction Of Tolerance Versus Pharmacological Immunosuppression/A. Handreck, B. Backofen-Wehrhahn, E. M. Mall, B. Petersen, H. Niemann, M. Gernert 1.070 Chronic Delivery Of Vigabatrin Into The Subthalamic Nucleus Is Anticonvulsant In A Rat Seizure Model/L. Gey, M. Gernert, W. Loscher 1.071 Development Of A Technique For Assessing The Effects Of Selective Sleep Restriction In Mice/ S. Sunderam, F. Yaghouby, C. Schildt, K. D. Donohue, B. F. O’Hara 1.072 Multichannel Portable fNIRSEEG System For Long-Term Monitoring Of Seizures/A. Kassab, P. Vannasing, J. Tremblay, D. Safi, F. Lesage, M. Sawan, D. Nguyen 1.073 Sensing-Enabled Hippocampal Deep Brain Stimulation In Idiopathic Nonhuman Primate Epilepsy/ W. J. Lipski, V. DeStefino, S. Stanslaski, A. Antony, J. Cameron, M. Richardson 1.074 Development Of A Depth Electrode Placement Planning System For Direct Cortical Stimulation Therapy/L. Cendejas, R. Dawe, M. A. Rossi 1.075 Performance Of Limb-Based Accelerometers In The Detection Of Hypermotor Seizures/G. Carlson, S. Sabesan, K. Rose, I. Chekhovtsov SATURDAY 1.039 GABA Agonists Restore Inhibitory GABA Neurotransmission In Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/ S. Stamboulian-Platel, A. Legendre, T. Chabrol, P. Polack, J. Platel, F. Pernot, V. Duveau, C. Roucard, S. Charpier, M. Baudry, A. Depaulis 1.040 Higher Seizure Susceptibility In Rats With Cortical Dysplasia: A Feedback Systems Perspective/ B. Krishnan, A. Nemes, Z. Ying, Z. I. Wang, I. Najm, A. Alexopoulos 1.041 Early Structural Changes In The Methionine Sulfoximine Model of Mesial Temporal Lobe Epilepsy/ H. Wang, Y. Huang, R. Dhaher, D. Coman, H. Zaveri, F. Hyder, T. Eid 1.042 Changes In Neurotransmitter Gene Expression Correlated With EEG Stages During Lithium/PilocarpineInduced Experimental Status Epilepticus/D. M. Treiman, D. E. Schooley, S. T. Marsh, L. J. Treiman 1.043 Modeling PIK3CA-Related Malformations Of Cortical Development And Epilepsy In Mice/ A. Roy, J. Ni, J. Skibo, S. Rankin, W. Dobyns, S. Baker, J. Zhao, F. Kalume, K. J. Millen 1.044 Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures/A. Gummadavelli, J. Motelow, N. Smith, Q. Zhan, N. Schiff, H. Blumenfeld 1.045 Electrical Stimulation Of The Cerebral Cortex With A Disk Electrode: A Modeling Study/P. Kudela, W. Anderson 1.046 Examining The Roles Of SCN3A And SCN9A In Epilepsy/T. Lamar, J. Wong, L. Papale, A. Escayg 1.047 Neuroanatomical And Neurodevelopmental White Matter Differences Between Rat Strains With Differing Vulnerability To Epileptogenesis And Behavioural Comorbidities/P. Sharma, M. E. Wlodek, L. A. Johnston, K. L. Powell, K. Gilby, T. J. O’Brien 1.048 PTEN Deletion From AdultGenerated Dentate Granule Cells Disrupts Granule Cell Mossy Fiber Axon Structure/C. L. LaSarge, V. R. Santos, S. C. Danzer 1.049 Effects Of Seizures On Breathing And Survival Are Dependent On Vigilance State/K. I. Claycomb, M. A. Hajek, D. A. Rappoport, G. Buchanan 1.050 Use Of An Automated-Feeding System For The Testing of Potential Anticonvulsant Compounds in Chronic Epileptic Rats/K. Thomson, C. H. Rueda, M. Barker-Haliski, H. White 1.051 Analysis Of Postictal Period In Developing Rats/Z. Ben Salem, H. Hanáková, J. Otáhal, P. Mares Poster Session 1 37 Saturday December 6, 2014 1.076 Prospective Driving Performance Evaluation Using A Portable Handheld Device In The Epilepsy Monitoring Unit/N. Li, J. Thomson, W. Chen, D. Kluger, C. Cunningham, R. Gebre, Y. Si, J. Blumenfeld, E. Chen, M. Johnson, P. Vitkovskiy, Y. Baykara, E. Gudbranson, A. Morawo, H. Blumenfeld 1.077 Scoring Sleep In Interictal Electrocorticographic Recordings/ F. Yaghouby, P. Modur, S. Sunderam 1.078 Medial Septal Theta Stimulation Increases Seizure Threshold And Improves Cognition In A Rat Model Of Epilepsy/A. Izadi, S. Seidl, D. Lee, A. Ekstrom, K. Shahlaie, G. Gurkoff Behavior/Neuropsychology/ Language Adult 1.079 Direct Physiologic Evidence For A Heteromodal Convergence Region For Proper Naming In The Left Anterior Temporal Lobe/T. J. Abel, A. E. Rhone, K. V. Nourski, H. Kawasaki, H. Oya, T. Ando, M. Howard, D. Tranel 1.080 Executive Functioning Changes In A Clinical Sample Of Older Adult Patients With Temporal Lobe Epilepsy/C. Sylvester, G. Risse, R. Doss 1.081 Factors Analysis Of Korean Version Of Liverpool Adverse Event Profile (K-LAEP): Factors Explaining The Scores Of K-LAEP And Their Association With Drug Load And Drug Number Of Antiepileptic Drugs/ O. Kwon, S. Kim, S. Park 1.082 The Influence Of Gender On Personality Assessment Inventory Scores Used To Support The Diagnosis Of Psychogenic Nonepileptic Seizures/M. Hoerth, K. Corallo, D. Locke, R. Lanyon 1.083 Stress Coping Strategies In Patients With Epilepsy And How They Relate To Mood/K. Isaacs Lebeau, L. Myers, M. Lancman, M. E. Lancman 1.084 Barriers And Facilitators To Self-Management Among Persons With Epilepsy And Mental Illness/ M. Sajatovic, R. K. Ramsey, E. Welter, K. Colón-Zimmermann, A. T. Perzynski 1.085 Effects Of Adjunctive Lacosamide On Mood And Quality Of Life In Adult Patients With Localization Related Epilepsy/ L. Nakhutina, S. D. Kunnakkat, M. Coleman, C. Lushbough, V. Arnedo, N. Soni, A. C. Grant 1.086 A Randomized Controlled Trial Of HOBSCOTCH: A Self-Management Intervention For Cognitive Impairment In Epilepsy/T. A. Caller, K. L. Secore, R. J. Ferguson, R. M. Roth, F. P. Alexandre, J. Kleen, J. Harrington, P. L. Henegan, B. C. Jobst 38 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.087 Effect Of Seizures On Sleep Quality In Patients With Chronic Epilepsy/K. Hwang, S. Cho, J. Kim, E. Joo, S. Hong 1.088 Depression, Anxiety And Quality Of Life In Hispanic SpanishSpeaking Patients With Psychogenic Non-Epileptic Seizures (PNES) Compared To Those With Epilepsy/ L. Myers, R. Zeng 1.089 Correlation Of Pre-Diagnosis Illness Perception And Clinical Outcome In Patients With Psychogenic Non-Epileptic Seizures/ S. Majmudar, D. K. Chen Pediatrics 1.090 Development Of The PedsQLEpilepsy Module/A. Modi, K. Junger, A. Arnett, K. Mann, S. Guilfoyle, D. Morita, J. Varni 1.091 Behavioral Medicine Services Integrated Into Pediatric Epilepsy Care/S. Guilfoyle, K. Junger, A. Arnett, A. Modi 1.092 Children With Early Onset Epilepsy Display Thalamic Abnormalities At Diagnosis/M. Yoong, M. Hunter, J. Shetty, M. McPhillips, A. McLellan, R. F. Chin 1.093 Impact Of Epilepsy Surgery On Behavior In Children/L. Ferguson, R. M. Busch, K. Kim, J. Haut, P. Klaas, W. Bingaman, D. Lachhwani, T. Lineweaver 1.094 Treatment Of Psychogenic Non-Epileptic Seizures In The Pediatric Population/J. Doss, E. Adams, M. Palmquist 1.095 Memory Functioning In LongTerm Outcome After Epilepsy Surgery In Childhood/M. Smith, K. Puka 1.096 Epilepsy Education: Parents And Adolescents Learn Differently/ L. Carbone, R. Derry, M. Plegue, S. Rau, R. Shellhaas 1.097 Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of Cognition?/S. Eom, R. Caplan, A. Berg 1.098 Continuous spikes And Waves During Sleep (CSWS). Changes In Seizure Frequency, Epileptiform Activity And Cognition After HighDose Clobazam Treatment/J. Klehm, I. Sánchez Fernández, C. Vega, J. Peters, S. Thome-Souza, C. Harini, M. Takeoka, G. Wilkening, K. Chapman, T. Loddenkemper 1.099 Intellectual And Memory Outcome Following Pediatric Epilepsy Surgery Using Reliable Change Methods/J. Haut, L. Ferguson, T. Lineweaver, P. Klaas, D. Lachhwani, W. Bingaman, R. M. Busch 1.100 Predictors Of Quality Of Life In Childhood Epilepsy: The Child’s Perspective/N. Fayed, A. M. Davis, D. L. Streiner, P. L. Rosenbaum, L. Lach, C. E. Cunningham, M. Boyle, G. Ronen 1.101 Support For Use Of The Meyers Neuropsychological System With Pediatric Patients With Epilepsy/ Y. C. Leon, S. Benbadis, D. Lisicki, C. Ramirez, J. Ferreira Genetics Human Studies 1.102 WITHDRAWN 1.103 The Expanding Role For Chromatin Remodeling In Epilepsy: Gene Discovery To Pathogenic Mechanisms/G. L. Carvill, J. McMahon, H. Wang, J. Stamatoyannopoulos, I. Scheffer, H. Mefford 1.104 Mutations In WWOX Gene In Early Infantile Epileptic Encephalopathy: Expansion Of The Phenotype And Genotype Disease Spectrum/ B. Melaiki, F. ALMutairi, A. ALHashem 1.105 Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/ J. Tohyama, M. Nakashima, Z. Rener Primec, C. Gaik-Siew, S. Nabatame, M. Kato, N. Matsumoto, H. Saitsu 1.106 Cornelia de Lange Syndrome:Clinical Features & Course of The Largest SMC1A Deletion/ L. R. Kaplan, N. Zadeh, A. Spitz, G. Fernandez 1.107 De Novo Mutation In Sodium Channel Gene SCN8A Causes Delay In Neuromuscular Junction Development In Early Onset Epileptic Encephalopathy /N. Barisic 1.108 Familial Focal Epilepsy With Paroxysmal Arousals Due To A Novel CHRNA2 Loss Of Function Mutation/ V. Conti, P. Aracri, L. Chiti, S. Brusco, F. Mari, C. Marini, A. Romigi, A. Becchetti, R. Guerrini 1.109 WITHDRAWN 1.110 Presenilin 1 Mutation In A Sporadic, Early-Onset Dementia With Myoclonus And Epilepsy/M. Kinoshita, H. Nakano, K. Park, H. Yamashita, T. Kondo, R. Takahashi, A. Ikeda 1.111 A Novel LGI1 Variant In Autosomal Dominant Lateral Temporal Lobe Epilepsy/W. O. Pickrell, C. Hope, J. G. Mullins, P. E. Smith, M. I. Rees, S. Chung 1.112 Antecollis And LevodopaResponsive Parkinsonism Are Late Features Of Dravet Syndrome/ A. Fasano, F. Borlot, A. E. Lang, D. Andrade 1.113 DEPDC5 Mutations In Familial Temporal Lobe Epilepsies/C. Nobile, E. Serioli, E. Dazzo, P. Striano, S. Striano, R. Michelucci 1.114 De Novo Mutations In Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies/ S. Weckhuysen 1.115 Copy Number Variations In Early Onset Absence Epilepsies/ H. Muhle, M. Pendziwiat, P. Striano, R. S. Møller, C. Marini, A. Suls, P. De Jonghe, B. Neubauer, M. von Deimling, J. Jähn, S. von Spiczak, Y. Weber, G. Kurlemann, T. Polster, I. Vater, I. Scheffer, T. Sander, R. Siebert, U. Stephani, I. Helbig Saturday December 6, 2014 Neuropathology of Epilepsy Human Studies 1.122 Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of 5HT1A and 5HT2A Receptos In Human Epileptogenesis/N. Fonseca, H. P. Joaquim, V. D. de Paula, S. Vincentiis, L. L. Talib, W. F. Gattaz, K. Valente Neurophysiology Video EEG Epilepsy-Monitoring 1.123 Electroencephalographic Patterns During Sleep In Children With Chromosome 15q11.2-13.1 Duplications (Dup15q)/D. Arkilo, O. Devinsky, R. Thibert 1.124 A Reduction Of Sleep Spindles Precedes Seizures In Focal Epilepsy By Minutes/J. Remi, F. Tezer-Filik, S. Noachtar Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.125 How Long Is A Single, Scalp Video EEG Monitoring Evaluation Valid In The Pre-Surgical Evaluation For Focal Epilepsy?/D. M. Bonno, A. Fessler 1.126 Representation Of Memory Strength And Subjective Confidence By Individual Neurons In The Human Medial Temporal Lobe/U. Rutishauser, S. Ye, M. Koroma, J. Chung, A. Mamelak 1.127 Synergy Between Epileptogenic Cortex And Thalamus Projecting Generalized Paroxysmal Fast Activity (GPFA) In Children With Intractable Localization-Related Epilepsy/S. Baba, M. Mohammadi, T. Okanishi, K. Okanari, S. Sakuma, A. Ochi, E. Widjaja, C. Go, O. C. Snead III, H. Otsubo 1.128 Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies: Possible Prediction Of Patients At Risk For SUDEP/L. Baysal Kirac, B. Baykan, C. Gurses, N. Bebek, A. Gokyigit 1.129 Scalp High Frequency Oscillations Help To Identify Patients With Poor Postsurgical Seizure Outcome/C. Klus, M. Duempelmann, M. Mader, A. Schulze-Bonhage, J. Jacobs 1.130 A Study On Clinical Usefulness Of 3D EEG Source Localization Analysis/C. Park, D. Kim, B. Abibullaev, H. Kwon, J. Seo, E. Joo, D. Seo, Y. Lee, S. Hong 1.131 The Diagnostic Yield Of VideoEEG in the inpatient versus Ambulatory Settings In Adults With Episodes Of Unclear Nature/E. Fertig, E. Feoli, J. Sabri, C. Lambrakis, O. Laban-Grant, S. Mesad, J. Politsky, M. Lancman 1.132 Electroencephalogram Characteristics In Pediatric Patients With Anti-NMDA Receptor Encephalitis/E. Cruz, S. Manganaro, L. Bello, M. Andriola, L. Manganas 1.133 Interictal And Ictal Video EEG Findings In Patients With Epilepsy And Autism Spectrum Disorder/ J. Avallone, J. Misajon, S. Iyer, O. Devinsky 1.134 Pathognomonic Electroencephalogram Findings In A Case Of Isodicentric Chromosome 15/V. S. Vajjala, J. B. Wollack, S. A. Hosain ICU EEG 1.135 Clinical Correlates And Outcome Of Lateralized Periodic Discharges In Patients Without Acute Brain Injury: A Case-Control Study/ R. Sainju, L. Manganas, E. Gilmore, O. Petroff, N. Rampal, L. Hirsch, N. Gaspard 1.136 Interrater Agreement In The Interpretation Of Neonatal Electroencephalography/C. J. Wusthoff, J. Sullivan, H. C. Glass, R. Shellhaas, N. Abend, T. Chang, T. Tsuchida 1.137 Development Of Epilepsy In Neonates With Hypoxic Ischemic Encephalopathy (HIE) Receiving Whole Body Therapeutic Hypothermia(TH) Compared To A Non-TH Group/ K. Khusiwilai, M. Cordeiro, T. Czech, K. Harris, A. Massaro, T. Chang, T. Tsuchida 1.138 Seizure Detection In Adults Using Feature Baseline Correction On A Neonatal EEG Trained Classifier/ G. Bogaarts, E. Gommer, D. Hilkman, V. van Kranen-Mastenbroek 1.139 Comparison Of Seizures Captured With Extended Versus Reduced EEG Electrode Arrays In Neonates Undergoing Therapeutic Hypothermia/G. Diaz-Medina, Y. Lai, A. L. Thompson, W. Laura, A. Anderson 1.140 Early Identification Of Patients With PRES Using Continuous EEG Reduces The Comorbidity Of SAH And Impacts its Treatment Approach/ J. Politsky, I. Ugorec, D. Baker, P. Rodgers, E. Fertig 1.141 Prognostic Value Of Continuous EEG During And After Therapeutic Hypothermia In Patients With Cardiac Arrest/B. Legros, M. Lamartine Sabido Monteiro, C. Depondt, I. Lamanna, N. Ligot, N. Mavroudakis, G. Naeije, J. Vincent, F. Taccone 1.142 Analysis Of Pediatric Electroencephalogram Characteristics During Therapeutic Hypothermia In Post Cardiac Arrest Patients/L. Bello, E. Cruz, S. Manganaro, M. Andriola SATURDAY 1.116 Epilepsy In STXBP1 Encephalopathy: Clinical Delineation Of 32 Japanese Patients Including 14 Novel Patients/M. Kato, H. Saitsu, H. Osaka, K. Nakamura, T. Watanabe, H. Terashima, T. Ikeda, T. Kumada, H. Matsumoto, T. Yamaguchi, J. Azuma, Y. Tominaga, M. Shinpoo, H. Arai, S. Hirai, S. Takeshita, E. Nakagawa, H. Uchio, Y. Nonoda, T. Iwasaki, T. Chiyonobu, A. Sudo, 1.117 Familial Focal Seizures And Anterior Pachyghria In A Large Family With A Novel DCX Mutation Combined With A TUBB1 Mutation That Might Be A Modifier For The Phenotype Of Cognitive Deficit/Y. Kim, M. Kim, S. Choi, Y. Woo 1.118 Distinctive Electro-Clinical Features Of Epilepsy In Severe Early Onset SCN8A Encephalopathy/ E. Gardella, J. Larsen, M. Wolff, G. Schmiedel, M. Kirkpatrick, N. Barisic, C. Depienne, M. Troncoso, B. Jepsen, M. Nikanorova, L. Troncoso, A. Bevot, H. Hjalgrim, S. Beniczky, R. S. Møller 1.119 Targeted Massively Parallel Sequencing Of Infantile Onset Epileptic Encephalopathy/B. Lim, H. Kim, H. Hwang, J. Chae, K. Kim, Y. Hwang 1.120 Familial Epilepsy Due To A Point Mutation In LIS1/D. E. Crompton, M. S. Hildebrand, R. J. Leventer, Y. Perchyonok, J. A. Damiano, C. A. Wise, I. E. Scheffer, G. D. Jackson, S. Berkovic 1.121 The Subcortical Band Heterotopia/Lissencephaly Spectrum And Epilepsy: Phenotypic, Molecular, Functional, And Structural Analysis Of Novel Causative DCX And LIS1 Mutations/D. Amrom, G. Brouhard, S. Bechstedt, K. Toropova, F. Andermann, F. Dubeau, D. Melanson, D. Tampieri, S. Reck-Peterson, E. Andermann Poster Session 1 MEG 1.143 Pre-Ictal And Ictal Pathological High Frequency Oscillations (HFOs) In Focal Epilepsy: Analysis Of MEG Recording/J. Velmurugan, S. Sinha, N. Mariyappa, P. Satishchandra 1.144 Magnetoencephalographic Characteristics Of Cortical Dysplasia In Children/N. Agarwal, U. Thome Costa, B. Krishnan, R. Burgess, R. Prayson, A. Alexopoulos, A. Gupta 1.145 Volume And Location Of Focal Cortical Dysplasia Type Ii Correlating With Magnetoencephalography; Convexity Vs. Bottom Of Sulcus/ M. Nakajima, Y. Sato, S. Wong, K. Okanari, S. Sakuma, C. Boelman, S. Baba, A. Ochi, S. Doesburg, H. Otsubo 1.146 Automatic Detection Of Focal Slow Waves In Patients After Epilepsy Surgery Is Related To Recurring Seizures/S. Rampp, M. Schönherr, K. Roessler, M. Buchfelder, H. Hamer, H. Stefan 1.147 Comparative Analysis Of Spike Source Between High-Density EEG And MEG/R. Honda, Y. Kaneko, Y. Saito, E. Nakagawa, K. Sugai, M. Sasaki, T. Kaido, A. Takahashi, T. Otsuki 39 Saturday December 6, 2014 1.148 Coherence And Source Localisation In Reflex-Eating Epilepsy: A MEG Based Analysis/S. Sinha, V. Jayabal, M. Narayanan, S. Parthasarathy 1.149 Application Of Multiple Equivalent Current Dipole Modeling And Minimum Norm Modeling For Analyzing Magnetoencephalography Activities Of An Unusual Form Of Benign Childhood Epilepsy With Occipito-Frontal Sharp Waves/ H. Murakami, J. Mosher, A. Naduvil Valappil, E. Wyllie, A. Alexopoulos, R. Burgess 1.150 MEG Source Imaging Of Interictal Spikes Using Samepi: Comparison With Area Of Surgical Resection And Seizure Outcomes/ J. Scott, S. Robinson, K. Zaghloul, J. Heiss, S. Sato, W. Theodore, S. Inati 1.151 Epileptic Networks In Genetic Generalized Epilepsy: A MEG Study/ A. Zillgitt, B. Assaad, J. Moran, K. Mason, D. Burdette, J. Constantinou, G. L. Barkley, S. Bowyer 1.152 Comparison Of Ictal And Interictal Source Localization Using MEG And dEEG In Pediatric Drug Resistant Epilepsy/H. Fujiwara, H. Greiner, J. Tenney, D. Rose Brain Stimulation 1.153 Cortical-Cortical Evoked Potentials (CCEPs) Distinguish Early Versus Late Seizure Spread In Stereoelectroencephalography/ A. Dionisio, B. Lega, J. Gonzalez-Martinez, P. Flanagan, D. Nair 1.154 Physiological Consequences Of Abnormal Connectivity In A Developmental Epilepsy/M. Shafi, M. Vernet, D. Klooster, M. E. Barnard, K. Romatoski, M. Westover, J. Christodoulou, J. D. Gabrieli, S. Whitfield-Gabrieli, A. Pascual-Leone, B. S. Chang 1.155 Chronic Cortical Optogenetic Stimulation For The Prevention Of Posttraumatic Epileptogenesis In Mice/X. Ping, W. Xiong, G. Chavez, J. Gao, X. Jin 1.156 (DYS) Functional Connectivity Of The Seizure Onset Zone: Low Frequency Stimulation And CorticoCortical Evoked Responses Study/ R. Alkawadri, H. Zaveri, R. Duckrow, D. Spencer, J. Gerrard, L. Hirsch 1.157 Exploring Seizure Networks Using Cortico-Cortical Evoked Potentials: Internally Hyperconnected, Externally Hypoconnected?/L. Entz, P. Megevand, D. Groppe, E. Toth, D. Fabo, Z. Fallil, C. Harden, S. Hwang, S. Bickel, C. Keller, A. Mehta 1.158 Paired-Pulse Transcranial Magnetic Stimulation (ppTMS) In Measures Of Cortical Inhibition During Propofol Infusion/C. F. Paredes Saenz, R. Gersner, J. Goldie, A. Rotenberg 40 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.159 State-Dependent Modulation Of Cortical Activity By Intracranial Stimulation/S. Alagapan, S. Schmidt, D. Bernardo, F. Frohlich, H. Shin 1.160 Sleep, Seizures And CorticoCortical Evoked Potentials: A Dynamical System Perspective/ J. Slater, G. Kalamangalam Animal Studies 1.161 Short-Term Synaptic Reorganization In The Rat Neocortex After Perinatal Hypoxia-Ischemia/ J. Bastar, J. Spampanato, F. Dudek 1.162 Supramammillary Hypothalamic Neurons That Co-Release GABA And Glutamate Promote Wakefulness And Hippocampal Theta Rhythm/ N. P. Pedersen, L. Ferrrari, J. L. Wang, E. Arrigoni, P. M. Fuller, C. B. Saper 1.163 Electroconvulsive Seizure Induces The Changes Of NMDAR, AMPAR, And STEP61 Protein In Rat Hippocampus/S. Jang 1.164 Peri-Ictal Impairment Of Brainstem 5-HT Neurons: Insight Into Depressed Arousal, Reduced Ventilation And Sudden Unexpected Death In Epilepsy (SUDEP)/Q. Zhan, G. Buchanan, J. Motelow, F. Serout, W. Chen, A. Gummadavelli, J. Andrews, P. Vitkovskiy, M. Furman, W. Li, G. Richerson, H. Blumenfeld 1.165 Seizure-Induced Kcnq Upregulation Alters The Functional Properties Of Hippocampal M Currents In The Pilocarpine Model Of Temporal Lobe Epilepsy/C. T. Taylor, D. B. Jaffe, M. S. Shapiro 1.166 Selective, Unilateral Ablation Of Hippocampal Interneurons Causes Acute Seizures/J. Spampanato, F. E. Dudek Computational Analysis & Modeling Of EEG 1.167 Power-Weighted Narrowband Changes During Epileptic Bursts In Invasive EEG Identify The Epileptogenic Zone/M. Heers, X. Wang, M. Duempelmann, J. Jacobs, A. Schulze-Bonhage, T. Ball 1.168 An Interictal EEG Spectral Metric For Temporal Lobe Epilepsy Lateralization/L. Cara, G. Kalamangalam 1.169 Correlation Of EEG Spectra With Quantitative Measures Of Intelligence And Attention In Children With Idiopathic Epilepsy/D. Hsu, K. Rayer, M. Hsu, P. Ferrazzano, K. Dabbs, D. Jackson, C. Stafstrom, G. Worrell, J. Jones, B. Hermann 1.170 Lateralizing Shift Of Current Source Of Generalized Spikes In Childhood Absence Epilepsy: Relationship Between The Shift And Response To Valproic Acid/O. Kwon, T. Yang, S. Jung, J. Yeom 1.171 High Frequency Oscillations And Spikes: Separating Oscillations From Broad Band Activities/M. Amiri, J. Gotman 1.172 Spatial Relationship Between The Fast And Slow Components Of Ictal Activities And Interictal Epileptiform Discharges In Children With Epileptic Spasms/T. Akiyama, M. Akiyama, K. Kobayashi, T. Okanishi, C. Boelman, D. A. Nita, A. Ochi, C. Go, C. Snead, J. Rutka, J. Drake, S. Chuang, H. Otsubo 1.173 Dynamic Measures Applied To A Cohort Of Children With Childhood Absence Seizures/M. J. Schwabe, K. C. Hecox 1.174 Epileptogenic Networks Revealed By Varying Patterns Of Propagation Of High Frequency Ictal Activity (70-175 Hz)/A. Korzeniewska, P. Franaszczuk, M. Cervenka, C. Jouny, G. Bergey, N. Crone 1.175 Pathologic Generation Of High Frequency Oscillations In The Seizure Onset Zone During A Motor Task/ P. A. Peters, J. Cimbalnik, B. Brinkmann, V. Svehlik, V. Vasoli, M. T. Kucewicz, R. Marsh, F. Meyer, M. Stead, G. Worrell, J. Matsumoto 1.176 WITHDRAWN 1.177 Modulation Of Neuronal Activity And Functional Connectivity In Transition To Ictus/T. Matsuo, R. Staba, A. Bragin, I. Fried 1.178 Scale-Free Properties Of Intracerebral EEG Improve Seizure Prediction In Mesial Temporal Lobe Epilepsy/K. Gadhoumi, J. Gotman, J. Lina 1.179 Coherence Analysis Of Diffuse Bisynchronous Ictal iEEG Discharges For Seizure Localization/P. Chen, M. Korostenskaja, E. Castillo, J. Seo, J. Baumgartner, K. Lee 1.180 Noninvasive Dense Array Electroencephalography For Localizing The Seizure Onset Zone/C. Kuo, D. Tucker, P. Luu, K. Jenson, M. D. Holmes Clinical Epilepsy Clinical Diagnosis 1.181 A Case Of Takotsubo Cardiomyopathy Due To Status Epilepticus – An Underreported And Lethal Sequela/N. Mirchandani, I. Khan, G. Pushchinska 1.182 Development And Validation Of A Seizure Prediction Model In Critically Ill Children/A. Yang, D. Arndt, R. Berg, J. Carpenter, K. Chapman, D. Dlugos, W. Gallentine, C. Giza, J. Goldstein, C. Hahn, J. Lerner, T. Loddenkemper, J. Matsumoto, K. Nash, E. Payne, I. Sánchez Fernández, J. Shults, A. Topjian, K. Williams, C. Wusthoff, N. Abend 1.183 Obesity In Adult Patients With Psychogenic Non-Epileptic Seizures/ A. Abubakr, I. Wambacq 1.184 Ambulatory EEG In Epilepsy Diagnosis For Adults Aged 65 And Older/K. Upchurch, D. McCarthy, E. Baker, J. Pathmanathan Saturday December 6, 2014 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.197 A Retrospective Study Of Continuous EEG Monitoring In A Single Tertiary Care Pediatric Site/ L. St. Louis, A. Sansevere, I. Sánchez Fernández, E. Nagarajan, J. Klehm, P. Pearl, R. Tasker, T. Loddenkemper 1.198 Comparison Of Number Of Patient-Reported Allergies In Adult Patients With Epileptic And NonEpileptic Seizures/A. Fu, D. Denny, S. Cerven, N. Moorley, S. S. Chung 1.199 Prevalence Of Headache In Patients With Epileptic Versus NonEpileptic Seizures/S. Cerven, A. Fu, N. Moorley, D. denny, S. S. Chung 1.200 Comparing Duration To Diagnosis Made Via VideoElectroencephalography For NonEpileptic Seizures And Epileptic Seizures/D. denny, A. Fu, S. Cerven, N. Moorley, S. S. Chung 1.201 Comparison Of Number Of Events Captured In Epilepsy Monitoring Unit Between Patients With Epileptic Versus Non-Epileptic Seizures/N. Moorley, A. Fu, D. Denny, S. Cerven, S. S. Chung 1.202 Cefepime Induced Encephalopathy In A Tertiary Medical Center In Korea/J. Jeon, H. Moon, G. Motamedi, Y. Cho Clinical Treatments 1.203 What Do Epileptologists Recommend About Discontinuing AEDs For A Second Time In SeizureFree Children When The First Attempt Failed?/A. McCarthy, C. Camfield, P. Camfield, I. Valencia 1.204 Clinical Predictors For Delirium Tremens In Patients With AlcoholWithdrawal Seizures/D. Kim 1.205 Repetitive Transcranial Magnetic Stimulation For Refractory Focal Status Epilepticus/ S. VanHaerents, S. Herman, T. Pang, A. Pascual-Leone, M. Shafi 1.206 Why Do Patients Get Admitted For ACTH For Infantile Spasms?A Survey Of ACTH Delivery Across United States/C. Joshi, A. Berg, E. Wirrell 1.207 Ictal Religious Speech In Temporal Lobe Epilepsy/I. Yildirim Capraz, M. Mercan, E. Bilir 1.208 Maximizing The Efficacy Of The Ketogenic Diet Treatment For SuperRefractory Status Epilepticus/ Y. C. Liu, H. Lowe, S. C. Shen, M. Zak, V. Chan, J. Kobayashi, E. J. Donner 1.209 Interrater Reliability In Interpretation Of Electrocorticographic Seizure Detections Of The Responsive Neurostimulator/M. Quigg, B. Jobst, N. Fountain, V. S. Wong, F. Sun, E. Mirro, S. Brown, D. Spencer 1.210 Hereditary Hyperekplexia And Generalized Epilepsy In A Child Responsive To Levetiracetam/ A. Lowden, J. Munoz, R. Said 1.211 Comparison Of Efficacy Between A Modified Atkins Diet And A Classic Ketogenic Diet In Childhood Intractable Epilepsy/J. Kim, J. Yoon, E. Lee, J. Lee, H. Kim, H. Kang 1.212 WITHDRAWN 1.213 Clinical Characteristics And Treatment Pattern In Cluster Seizures: A Preliminary Chart Review Analysis/B. Vazquez, E. Wu, D. Macaulay, M. Sidovar, H. Roberts, D. Squillacote, A. L. Rabinowicz, A. Guo 1.214 IV Lacosamide As Adjunctive Therapy In Treatment Of Refractory Status Epilepticus/S. Kohli, P. Li, B. Teter, K. Kavak, A. Weinstock 1.215 Effectiveness Of Routine Management Of Status Epilepticus In Dravet Syndrome/S. N. Misra, S. Agadi 1.216 Responsive Neurostimulation in Patients with Mesial Temporal Lobe Epilepsy and Prior Temporal Lobectomy/T. Crowder Skarpaas, R. Duckrow, A. Herekar, C. Heck, C. Skidmore, D. Spencer, G. Bergey, D. Shields, D. Nair, D. King-Stephens, M. Morrell 1.217 The Effects Of Experimental Febrile Seizures On The Expression Of Forelimb Motor Maps In A Rodent Model Of Mesial Temporal Lobe Epilepsy/K. B. Rivard, K. Scullion, G. Teskey, M. Scantlebury SATURDAY 1.185 Coprolalia As A Manifestation Of Epileptic Seizures/A. Massot-Tarrús, C. Dove, R. McLachlan, J. G. Burneo, S. Mirsattari 1.186 Comparison Of Patients With Coexisting Epileptic Seizures And Psychogenic Nonepileptic Spells To Patients With Psychogenic Nonepileptic Spells Only: A Search For Unique Clinical Characteristics/ S. C. Block, B. Abou-Khalil, H. Sonmezturk 1.187 Which Clinical Features Help In Differentiating Epileptic From Nonepileptic Convulsive Seizures? A Systematic Review Of Initial Clinic Encounters/K. Kleinfeld, A. Peltier, N. Azar 1.188 Delays In Diagnosis And Treatment Of Acute Seizures/ S. VanHaerents, E. Bachman, K. Romatoski, L. Knopf, M. Ebril, T. Pang 1.189 Clinical, EEG, MRI And Surgical Outcomes Of Pediatric Epilepsy With Astrocytic Inclusions Versus Focal Cortical Dysplasia/L. Alshafai, A. Ochi, C. Go, B. McCoy, C. Hawkins, H. Otsubo, O. Snead, J. Rutka, E. Widjaja 1.190 Sleep Homeostasis In Children With Focal Epilepsy Following Sleep Deprivation: Relationship To Seizure Propensity/S. Chan, C. Chevalier-Riffard, T. Baldeweg, J. Cross 1.191 Networks Of Laughing Seizures – A Stereoelectroencephalographic Study/I. Mindruta, L. Minotti, A. Job, D. Hoffmann, S. Chabardes, A. Barborica, J. Ciurea, P. Kahane 1.192 Super Refractory Status Epilepticus: A Case Report/ I. Noviawaty, A. Naduvil Valappil, A. Zeft, D. Lachhwani 1.193 Predictors Of Length Of Stay In Children Admitted For A PreSurgical Evaluation/P. Y. Sun, K. Wyatt, K. Nickels, L. Wong-Kisiel, E. Wirrell 1.194 Navigating The Benefits And Limitations Of Current Molecular Testing Options For The Clinical Identification Of Disease-Causing PCDH19 Mutations/S. Gandomi, M. Parra, K. D. Farwell Gonzalez, K. Waller, R. Baxter, B. Tippin Davis 1.195 Electroencephalographic Findings By Stage In Rasmussen’s Encephalitis/H. Kim, H. Ryu, B. Lim, H. Hwang, J. Chae, J. Choi, K. Kim, Y. Hwang 1.196 Type I Interferon Levels In Cerebrospinal Fluid Samples From Newborn Infants With Seizures, Rotavirus Infections, And Diffuse Cerebral White Matter Lesions/ K. Lee, C. Moon Poster Session 1 Prognosis 1.218 Family Factors Contributing To Depression In People With Epilepsy/ S. Han, B. Kim, E. Koh, M. Kim, D. Shin, J. Lee, K. Ji, S. Park, H. Nam, Y. Cho, E. Joo, S. Kim, D. Kim, K. Park, S. Han, Y. Sohn, K. Heo, E. Lee, H. Han, K. Kim, W. Shin, G. Kim, J. Lee, S. Koh, W. Kim, Y. Cho, J. Kim, S. Lee 1.219 Early Intensive Care Is Critical For The Outcome Of The Refractory Status Epilepticus/Y. Choi, K. Kang, S. Lee, M. Kim 1.220 Demographics And Outcomes Of Pediatric Febrile Convulsive Status Epilepticus/M. Nishiyama, T. Tanaka, K. Fujita, A. Maruyama, H. Nagase, D. Toyoshima, T. Nakagawa, N. Morisada, S. Takada, K. Iijima 1.221 Predictors Of Recurrent Febrile Seizure/M. Oh, S. Kim 1.222 Early Anatomical Injury Patterns Predict Post-neonatal Epilepsy In Infants Treated With Selective Head Cooling For Neonatal Hypoxic Ischemic Injury/D. Jung, C. Venkatesan, D. Nordli, D. G. Ritacco, S. Koh 1.223 Gender Alters The Prognosis Of Cryptogenic Epilepsy/F. Babtain, M. Abu Abthan, S. Al Ghamdi, H. Bhatia, M. Velmurugan 41 Saturday December 6, 2014 1.224 Epilepsy In Childhood After Acute Encephalopathy With Reduced Subcortical Diffusion/Y. Ito, J. Natsume, H. Kidokoro, N. Ishihara, Y. Azuma, T. Tsuji, A. Okumura, T. Kubota, N. Ando, K. Miura, T. Negoro, K. Watanabe 1.225 Succinic Semialdehyde Dehydrogenase Deficiency And Worsening Epilepsy In Adulthood/ S. LaPalme-Remis, E. Lewis, W. Theodore, M. Gibson, P. Pearl 1.226 The Relevance Of Somatosensory Auras In Refractory Temporal Lobe Epilepsies/G. Perven, L. Jehi, R. Yardi 1.227 Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies/ U. Seneviratne, M. Cook, W. D’Souza 1.228 How Many Patients With Temporal Lobe Epilepsy Are Well Controlled With Medications?/ J. Tellez-Zenteno, L. Hernandez Ronquillo, S. Buckley, L. D. Ladino 1.229 The Evaluation Of Left Ventricular Diastolic Function Of Newly Diagnosed Idiopatic Generalized Epilepsy Patients With Tissue Doppler Imaging/O. Dokgoz, C. Yilmaz, A. Ünalp, T. Mese, U. Karaarslan 1.230 Clinical Outcome Following Medical Treatment In Drug-Naïve Epilepsy Patients With Cavernous Malformation/K. Cho, Y. Lee, Y. Cho, K. Heo, B. Lee 1.231 Mortality In Patients Assessed For Suspected New-Onset Seizures/ T. O’Brien, T. Hakami, M. Todaro, L. Danny, P. Kwan, S. Yerra, M. Tan, C. French, S. Li, Z. Matkovic, A. McIntosh 1.232 Long Term Surgical Outcome Of Non-Lesional Temporal Lobe Epilepsy (NLTLE)/J. Chu, W. D’Souza, M. Murphy, S. Schachter, M. Cook Neuroimaging Animal Studies 1.233 Intrinsic Optical Signal Imaging Of Afterdischarges Induced By Acute Kindling Of The Rat Hippocampus/ K. Tsuchiya, A. Kobayashi, N. Inoue, S. Kogure, M. Nemoto 1.234 The Effect Of De Novo KCNQ2 Epileptic Encephalopathy Mutations On KCNQ2/3 Channel Trafficking And Hippocampal Neuronal Excitability/ J. Cavaretta, K. Lee, H. Chung Structural Imaging 1.235 Diffusion Tensor Imaging Study In Dravet Syndrome/J. Natsume, O. Chikako, H. Yamamoto, Y. Ito, T. Takeuchi, S. Yokoi, Y. Sakaguchi, Y. Azuma, N. Ishihara, H. Kidokoro, K. Miura, T. Negoro, K. Watanabe 1.236 Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures/S. Lee, J. Allendorfer, T. Gaston, K. Hernando, R. C. Knowlton, J. Szaflarski, L. W. Ver Hoef 42 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.237 The Severity Of Brain Atrophy In Temporal Lobe Epilepsy Is Unrelated To The Side Of The Focus: An Engel Class I Study/M. Liu, N. Bernasconi, A. Bernasconi, B. Bernhardt 1.238 Epileptogenic Tubers: Conventional MRI Findings/Y. Hirata, A. Yogi, R. Harris, B. Ellingson, N. Salamon 1.239 Unilateral Brain Oedema Related To Focal Status Epilepticus/ N. Ali, S. Palat Chirakkara, J. Reddy, S. Sinha 1.240 Voxel-Based Morphometric MRI Post-Processing May Provide Relevant Targets For Reoperation In Nonlesional Epilepsies/Z. Wang, P. Suwanpakdee, S. E. Jones, Z. Jaisani, B. Krishnan, R. Prayson, R. Burgess, I. Najm, J. Gonzalez-Martinez, W. Bingaman, A. Alexopoulos 1.241 Callosal And Diffusion Features In High-Functioning Subjects With Pyridoxine-Dependent Epilepsy/ S. D. Friedman, G. E. Ishak, A. V. Poliakov, S. L. Poliachik, C. B. Budech, D. W. Shaw, S. M. Gospe 1.242 A Case Of Periodic Lateralized Epileptiform Discharges (PLEDs) Causing Concordant Reversible MRI Changes/S. Chen, S. Schmitt, K. Davis 1.243 Longitudinal Diffusion Tensor Imaging Study In Cryptogenic West Syndrome/C. Ogawa, J. Natsume, T. Fukasawa, H. Kidokoro, H. Yamamoto, Y. Sakaguchi, Y. Ito, T. Takeuchi, S. Yokoi, Y. Azuma, N. Ishihara, K. Miura, T. Kubota, N. Ando, T. Negoro, K. Watanabe 1.244 MRI Spectrum Of Unilateral Temporal Lobe Epilepsy: A SurfaceBased Pattern Analysis Of Mesiotemporal Sub-structures/ B. Bernhardt, H. Kim, A. Bernasconi, N. Bernasconi 1.245 Usefulness Of DTI Analysis Of Brain Tissue Surrounding The Cortical Tuber For Predicting Epileptogenicity In Tuberous Sclerosis Patients/A. Yogi, Y. Hirata, E. Karavaeva, J. Wu, S. Yudovin, B. Ellingson, G. Mathern, N. Salamon 1.246 Impaired Perception Of Anxiety In Others Is Related To Right Superior Temporal Gyrus Volume In Temporal Lobe Epilepsy/G. P. Thomas, K. Bujarski 1.247 Hippocampal Internal Architecture Asymmetry In WellControlled And Drug-Resistant Temporal Lobe Epilepsy/T. E. Gaston, L. Perry, L. Ver Hoef 1.248 Evidence Of Regional Thinning Of The Cerebral Cortex In Asymptomatic Siblings Of Patients With Mesial Temporal Lobe Epilepsy/ S. Alhusaini, C. Doherty, M. Fitzsimons, G. Cavalleri, N. Delanty 1.249 Toward A Quantitative Measure Of Hippocampal Internal Architecture Clarity: A Proposed Method And Its Utility In Predicting Seizure Laterality In Temporal Lobe Epilepsy/L. Perry, T. E. Gaston, L. Ver Hoef 1.250 Volume Renderings Of Intraoperative Electrocorticography In Epilepsy/S. Poliachik, R. Hevner, E. Novotny, A. V. Poliakov, G. Ishak, H. Eslamy, J. Kuratani, R. Saneto, J. Ojemann 1.251 Cortical Thickness And Surgical Outcome In Patients With Non-Lesional Neocortical Epilepsy/ V. Pilli, D. Kamson, C. Juhasz, J. Jeong, E. Asano, S. Sood, H. Chugani 1.252 Psychopathology, Cortical Thickness And Sulcal Depth In Pediatric Epilepsy/R. Caplan, P. Siddarth, D. Tosun, S. Gurbani, J. Levitt 1.253 Loss Of Hippocampal Internal Architecture In Temporal Lobe Epilepsy Demonstrated With High Resolution 4.7-T Fast Spin Echo Imaging/T. A. Steve, Y. Huang, N. V. Malykhin, A. H. Wilman, D. W. Gross 1.254 Pediatric Epilepsy: Developmental Vulnerability Of Cortical Thickness And Sulcal Depth/ P. Siddarth, D. Tosun, S. Gurbani, J. Levitt, R. Caplan Functional Imaging 1.255 Can Resting-State Functional Connectivity Predict Seizure Outcome After Anterior Temporal Lobectomy?/G. Doucet, D. Pustina, P. Barnett, A. Ghani, C. Skidmore, A. Sharan, J. Evans, M. Sperling, J. Tracy 1.256 Spatiotemporal Mapping Of Multiple Spikes Using Distributed Source Analysis/N. Tanaka, N. Suzuki, S. Stufflebeam 1.257 Stress Perception And Seizure Control Modulate The Neural Response To Psychosocial Stress In Patients With Left Temporal Lobe Epilepsy/J. B. Allendorfer, H. Heyse, B. A. Szaflarski, L. Mendoza, N. Cohen, E. B. Nelson, J. C. Eliassen, J. M. Storrs, J. Szaflarski 1.258 Language Mapping In Epileptic Patients Represented By Magnetoencephalography: Utility Of Movement Compensation Algorithm/ N. Suzuki, N. Tanaka, S. Stufflebeam 1.259 Temporal Lobe Spikes: EEGfMRI Contributions to the “Mesial Vs. Lateral” Debate/S. Watanabe, F. Dubeau, J. Gotman 1.260 Modeling Channel-Specific Hemodynamic Response Function In Epilepsy With EEG-fNIRS Data/ K. Peng, D. K. Nguyen, T. Tayah, P. Vannasing, J. Tremblay, M. Sawan, F. Lesage, P. Pouliot Saturday December 6, 2014 Comorbidity (Somatic and Psychiatric) Medical Conditions 1.270 Analgesic Opioid Use In A Health-Insured Epilepsy Population During 2012/A. Wilner, B. Sharma, A. Soucy, A. Krueger 1.271 Prevalence Of Restless Leg Syndrome In Patients With Epilepsy/ N. K. Sethi, T. Tropea, L. Katus 1.272 Prevalence Of Epilepsy As A Comorbidity With Stroke In The U.S./ A. K. Birnbaum, I. E. Leppik, K. H. Svendsen, L. E. Eberly Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.273 Association Between Depressive Symptoms And Seizure Response Among Subjects With Refractory Partial-Onset Seizures In Clinical Trials Of Eslicarbazepine Acetate/F. F. Velez, T. C. Bond, X. Wang, K. P. Anastassopoulos, R. Sousa, D. Blum, F. Rocha, J. A. Cramer 1.274 Non-Epileptic Seizures In A Population Of Diagnosed Pediatric Epilepsy Patients/R. Villalobos, E. Gonzales 1.275 Reproductive Health In Indian Women With Epilepsy – A Cross Sectional Quantitative Survey/ M. Singh, A. EB, M. Agarwal, R. Pandey Psychiatric Conditions 1.276 Paroxysmal Non-Epileptic Events In A Pediatric Population/ T. Sawchuk, J. D. Smith, S. D’Alfonso, J. Buchhalter 1.277 Medications Implicated In Psychogenic Seizures: Insights From The OpenFDA Initiative/V. S. Wong, P. Motika 1.278 Differentiating Epileptic From Non-Epileptic Seizures Through Patterns Of Comorbidities And Pharmacologic Management/ W. T. Kerr, E. A. Janio, C. T. Braesch, J. M. Hori, J. M. Le, K. R. Raman, A. B. Patel, S. E. Barritt, E. S. Hwang, E. C. Davis, D. Torres-Barba, N. Salamon, J. Engel, J. Stern, M. S. Cohen 1.279 Psychiatric Comorbidity In Idiopathic Generalised Epilepsies/ A. Loughman, N. Bendrups, S. C. Bowden, W. D’Souza 1.280 Stress-Triggered Seizures: A Focus On Anxiety, Depression, And Childhood Trauma/H. R. McKee, A. Linane, R. Azzam, B. Abou-Khalil 1.281 Personalities Of Patients With Psychogenic Non-Epileptic Seizures/ P. Rawal, M. Szaflarski, J. Saenz, Z. Richardson, B. Dworetzky, J. Szaflarski 1.282 The Impacts Of AttentionDeficit Hyperactivity Disorder On Epilepsy Children/S. Park 1.283 Behavioural Features Of Patients With Psychogenic NonEpileptic Seizures (PNES)/ C. Helmstaedter 1.284 Why Are We Excluding Patients With Epilepsy From Clinical Trials Of Transcranial Magnetic Stimulation To Treat Depression?/ S. D. Forman, J. Roberts, B. A. Congedo, B. H. Hanusa, A. C. Van Cott 1.285 Patterns And Frequency Of The Treatment Of Depression In Persons With Epilepsy/K. M. Fiest, S. B. Patten, C. Altura, A. G. Bulloch, C. Maxwell, S. Wiebe, S. Macrodimitris, N. Jetté 1.286 Reducing Severity Of Comorbid Psychiatric Symptoms In An Epilepsy Clinic Using A Co-Location Model/ J. J. Chen, T. Caller, J. N. Mecchella, D. S. Thakur, K. A. Homa, C. Finn, E. Kobylarz, K. Bujarski, V. Thadani, B. Jobst 1.287 Seizure Severity Among Subjects With Refractory PartialOnset Seizures: Analysis Of The Seizure Severity Questionnaire In A Phase III Trial Of Eslicarbazepine Acetate/J. A. Cramer, T. C. Bond, F. F. Velez, X. Wang, K. P. Anastassopoulos, R. Sousa, F. Rocha, D. Blum 1.288 New Risk Factor Considerations In The Nonepileptic Patient Population: A Medication Use Review/S. Mason, P. Penovich, R. Lyons Animal Studies 1.289 Interaction Between Recurrent Seizures And Autism-Like Behavior In A Mouse Model Of Maternal Immune Activation/A. Mazarati, J. Washington III, R. Sankar, D. Shin, U. Kumar 1.290 Seizures Amplify Autistic Behavioral Deficits In Mouse Models Of 15q Duplication: A Potential Role For Heightened PI3K/AKT Signaling/ V. Krishnan, M. Anderson 1.291 Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts/S. J. Petty, C. J. Milligan, M. Todaro, T. J. O’Brien, J. D. Wark, E. J. Mackie, S. Petrou 1.292 A Single Acute Pre-Training Seizure Impairs Long Term Fear Memory In Mice/A. Holley, J. Lugo 1.293 Seizure Propagation To Sleep Triggers In The Lateral Hypothalamus Of Kcna1-Null Knockout Mice/ K. Simeone, T. Simeone SATURDAY 1.261 Can FDG-PET Find Epileptogenic Tuber In Tuberous Sclerosis Complex?/Y. Hirata, A. Yogi, E. Karavaeva, R. Harris, B. Ellingson, N. Salamon 1.262 Studies In Epilepsy Patients Using Simultaneous PET/MR: Preliminary Results/Y. S. Ding, B. Chen, C. Glielmi, K. Friedman, O. Devinsky 1.263 Electric Source Imaging (ESI) In Presurgical Epilepsy Investigations: The Importance Of High Electrode Density And Temporal Lobe Coverage In Patients With Mesiotemporal And Neocortical Temporal Foci/G. Lantz, M. Terrill, T. Gilbert, P. Luu, A. Bunnenberg, D. Tucker 1.264 Widespread BOLD Activation In MR Negative Patients With Bi-Temporal Epileptiform Discharges Studied With Simultaneous Intracranial EEG fMRI/ C. Beers, I. Gaxiola Valdez, D. J. Pittman, Y. Aghakhani, P. Federico 1.265 Evaluation Of The Changes In Interictal Magnetoencephalography (MEG) Spikes By Gradient Magnetic Field Topography (GMFT) Analysis Before And After Anterior Corpus Callosotomy For Symptomatic Generalized Epilepsy With DropAttacks/K. Kagawa, K. Iida, A. Hashizume, M. Kartagiri, Y. Kiura, R. Hanaya, K. Arita, K. Kurisu 1.266 Quantitative FDG-PET Neuroimaging In Medically Refractory Epilepsy: UPenn Experience/ A. A. Thaker, J. G. Dubroff, M. Brown, K. A. Davis 1.267 MRI, PET, SPECT, And Pathology Results Do Not Predict Seizure Outcome Following Epilepsy Surgery In Children With Focal Cortical Dysplasia/R. W. Dudley, B. Badesch, V. Allen, A. White, D. Mirsky, S. Nick, B. O’Neill, S. Koh, M. Handler, P. Laoprasert 1.268 Effect Of EEG Electrode Number On Epileptic Source Localization In Pediatric Patients/ A. Sohrabpour, Y. Lu, P. Kankirawatana, B. He 1.269 Dynamic FRET-FLIM Imaging Of TrkB Activation In Living Cells/ S. C. Harward, N. G. Hedrick, R. Yasuda, J. McNamara Poster Session 1 Antiepileptic Drugs Mechanisms Of Action 1.294 Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol/R. Patel, C. Barbosa-Nunez, T. R. Cummins 1.295 Levetiracetam Modify Synaptic Vesicle Protein Expression And Reduce Abnormally Augmented Presynaptic Vesicular Release After Pilocarpine-Induced Status Epilepticus/E. Garrido, L. Pacheco, V. Funck, N. Ruvalcaba, J. Rodriguez, D. Taylor, R. Garcia, J. Martinez, C. Castro, C. Upreti, P. Stanton 1.296 Novel GABAA Positive Alllosteric Modulator Neuroactive Steroids As Potential Therapies For Epilepsy/A. J. Robichaud, J. Doherty, R. Hammond, G. Belfort, F. Salituro, G. Martinez, M. Ackley 43 Saturday December 6, 2014 Animal Studies 1.297 Inhibitory Effect Of Cys LT Receptor Antagonist Pranlukast On MES And PTZ Induced Seizures/ Y. Ueda, L. Willmore 1.298 Consistent Seizure Suppression By Brivaracetam In Animal Models Of Partial Epilepsy Includes Protection Against Pilocarpine- And Kainic Acid-Induced Partial Seizures In Rats/A. Matagne, H. Klitgaard 1.299 TrkB Receptor Activation Improves Interneuronal Function And Suppresses Epileptiform Activity Following Traumatic Brain Injury/F. Gu, Y. Ma, I. Parada, L. Faria, F. M. Longo, D. A. Prince 1.300 High Dose Levetiracetam Could Be Used Prophylactically To Reduce The Severity Of Brain Damages Associated With Status Epileptics In Pilo Model/K. Itoh, Y. Ishihara, Y. Chiba, M. Ueno 1.301 Lacosamide And Levetiracetam Modulate The Development Of Interictal Spikes And High-Frequency Oscillations During Epileptogenesis/ M. Lévesque, C. Behr, M. Avoli 1.302 Huperzine A Increases Cortical Inhibition And Prevents Pentylenetetrazole-Induced Seizures In Rat/R. Gersner, D. Ekstein, S. Schachter, A. Rotenberg 1.303 Neuroactive Steroids Halt Electrographic Seizures In The Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/G. Belfort, R. Hammond, E. Christian, M. Ackley, C. Maciag, A. Robichaud, J. Doherty 1.304 Acute Spasm Reduction With Celastrol In The Multiple-Hit Rat Model Of Infantile Spasms/ O. Shandra, W. Mowrey, A. S. Galanopoulou 1.305 Efficacy And Tolerability Of An Interleukin 1 Receptor Antagonist (IL-1Ra) In The Multiple- Hit Rat Model Of Refractory Infantile Spasms/T. Brima, W. Mowrey, S. Moshé, A. S. Galanopoulou Clinical Trials 1.306 An Evaluation Of The Impact Of Memory On Antiepileptic Drug Adherence/J. McAuley, N. Passen, C. Prusa, J. Jih, S. Hart, B. Shneker 1.307 Efficacy Of USL255 (Qudexy™ XR; Extended-Release Topiramate) In Patients With Refractory PartialOnset Seizures: PREVAIL and PREVAIL OLE/A. M. Clark, S. S. Chung, I. Blatt, B. Anders, M. B. Halvorsen, R. E. Hogan 1.308 Long-Term Efficacy Of USL255 (Qudexy™ XR; Extended-Release Topiramate) In Patients With Refractory Partial-Onset Seizures: PREVAIL OLE/R. Hogan, I. Blatt, A. M. Clark, B. Anders, M. B. Halvorsen, S. S. Chung 44 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.309 Effects Of Topiramate On Growth And Development In Children With New Or Recent- Onset Epilepsy: A Phase-4 Randomized, ActiveControlled Study/L. Ford, Y. Shi, P. Manitpisitkul 1.310 Prospective Randomized Single-Blinded Trial Of Lacosamide Versus Fosphenytoin For Seizure Prophylaxis In Traumatic Brain Injury/J. Szaflarski, L. A. Shutter, L. Mendoza, M. Szaflarski 1.311 Treatment Of Refractory Status Epilepticus With Enteral Topiramate/A. Asadi-Pooya 1.312 Relationship Between Eslicarbazepine Exposure And Safety Endpoints For Eslicarbazepine Acetate Monotherapy/T. Fakhoury, J. Harvey, R. T. Wechsler, J. Passarell, J. Fiedler-Kelly, E. Ludwig, D. Blum, S. Sunkaraneni 1.313 The Impact Of Anticonvulsants On Neurological Outcomes In Neonatal Seizures/J. Han, I. Lee, E. Kim, S. Park 1.314 Relationship Between Exposure And Efficacy Of Eslicarbazepine Acetate Monotherapy/J. Rogin, A. J. Cole, L. Strom, J. Passarell, J. Fiedler-Kelly, E. Ludwig, D. Blum, S. Sunkaraneni 1.315 Incidence Of Falls, Fractures, And Injuries With Adjunctive Eslicarbazepine Acetate In Patients With Refractory Partial-Onset Seizures: A Pooled Analysis Of Three Placebo-Controlled Trials/ W. Rosenfeld, S. Benbadis, P. Klein, L. Specchio, P. Kowacs, H. Gama, F. Rocha, R. Claus, D. Blum 1.316 Hepatic Safety Of Eslicarbazepine Acetate: Summary Of Five Phase II And Three Phase III Adjunctive Trials/D. Blum, P. Van Ness, G. Krauss, S. Chung, C. Elger, C. Galimberti, H. Gama, F. Rocha, R. Claus 1.317 Eslicarbazepine Acetate As Adjunctive Therapy For Refractory Partial-Onset Seizures: Analysis Of Cognitive Adverse Events/ E. Andermann, S. Benbadis, A. Shah, E. Trinka, A. Biraben, R. Sousa, H. Gama, D. Blum, R. Claus 1.318 Eslicarbazepine Acetate Monotherapy In Adults With PartialOnset Seizures: A Pooled Analysis Of Two Randomized Double-Blind Studies With Use Of A Historical Control/ L. Pazdera, J. French, M. Sperling, M. Jacobson, H. Cheng, D. Blum 1.319 Relationship Between Eslicarbazepine Exposure And Efficacy Of Eslicarbazepine Acetate Adjunctive Therapy/J. Harvey, E. Andermann, S. Chung, E. Trinka, F. Cendes, J. Passarell, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, R. Sousa, F. Rocha, D. Blum 1.320 Relationship Between Eslicarbazepine Exposure And Safety Endpoints For Eslicarbazepine Acetate Adjunctive Therapy/ P. Penovich, G. Krauss, M. R. Sperling, S. Striano, C. Elger, J. Passarell, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, R. Sousa, F. Rocha, D. Blum 1.321 Eslicarbazepine Acetate Monotherapy: A Population Pharmacokinetic Analysis/ B. Abou-Khalil, I. Ali, A. Shah, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, D. Blum 1.322 Lack Of Exacerbation Of Partial-onset Seizures During Adjunctive Treatment With Eslicarbazepine Acetate: A Pooled Analysis Of Three Phase III Controlled Trials/S. Benbadis, M. Carreño, S. Striano, R. Sousa, F. Rocha, D. Blum, H. Cheng 1.323 Evaluation Of Physical Dependence Potential Following Abrupt Discontinuation Of Adjunctive Eslicarbazepine Acetate: A Pooled Analysis Of Adverse Events From Ten Studies/K. A. Schoedel, M. R. Sperling, M. Bensalem-Owen, D. Blum, R. Sousa, H. Gama, R. Claus 1.324 Bioequivalence Testing Of Disparate Generic Lamotrigine Products Using Chronic Dosing In People With Epilepsy: The Equigen Study/M. Privitera, F. Diaz, B. Dworetzky, P. Bolger, R. Krebill, B. Gidal, E. Elder, A. Paige, J. Szaflarski, T. Welty, J. Pollard, W. Jiang, N. McBee, M. Berg 1.325 Assessment Of Renal Toxicity In Perampanel-Treated Subjects: Pooled Results From Phase III Clinical Studies/I. Leppik, H. Yang, B. Williams, D. Xing, A. Laurenza Cohort Studies 1.326 Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For Medically Refractory Epilepsy/C. Press, K. Knupp, K. Chapman 1.327 Lacosamide Efficacy And Tolerability In Clinical Practice – Post Marketing Analysis/M. Baker, H. Sonmezturk, A. Arain, K. Haas, N. Azar, B. Abou-Khalil 1.328 Efficacy And Tolerability Of Intravenous Levetiracetam Versus Phenobarbital In Children With Status Epilepticus Or Acute Repetitive Seizures/Y. Lee, M. Yum, E. Kim, T. Ko 1.329 Clobazam Higher-Evening Differential Dosing As An Add-On Therapy In Refractory Epilepsy/ M. Jackson, S. Thome-Souza, J. Klehm, N. E. Kadish, I. Sánchez Fernández, T. Loddenkemper Saturday December 6, 2014 Other 1.337 Population Pharmacokinetic Modeling Of Immediate And ExtendedRelease Topiramate (SPN-538, Trokendi XR®) In Adults With Epilepsy: Characterization f Different Absorption Rates/E. Roers, S. T. Brittain, J. D. Stocks, J. K. Johnson 1.338 Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear Elimination Kinetics In Some Individuals/P. Ramey, M. Osborn, K. Lowen, B. Abou-Khalil 1.339 A New Method To Determine Linear Non-Steady State Pharmacokinetic Parameters In The Acute Care Setting/L. Olson 1.340 A Comparison Among The Various Carbamazepine-Related Antiepileptic Drugs/E. Vernier, S. R. Benbadis, M. Giarratano Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.341 Acute Seizure Management With Intravenous Levetiracetam In Neonates And Children/B. Kirmani, W. Hastings, O. Khan, P. Patel, A. Sarode, R. Castillo, M. Kempapura, S. Agadi, J. Aceves 1.342 A Systematic Review And Network Meta-Analysis Of Eslicarbazepine Acetate And Other Recently-Approved Anti-Epileptic Drugs For Adjunctive Treatment Of Partial-Onset Seizures In Adults/ K. Betts, V. Bollu, G. De, D. Blum, F. Velez 1.343 Once-Daily Trokendi XR® (SPN-538) Dosing In Children With Epilepsy/J. D. Stocks, S. T. Brittain, J. K. Johnson 1.344 Cost-Effectiveness Of Eslicarbazepine Acetate In Refractory Partial-Onset Epilepsy/K. O’Day, F. Velez, K. Meyer 1.345 Ezogabine Usage In Pediatric Patients: A Retrospective Review Of Safety And Efficacy From Two Academic Institutions/J. Toler, K. Chapman, T. Loddenkemper, J. Klehm Surgery Adult 1.346 MagnetoencephalographyGuided Surgery In MRI Negative Or Ill-Defined Frontal Lobe Epilepsy Using Neuronavigation And Intraoperative MR Imaging/B. Sommer, K. Roessler, I. Blumcke, S. Rampp, H. Hamer, M. Buchfelder, H. Stefan 1.347 Effects Of Invasive EEG Monitoring On Memory And Language After Left Anterior Temporal Lobectomy: A Propensity Model Analysis/R. M. Busch, T. E. Love, L. E. Jehi, L. Ferguson, R. Yardi, W. Bingaman, J. Gonzalez-Martinez 1.348 Temporal Plus Seizures Are The Main Prognostic Factor For Unfavourable Surgical Outcome In Patients With Temporal Lobe Epilepsy/C. Barba, S. Rheims, L. Minotti, J. Isnard, D. Hoffmann, S. Chabardes, M. Guenot, P. Ryvlin, P. Kahane 1.349 Stereotactic Laser Ablation Is A Potentially Curative Procedure After Unsuccessful VNS Or RNS For Mesial Temporal Lobe Epilepsy/J. J. Shih, R. Wharen, W. Tatum, R. Gross, J. Willie, D. Labiner, M. Weinand, A. Sharan, M. Sperling 1.350 Intraoperative Supplementary Motor Area (SMA) Monitoring For Medial Frontal Lesions/S. Shibata, T. Kunieda, R. Matsumoto, Y. Yamao, R. Inano, S. Nishida, T. Nakae, T. Kikuchi, Y. Arakawa, Y. Takagi, A. Ikeda, R. Takahashi, S. Miyamoto 1.351 Postoperative Interictal Epileptiform Discharges Within One Month After Selective Amygdalohippocampectomy For Mesial Temporal Sclerosis/H. Yu, S. Hsu, C. Lin, Y. Shih 1.352 Individualized Epilepsy Surgical Outcome Prediction Based On Neural Network Architecture/L. Bonilha, J. Lin, D. Drane, J. Jensen, R. Kuzniecky Pediatrics 1.353 Language Mapping By Spontaneous Conversation Related High-γ Synchronization And Comparison With Conventional Electrical Cortical Stimulation/ R. Arya, J. A. Wilson, J. Vannest, A. W. Byars, H. Greiner, J. Buroker, H. Fujiwara, F. Mangano, K. Holland, N. Crone, D. Rose 1.354 The Influence Of Lesion Volume, Perilesional Resection Volume And Completeness Of Resection On Seizure Outcome Following Resective Epilepsy Surgery For Cortical Dysplasia In Children/C. Oluigbo, D. Depositario-Cabacar, S. Magge, J. Myseros, M. Whitehead, R. Keating, W. Gaillard 1.355 Yield And Predictors Of Epilepsy Surgery Candidacy In Children Admitted For Surgical Workup/ O. Haque, K. Nickels, N. Wetjen, L. Wong-Kisiel, E. Wirrell 1.356 Epilepsy Surgery Outcomes For Lesionectomy In Non-Dysplastic Lesions In Children With Intractable Epilepsy/R. Villalobos, E. Gonzales, J. Torrez-Corzo 1.357 A Circuitous Journey: Parent Perspectives Of Getting To Pediatric Resective Epilepsy Surgery/C. Bower Baca, H. Pieters, T. Iwaki, G. Mathern, B. Vickrey 1.358 Posterior Quadrant Disconnection Surgery For Sturge-Weber Syndrome/H. Sugano 1.359 Central Cortex-Preserving Multilobar Surgery: An Alternative Option For Patients With Hemispheric Pathology And Minimal Motor Deficit/T. Ono, H. Baba, K. Toda, R. Honda 1.360 The Impact Of Epilepsy Surgery On Paediatric Quality Of Life/W. Hader, L. Ruttle-Soon, H. Carlson, D. Slick, L. Bello-Espinosa, E. Sherman 1.361 Is Diffusion Tensor Imaging Useful To Localize The Epileptic Focus In Children With MRI-Negative Epilepsy?/K. Toda, H. Baba, T. Ono, R. Honda 1.362 Seizure Outcomes After Resective Epilepsy Surgery In Children With Lennox-Gastaut Syndrome/ P. Suwanpakdee, A. Naduvil Valappil, L. Jehi, A. Gupta, W. Bingaman, J. Gonzalez-Martinez, I. Najm, E. Wyllie 1.363 Analysis Of Epileptic Discharges Using Implanted Subdural Electrodes In Patients With SturgeWeber syndrome/Y. Iimura, H. Sugano, M. Nakajima, T. Higo, H. Arai SATURDAY 1.330 The Effects Of Antiepileptic Drugs On Cortical Irritability In Patients With Tumoral Epilepsies/ P. Warren, L. B. Nabors, J. Szaflarski 1.331 Adjunctive Perampanel For Focal-Onset Seizures – An Interim Analysis/K. Kelly, L. Stephen, P. Parker, M. Brodie 1.332 Fydata Study: Retrospective Analysis Of Perampanel In A Real-Life Setting/V. Villanueva, M. Garces, F. López Gonzalez, X. Rodriguez-Osorio, J. Rodriguez Uranga, E. López-Gomáriz, J. Montoya, J. Poza Aldea, A. Molins, R. Saiz-Diaz, J. González de la Aleja, J. Mauri, A. Castillo, F. Lopez-Trigo Picho, M. Toledo, J. Salas Puig, D. Campos Blance, J. Flores 1.333 Intravenous Intiation Of Lacosamide For Status Epilepticus And Following Video EEG Monitoring/ G. Morris, J. Burgos, A. Van Kampen, M. Hanson, J. Dagam 1.334 Clobazam Vs. Clonazepam For Adults With Epilepsy: Long-Term Results From A UK Primary Care Database/M. Brodie, S. S. Chung, A. G. Wade, C. Quelen, A. Guiraud-Diawara, C. François, P. Verpillat, V. Shen, D. Jones, J. Isojarvi 1.335 Long-Term Utilization Differences Between Children Treated With Clobazam Vs. Clonazepam For Epilepsy In The UK/S. S. Chung, M. Brodie, A. G. Wade, C. Quelen, A. Guiraud-Diawara, C. François, P. Verpillat, V. Shen, D. Jones, J. Isojarvi 1.336 Evolution Of Clobazam, Clonazepam, And Diazepam Usage In The UK For Epilepsy And Other Diseases/D. Jones, S. S. Chung, M. Brodie, A. G. Wade, C. Quelen, A. Guiraud-Diawara, P. Verpillat, V. Shen, J. Isojarvi, C. François Poster Session 1 45 Saturday December 6, 2014 1.364 Risk Of Seizure Recurrence In Children With Pathology Confirmed Focal Cortical Dysplasia Undergoing Surgical Resection/A. Mrelashvili, E. Wirrell, K. Nickels, L. Wong-Kisiel 1.365 Surgical Versus Medical Treatment For Children With Epileptic Encephalopathy In Infancy And Early Childhood. An Observational Cohort Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/T. Otsuki, H. Kim, G. Luan, Y. Inoue, H. Baba, H. Oguni, S. Hong, S. Kameyama, K. Kobayashi, S. Hirose, H. Yamamoto, S. Hamano, K. Baba, A. Takahashi, T. Kaido, K. Sugai 1.366 Visualization Of Epileptogenic Networks From Interictal iEEG Using Granger Causality/J. R. Madsen, E. Park 1.367 Clinical Factors For Long-Term Seizure Remission And Developmental Outcome After One-Stage Total Corpus Callosotomy/M. Iwasaki, M. Uematsu, T. Nakayama, N. Hino-Fukuyo, K. Haginoya, S. Osawa, Y. Shimoda, K. Jin, N. Nakasato, T. Tominaga All Ages 1.368 Long-Term EEG And Clinical Outcome Of Laser Thermal Ablation In Large Series Of Lesional And NonLesional Epileptic Foci In Adults And Children/M. Chez, A. Ghassemi, S. Ciricillo 46 Poster Session 1 Noon - 6:00 p.m. Convention Center – Hall 4B, Level 4 1.369 Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery/D. J. Englot, K. Raygor, P. Garcia, R. C. Knowlton, K. I. Auguste, E. Chang 1.370 Inflammatory Mediators Role In Epileptogenesis Caused By Cavernous Angioma/M. Nakajima, H. Sugano, Y. Iimura, T. Higo, Y. Harada, H. Arai 1.371 The Role Of Corpus Callosotomy And Vagus Nerve Stimulation For Medically Refractory Epilepsy And Their Future As Palliation In Epilepsy Surgery/T. Yamamoto, A. Fujimoto, T. Yamazoe, T. Okanishi, T. Yokota, H. Enoki 1.372 Temperatures Achieved In Human And Canine Neocortex During Intraoperative Passive Or Active Focal Cooling/R. Han, C. Yarbrough, S. Rothman, E. Patterson, X. Yang, J. Miller, R. D’Ambrosio, M. Smyth 1.373 Medical Cost Reduction By Vagus Nerve Stimulation/A. Onomura, T. Yamamoto, H. Iseki, K. Iwasaki, M. Umezu 1.374 Surgical Outcome Of Lesionectomy Vs Lesionectomy + Temporal Lobectomy For Lesional Temporal Lobe Epilepsy/V. Rajasekaran, D. B. Burkholder, G. Worrell, R. Marsh, F. Meyer, J. Mandrekar, J. Britton 1.375 Long-Term Product Reliability For Implantable VNS Therapy Generators And Leads/C. M. Gordon, M. T. Bunker 1.376 Conformal Laser Ablation: A Safe & Effective Treatment For Focal, Non-Mesial Temporal Lobe Epilepsy/ S. Bandt, A. H. Hawasli, R. E. Hogan, E. Leuthardt 1.377 Development And Validation Of A Prognostic Nomogram Of SeizureFreedom After Resective Epilepsy Surgery/L. Jehi, R. Yardi, K. Chagin, L. Tassi, G. Worrell, F. Cendes, M. Morita, F. Bartolomei, P. Chauvel, I. Najm, J. Gonzalez-Martinez, W. Bingaman, M. Kattan • AES 68TH ANNUAL MEETING Seattle, WA • SUNDAY December 7, 2014 www.AESnet.org 8:45 a.m. – 4:45 p.m. Investigators’ Workshops Location listed under each session Overview These workshops, conducted informally and designed to encourage interaction, will address several important areas of rapidly-emerging knowledge in clinical and basic research in epilepsy. The workshops are intended to identify challenges in current research, propose methods to overcome those challenges, and encourage areas for future investigation. The Basic Science Investigator Workshops will highlight a number of research areas that have been developing rapidly over the last year. Participants include established and junior epilepsy investigators as well as researchers outside the epilepsy community who have specialized expertise that may be applied to epilepsy basic science. In addition, one of the workshops features presentations by junior investigators in cutting-edge areas of research. Most of the workshops will run as concurrent sessions on Sunday, with a single workshop on Saturday afternoon on cannabis and epilepsy and another Monday afternoon on stem cells. Target Audience Basic scientists, neurologists, neuroscientists, pharmacologists, neuropsychologists and neurosurgeons who are performing research in epilepsy Program Investigators’ Workshop Chair: Michael Wong, M.D., Ph.D. Clinical Investigators’ Workshop Chair: Hal Blumenfeld, M.D., Ph.D. Morning Session I – 8:45 a.m. - 10:15 a.m. 1. Yes, Focal Epilepsy Is a Network, But Does it Matter? Convention Center – Room 608, Level 6 Moderator: Jean Gotman, Ph.D. Speakers: Christophe Grova, Ph.D., Philippe Kahane, M.D., Ph.D., Michael R. Sperling, M.D. This Investigator Workshop is supported in part by Acorda Therapeutics. 2. How Does Status Epilepticus Provoke the Generation of 'Epileptic Neurons'? Convention Center – Room 613, Level 6 Moderator: Tallie Z. Baram, M.D., Ph.D. Speakers: Katja Kobow, Ph.D., Jong M. Rho, M.D., Ph.D., Gary P. Brennan, Ph.D. 3. Unraveling the Basis of Heterogeneity in Genetic Epilepsy Convention Center – Room 609, Level 6 Moderator: Samuel F. Berkovic, M.D. Speakers: Christopher Reid, Ph.D., Dennis Dlugos, M.D., Peter B. Crino, M.D., Ph.D. Break: 10:15 a.m. - 10:30 a.m. 4. Teratogenesis of Antiepileptic Drugs Convention Center – Room 608, Level 6 Moderator: Kimford J. Meador, M.D. Speakers: Patrick Forcelli, Ph.D., Page B. Pennell, M.D., Kimford J. Meador, M.D. 5. Hot Topics and Late-breaking Research from Young Investigators in the Epilepsy Community Convention Center – Room 613, Level 6 Moderators: Chris Dulla, Ph.D., Michael Wong, M.D., Ph.D. Speakers: Gemma Carvill, Ph.D.: The Expanding Role for Chromatin Remodeling in Epilepsy: Gene Discovery to Pathogenic Mechanisms Bethany Hosford, Ph.D.: Impact of Targeted Ablation Of Developing Dentate Granule Cells On Temporal Lobe Epileptogenesis Matt Weston, Ph.D.: Hyperactivation of mTOR Signaling in a TwoNeuron Microcircuit Alters the Dynamics of Synaptic Transmission” Dan Xu, Ph.D.: A Novel Therapy for Status Epilepticus Using Biodegradable Immune-Modifying Nanoparticles 6. Low-frequency Stimulation in Epilepsy Convention Center – Room 609, Level 6 Moderator: Mohamad Koubeissi, M.D. Speakers: Mohamad Koubeissi, M.D., Dominique Durand, Ph.D., G. Campbell Teskey, Ph.D. SUNDAY The Clinical Investigators’ Workshops provide a series of working seminars in matters of active clinical investigation and controversy. Speakers present results from their ongoing research and place their findings in the context of current understanding. Morning Session II – 10:30 a.m. - Noon Noon - 1:30 p.m. Poster Session (Lunch) Convention Center – Room 6F, Level 6 Note: Number below refers to poster assignment 1.001 Enhanced Histamine Release During The Pilocarpine-Induced Status Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats: Effects Of Sodium Cromoglycate/Luisa Rocha 1.003 Time- And Region-Specific Alterations In Cyclin D1 Expression Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/ Y Cruz Del Angel 1.007 Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability In The Normal And Injured Brain/Viji Santhakumar 1.014 Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of Temporal Lobe Epilepsy/Paul Buckmaster 1.018 Human Single Neuron Correlates Of High Frequency Oscillations During Seizures/Omar Ahmed 1.024 The mTOR Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced Dendritic Injury In Mice/Dongjun Guo 1.025 TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice/Karlene Barrett 1.026 Hypothermia Prevents The Development Of The Calcium Plateau Following Status Epilepticus/Kristin Phillips 1.027 Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In Mice Following Controlled Cortical Impact/Jeffery Boychuk 1.030 Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces Hippocampal Structural Pathology And Spontaneous Recurrent Seizures/Cezar Gavrilovici 1.039 GABA Agonists Restore Inhibitory GABA Neurotransmission in Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/ Antoine Depaulis 1.043 Modeling PIK3CA-Related Malformations Of Cortical Development And Epilepsy In Mice/Franck Kalume 1.044 Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures/Abhijeet Gummadavelli 47 SUNDAY December 7, 2014 1.054 Treatment Of Convulsive Status Epilepticus In An Animal Model Of Glucose Transporter Type 1 Deficiency (G1D) Syndrome/Cary Trent 1.055 Minocycline Reverses Pro-Epileptogenic Effect Of Viral-Like Brain Inflammation In The Mature And Immature Rat Brain/Nina Dupuis 1.056 Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat Pups But Does Not Affect The Adult Rats/Stephane Auvin 1.105 Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/ Jun Tohyama 1.294 Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol/Reesha Patel 1.303 Neuroactive Steroids Halt Electrographic Seizures In The Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/ James Doherty 1.377 Development And Validation Of A Prognostic Nomogram Of Seizure-Freedom After Resective Epilepsy Surgery/Lara Jehi 3.001 Increase In Dendritic Spines Correlates With Increased Synapses In Hippocampal CA1 Following Hypoxia-Induced Neonatal Seizures/ Jocelyn Lippman-Bell 3.005 Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. AdultBorn Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/ Xi Du 3.006 Disabled 1-Deficient Mice Exhibit Hippocampal Structural Abnormalities And A Reduced Seizure Threshold/Matthew Korn 3.014 Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep Syndrome/Hongjie Yuan 3.016 Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To KCNT1 Mutations/Imran Quraishi 3.017 A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel Targeting To The Axon Initial Segment/Baouyen Tran 3.022 Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of Drug-Resistant Seizures/Volodymyr Dzhala 3.027 Unravelling The EEG Footprints That Develop Into Spontaneous Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse Model Of Temporal Lobe Epilepsy (TLE)/Thimmasettappa Thippeswamy 3.030 New Model Of Focal Cortical Dysplasia Associated Epilepsy/ Lawrence Hsieh 3.032 Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe Epilepsy/Jennifer Pearson 3.035 Enhancing KCC2 By Acute TrkB Inhibition Rescues PhenobarbitalResistant Seizures In A Model Of Neonatal Ischemia/Shilpa Kadam 3.036 Cardiac Consequences Of Repeated Brief Seizures In Chronic Experimental Temporal Lobe Epilepsy/John Jefferys 3.039 Flupirtine Is More Efficacious Than Phenobarbital In The Treatment Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/ Dayalan Sampath 3.043 Lithium-Pilocarpine And DFP-Induced Status Epilepticus In Immature Rats: Behavioral, Electrographic, And Neuropathological Characteristics/Erika Scholl 3.047 Comparison Of Spike-Wave Discharges And Other Oscillatory Activity In Normal Animals With Spontaneous Recurrent Seizures Across Several Animal Models Of Acquired Epilepsy/F. Edward Dudek 3.050 Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia/Lena Nguyen 3.063 Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By Nanoparticles/Sara Eyal 3.070 Early Seizure Detection Using Relative Gamma And Ripple Band Phase Decoherence/Zoltan Nadasdy 3.089 Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive Myoclonus Epilepsy/Mikko Muona 3.145 Etiologies And Yield Of Investigations For Infantile Spasms: Results Of A US Multicenter, Prospective Study/Elaine Wirrell 48 Afternoon Session I – 1:30 p.m. - 3:00 p.m. 7. Brain Connectivity in Health and Epilepsy Convention Center – Room 608, Level 6 Moderator: Jeffrey G. Ojemann, M.D. Speakers: Catherine Chu-Shore, M.D., Luigi Maccotta, M.D., Ph.D., Kurt Weaver, M.D. 8. SUDEP Mechanisms: A Basic Science Perspective Convention Center – Room 613, Level 6 Moderators: Gordon F. Buchanan, M.D., Ph.D. Speakers: Gordon F. Buchanan, M.D., Ph.D., Isamu Alba, Ph.D., Carl L. Faingold, Ph.D. 9. Finding Risk Alleles in Generalized Epilepsies: Next Generation Sequencing and the Virtues of Large Collaborations Convention Center – Room 609, Level 6 Moderator: Slavé Petrovski, Ph.D. Speakers: Slavé Petrovski, Ph.D., Roland Krause, Dr. Sci., Patrick Cossette, M.D. Break: 3:00 p.m. - 3:15 p.m. Afternoon Session II – 3:15 p.m. - 4:45 p.m. 10. Stress and Seizures Convention Center – Room 608, Level 6 Moderators: Michael D. Privitera, M.D. Speakers: Jane B. Allendorfer, Ph.D., James Herman, Ph.D., Michael D. Privitera, M.D. 11. Understanding Infantile Spasms: A Pathogenic Perspective Convention Center – Room 613, Level 6 Moderators: Chris Dulla, Ph.D., Aristea S. Galanopoulou, M.D., Ph.D. Speakers: Chris Dulla, Ph.D., Jeffrey L. Noebels, M.D., Ph.D., John W. Swann, Ph.D. 12. Which Parts of the Brain Participate in Seizures, and Why Does It Matter? Convention Center – Room 609, Level 6 Moderator: Catherine Schevon, M.D., Ph.D. Speakers: Andrew Trevelyan, M.D., Ph.D., Hal Blumenfeld, M.D., Ph.D., Catherine Schevon, M.D., Ph.D. SUNDAY December 7, 2014 8:45 a.m. – 5:15 p.m. Annual Course: Seizures and EEG in the Critically Ill Patient (6.0 CME Credits) Convention Center – Ballroom 6C, Level 6 11:50 a.m. Noon-2:00 p.m. Overview Who Should be Reading cEEGs? The Role of the Neurointensivist Edward M. Manno, M.D. Morning Wrap-Up Eric Kossoff, M.D. Lunch Break in Exhibit Hall The Annual Course will focus on diagnosis and management of seizures in patients admitted to intensive care units (ICU), both those with known epilepsy and those with seizures due to systemic illnesses or infection. Topics include: diagnostic challenges, initially regarding etiologies of seizures in ICU patients; how routine and / or continuous EEG can help (or hinder) management. Financial issues and management options for patients having seizures as well as Status Epilepticus in ICU settings. Lectures will cover standard anticonvulsants, sedative and coma-inducing agents, as well as non-standard treatments such as surgery, diet, immunomodulatory agents, and TMS. The Annual Course will conclude with a discussion of prognosis and outcomes from seizures as well as status epilepticus. The course will include case presentation, debate and use of audience response system. Treatment Challenges Learning Objectives 2:55 p.m. Recognize interictal and ictal EEG patterns in critically ill patients u Define intervention strategies for critically ill patients with both subclinical and refractory clinical Status Epilepticus u Implements rational medical therapy for seizures in critically ill patients u Counsel families regarding implications and prognosis of sub-clinical and clinical Status Epilepticus u Assist physicians in treating subclinical and clinical seizures through use of appropriate medications u Recognize the implications of seizures in a critically ill patient who survived and is now facing neuropsychological difficulties. 2:05 p.m. 2:10 p.m. 2:30 p.m. 3:25 p.m. 3:40 p.m. 3:55 p.m. Target Audience Intermediate and Advanced (see page 120 for details) Program Chair: Eric Kossoff, M.D. Diagnostic Challenges 8:45 a.m. 8:55 a.m. 9:00 a.m. 9:25 a.m. 9:50 a.m. 10:20 a.m. 10:35 a.m. 10:40 a.m. 11:05 a.m. 11:30 a.m. Introduction to Morning Session Eric Kossoff, M.D. Case Presentation (Johnny, Part 1) Andreas Alexopoulos, M.D., M.P.H. Lecture: Etiologic Considerations in Seizure Screening Nicholas S. Abend, M.D. Lecture: EEG in the ICU: Nomenclature and Current Trends Susan T. Herman, M.D. Debate: Utility of Continuous EEG – Monitor All vs. Be Selective? Lawrence J. Hirsch, M.D. (Pro) / Paul Vespa, M.D. (Con) Break Case (Johnny, Part 2) Lily Wong-Kisiel, M.D. Lecture: Neonates and Children: Are They Different? Cecil Hahn, M.D. Lecture: NORSE, FIRES, and Encephalitis Nicolas Gaspard, M.D., Ph.D. Flash Panel: Financial and Logistical Issues Is Continuous EEG Worth the Cost and Use of Resources? Thomas P. Bleck, M.D. 4:35 p.m. 4:55 p.m. 5:00 p.m. Introduction to Afternoon Session Eric Kossoff, M.D. Case (Johnny, Part 3) Jack Lin, M.D. Lecture: Pharmacologic Treatment of Status Epilepticus in the ICU Daniel H. Lowenstein, M.D. Lecture: Pharmacologic Treatment of Super-refractory Status Epilepticus Joseph I. Sirven, M.D. Debate: Should We Treat Anoxic / Myoclonic Seizures? David M. Ficker, M.D. (Pro) / Jennifer L. Hopp, M.D. (Con) Lecture: AES Treatment Guidelines for Status Epilepticus Tracy A. Glauser, M.D. Break Flash Panel: Other Treatments to Try When Nothing Else Works Surgery Yu-tze Ng, M.D. Ketogenic Diet Mackenzie Cervenka, M.D. Steroids / IVIG – How Do They Work? Annamaria Vezzani, Ph.D. Transcranial Magnetic Stimulation Alexander Rotenberg, M.D., Ph.D. Lecture: Long-term Prognosis and Outcomes Elizabeth J. Waterhouse, M.D. Case (Johnny, Part 4 and Conclusion) Jerzy P. Szaflarski, M.D., Ph.D. Conclusions Eric Kossoff, M.D. SUNDAY u 2:00 p.m. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 6.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 6.0 contact hours (0.6 CEUs). UAN 0077-9999-14-034-L01-P. Initial Release Date: 12/7/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Annual Course Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Medical Knowledge and Practice-based Learning Acknowledgment This program is supported in part by an educational grant from Electrical Geodesics, Inc. 49 SUNDAY December 7, 2014 6:00 p.m. – 7:30 p.m. Special Interest Group Meetings Location listed under each session Drug Resistant Epilepsy – Definition, Epidemiology, Predictors, Using Big Data for Epidemiological Research Convention Center – Room 617, Level 6 Coordinator: Nathalie Jetté, M.D., FRCPC Speakers: Samuel Wiebe, M.D., Martin J. Brodie, M.D., Elaine C. Wirrell, M.D., Jakob Christensen, M.D., Ph.D. This SIG will provide participants with an up to date review about drug-resistant epilepsy. We will begin by reviewing the latest definition of drug resistant epilepsy and consider the evidence behind it. We will review the epidemiology of drug-resistant epilepsy and whether patterns are changing over time, discuss risk factors for pharmaco-resistance in children with epilepsy and will examine whether big data can be exploited to study drug-resistance in epilepsy. Frontal Lobe Epilepsy: Semiology and Cognitive Aspects Convention Center – Room 608, Level 6 Coordinators: Andrea Bernasconi, M.D., Fernando Cendes, M.D., Ph.D. Speakers: Prof. Patrick Chauvel, Bruce Hermann, Ph.D. Frontal lobe epilepsy is the second most common type of localization-related epilepsy that undergoes surgical treatment, and probably the most challenging in terms of medical and surgical management. The causes are diverse and often undetected by current standards of neuroimaging investigation, and a large proportion of patients need invasive EEG investigation. Despite advances in technology, many patients with frontal lobe epilepsy cannot undergo surgery either due to the seizure onset zone being close to or involving eloquent areas (motor and language) or because there is a lack of clear localization of epileptogenic lesion / seizure focus. We will discuss the pathophysiological aspects of the complex seizure semiology and cognitive changes in frontal lobe epilepsy. Coordinator: D. Samba Reddy, Ph.D., RPh Speakers: Aristea S. Galanopoulou, M.D., Ph.D., Cynthia L. Harden, M.D., D. Samba Reddy, Ph.D., RPh, Asla Pitkanen, M.D., Ph.D. Sex difference in seizure susceptibility is one of the long-standing issues of epilepsy. Clinical evidence shows gender- and age-related expression of many seizure syndromes. The incidence of epilepsy is generally higher in males than in females. More women than men are diagnosed with idiopathic generalized epilepsy, but localization-related symptomatic epilepsies are more frequent in men, and cryptogenic localization-related epilepsies are more frequent in women. Changes in seizure sensitivity are also evident at puberty, which is associated with rigorous changes in reproductive hormones and behavioral patterns. Overall, there is considerable evidence indicating that men exhibit greater seizure susceptibility than females, while many females exhibit greater fluctuations in susceptibility to seizures, including menstrual cycle-related changes in seizure activity. Although sex differences in epileptogenesis are widely recognized, there is little discussion on their mechanisms and therapeutic implications. In this SIG, sex-based differences in seizure sensitivity and epileptogenesis will be discussed, with emphasis on variations between men and women in factors such as steroid hormones, gender-specific developmental consequences, biologic differences in neuronal networks in the brain and gender-based differential therapeutic interventions. Pediatric Case Discussions Convention Center – Room 612, Level 6 Coordinator: Elaine Wyllie, M.D. Speakers: TBA Six expert faculty will present impactful cases illustrating important clinical points in diverse topics including pediatric epilepsy diagnosis, seizure semiology, EEG, antiepileptic medications, surgery, genetics, comorbidities, and other topics. Magnetoencephalography (MEG) / Magnetic Source Imaging (MSI) Source Localization Results: Blind Faith, Black Art, or Scientific Method? Psychogenic Nonepileptic Seizures: What Can We Learn from PNES Semiology? Convention Center – Room 620, Level 6 Coordinators: Markus Reuber, M.D., Ph.D., FRCP, Sigita Plioplys, M.D. Speakers: Roderick Duncan, M.D., Ph.D., FRCP, Gaston C. Baslet, M.D., Julia Doss, Psy.D., LPN Coordinators: Anto I. Bagic, M.D., Ph.D. Speakers: Steven Stufflebeam, M.D., Ph.D., Richard C. Burgess, M.D., Ph.D., Michael Funke, M.D., Ph.D., John S. Ebersole, M.D. Although MEG is an established tool for localizing normal and pathological fields, and clinical MEG is a recognized diagnostic subspecialty, there is a need to improve the understanding and thus usefulness of MEG source modeling results for the practitioner to facilitate further growth of the field. To this end, it is essential to review the concepts of source localization accuracy based not only on the equivalent current dipole (ECD) but also on various extended models. Thus, Dr. Stufflebeam will introduce distributed source localization methods; Dr. Burgess will scrutinize the criteria for acceptance of a dipole fit; Dr. Funke will discuss the methods for improving source localization yield and accuracy (spike averaging, tSSS, region of interest sub-selection, etc.) and Dr. Ebersole will elucidate on the concept of dipole-worthiness. Neonatal Seizures: Should We Pursue Comparative Effectiveness Studies for the Treatment of Neonatal Seizures? Convention Center – Room 609, Level 6 Coordinators: Renee A. Shellhaas, M.D., M.S., Courtney Wusthoff, M.D. Speakers: Ronnie Guillet, Tracy A. Glauser, M.D. There remains a paucity of evidence regarding optimal treatment for neonatal seizures. While there are a few ongoing RCTs for specific agents in the treatment of neonatal seizures, all have faced significant challenges. Some have proposed the solution to this knowledge gap lies in comparative effectiveness research, using the existing wide variation in clinical practice to study impact on outcomes. Others argue that a well-designed and executed RCT remains feasible and is preferable as the gold standard to provide an evidence basis in this area. Following presentation of three relevant posters, our speakers will debate the sides of this issue. 50 Neuroendocrinology: Sex Differences in Epileptogenesis Convention Center – Room 613, Level 6 Convention Center – Room 615, Level 6 This SIG will focus on the visible and subjective symptomatology of PNES in adults and children and explore whether different semiological features can tell us anything about the etiology, course or optimal management of patients with PNES. A wide range of subjective semiological features have been reported during PNES, including sensory experiences from different modalities, symptoms indicative of hyperarousal, distressing experiences and varying degrees of preserved awareness. Similarly, the objectively observable semiology of PNES has been studied extensively, and characteristic features have been described. Some PNES experiences have been linked to antecedent trauma and better or worse outcome. Other than this, little is known about how PNES semiology might relate to etiology or mechanism, and whether some elements of it might have implications for choice of therapy. Drs. Duncan and Baslet will summarize published observations of PNES subjective and objective semiology in adults, will discuss the implication of these observations and will explore possibilities for future research. While PNES in children shares similar semiological features to those in adults, there are few studies assessing subjective experience and how this may inform treatment choice or treatment outcome. Dr. Doss will discuss PNES semiology in the pediatric population. 8:00 p.m. – 10:00 p.m. Social Networking Groups Sheraton – Madrona, Second Floor (registration is not required) Informal gathering and networking for SIG participants. Space is limited so participants are welcome on a first-come, first-served basis. Roundtable topics include: Adolescent Epilepsy and Transitional Clinics. Sunday December 7, 2014 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 Authors Present: Noon – 2:00 p.m. Poster Walking Tours begin at 12:15 p.m. (see page 15 for details) Behavior/Neuropsychology/ Language Pediatrics 2.012 Neuropsychological Outcome In Children With Focal Cortical Dysplasia Following Surgical Resection For Intractable Epilepsy/R. Boada, G. Berrios-Siervo, D. L. Cohen, G. Wilkening, P. Laoprasert 2.013 Memory And Executive Functioning In Monolingual And Bilingual Children With Epilepsy/ A. Veenstra, J. Riley, J. Romain, M. Muhonen, J. Lin, M. Zupanc, G. Mucci All Ages 2.025 Cognitive Consequences Of Interictal Spikes/L. Groomes, R. Madhavan, H. Tang, N. E. Crone, J. Madsen, A. Golby, F. Lenz, G. Kreiman, W. Anderson 2.026 Use Of Magnetic Source Imaging Language Mapping To Predict Language Decline Following Left Temporal Lobe Epilepsy Surgery/ R. Doss, G. Risse, W. Zhang, R. Lyons 2.027 Spatial Dissociation Between Phonological And Semantic Speech Processing In The Lateral Temporal Lobe/M. J. Hamberger, G. M. McKhann, II, M. Miozzo 2.028 Pre- And Post-Neurosurgical Longitudinal Psychiatric Outcome In Intractable Mesial Temporal Lobe Epilepsy Patients Receiving Psychiatric Care/R. Pella, A. Velez, O. Lie, L. Morgan, K. Karkar, C. Szabo 2.029 The Impact Of Mood On Memory Complaints And Memory Performance In Patients With Epilepsy/Y. Cukier, K. Janke, B. Rabinovitz, D. Hwang, D. Mehta, C. Harden, D. Schaffer 2.030 Complication Rates During The WADA Test: One Center’s Experience/N. J. Beimer, H. Buchtel, S. Glynn Health Services Delivery of Care 2.031 Survey Of Online Patient Communities To Analyze Perceptions Of Healthcare Value/G. Cohen, B. Leymon-Porter, J. Fishman 2.032 Epilepsy Surgery Trends In A Universal Health System: Ontario, Canada (1999-2010)/J. G. Burneo, K. Liu, S. Shariff, S. Leonard, A. Garg, G. Saposnik 2.033 Antiepileptic Drug Therapy And Model Predictions Of Treatment Success/C. Dilley, M. Rozen-Zvi, J. Harrington, Y. Goldschmidt, C. Clark, P. Fritz, O. Devinsky 2.034 Outpatient Education Reduces Emergency Room Use By Epilepsy Patients/F. T. Pascual, K. Hoang, C. Hollen, R. Swearingen, A. Hakimi, J. King, D. M. Thompson 2.035 Time Elapsed From Onset Of Infantile Spasms To Diagnosis And Treatment/S. An, E. Nagarajan, I. Sánchez Fernández, C. Joshi, K. Knupp, I. Valencia, E. Wirrell, A. Berg, T. Loddenkemper 2.036 Review Of Outpatient Home Clinical Video Telehealth (CVT) In Epilepsy And Pilot Experience Within The Veterans Health Administration (VHA)/T. T. Tran, P. Kelly, A. Husain 2.037 Standardized Seizure Assessment In The EMU/O. Hope, M. Tapia, A. Balabanov 2.038 Impact Of Psychogenic NonEpileptic Seizure (PNES) Diagnosis On Acute Care Resource Utilization, Role For Psychiatric Consultation, And Follow-Up Within A Dallas County Hospital System/C. B. Culver, J. J. Konikkara, L. Howe-Martin, P. Van Ness, M. Agostini, R. Hays, P. Modur, K. Ding, P. Gupta SUNDAY Adult 2.001 Utility Of RBANS In Intractable Epilepsy Patients In A Arab Cohort/ N. A. Moussa, S. A. Al Jarrah, K. A. Siddiqui 2.002 Quality Of Life And Mood Status Of New Patients In Outpatient Clinic For Epilepsy/R. Hanaya, Y. Kashida, H. Hosoyama, K. Iida, T. Otsubo, K. Arita 2.003 Long-Term Follow-Up Of Memory Functions In Patients With Chronic Vagal Nerve Stimulation/I. Tyrlikova, Z. Hummelova, R. Kubikova, S. Telecka, M. Tyrlik, R. Kuba, M. Brazdil, J. Chrastina, J. Hemza, Z. Novak, I. Rektor 2.004 Mapping The Cognitive Network In Adults With Temporal Lobe Epilepsy/T. Kellermann, J. Lin, L. Bonilha, B. Hermann 2.005 Better Executive Function Associated With Higher Frontoparietal Functional Connectivity In The Spared Hemisphere In Left Mesial TLE/N. Kucukboyaci, K. Leyden, N. Kemmotsu, E. Tecoma, R. Q. Loi, D. Lee, C. McDonald 2.006 The Social Experience Of Stigma In A Midwestern Epilepsy Population/J. L. Moore, C. Bosler Walton 2.007 Mediators Of Quality Of Life In An Underserved Population Of Epilepsy Patients/D. Becker, A. Shallcross, D. Friedman, A. Singh, J. French, R. Jurd, T. Spruill, O. Devinsky 2.008 Unprovoked Seizures In Patients Diagnosed With Dementia: Clinical And Neurophysiologic Characteristics/R. Sarkis, B. Dickerson, Z. Chemali 2.009 A Randomized Efficacy Trial Of A Clinic-Based Decision Support System For Epilepsy Self-Management/ R. Shegog, C. Begley 2.010 Reinstatement Of Distributed Spatiotemporal Patterns Of Oscillatory Power During Associative Memory/K. A. Zaghloul, R. B. Yaffe, M. S. Kerr, S. Damera, S. V. Sarma, S. K. Inati 2.011 Relations Between Social Cognition And Quality Of Life In Epilepsy/K. Janke, Y. Cukier, S. Hwang, A. Mehta, C. Harden, S. Schaffer 2.014 Language Localization In Pediatric Epilepsy: Comparison Between Functional Magnetic Resonance Imaging (fMRI) And Electrical Stimulation Mapping (ESM)/C. M. Salinas, P. Chen, M. Korostenskaja, E. Castillo, J. Baumgartner, J. Seo, K. Lee, M. Westerveld 2.015 Neurodevelopment In Preschool Children Of Fife And Lothian Epilepsy Study: Neuroprofiles – A Population-Based Study/M. B. Hunter, K. Verity, R. Sumpter, A. McLellan, J. Shetty, M. Yoong, R. Chin 2.016 Unexpected Subclinical Spikes: Clinical And Neurophysiological Correlations/M. Mintz, L. Szklarski, M. Chadehumbe, G. Alberts, S. Woldoff, M. Mohamadpour, J. Keating 2.017 Neuropsychological Profiles Of Children With Benign Rolandic Epilepsy Highlight Vulnerability In Cognitive Efficiency, Learning And Memory/ K. Boyer, J. Girard, C. Vega, D. P. Waber, M. Takeoka 2.018 Psychiatric Disturbance In Children With Epilepsy/F. Besag, A. Aldenkamp, R. Caplan, D. Dunn, G. Gobbi, M. Sillanpaa 2.019 Computerized Training Of Working Memory In Children With Epilepsy Update/V. Terwilliger, M. Berl, E. Fisher, L. Sepeta 2.020 Gender Differences And ADHD Among Children With Epilepsy/R. Trobliger, M. E. Lancman, M. Lancman 2.021 Minnesota Epilepsy Group’s Multidisciplinary Clinic for New Onset Pediatric Epilepsy (NOPE)/E. Adams, J. Doss, K. Berg, C. Opperman, F. Ritter 2.022 Postoperative Neuropsychological Outcomes in Pediatric Patients Undergoing Temporal Lobe Epilepsy Surgery/ L. Bailey, T. Parsons, H. Blumenthal, A. Boals, M. Perry 2.023 Psychiatric Comorbidity In Children With Recent-Onset Epilepsy: A 2-Year Prospective Controlled Investigation/J. Jones, D. Almane, D. Jackson, D. Hsu, L. Zawadzki, C. Stafstrom, M. Seidenberg, B. Hermann 2.024 Left Centrotemporal Spikes Affect Language Function In BECTS/ J. Vannest, T. Maloney, J. Tenney, J. Szaflarski, K. Hibbard, D. Morita, T. Glauser 51 Sunday December 7, 2014 2.039 PACES In Epilepsy: Results Of A Self-Management Randomized Controlled Trial/R. T. Fraser, E. K. Johnson, S. Lashley, J. Barber, N. Chaytor, J. Miller, P. Ciechanowski, N. Temkin, L. Caylor 2.040 A Survey Of Family Satisfaction Of Pediatric Epilepsy Care Via Telemedicine In British Columbia (BC)/A. Faber, S. Peinhof, S. Richards, Y. Pan, M. Connolly 2.041 Yield Of Monitoring In An Adult Epilepsy Monitoring Unit/S. Agrawal, L. Turco, S. Goswami, M. Faulkner, S. P. Singh 2.042 Reducing Urgent Hospital Re-Encounters Following Epilepsy Monitoring Unit Discharge/K. Secore, J. J. Chen, A. F. Van Straten, S. P. Wei, K. A. Birney, J. J. Harrington, B. Jobst, K. Bujarski, E. J. Kobylarz, V. Thadani, T. A. Caller 2.043 Hospital Crossover Increases Utilization For People With Epilepsy: A Retrospective Cohort Study/ Z. Grinspan, J. S. Shapiro, E. L. Abramson, H. Jung, R. Kaushal, L. M. Kern 2.044 Health Care Resource Utilization And Costs Of Immediate vs. Delayed Second-Line Treatment Initiation Among Patients With Epilepsy/V. Divino, V. Bollu, C. Makin, F. Velez 2.045 Does Adherence To Epilepsy Quality Measures Predict Seizure Control?/L. V. Moura, D. Mendez, B. Vickrey, D. Hoch 2.046 Quality Of Life Outcomes After Referral To A Tertiary Epilepsy Center/M. Tom, P. Penovich, R. Doss, A. Olson 2.047 Improving The Standard Of Care For Patients With Epilepsy: Factors Influencing Hospitalization Rates/C. Begley, S. Helmers, D. Thurman, C. Dilley, C. Clark, P. Fritz, E. Faught Access to Care 2.048 Leveraging Technology To Improve Access - Epilepsy Centers Of Excellence (ECoE) Capitalizes On The Telemedicine Opportunity/P. Kelly, R. Rehman, A. Husain 2.049 Reduction Of ED Visits By Implementation Of An Urgent Clinic For Children With Established Epilepsy/D. Terry, J. Pacheco-Phillips 2.050 The Michigan Pediatric Epilepsy Telemedicine Project- Innovative Subspecialty Care Within A Medical Home/S. Joshi, S. Clark, L. Fletcher, S. Jordan 2.051 Patterns Of Neurological And Neurosurgical Care For Persons With Epilepsy/K. Sauro, S. Mah, B. Li, L. Svenson, C. DeCoster, S. Wiebe, N. Jetté 2.052 Gaps In Medicaid Coverage Among Persons With Epilepsy/ P. Bakaki, S. Koroukian, J. Albert, K. Kaiboriboon 52 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.053 Process Improvement To Reduce Time To Epilepsy Surgery/ C. Drees, R. DeBello, L. Frey, P. Korb, A. Shrestha, L. Strom, M. Spitz, C. O’Brien 2.054 Assessment Of Knowledge And Attitudes As Well As Patterns Of Referral About Epilepsy Surgery Among Family Doctors In Ontario, Canada/N. Cothros, J. G. Burneo, S. Brown, D. Steven Health Care Models 2.055 Comorbidities Associated With Frequent Emergency Department Visits Among Children With Epilepsy/A. Patel, B. Haridas, Z. Grinspan 2.056 Using The Measure Of Processes Of Care (MPOC-20) To Assess Family-Centred Care In Children With Epilepsy: Evaluating This Application/K. C. Joachim, P. Wilk, B. Ryan, K. Speechley 2.057 Changing Practice Pattern Before And After The Modification Of EMU At UNC/R. Davis, N. Odom, S. Sutton, B. Vaughn, A. Hinn, E. Ryan, H. Ritchie, H. Shin 2.058 The POEM Study: Patient Usage And Satisfaction With An Online Health Management Platform For Epilepsy/J. Hixson, D. Barnes, K. Parko, T. Durgin, S. Van Bebber, P. Wicks, A. Graham 2.059 Mapping Epilepsy Subspecialty Care By Physician Networks/H. Hamid, J. Bates, M. Pugh, J. Neil, C. Brandt 2.060 Developing An Effective Vocational Rehabilitation Model For Individuals With Epilepsy And Comorbid Disabilities In Japan: A New Hospital-Based Service Delivery System/Y. Namihisa, M. Sakata, M. Ohshima, M. Osako, M. Fujikawa Practice Resources 2.061 Characteristics Of Pediatric Inpatients In Whom Clinical Decision Making Is Changed By Continuous Video EEG Monitoring/ M. C. Spiciarich, K. Ballaban-Gil, J. C. Beal 2.062 Utility, Applications, Validity And Reliability Of The Inventory Of Neppe of Symptoms of Epilepsy and the Temporal Lobe (INSET) Compared With Ambulatory Electroencephalographic Parameters, Longitudinal Clinical Features, Anticonvulsant Responsiveness/ V. M. Neppe 2.063 Frequency, Findings, And Comparisons Of Seizure Montage Polysomnography/A. Slansky, S. Manganaro, R. Ribot, L. Tornes 2.064 Designing And Assessing Digital Patient Education Materials In An Outpatient Epilepsy Practice Setting/F. Blezin, H. Quinn, L. Ponticello, J. Richardson, J. Stribling 2.065 SUDEP: What Do Patients Want To Know?/R. RamachandranNair, A. Rama Madhava, S. M. Jack, M. J. Shapiro 2.066 Pregnancy And Seizures: Review Of Practice At George Washington University In The Past 5 Years/G. T. Que, C. Agha, U. Menon, R. Aly Epidemiology 2.067 Epilepsy In The Elderly: A Distinct Entity?/C. Josephson, N. Jette, Y. Aghakhani, P. Federico, A. Hanson, W. Murphy, N. Pillay, S. Wiebe 2.068 Mortality In Adult Epilepsy Patients Decreased Over 3 Decades: A Hospital-Based Cohort/ C. Granbichler, W. Oberaigner, G. Kuchukhidze, G. Bauer, J. Ndayisaba, K. Seppi, E. Trinka 2.069 Research Project Management In Multi-Centre Long-Term Follow-Up Studies: Meeting The Challenges/ J. Terhaerdt, K. Speechley 2.070 A Survey Of Medical Examiner Death Certification Of Vignettes On Death In Epilepsy: Gaps In Identifying SUDEP/D. Atherton, G. G. Davis, C. Wright, D. Hesdorffer 2.071 Quality Of Life In Persons With Epilepsy/N. Jette, S. Patten, S. Wiebe, A. G. Bulloch, S. Macrodimitris, K. Fiest 2.072 Epilepsy In Young Children: A Nationwide Population-Based Study/ K. Aaberg, P. Suren, C. Soraas, I. Bakken, M. Lossius, C. Stoltenberg, R. Chin 2.073 Mortality In Patients With Epilepsy And Psychogenic Nonepileptic Seizures/ C. Garcia Gracia, K. Unnwongse, K. Shea, R. Burgess, I. Najm, L. Jehi 2.074 Cause-Specific Mortality Among Children And Young Adults With Epilepsy: Results From The United States National Child Death Review Case Reporting System/ N. Tian, E. C. Shaw, M. Zack, R. Kobau, H. Dykstra, D. Thurman, T. M. Covington 2.075 The Epidemiology, Management And Outcome Of Convulsive Status Epilepticus In Children/M. Uzun 2.076 TBI Study In Moscow – Predictors Of Seizures And Outcomes/A. Guekht, V. Krylov, N. Gulyaeva, E. Gusev, I. Kaimovsky, I. Trifonov, A. Talypov, S. Asratyan, A. Yakovlev, A. Lebedeva, A. Hauser 2.077 Creation Of An Epilepsy Registry In The Veterans Health Administration/R. Rehman, P. Kelly, A. Husain 2.078 A Community-Based Study Of The Sociodemographic Risk Factors Of Epilepsy Among Adults In The Province Of Alicante (Spain)/S. Palao-Duarte Sunday December 7, 2014 2.079 Prevalence And Risk Factors Of Peri-Ictal Autonomic Changes In Children With Temporal And Frontotemporal Lobe Seizures/ M. A. Whealy, E. Wirrell, L. Wong-Kisiel, K. Nickels 2.080 Epileptic Seizures In Japanese Patients With Lacunar Infarction And Branch Atheromatous Disease/ K. Obata, M. Kinoshita, K. Sato, M. Chin, S. Yamagata, K. Shindo 2.081 Evidence Mesial TLE Is Not Always Medically Refractory/P. Tseng, M. Liu, N. Fountain 2.082 Resective Focal Epilepsy Surgery – Has Selection Of Candidates Changed?/C. Kwon, J. Neal, J. Tellez-Zenteno, A. Metcalfe, W. Hader, S. Wiebe, N. Jetté 2.083 The Clinical Characteristics Of Preschool-Aged Children Visited Emergency Room By Epileptic Seizures/B. Cha, G. Noh Public Health 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.094 Antiepileptic Drug And Cardiovascular Risk In Patients With Epilepsy/C. Huang, C. Hsieh, Y. Yang Kao 2.095 Epilepsy Transition: Challenges Of Caring For Adults With ChildhoodOnset Seizures/F. Borlot, J. Tellez-Zenteno, A. Allen, A. Ali, O. Snead III, D. Andrade 2.096 Epilepsy Knowledge And Understanding Among Parents/Caregivers Of Children With Epilepsy/L. Sanchez-Ortiz, R. Rios-Motta, M. Rios-Motta 2.097 Implicit Attitudes Toward Epilepsy In Japan/S. Tohma, K. Hara, A. Tabata, S. Tanaka, M. Hara, M. Matsuura, K. Ohta, M. Inaji, T. Maehara, Y. Sumi History of Epilepsy 2.098 Diet And Epilepsy – A Historical Review 1875-1938/ S. Goswami, S. P. Singh 2.099 Otto Löwenstein (18891995): The Forgotten Pioneer Of Video-Monitoring In Epilepsy/ G. Kraemer 2.100 The Birth Of Stigma In Antiquity: Phaedrus As Disabling Text/A. Swenson Case Studies 2.101 Refractory Partial Seizures As Manifestation Of Polymerase Gamma (POLG) Mutation In Pediatric Patients/N. Dalvi, L. Vargas, S. Karkare 2.102 Pre- And Post-Ictal Body Positions In Patients With Generalized Convulsive Seizures/S. Graf, S. Wu, J. Liebenthal, S. Rose, J. Tao 2.103 Alexia Without Agraphia In A Child – An Unusual Complication Of Epilepsy Surgical Resection In The Left Posterior Head Region/ G. Wilkening, N. Stence, M. Handler, P. Laoprasert 2.104 Resolution Of Seizures And Normalization Of EEG After Initiation Of CBD In A Patient With Doose Syndrome/J. Gold, S. Sattar, S. Wang, M. Nespeca 2.105 EEG-Based Identification Of Command-Following After Cardiac Arrest In The Minimally Conscious State/P. B. Forgacs, N. Schiff 2.106 Prolonged Propofol Infusion In Pregnant Women With Refractory Status Epileptics/N. O. Al Matrooshi, N. Ali, S. Sinha 2.107 Super Refractory Status Epilepticus In An 8 Year Old Female With Congenital Brain Anomalies, Metabolic Myopathy, And Progressive Epilepsy – Brain Autopsy And Genetic Testing Correlates/F. Khan, E. Ramsay, H. Dave, V. Sabharwal, L. Finger 2.108 Photosensitive Epilepsy With OCD Type Behavior: A Case Series Report/N. Olney, R. Rajaraman, R. Sankar, S. A. Hussain 2.109 Case Report: Seizure As The First Clinical Presentation In Adult With Childhood Genetic Disorder (Tuberous Sclerosis Complex)/T. Aung 2.110 Use Of Nicotine Patch For Drug-Resistant ADNFLE In Children: A Case Study/C. Gonsalves, K. Lee, J. Seo, B. Pullum, J. L. Norman 2.111 Surgical Treatment Of Recurrent Super-Refractory Status Epilepticus: A Case Report/U. Uysal, M. Mittal, N. Hammond 2.112 Eye Closure Sensitivity In An Adult With Suspected Temporal Lobe Epilepsy/B. Chapman, J. Vidaurre 2.113 Ischemic Epilepsia Partialis Continua And Age Of Onset: A Tale Of Two Patients And Review Of The Literature/T. Gholipour, M. Ng 2.114 Baclofen Induced NonConvulsive Status Epilepticus/ R. C. Martinez, W. Richeh, E. Mader 2.115 Bizarre Visual Hallucinations In A Child With PRES Syndrome/ P. Maertens, M. Bramhall, M. Cobia 2.116 Child Youth Epilepsy (CYE) TeleECHO – Innovative Tele-Mentoring Clinic For Child & Youth Epilepsy Care/M. Yamada 2.117 Small Temporal Encephaloceles: An Under-Recognized Cause Of “NonLesional” Temporal Lobe Epilepsy/ R. Azzam, P. Singh, A. Arain, V. Morgan, J. Neimat, B. Abou-Khalil 2.118 The Ictal Guardian Angel: A Case Report Of An Ictal Spiritual Visual Hallucination/M. A. Kellogg, V. S. Wong 2.119 Hemimegalencephaly In Tuberous Sclerosis Complex: Is Surgery The Only Treatment?/ P. B. Cerqueira, E. V. Caetano, M. G. Manreza, U. C. Reed, L. B. Sampaio, E. C. Miotto, F. A. Costa, P. S. Mendes, B. J. Correa 2.120 Asynchronous Leg Jerking With Normal Sensorium As A Presentation Of Frontal Lobe Seizures/L. Vargas, N. Dalvi, S. Karkare 2.121 Case Report Of A 24-Year-Old Patient Suffering From Seizures With G13513A Mutation In The ND5 Gene Of Mitochondrial DNA/M. Prieschl, W. Nachbauer, P. Lackner, B. Matosevic, I. Unterberger, U. Athing, G. Luef, B. Frauscher 2.122 Are Interictal Epileptiform Discharges Always Subclinical? A Study Of Cognitive Function During Interictal Epileptiform Discharges/ A. Serafini, M. Gubernale, M. Da Rold, S. Negrin, P. Bonanni 2.123 WITHDRAWN 2.124 A Case Of Neonatal Epilepsy With KCNQ2 And SCN1A Mutations/ F. Baumer, L. Rodan, J. Heath, D. Harris, J. Soul 2.125 Sudden Onset Alexia Without Agraphia Caused By A Reversible Splenial Lesion (RSL); Two Cases Of RSL In Non Epileptic Patients On Lamotrigine And Topomax/R. K. Gupta, P. Sofat, P. Li, T. Guttuso, R. Sawer, Jr. 2.126 Lesion Negative Anterior Cingulate Epilepsy/N. Lacuey Lecumberri, J. Chapa Davila, M. Pelayo, S. Amina, J. Turnbull, J. Miller, H. Luders, S. Lhatoo SUNDAY 2.084 Effects Of Epilepsy In ADHD And Quality Of Life/M. Salam, K. Works 2.085 A Mobile Health-Intensive Comprehensive Care Delivery Model For Amplifying Outreach For Refractory Epilepsy And Comorbid Mood Disorders/M. A. Rossi, N. Monica, K. Babiarz, L. Cendejas, R. Hanson, M. Tshionyi, J. Endres, M. Jain 2.086 Attitude Of Neurologists In The United Arab Emirates Towards Epilepsy And Motor Vehicle Accidents/A. Shatila, O. Khaddam, N. O. Al Matrooshi, T. Alsaadi 2.087 Trends In Healthcare Charges And Length Of Stay For People With Epilepsy, South Carolina, 20002011/D. A. Wilson, A. Selassie 2.088 Engaging Primary Care Providers In Epilepsy Quality Measures/S. T. Arnold, R. R. Said, D. Sirsi, E. A. Burch 2.089 BE- Beyond Epilepsy, Education, Awareness And Advocacy Program For Frontline Healthcare Providers In Tanzania/L. Jurasek, S. Mbelwa 2.090 Premature Mortality In Poor Health And Low Income Adults With Epilepsy/K. Kaiboriboon, N. Schiltz, P. Bakaki, S. Lhatoo, S. Koroukian 2.091 What Affects The Self-Stigma And Self-Esteem Of Persons With Epilepsy?/A. Tabata, K. Hara, S. Tohma, S. Tanaka, M. Hara, K. Ohta, M. Matsuura, M. Inaji, T. Maehara, Y. Sumi 2.092 Do Drivers With Epilepsy Have Higher Rates Of Motor Vehicle Accidents Than Those Without Epilepsy?/P. Naik, M. Fleming, P. Bhatia, C. Harden 2.093 The Effects Of Reports Of Car Accidents Caused By Persons With Epilepsy On Its Stigma In Japan/ K. Hara, S. Tanaka, Y. Hirose, S. Tohma, M. Matsuura, K. Ohta, M. Inaji, M. Hara, T. Maehara, Y. Sumi Poster Session 2 53 Sunday December 7, 2014 2.127 Refractory Focal-Onset Seizures As A Consequence Of Cerebral Amyloid Angiopathy-Related Inflammation: A Case Study/ B. Appavu, H. Seif Eddeine 2.128 Desmoplastic Infantile Ganglioglioma Presenting With Neonatal Status Epilepticus/E. Ng, S. Karkare, M. Laureta, J. Maytal, S. Schneider 2.129 Seizure After Laminectomy Associated With Pneumocephalus/ N. Cinar, M. Cakmak, S. Sahin, B. Kelten, S. Karsidag 2.130 Insight Into The Precuneus: A Novel Seizure Semiology In A Child With Epilepsy Arising From The Mesial Parietal Region/J. A. Mailo Professionals in Epilepsy Care Nursing 2.131 Quality Assurance In The Epilepsy Monitoring Unit: Time To Seizure Recognition And Intervention/D. Nelson, D. Briggs, J. Shen, K. Lovell, E. Harrell, E. Wedberg, P. Modur 2.132 Seizure-Related Falls In The Epilepsy Monitoring Unit/E. Yagiri, H. Arai, H. Suzuki, K. Jin, M. Fujikawa, K. Kato, Y. Kakisaka, M. Iwasaki, K. Yamauchi, N. Nakasato 2.133 Role Of A Nurse Program Coordinator: Comprehensive Epilepsy Clinic/M. Gustafson, K. Gugler 2.134 To Coordinate Or Not To Coordinate?/K. Orton, G. R. Nelson, C. Van Orman 2.135 Improving Quality Of Care Following EMU Discharge/R. Mealey, J. Pollard, K. Davis, C. Kohler, R. Shmuts, S. Chen, B. Oommen, C. Hill 2.136 Creating A Standard Of Care For Epilepsy Patients: Starting with Nursing Staff in the Adult Epilepsy Monitoring Unit/R. Ward-Mitchell, M. Bensalem-Owen, G. Plank, R. Woodward 2.137 Epilepsy Nurse Led Vagus Nerve Stimulator Program: Comprehensive Epilepsy Center/ K. J. Gugler, M. Gustafson Psychosocial 2.138 Perception Of Happiness In Adults With Epilepsy/J. Cohen, D. F. Tovar Quiroga 2.139 Driving Safety In People With Non-Epileptic Events/K. S. Ziemba, J. F. Drazkowski Education 2.140 A Case Report - Importance Of Early Treatment In Anti-NMDA Receptor Encephalitis/T. Aung 2.141 What’s In A Year? EEGs Encountered In An ACGME-Accredited Clinical Neurophysiology Fellowship/ E. C. Lewis 2.142 SUDEP Experience And Practice In A Large Group Of Child Neurologists/J. Reese, Jr, D. Friedman, W. Gaillard 54 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.143 A Single Center Survery Of Pediatric Neurologists’ Views On Epilepsy Surgery And Medically Refractory Epilepsy/J. Bolton, G. Dabscheck Neurophysiology Video EEG Epilepsy-Monitoring 2.144 Spread Of The Ictal Discharge From Hippocampus And Cortex To Scalp EEG Electrodes In Temporal Lobe Epilepsy/D. G. Vossler, A. J. Bell, D. L. Kraemer 2.145 WITHDRAWN 2.146 The Prognostic Value Of Early EEG Background During Hypothermia On MRI And Neurodevelopmental Outcome In Neonates With HypoxicIschemic Encephalopathy/M. Balestri, M. Lispi, S. Pro, D. Longo, F. Vigevano, M. Cilio 2.147 Microseizures Recorded With Clinical EEG Acquisition System/ L. Higdon, G. Ghearing, M. Richardson, C. Plummer 2.148 Prevalence Of Ictal Infraslow Potentials (IISPs) In Scalp EEG/ N. Dorland, J. Lavingia, C. Carlson, M. Raghavan 2.149 Right Temporal Lobe Seizure Frequently Induces Precipitous Heart Rate Increase/K. Kato, K. Jin, Y. Kakisaka, M. Iwasaki, M. Fujikawa, M. Aoki, N. Nakasato 2.150 Intracranial Ictal EEG Patterns And Seizure Onset Zone: A Systematic Review/S. SINGH, S. Sandy, Y. Aghakhani, N. Pillay, S. Wiebe 2.151 Evidence For A Multi-Night Improving Trend In Sleep During Intracranial EEG Monitoring/R. Joshi, N. Gaspard, I. Goncharova, M. Pavlova, R. Duckrow, J. Gerrard, D. Spencer, L. Hirsch, H. Zaveri 2.152 Interictal Epileptiform Discharges Before And After A Generalized Tonic Clonic Seizure In A Patient With Generalized Epilepsy – Case Report/D. Sabau, D. W. Harvey, M. Mehrizi 2.153 Semiological Characterization And Clinical Profile Of Patients With Psychogenic Non-Epileptic Seizures/ S. Cieza, P. Amaro, I. Marcotegui, C. Viteri Torres, M. Alegre, J. Iriarte, E. Urrestarazu 2.154 Cardiac Sympathetic Nerve Activity Is Abnormally Suppressed During Wakefulness In Patients With Epilepsy/N. Suzuki, K. Jin, K. Kato, Y. Kakisaka, M. Iwasaki, N. Nakasato 2.155 Texting in Epilepsy: Activation or Distraction?/B. DiCaccio, K. H. Yelvington, W. Tatum ICU EEG 2.156 High Frequency Oscillations Are Associated With Cognitive Processing In Human Recognition Memory/M. T. Kucewicz, J. Cimbalnik, J. Matsumoto, B. Brinkmann, M. Bower, V. Vasoli, V. Sulc, F. Meyer, R. Marsh, M. Stead, G. Worrell 2.157 Misleading EEG Lateralization Associated With Midline Shift/ S. Abramovici, G. Ghearing 2.158 The Adequacy Of Density Spectral Array (DSA) And AmplitudeIntegrated EEG (aEEG) For Neonatal And Pediatric Seizure Identification/ H. Yamamoto, J. Natsume, H. Kidokoro 2.159 The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic Ischemic Encephalopathy Undergoing Hypothermia/R. Obeid, M. Naik, M. Painter, R. Telesco, Y. Sogawa, S. Gedela, V. Lee, J. Wisnowski, A. Panigrahy 2.160 Inter-Rater Agreement For Identification Of Electrographic Seizures And Periodic Discharges In Critically Ill Patients/D. Shiau, J. A. Desrochers, J. J. Halford, B. J. Kolls, G. U. Martz, S. R. Sinha, K. F. Haas, E. E. Kutluay, N. J. Azar, R. T. Kern, K. M. Kelly, J. C. Sackellares, S. M. LaRoche 2.161 EEG Predictors Of Antiepileptic Drug Adjustments In Critically Ill Patients – A Prospective Observational Study/G. Wang, A. M. Khawaja, G. Cutter, J. Szaflarski 2.162 Skin Breakdown In Patients Undergoing EEG Monitoring In The NICU/S. Manganaro, E. Cruz, M. Andriola, A. Slansky, L. Manganas 2.163 EEG Predictors Of Outcomes In Critically Ill Patients – A Prospective Observational Study/ A. M. Khawaja, G. Wang, G. Cutter, J. P. Szaflarski Clinical Epilepsy Classification and Syndromes 2.164 Clinical Characteristics Of Benign Convulsions With Mild Gastroenteritis/H. Kim, S. Kim, Y. Kim, J. Kim, W. Kim 2.165 Ictal And Postictal Aphasia Are Most Common In Temporal Lobe Epilepsy/A. M. Loesch, H. Steger, C. Losher, C. Vollmar, J. Remi, E. Hartl, S. Noachtar 2.166 Comparing EMU Staffing Models For Spell Classification Admissions/S. D. Spritzer, B. D. Pirotte, S. Agostini, K. Noe, J. Drazkowski 2.167 Seizure Semiology In Pediatric Posttraumatic Epilepsy/J. T. Park, H. T. Chugani 2.168 Incidence And Seizure Characteristics In Autoimmune Epilepsy Patients/J. Byun, J. Sunwoo, J. Moon, J. Shin, K. Jung, S. Lee, K. Jung, S. Lee, K. Chu, J. Jun 2.169 Familial Ring Chromosome 20 Syndrome – A Case Report/ I. Unterberger, H. Schober, D. Kotzot, C. Fauth Sunday December 7, 2014 Clinical Diagnosis 2.177 Impact Of Specialty Epilepsy Consultation On Management And Outcomes Among Veterans/ A. Panduranga, E. Boudreau, M. Salinsky 2.178 Radiological And Pathological Discordance Of Mesial Temporal Lobe Sclerosis In Pediatric Temporal Lobectomy/J. Kassiri, D. Sinclair, M. Wheatley 2.179 Left Temporal Lobe Epilepsy Presenting As Apparent LifeThreatening Events In Infants/ J. Kassiri, R. Tang-Wai 2.180 Longer Seizure Duration Terminates A Seizure Cluster During Epilepsy Monitoring/V. Ferastraoaru, S. R. Haut, R. B. Lipton, A. D. Legatt, J. Blumberg, M. Dumpelmann, A. Schulze-Bonhage 2.181 Initial Involvement Of The Posterior Orbital Gyrus In Prolonged Panic Attack Associated With Simple Partial Status Epilepticus On Depth Electrodes/J. M. Chung, C. M. Reed, U. Rutishauser, A. N. Mamelak 2.182 Seizure Types And Electrographic Patterns Of Angelman Syndrome In South Indian Children/ V. Puthenveettil, A. G. Roy, S. Nampoothiri 2.183 Epileptic Pain As A Rare Symptom Of Seizures/N. Pazarci, N. Bebek, B. BAYKAN, C. Gurses, A. Gokyigit 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.184 Bitemporal Epilepsy: AnatomoElectro-Clinical Features And Comparison With Unitemporal Epilepsy/G. Didato, V. Chiesa, F. Villani, V. Pelliccia, F. Deleo, F. Gozzo, M. Canevini, R. Mai, R. Spreafico, M. Cossu, L. Tassi 2.185 Predictors For Seizure Recurrence In 228 Developmentally And Neurologically Normal Children With A Newly Diagnosed, Unprovoked Seizure/H. Kim, A. Oh, X. de Grauw, A. de Grauw 2.186 Drug-Resistant Epilepsy With Neurocysticercosis And Mesial Temporal Lobe Sclerosis/ L. M. Espaillat Solano, A. Martinez-Perez, M. Leon-Vazquez, J. Perez-Ruiz, R. Carrillo, M. Alonso-Vanegas, A. Fleury, I. E. Martinez-Juarez 2.187 TOSCA – Tuberous Sclerosis Registry To Increase Disease Awareness: First Interim Data On Epilepsy/R. Nabbout, C. Hertzberg, P. Curatolo, P. de Vries, M. Feucht, E. Belousova, M. Dahlin, J. Ferreira, J. lawson, A. Macaya, F. O’ Callaghan, M. Benedik, V. Sander, S. Youroukos, A. Jansen, S. Jozwiak 2.188 Concordance Between History And Epilepsy Monitoring Unit Evaluation For Diagnosing Seizures/ K. Siddiqui, E. Khalid, R. S. Siddiqui, S. Sinha 2.189 Autoimmune Epilepsy: Clinical Features, Management And Outcomes/D. Dubey, R. Hays, P. Gupta, K. Ding, M. Agostini, P. Van Ness, S. Vernino 2.190 Electroclinical Correlation Of Typical Absence In Idiopathic Generalized Epilepsies (IGE)/ W. S. Sanchez Barrera 2.191 Is Treatment-Resistant Focal Epilepsy Less Frequent In Veterans?/M. Lopez, A. Kanner 2.192 New Onset Temporal Lobe Epilepsy And REM Sleep Behavior Disorder: Further Demonstration Of A Possible Association?/M. Junna, E. St. Louis, E. Duwell 2.193 Rhythmic ictal Nonclonic Extremity Movements In Temporal Lobe Epilepsy: A Reappraisal/K. Ding, M. Agostini, P. Gupta, R. Hays, P. Van Ness, P. Modur 2.194 Predictors Of Postneonatal Epilepsy And Sensitivity Of The First Hour Of EEG Monitoring In Predicting Risk Of Seizures In The Neonatal Period/A. J. Hani, K. Cornett, B. Smith, W. Gallentine 2.195 Improving Long-Term Management Of Epilepsy Using Wearable Multi-Modal Seizure Detection System/S. Sabesan, K. Rose, G. Carlson, A. Mueller, R. Sankar, J. Wheless 2.196 Ambulatory EEG In Children: When Is It Most Helpful?/S. Adhami, K. Singh, C. Harini 2.197 Siblings with Juvenile Huntington’s Disease having two different Seizure Types: A Case report/C. Srikanth Mysore, D. Madhavan, D. Mudugal, T. Jasinski Clinical Treatments 2.198 Surgical Outcomes Of Patients With Focal Epilepsy Evaluated By Intracranial EEG Monitoring/S. Sandy, S. Singh, Y. Agha-Khani, N. Pillay, S. Wiebe 2.199 Efficacy And Tolerability Of Intravenous Lacosamide In Daily Practice – Results Of A Large Independent Registry/N. Lang, U. Stephani 2.200 Successful Treatment Of Febrile Illness-Related Epilepsy Syndrome (FIRES) And New Onset Refractory Status Epilepticus (NORSE) With Plasma Exchange And Rituximab/J. Berkeley, P. Foreman, A. Foroughi, F. Tirol 2.201 Efficacy And Safety Of Intravenous Lacosamide In Pediatric Status Epilepticus/K. Poddar, R. Sharma, Y. Ng 2.202 Application Of A EEG To Severe Motor And Intellectual Disability (SMID) – Utility In Control Of Seizures/T. Nagasawa, Y. Okoshi, S. Atsumi, N. Tanuma, M. Fukumizu, K. Tominaga 2.203 Acetazolamide For Spike-Wave Index Reduction In Electrical Status Epilepticus In Slow Wave Sleep/ A. Fine, E. Wirrell, L. Wong-Kisiel, K. Nickels 2.204 A Double-Blinded, Randomized Evaluation Of Neuropsychological And Behavioral Changes In Children With Benign Epilepsy With Centrotemporal Spikes Treated Either With Levetiracetam Or Sulthiame/ I. Borggraefe, M. Bonfert, L. Gerstl, F. Heinen, B. Neubauer 2.205 Efficacy And Tolerability Of Modified Atkins Diet (MAD) And Low Glycemic Index Diet (LGID) Among Adults With Medically Intractable Epilepsy/A. Balabanov, K. Roehl 2.206 Glioma Associated Epilepsy/ M. Fiol, M. Qureshi, M. Hunt, A. Malik 2.207 Epilepsy And Bicycle: Observation In The Epilepsy Monitoring Unit/J. Kim, K. Hwang, E. Joo, S. Hong, D. Seo 2.208 Outcomes Of Vagal Nerve Stimulation (VNS) For Intractable Epilepsy/V. S. Wasade, K. Mohanarangan, A. Gaddam, L. Schultz, J. Schwalb, M. Spanaki 2.209 Responsive Neurostimulation In Patients With Periventricular Nodular Heterotopia (PNH)/P. Rutecki, A. Herekar, P. Van Ness, G. Bergey, C. Bazil, D. King-Stephens, F. Sun, R. Kapur, M. Morrell 2.210 High Dose Oral Steroids For Treatment Of Infantile Spasms: The Wake Forest Baptist Medical Center (WFBMC) Experience/I. Khaytin, M. Silvia, G. Popli, A. Grefe, C. Lee SUNDAY 2.170 SUDEP Awareness Among Pediatric Practitioners: A Descriptive Survey of United States Physicians/ S. Massey, D. Friedman, N. Berberi, O. Devinsky, S. Kothare 2.171 Epilepsy Syndrome, MRI Pathologies and Treatment Response In Patients With First Seizure And New-Onset Epilepsy – A Comparison Of Patients Of Middle Age (50-60 Years) Versus Elderly Patients (> Older 60 Years)/B. Pohlmann-Eden, C. Crocker, K. Legg, M. Schmidt 2.172 Semiology Of Hypermotor Seizures/K. Alqadi, R. R. Sankaraneni, U. Thome Costa, P. Kotagal 2.173 Participant Eligibility In The Human Epilepsy Project/S. Cristofaro, C. Freyer, V. Mays, O. HEP Investigators 2.174 Not All But The Most Patients With CSWS Are Atypical Benign Partial Epilepsy In Childhood/ H. Shiraishi, K. Egawa, K. Otsuka, M. Nakajima, T. Ito, M. Narugami, S. Nakane, K. Takahashi 2.175 Patterns Of Disease Progression In Epilepsy/D. Ekstein, M. Nassar, T. Ben Hur, R. Bar Yossef, M. Benifla, O. Bennett 2.176 Delay To Initiation Of Treatment: Data From The Human Epilepsy Project/R. Hennessy, M. Mendoza, J. French, S. Haut, J. Hixson, K. Detyniecki, O. HEP Investigators Poster Session 2 55 Sunday December 7, 2014 2.211 Evaluation Of Clobazam Conversion Therapy Replacing Clonazepam In Patients With Medically Refractory Epilepsy/S. Marsh, S. S. Chung 2.212 Responsive Stimulation Of Eloquent Cortex/R. Kapur, R. Duckrow, C. Heck, S. Eisenschenk, R. Gwinn, E. Geller, M. Smith, A. M. Murro, G. Worrell, R. Wharen, V. Salanova, G. L. Barkley, R. Gross, B. Jobst, C. Bazil, D. Nair, D. King-Stevens, E. Mizrahi, T. Crowder Skarpaas, M. Morrell Prognosis 2.213 Electrodermal Activity During Complex Partial Seizures Is Dependent Of Age And MRI Lesions/ S. Thome-Souza, J. Klehm, R. Sarkis, K. kapur, E. Nagarajan, R. Picard, M. Jackson, C. Doshi, C. Papadelis, B. Dworetzky, C. Reinsberger, T. Loddenkemper 2.214 Predictive Risk Factors Of Seizure-Related Injury And Postictal Behavioral Changes/C. Maideniuc, A. Stino, M. Basha 2.215 Outcomes Of Genetic Generalized Epilepsy At A Comprehensive Epilepsy Center/ S. Maturu, T. Dayyoub, B. Assaad, L. Schultz, V. S. Wasade, E. Muma, T. Howard, J. Snyder, S. Gaddam, N. Mahmood, J. Constantinou, G. L. Barkley, M. Spanaki, A. Zillgitt 2.216 Latency To Treatment Of Status Epilepticus: Long-Term Outcomes/J. Cheng 2.217 Prognosis Of Idiopathic Generalized Epilepsy Patients Who Had At Least 10 Years Follow Up And Predictors Of At Least 5 Years Seizure Remission Off Medication/ H. Hosny 2.218 Relationship Between Biomarkers Of Vascular And Metabolic Health And Cognition In Aging Persons With Chronic Epilepsy/B. Hermann, M. Sager, R. Koscik 2.219 WITHDRAWN 2.220 Comparison Between Febrile And Afebrile Convulsion With Mild Gastroenteritis/S. Kim, I. Lee, T. Eom 2.221 Prediction of Future Epilepsy in Neonates Who Received Selective Head Cooling for HIE/T. McDonough, J. Paolicchi, L. A. Heier, N. Das, M. Engel, J. M. Perlman, Z. Grinspan 2.222 Treatment Resistance Correlates With ECG Abnormalities In A Pilot Clinical Surveillance Of Epilepsy Patients/P. Zohrevand, M. Diaz, A. Amador, A. Goldman 2.223 Detrimental Impact Of Convulsive Status Epilepticus On Health-Related Quality Of Life Apparent At 24 Months after Epilepsy Diagnosis In Children: A Longitudinal Population-Based Study/M. Ferro, S. Levin, S. Wiebe, R. Chin, C. Camfield, K. Speechley 56 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.224 How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones?/ E. Vanli- Yavuz, B. Baykan, S. Sencer, Z. Matur, N. Bebek, A. Gokyigit, O. Oktem, C. Gurses 2.225 N20 Of Median Nerve SSEP Is An Early Predictor For Developmental Outcome After Hemispherotomy In Patients With Ohtahara Syndrome With Hemimegalencephaly/K. Sugai, R. Honda, T. Saito, E. Nakagawa, H. Komaki, M. Sasaki, A. Takahashi, T. Kaido, Y. Kaneko, T. Otsuki 2.226 Risk Factors Of Postictal Generalized Electroencephalographic Suppression In Generalized Convulsive Seizures/V. Alexandre, B. Mercedes, L. Valton, L. Maillard, J. Petit, A. Biraben, F. Chassoux, P. Kahane, B. De Toffol, F. Bartolomei, P. Derambure, V. Navarro, E. Hirsch, A. Crespel, C. Marchal, P. Thomas, P. Ryvlin, S. Rheims 2.227 Initial EEG Patterns As An Adjunctive Prognostic Indicator In Cardiac Arrest Patients Undergoing Therapeutic Hypothermia/ E. Tsimerinov, D. Maher, H. Tran, M. Nuno, D. Eliashiv, D. Palestrant, A. Moheet, W. Yu, J. Chung Women’s Issues 2.228 Improving The Prescription Of Folic Acid To Women Taking Antiepileptic Drugs/A. Sharma, J. Cavitt, M. Privitera, B. D. Moseley 2.229 A Transdisciplinary Professional Clinic For Pregnant Adolescents And Young Adults With Epilepsy In A Midwest Children’s Hospital/M. Turner, L. Garrity, K. Junger, S. Standridge 2.230 Epilepsy And Reproductive Issues In Women With Epilepsy: Survey Of An Unselected Community Of Women With Epilepsy/ O. Laban-Grant, E. Fertig, M. Malik, C. B. de la Pena, M. Fleming, M. E. Lancman, P. Klein, M. Lancman 2.231 Occurrence Of Obstetric Complications In Women With Epilepsy Results From The Oppland Perinatal Database In Norway/A. Farmen, T. Tomson, K. Nakken, M. Lossius 2.232 Quality Of Life In Women With Epilepsy In Pregnancy: Experience At A Tertiary Care Centre/J. Qiang, E. Bui 2.233 Menstrual Cycle Length In Women With Epilepsy Trying To Conceive Compared To Healthy Controls/C. Harden, C. Lau, P. Pennell, E. Bagliella, J. Huynh, R. Kashambwa, N. Llewellyn, B. Kaufman, A. Davis, J. French 2.234 Seizure Control, Acceptability, And Drug Interactions During Use Of The Levonorgestrel Intrauterine System In Women With Epilepsy/ A. Davis, A. Pack, H. Saadatmand Neuroimaging Functional Imaging 2.235 MSI/MEG And DTI Tractography In Tuberous Sclerosis Complex/ W. Zhang, D. Dickens, J. Doescher, T. Passe, F. Ritter, M. Dunn, M. Frost 2.236 Individual-Subject Frontolimbic Neurocircuit Activations During Emotional Processing And Behavioral Inhibition In Psychogenic Non-Epileptic Seizures/D. L. Perez, B. A. Dworetzky, H. Pan, G. Baslet, D. R. Vago, L. Leung, J. Epstein, D. A. Silbersweig, E. Stern 2.237 The Temporal Instability Of The Ventral Default Mode Network Connectivity In Intractable Epilepsy/ L. Robinson, P. Barnett, G. Doucet, D. Pustina, A. Ghani, J. Tracy 2.238 In Vivo Optical Signal Changes Observed With Optical Coherence Tomography In A Focal Cortical Seizure Model/J. Szu, M. Eberle, C. Rodriguez, M. Hsu, B. Park, D. Binder 2.239 Simultaneous EEG-NIRS (Near InfraRed Spectroscopy) Guided By MEEG And EEG-fMRI To Assess The Neurovascular Coupling In Focal Epilepsy: A New, Non-Invasive, Multimodal Approach/G. Pellegrino, A. Machado, S. Watanabe, N. Drouin, L. Allard, J. Lina, J. Hall, E. Kobayashi, C. Grova 2.240 Computer-Automated Focus Lateralization Of Temporal Lobe Epilepsy Using fMRI/S. Chiang, H. Levin, Z. Haneef 2.241 Moving Towards New Techniques In The Evaluation Of The Ictal Onset Zone: Ratio Ictal SPECT (RISCOM) Using A 72-Detector Focused Collimator Ring SPECT Scanner System/M. Jain, K. Krug, P. Balaguera, C. M. Millan, A. Jalota, V. Pylypyuk, R. W. Byrne, M. A. Rossi 2.242 Frequency Dependent Evolution Of Functional Networks Over Years Of Duration In Temporal Lobe Epilepsy/ V. L. Morgan, B. Abou-Khalil, B. P. Rogers 2.243 Classification Of Individuals With Temporal Lobe Epilepsy Using Network Analysis Of Resting-State Functional MRI/D. Vaughan, M. Pedersen, C. Tailby, G. Jackson 2.244 Components Of Epileptic Networks Show Pathological Coherent Fluctuations Even In The Absence Of Scalp Spikes/F. Pittau, G. Iannotti, E. Abela, F. Grouiller, M. Seeck, C. Michel, S. Vulliemoz 2.245 Nonverbal Memory In Patients With Mesial Temporal Lobe Epilepsy And Amygdala Lesions/G. Kuchukhidze, L. Zamarian, E. Schmid, F. Koppelstaetter, C. Siedentopf, M. Delazer, H. Jokeit, E. Gizewski, G. Luef, I. Unterberger, E. Trinka 2.246 Inter-Hemispheric Asymmetries In Resting-State fMRI Activity For Identifying Seizure Onset And Irritative Zones/D. Groppe, P. Mégevand, Z. Fallil, S. Hwang, J. Hira, A. Abisogun, C. Yan, R. C. Craddock, M. Milham, S. Bickel, C. Harden, A. Mehta Sunday December 7, 2014 2.247 Brain Graph Theory Topology Changes Associated With Antiepileptic Drug Use/Z. Haneef, H. Levin, S. Chiang 2.248 Real-Time Functional Mapping (RTFM) Of Language Function In Patients With Intractable Epilepsy/ B. Edmonds, M. Korostenskaja, P. Chen, A. Schaal, C. M. Salinas, M. Westerveld, E. Castillo, G. Schalk, P. Brunner, J. Baumgartner, K. Lee 2.249 Comparing Four Connectivity Measures: From Simultaneous Direct Intracranial Stimulation And fMRI, EEG, DWI, And rs-fMRI/S. E. Jones, A. Alexopoulos, J. Bulacio, J. Gonzalez-Martinez, J. Mosher, D. Nair, I. Najm, M. Zhang 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 Cormorbidity (Somatic and Psychiatric) Medical Conditions 2.257 Mortality In Elderly Veterans With New And Chronic Epilepsy/ P. J. Foreman, A. VanCott, M. Pugh 2.258 Post Ictal Headache Phenotype In Epileptic Seizures And NonEpileptic Spells/S. Kapoor, A. Swaminathan 2.259 Diagnosis Of Pnes In Childhood: Is It Possible To Suspect Of Non Epileptic Seizures In The First Standard Neurological Interview For Epilepsy?/R. Alessi, P. Rzezak, S. Vincentiis, K. Valente 2.260 Delay In Diagnosis Of Psychogenic Non-Epileptic Seizures In Children And Adolescents: Age Matters/K. Valente, R. Alessi, S. Vincentiis 2.261 Post Ictal Cardiac Asystole In A Series Of Pediatric Cases With Epilepsy Refractory To Medical Treatment/E. Andrade, Z. Liu 2.262 Sleep Disorders And Circadian Rhythm In Epilepsy Revisited: A Prospective Controlled Study/G. Luef, B. Frauscher, D. Gabelia, M. Prieschl, K. Chea, M. Hofer, B. Hoegl, I. Unterberger Psychiatric Conditions 2.263 ADHD In Childhood Epilepsy: Clinical Determinants Of Severity And Of Response To Methylphenidate/ S. Rheims, V. Herbillon, M. Milh, S. Auvin, S. Napuri, C. Cances, P. Berquin, P. Castelnau, S. N. Guyen, The Tich, F. Villega, H. Isnard, R. Nabbout, B. Kassai, A. Arzimanoglou 2.264 Recognition Of Mood And Anxiety Disorders In Patients With Epilepsy By General Neurologists: A Comedy Of Contradictions/R. Ribot, A. Kanner 2.265 Does Screening For Major Depressive Episodes And Generalized Anxiety Disorder By Epileptologists Translate In Their Remission?/ A. Kanner, J. Kozupsky 2.266 Comorbidity Between Epilepsy And Psychiatric Disorders – A Population-Based Study/ J. Christensen, C. Petersen, M. Vestergaard 2.267 Stigma Is Uncommonly Reported By Adolescents With Epilepsy/J. Langer, M. Thompson, D. Taplinger 2.268 Autism Spectrum Disorder And Neurocognitive Comorbidities In Patients With Epilepsy And ESES/ M. El-Hagrassy, R. C. Gunasekara, K. Mehrotra, C. Mohan, D. Francois, L. Probst, Y. Eksioglu 2.269 Health Care Utilization Following Diagnosis Of Psychogenic Seizures In U.S. Veterans/M. Salinsky, C. Evrard, D. Storzbach, E. Goy, E. Boudreau 2.270 Sleep Problems, Risk Factors, And Clinical Implications Among Children At A Tertiary Care Epilepsy Center/K. Fehr, E. Adams, K. Berg, M. Frost 2.271 Depression Screening In Youth With Epilepsy: The NDDI-E-Y/ J. Wagner, G. Smith, B. Brooks, M. Mueller 2.272 Subjective Forgetfullness In People With Epilepsy/I. Elmenshawi, M. A. Mohamed, A. Zaher 2.273 Psychiatric Assessment Of Psychogenic Nonepileptic Seizures: A Comparison Of Approaches/ X. F. Jimenez, J. Bautista 2.274 Psychosis In Temporal Lobe Epilepsy With Hippocampal Sclerosis: Corroborating The Relevance of Laterality/ K. Rodrigues Ximenes Goldberg, S. de Vincentiis, S. E. de Melo-Souza, F. J. Arruda, P. C. Ragazzo, H. van der Linden Jr., K. Dualibi Ramos Valente 2.275 Predictors Of Major Depression In Multiplex Epilepsy Families/S. T. Sorge, J. O. Okeke, V. Tangel, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman Antiepileptic Drugs SUNDAY Other Emerging Techniques 2.250 Impact Of coregistered Multimodal Neuroimaging On Pediatric Epilepsy Surgery Planning And Postoperative Outcome/D. Freedman, L. Bailey, A. Hernandez, S. Malik, C. Keator, D. Donahue, M. Perry 2.251 White Matter Compromise Modulates Verbal Fluency Performance In Patients With Atypical Language Dominance/N. Kemmotsu, K. Leyden, N. Kucukboyaci, V. Iragui-Madoz, E. Tecoma, C. McDonald 2.252 Detection Of The Dominant Brain Network In Bitemporal Lobe Epilepsy With MEG/S. Bowyer, A. Zillgitt, M. Spanaki, K. Mason, V. S. Wasade 2.253 Clinical Validity Of MEG-Guided Tractography (MEG-GT) To Characterize Networks Supporting Word Comprehension/E. Castillo, T. Kleineschay, C. M. Salinas, M. Korostenskaja, P. Chen, J. Baumgartner, J. Seo, K. Lee 2.254 Regional Cerebral Hypoperfusion From Arterial Spin Labeling Correlates With EEG Lateralization In Patients With Epilepsy/H. Kadiwala, A. Verma, S. H. Fung 2.255 Predicting Post-Surgical Language Outcome With ECoG-Based Real-Time Functional Mapping (RTFM)/M. Korostenskaja, P. Chen, C. M. Salinas, M. Westerveld, J. Seo, E. Castillo, A. Schaal, B. Edmonds, G. Schalk, P. Brunner, M. Elsayed, J. Baumgartner, K. Lee 2.256 Stereotactic Laser Ablation: How Much Hippocampus And Amygdala Ablation Volume Optimizes Seizure Freedom?/A. Sharan, C. Wu, M. Sperling, R. Gross, J. Willie, D. Labiner, M. Weinand, R. Marsh, G. Worrell, G. Cascino, G. Popli, D. Couture, J. J. Shih, W. Tatum, A. Mehta, C. Harden, R. Patwardhan, B. Fernald, A. Shetty, A. Gowda Poster Session 2 Clinical Trials 2.276 Review Of Suicidality Events In Perampanel Clinical Studies/ A. B. Ettinger, C. Dobrinsky, H. Yang, B. Williams, D. Xing, R. Fain, A. Laurenza 2.277 Safety Of Levetiracetam Among Infants Younger Than 12 months – Results From A European Multicenter Observational Study/ A. Arzimanoglou, P. Berquin, C. Lösch, J. Bentz 2.278 Analysis Of Psychiatric Adverse Events In Three Phase III Controlled Trials Of Eslicarbazepine Acetate As Adjunctive Therapy For Refractory Partial-Onset Seizures/ V. Biton, B. Shneker, M. Carreño, E. Ben-Menachem, F. Rocha, H. Gama, D. Blum, R. Claus 2.279 Perampanel Discontinuation Is Not Associated With Self-Reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies/M. A. Rogawski, H. Yang, R. V. Fant, B. Williams, D. Xing, C. Dobrinsky, A. Laurenza 2.280 Clinical And Quality Of Life Assessments Following Long-Term Treatment With USL255 (Qudexy™ XR; Extended-Release Topiramate) In Patients With Refractory PartialOnset Seizures: PREVAIL OLE/ B. Anders, R. Hogan, S. S. Chung, A. M. Clark, I. Blatt 57 Sunday December 7, 2014 2.281 Long-Term Safety And Tolerability Of USL255 (Qudexy™ XR; Extended-Release Topiramate) In Patients With Refractory PartialOnset Seizures: PREVAIL OLE/I. Blatt, S. S. Chung, B. Anders, A. M. Clark, R. Hogan 2.282 High Retention Rate In Patients With Refractory Epilepsy Treated With Eslicarbazepine Acetate/T. Svendsen, E. Brodtkorb, A. Reimers, E. Sætre, S. Johannessen, C. J. Landmark 2.283 High Predictability Of Plasma Lacosamide And No Differences By Different Age And Gender Through Normalization Processes/C. Schaefer, W. Cawello, J. Andreas 2.284 Is Half-Life A Clinically Relevant Measure For Extended-Release Drugs? Data Comparing IR Vs XR Topiramate (USL255; Qudexy™ XR)/ B. Gidal, A. M. Clark, B. Anders 2.285 Patients Reporting Problems After Generic Antiepileptic Drug Switches Are Unlikely To Participate In A Generic Bioequivalence Trial D. Ficker, M. Berg, P. Bolger, F. Diaz, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, M. Privitera, J. Szaflarski, T. Welty 2.286 Subject-Unrecognized Medication Adherence Errors In The Equivalence Among Generic AED (EQUIGEN) Chronic Dose Trial/ D. Smith, M. Berg, N. Cohen, N. Llewellyn, M. Lozano, D. Schwieterman, J. Sieren, P. Bolger, F. Diaz, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, M. Privitera, J. Szaflarski, T. Welty, D. Ficker 2.287 Equivalence Among Generic AEDs (EQUIGEN) – Single-Dose Study/M. Berg, F. Diaz, P. Bolger, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, J. Szaflarski, T. Welty, D. Ficker, M. Privitera 2.288 Aggression Adverse Events With Concomitant Levetiracetam Use In Perampanel Phase III Partial-Onset Seizure Clinical Studies/R. Fain, S. Chung, H. Yang, D. Xing, B. Williams, A. Laurenza 2.289 Subgroup Analysis By Race In Perampanel Phase III Clinical Studies/A. Laurenza, H. Yang, B. Williams, S. Huang, M. Sperling 2.290 Long-Term Safety And Efficacy Of Eslicarbazepine Acetate Monotherapy In Adults With Refractory Partial-Onset Seizures: A One-Year Open-Label Extension Study/M. R. Sperling, J. Rogin, J. H. Harvey, H. Cheng, D. Blum 2.291 Placebo-Adjusted Estimation Of Treatment Effect Of Perampanel/ R. T. Wechsler, S. Mintzer, H. Yang, B. Williams, D. Xing, A. Laurenza 58 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.292 Improvement In Seizure Control During Conversion To Eslicarbazepine Acetate Monotherapy: A Pooled Analysis Of Two Trials In Adults With Refractory Partial-Onset Seizures/G. Krauss, V. Biton, H. Cheng, D. Blum 2.293 Effect Of Adjunctive Perampanel On Growth And Development In Adolescents With Inadequately Controlled Partial-Onset Seizures/J. E. Pina-Garza, H. Yang, B. Williams, D. Kumar, A. Laurenza 2.294 Adjunctive Perampanel In Adolescents With Inadequately Controlled Partial-Onset Seizures: Efficacy And Safety Results From Study 235/B. Renfroe, L. Lagae, B. Williams, H. Yang, D. Kumar, A. Laurenza 2.295 Pharmacokinetic, Pharmacodynamic And Cognitive Effects Of Adjunctive Perampanel In Adolescents With Inadequately Controlled Partial-Onset Seizures/ Z. Hussein, B. E. Gidal, H. Yang, B. Williams, D. Kumar, A. Laurenza, J. Ferry, K. J. Meador Cohort Studies 2.296 Changes In Antiepileptic Drug Prescribing Patterns In A Large, Tertiary-Care Epilepsy Center (20002011)/J. Moeller, A. Legge, K. Detyniecki, L. Hirsch, R. Buchsbaum, H. Choi 2.297 Lacosamide Monotherapy Treatment Pathways In Epilepsy Patients In A U.S. Managed Care Population/T. Durgin, R. Wade, C. Chen, D. Hines, C. Makin 2.298 Analysis Of Real-World Rufinamide Utilization In The Treatment Of Epilepsy: Demographic And Socioeconomic Factors/ R. L. Knoth, J. H. Lasley, S. A. Field, J. Kerrick Walker, S. Mendes 2.299 Beyond Lennox-Gastaut Syndrome: A Retrospective Study Of Clobazam In Pediatric Refractory Epilepsy/S. Reddy, C. Lopez, M. Messinger, D. Elledge, A. Wilfong 2.300 Experience With Lacosamide In Galicia, Spain (GALACO Study): Results At 12 Months/X. Rodriguez Osorio, F. López González, A. Pato, M. Saavedra Piñeiro, E. Rubio-Nazábal, I. Cabo López, N. Raña Martínez, M. Sobrido, M. Aguado Valcárcel 2.301 Efficacy Of Clobazam Add On Treatment Of Refractory Focal Epilepsy In Adults/P. Klein, A. Barber, I. Tyrlikova, J. Janousek, A. Azarion, L. Goldman, D. Gorelik 2.302 Lacosamide Effectiveness In Pediatric Epilepsy: Effect Of Concomitant NA Channel Medications/E. Robbins, J. W. Cohen, S. Kessler 2.303 Clinical Outcomes Of Treatment With Oxtellar XR® Or Immediate-Release Oxcarbazepine (OXC-IR) In Typical Care Settings: A Standardized Case Record Review/W. O’Neal, E. E. Hur, K. Stringer, T. Resnick 2.304 Long-Term Follow-Up Of Lacosamide As Add-On Therapy In Refractory Partial Onset Epilepsy In Adults In Real Clinical Practice Of University Hospital, Bratislava/ G. Timarova, S. Mehešová 2.305 Analysis Of Real-World Rufinamide Utilization In The Treatment Of Epilepsy: Dosing, Titration, And Concomitant Antiepileptic Drugs/S. Mendes, S. A. Field, J. H. Lasley, J. Kerrick Walker, R. L. Knoth 2.306 Valproate And Lamotrigine: Is Clobazam More Effective Than Other Drugs As Adjunctive Therapy?/ V. Moraes, S. Vincentiis, K. Valente Drug Interaction 2.307 Interaction Study Between Brivaracetam And Ethanol In Healthy Subjects/A. Stockis, A. C. Kruithof, J. M. van Gerven, M. L. de Kam, S. Watanabe, P. A. Peeters 2.308 Pharmacokinetic Variability Of Clobazam And Its Metabolite Desmethylclobazam In Clinical Practice – Impact Of Comedication/ M. Burns, S. Johannessen, C. J. Landmark 2.309 The Effect Of Epidiolex (Cannabidiol) On Serum Levels Of Concomitant Anti-Epileptic Drugs In Children And Young Adults With Treatment-Resistant Epilepsy In An Expanded Access Program/ D. Friedman, M. Cilio, N. Tilton, J. Sullivan, J. Hedlund, E. Rosenberg, J. Bluvstein, O. Devinsky 2.310 In Vitro Pharmacokinetic Profile Of Brivaracetam Reveals Low Risk Of Drug-Drug Interaction And Unrestricted Brain Permeability/ H. Chanteux, S. Kervyn, B. Gerin, M. Rosa, N. Latour, A. Stockis, J. Nicolas 2.311 Seizure Control In Patients Initiated On Clobazam Who Use Frequent 1,4-Benzodiazepines/ G. Russo, T. Vollaro, R. Davis, N. Le Drug Side Effects 2.312 Adverse Visual Side Effects Of Antiepileptic Drugs In Adults With Epilepsy/B. Chen, K. Detyniecki, L. Hirsch, R. Buchsbaum, H. Choi 2.313 Antiepileptic Use And Dyslipidemia: A Systematic Review/ M. Vyas, J. Costel, L. Escalaya, J. G. Burneo 2.314 Anti-Epileptic Drugs And Vitamin D Deficiency In Children With Epilepsy/J. Yu, S. Lee, J. Koh Sunday December 7, 2014 Other 2.325 Generic Antiepileptic Drugs, Mood Disorders And Pharmacovigilance: Case Analyses And Literature Review/K. R. Kaufman, A. M. Zimmerman, S. Wong, N. D. Kaufman, P. J. Struck 2.326 Adherence Concerning Antiepileptic Medication: The Patients’ View/A. Villagran, M. A. Mevåg, V. Kjærvik, S. Johannessen, C. J. Landmark, O. Henning 2.327 Effectiveness And Tolerance Of Clobazam Used As Adjunctive To A Sodium-Blocker Antiepileptic Drug In Maximum Tolerated Doses In Focal Seizures/E. A. Seraphim, L. Rodrigues, J. T. Corso, P. Naves, G. Bienes, E. Yacubian 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.328 An In Vitro Screen For Antiepileptogenic Compounds Utilizing Organotypic Hippocampal Slice Cultures/Y. Saponjian, Y. Berdichevsky, W. Swiercz, K. Staley 2.329 Topiramate (TPM) And Impaired Verbal Fluency: Observations From Three Formulations With Different Input Rates/S. E. Marino, S. T. Brittain, S. V. Pakhomov 2.330 Individual Pharmacokinetic Profile Analysis From An Average Bioequivalence Study Of Lamotrigine In Generic-Brittle Patients: What Can Be Learned About Patients With Switchability Issues/T. Ting, W. Jiang, X. Jiang, J. Polli 2.331 Use Of Computer Simulations To Test The Concept Of Dose Forgiveness In The Era Of ExtendedRelease (XR) Drugs/S. T. Brittain 2.332 Brivaracetam Achieves Brain SV2A Occupancy Faster Than Levetiracetam/J. Mercier, D. Holden, A. K. Deo, K. Fowles, S. Kervyn, N. Nabulsi, J. Nicolas, H. Klitgaard, Y. Huang, J. D’Souza, R. E. Carson, J. Hannestad 2.333 Evaluation Of Weight-Based Dosing Of Fosphenytoin In Obese Pediatric Patients/M. M. Messinger, S. J. Bork, B. S. Moffett, G. G. Burgess, A. Wilfong Surgery Adult 2.334 Neurological And Medical Complications Of Epilepsy Surgery At A Tertiary Level Hospital In A Developing Country/M. Leon-Vazquez, F. Chavez-Hassan, L. M. Espaillat Solano, J. Villeda Hernandez, M. Alonso-Vanegas, D. Crail Melendez, A. Ruiz Chow, I. E. Martinez-Juarez 2.335 Preoperative Evaluation Of Speech And Memory Dominance Estimated By Intracarotid Propofol Test/T. Kunieda, N. Mikuni, T. Kikuchi, R. Inano, T. Inada, Y. Takahashi, S. Nishida, T. Nakae, S. Shibata, Y. Yamao, Y. Arakawa, R. Matsumoto, A. Ikeda, S. Miyamoto 2.336 Failed Epilepsy Surgery Deserves A Second Chance/ C. M. Reed, S. Dewar, D. Eliashiv 2.337 Stereotactic Laser Ablation: How Much Hippocampal Atrophy Optimizes Seizure Freedom?/G. Popli, D. Couture, A. Laxton, R. Gross, J. Willie, A. Sharan, M. Sperling, D. Labiner, M. Weinand, R. Marsh, G. Worrell, G. Cascino, J. J. Shih, R. Wharen, W. Tatum, R. Patwardhan, B. Fernald, A. Shetty 2.338 Outcomes After Temporal Lobectomy After Invasive Monitoring Versus No Monitoring/A. Romeo, B. Agee, L. Ver Hoef, K. Riley 2.339 Stereotactic Laser AmygdaloHippocampotomy For Mesial Temporal Lobe Epilepsy: Collective Experience From Seven Single-Center, Prospective, Investigator-Initiated Studies Objectives/R. Gross, J. Willie, S. Helmers, K. J. Meador, S. Laroche, R. Faught, E. Gedzelman, A. Sharan, M. Sperling, R. Marsh, G. Cascino, G. Worrell, J. J. Shih, R. Wharen, W. Tatum, G. Popli, A. Laxton, D. Couture, M. Weinand, D. Labiner, A. Mehta, C. Harden, D. 2.340 Robotic-Assisted MRI-Compatible Stereoelectroencephalography: Technique And Complications/J. Hall Pediatrics 2.341 WITHDRAWN 2.342 Pediatric Epilepsy Surgery Strategy And Complications: InterCenter Worldwide Variability/ B. Rydenhag, A. Cukiert, W. Harkness, I. Panel 2.343 Pediatric Epilepsy Surgery Techniques General Issues: InterCenter Worldwide Variability/ A. Cukiert, B. Rydenhag, W. Harkness, T. International Pediatric Epilepsy Surgery Panel 2.344 Seizure Outcome After Battery Depletion In Patients With Secondary Generalized Epilepsy Submitted To Vagus Nerve Stimulation/A. M. Lima, J. A. Burattini, C. M. Cukiert, A. Cukiert 2.345 ‘Subtotal’ Hemispherectomy In Children With Intractable Focal Epilepsy/H. Chugani, E. Asano, C. Juhasz, A. Kumar, W. Kupsky, S. Sood 2.346 MR-Guided Laser Interstitial Thermal Therapy For Drug-Resistant, Lesional Epilepsy in Children/ E. C. Lewis, J. Ragheb, M. Duchowny, I. Miller 2.347 Corpus Callosotomy With Stereotactic Laser Ablation In A Pediatric Patient/A. Dolce, D. Curry, A. Wilfong 2.348 Usefulness Of Intraoperative Insular Electrocorticography During Modified Functional Hemispherectomy/ G. Kim, J. Seo, J. Baumgartner, K. Lee 2.349 The Ultimate Case Of Curative Focal Heterotopia Resection: Resolution Of Lennox-Gastaut Syndrome And Epileptic Encephalopathy/J. R. Fesler, S. Kanaan, T. B. Mapstone, Y. Ng 2.350 Surgical Outcome In Adolescents With Mesial Temporal Sclerosis (MTS): Is It Different Than Adults?/P. Farooque, L. Hirsch, S. Levy, F. Testa, R. Mattson, H. Zaveri, J. Bonito, D. Spencer 2.351 Repeat Epilepsy Surgery For Children With Refractory Seizures: Profiles And Outcomes/J. Ziobro, D. Depositario-Cabacar, K. Havens, J. Conry, S. Weinstein, T. Zelleke, A. Kao, T. Tsuchida, M. Kolodgie, A. Yaun, C. Oluigbo, W. Gaillard SUNDAY 2.315 Adverse Drug Reactions To Antiepileptic Drugs In Children With Epilepsy/J. Kim, H. Park, W. Kim, H. Kim, J. Kang, S. Kim, J. Yu, Y. Kim 2.316 The Pediatric Epilepsy Side Effects Questionnaire©: Establishing Minimal Clinically Important Difference Scores/K. Junger, D. Morita, A. Modi 2.317 Adverse Effects Of Antiepileptic Drug Treatment: The Patients’ View/V. K. Kjærvik, M. A. Mevåg, A. Villagran, S. Johannessen, O. Henning, C. J. Landmark 2.318 Pigmentary Abnormalities (Discoloration) Associated With Ezogabine/Retigabine Treatment: Clinical Aspects/S. Evans, A. Alio Saenz, C. Harrington, D. Kelly, N. Walsh, S. McDonald, W. Lee, N. Brickel 2.319 Unusual Case Of Drug Rash With Eosinophilia And Systemic Symptoms (DRESS) With Ethosuximide/S. Paudel, A. Patel, P. Kandel, P. Rawal 2.320 Randomized Crossover Study Comparing Neuropsychological Effects Of Lacosamide Versus Carbamazepine Immediate Release In Healthy Subjects/K. J. Meador, D. W. Loring, A. Boyd, W. Byrnes, D. Dilley, E. Webster, S. Borghs, M. De Backer, T. Story, P. Dedeken 2.321 An Interesting Case Of Sinus Nodal Dysfunction Following Use Of Lacosamide/M. Gurme, C. M. Reed, D. Eliashiv 2.322 Beyond Efficacy: Focus On Safety And Effectiveness Of Antiepileptic Drugs (AEDs)/M. Wen, V. Nguyen, Y. Bukovskaya, S. Dergalust 2.323 Effect Of Long-Term Administration Of Low Dose Of Rapamycin On Development And Immunity In Young Rats/L. Zeng 2.324 Pigmentary Abnormalities (Discoloration) Associated With Ezogabine/Retigabine Treatment: Nonclinical Aspects/J. S. Prescott, C. Evans, A. Alio Saenz Poster Session 2 59 Sunday December 7, 2014 2.352 The Spectrum Of Sleep Disorders In Children Undergoing PreSurgical Evaluation For Refractory Epilepsy/S. Jain, P. Horn, H. Greiner 2.353 REM Sleep EEG Indicates Epileptogenic Hemisphere For Successful Epilepsy Surgery In Children With Generalized Interictal Epileptiform Discharges/K. Okanari, S. Baba, H. Otsubo, E. Widjaja, S. Sakuma, C. Go, K. Jones, K. Nishioka, S. Oba, T. Matsui, M. Ueno, S. Ukitsu, J. Rutka, J. Drake, E. Donner, S. Weiss, O. Snead, A. Ochi 2.354 Thermal Ablation For Patients Who Failed Surgery Or Would Seldom Be Considered As Surgical Candidate/ D. F. Clarke, J. B. Titus, N. Nussbaum, F. F. Perkins, K. C. Keough, M. R. Lee 2.355 Complete Resection Of Fast Ripples Is A Superior Predictor Of Seizure-Freedom After Epilepsy Surgery In Comparison To Conventional Intraoperative Electrocorticography Findings/ S. A. Hussain, G. Mathern, R. Sankar, J. Wu All Ages 2.356 Predictive Power Of Presurgical Studies For Temporal Lobectomy Seizure Freedom/ O. I. Khan, D. M. Goldenholz, A. Jow, W. Theodore 2.357 Frameless Image-Guided Stereotactic Implantation Of Depth Electrodes Via Craniotomy For Presurgical Evaluation Of Pharmacoresistant Epilepsy/H. Khoo, H. Kishima, S. Oshino, N. Tani, T. Maruo, T. Yanagisawa, K. Edagawa, Y. Inoue, M. Hirata, T. Yoshimine 2.358 Surgical Removal Of High Frequency Oscillations Correlates With Postsurgical Outcome – A Prospective Multi-Center Study/ J. Jacobs, J. Y. Wu, P. Perucca, R. Zelmann, M. Mader, F. Dubeau, A. Schulze-Bonhage, G. Mathern, J. Gotman 2.359 Appropriating Surgical Intervention In Mesial Temporal-Lobe Epilepsy (MTLE) Patients: Comparison Of Parameters Influencing Timing Of Surgery In Patients With Epilepsies With Different Evidence Levels For Surgery/K. Iida, K. Kagawa, M. Kartagiri, A. Hashizume, K. Kurisu 2.360 Laser Ablation Therapy For The Management Of Medically-Resistant Epilepsy After Age 50/F. Vale, H. Waseem, M. Schoenberg, V. Kelley, A. Bozorg, S. Benbadis, D. Cabello 60 Poster Session 2 8:00 a.m. – 6:00 p.m. Convention Center – Hall 4B, Level 4 2.361 Temporal Lobe Epilepsy With Bilateral Features: Prognostic Factors And Outcomes/H. Waseem, K. E. Eichstaedt, M. Schoenberg, V. Kelley, A. Bozorg, S. Benbadis, F. Vale 2.362 Electrical Stimulation Of The Centromedian Nucleus Of The Thalamus For The Treatment Of Intractable Epilepsy/Y. Shon, S. Lim, W. Kim 2.363 Acute Intraoperative Entropy Rise During Hippocampal Deep Brain Stimulation Surgery/A. Marin, H. Carmona, N. Sinisterra, A. Liscano, C. M. Cukiert, A. Cukiert 2.364 Safety And Efficacy Of Complete Corpus Callosotomy As A Localization Tool For Catastrophic Unlocalizing Epilepsy/J. Seo, K. Lee, J. Baumgartner, B. Pullum 2.365 Does Seizure Outcome Influence Nonseizure Outcome, LongTerm Outcome After Surgery For MTS/M. Tripathi, K. Garg, A. Garg, A. Wadhawan, M. Goel, C. Bal, C. Sarkar, V. Kumar, P. Madakasira, S. Chandra Health Services 2.366 Incidence And Prevalence Of Epilepsy In Low-Income Children: Preliminary Analysis/A. Chandran Pillai, K. Kaiboriboon, S. Koroukian, E. Pestana Knight • AES 68TH ANNUAL MEETING Seattle, WA • MONDAY December 8, 2014 www.AESnet.org 7:00 a.m. – 8:30 a.m. Special Interest Group Meetings Location listed under each session Ketogenic Diet: Does the Ketogenic Diet Offer a “Cure” for Epilepsy? Convention Center – Room 613, Level 6 Coordinators: Susan Masino, Ph.D., Christina A. Bergqvist, M.D. Speakers: Detlev Boison, Ph.D., Sudha Kessler, M.D., Renee A. Shellhaas, M.D., Timothy A. Simeone, Ph.D. We have an arsenal of treatments for epilepsy, but do we have any cures? More specifically, could the time-honored treatment of a ketogenic diet also be an anti-epileptogenic treatment and offer insight into a cure? What proof do we have that this is, or is not, the case? This year the discussion will be organized into a pro/con debate of clinical evidence and basic science evidence — with ample time for rebuttal and audience participation. Our invited speakers are expected to take a side as we explore this hot topic. We hope to have fun and inspire the community to share their thoughts, suggest experiments and put forth provocative ideas to help move the field forward. Neuropsychology: Can We Spare Memory with Newer Surgical Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data from Laser Ablation, Multiple Hippocampal Transection, and Fornix DBS Convention Center – Room 609, Level 6 Emergent neuropsychological outcome data will be presented on three novel surgical techniques and will be critically evaluated and discussed with the audience. The topic (neuropsychology, surgery, temporal lobe) and the neuropsychologist-neurosurgeon paired presentations are expected to draw a diverse multidisciplinary audience. NINDS and Non-Profit Research Resources Convention Center – Room 620, Level 6 Coordinators: Brandy Fureman, Ph.D., Randall Stewart, Ph.D., William Benzing, Ph.D., Steve Roberds, Ph.D., Ilene Miller, J.D., Seth Wohlberg Speakers: Abigail Hemani, Scott C. Baraban, Ph.D. The purpose of this SIG is to generate focused two-way discussion between government and non-profit funders and basic and clinical researchers attending the AES annual meeting. This discussion will educate researchers on how government and non-profits set their priorities and fund research or make other resources available, and it will educate non-profit leaders on what else they could do to support basic and clinical researchers in the epilepsies. The ultimate goal of this group is to accelerate research on the epilepsies by more effectively making valuable resources available to the research community. Nursing Convention Center – Room 612, Level 6 Coordinators: Frank W. Drislane, M.D., Howard Goodkin, M.D., Ph.D. Speakers: Peter Kaplan, M.B.B.S., Lawrence J. Hirsch, M.D., Howard Goodkin, M.D., Ph.D. Neurologists agree readily that generalized convulsive Status Epilepticus (SE) is a neurologic emergency and that it should be halted immediately and the patient kept from having recurrence of seizures. There is no consensus, however, that all forms of SE (particularly nonconvulsive SE) need be treated so aggressively. Even after interruption of convulsive SE, there is disagreement on how long seizures need be suppressed, and on which EEG abnormalities signify seizures that require re-treatment. Prolongation of medically-induced coma with highly sedating drugs keeps patients at risk of prolonged ICU stays and of new medical complications. Dr. Peter Kaplan, who has written on the risks of overtreatment (including a paper this year on worsened outcome for aggressively treated SE patients) will make the case that much of current treatment is excessive. Dr. Larry Hirsch, who has studied the treatment of ICU patients with refractory SE, as well as the deleterious consequences of SE itself, will speak in favor of vigorous seizure suppression. Finally, Dr. Howard Goodkin, with both a clinical and basic science perspective, will discuss what evidence from basic and clinical research can guide us in determining how aggressively to treat NCSE. 8:45 a.m. – Noon Merritt-Putnam Symposium: Stress, Cannabinoids and Epilepsy: The Science Behind the Buzz (3.0 CME Credits) Convention Center – Ballroom 6C, Level 6 Presentation: Hans O. Lüders, M.D., Ph.D., William G. Lennox Award MONDAY Coordinators: Philip S. Fastenau, Ph.D., Gail L. Risse, Ph.D. Speakers: Daniel L. Drane, Ph.D., Robert Gross, M.D., Philip Fastenau, Ph.D., Jonathan P. Miller, M.D. Status Epilepticus: Are We Over-Treating Status Epilepticus, and Especially, Nonconvulsive Status Epilepticus? Overview The impact of stress on seizure control has long been recognized but the neurobiology of stress impact on neurophysiology is not widely known. Similarly, cannabinoids have been considered as potentially effective adjunctive treatment for epilepsy as an alternative to traditional medications but here, too, the neurobiology requires further elucidation. There is evidence of shared mechanisms between stress impact on neurologic function and the neurobiology of cannabinoids. These topics will be explored, providing information necessary for improved management of patients with pharmacoresistant epilepsy. Presentations on basic science related to stress and to cannabinoids, and clinical data regarding both will be presented. Research on how cannabinoid receptors alter the brain’s immune system will be presented, as well as progress that has been made in identifying cannabinoid agents devoid of drug of abuse properties that may provide treatment for diverse neurological disorders. Learning Objectives Convention Center – Room 608, Level 6 u Identify a patient for whom stress is contributing to difficulties in management of seizures and develop treatment strategies to address the role of stress The Nurse Travel Award winners will present their poster topics in a 10-minute synopsis with audience discussion and question session. In addition, we will hold a discussion on an epilepsy certificate program and feasibility of epilepsy certification in nursing. u Query patients regarding use of cannabinoids and address the impact of such use in developing treatment plans u Identify a patient who is using cannabinoids for treatment of epilepsy and discuss the impact of the use of cannabinoids Coordinators: Tara Myers, CPNP, Wendy Miller, Ph.D., RN, CCRN Speakers: Nurse Travel Award Winners 61 MONDAY December 8, 2014 Assist clinicians in developing treatment plans that account for the impact of cannabinoids and their interaction with traditional medications u Counsel patient regarding the need for stress management in treatment of epilepsy Location listed under each session u Counsel patients regarding the impact of stress on seizure control and develop plans for managing stress NEW – Epilepsy and Aging u Evaluate the possible adverse effects of cannabinoids on cognitive function in patients using cannabinoids for seizure treatment. Target Audience Basic, Intermediate and Advanced (see page 120 for details) Program Chair: Amy Brooks-Kayal, M.D. 9:00 a.m. Introduction Amy Brooks-Kayal, M.D. 9:15 a.m. The Neurobiology of Stress: How Stress and Epilepsy Intersect at the Synapse Tallie Z. Baram, M.D., Ph.D. 9:45 a.m. Stress and Epilepsy: What Are the Clinical Data? Sheryl Haut, M.D. 10:15 a.m. Stress and Cannabinoids: What Is the Link? Jaideep Bains, Ph.D. 10:45 a.m. Cannabinoids and Epilepsy: What Are the Clinical Data? Allen Hauser, M.D. Special Interest Group Meetings Convention Center – Room 620, Level 6 Coordinators: Bruce P. Hermann, Ph.D., Kimford J. Meador, M.D., Helen E. Scharfman, Ph.D. Speakers: Carrie McDonald, Ph.D., David Loring, Ph.D., Ilo Leppik, M.D., R. Eugene Ramsay, M.D., Helen Scharfman, Ph.D., Manisha Patel, Ph.D. This SIG will focus on neurological, neuropsychological, imaging and basic science aspects of the relationship between epilepsy and aging. This includes the complications of aging with chronic epilepsy and the issue of new onset epilepsy with advancing chronological age. The initial meeting will include brief invited presentations and discussants from clinical neurology, neuropsychology, and basic science. Surgery: Surgical Failure in Pediatric and Adult Epilepsy: “The Slam Dunk Case That Wasn’t!” Convention Center – Room 609, Level 6 Coordinators: Saadi Ghatan, M.D., Gerald Grant, M.D. Speakers: TBA We will solicit cases from pediatric and adult surgical epilepsy programs and select 3-5 cases for presentation, reviewing cases in advance and sticking to a strict timeline. Presenters are asked to provide a case that was predicted to be an unequivocal success but resulted in a failure to adequately treat the patient’s epilepsy or realize the goal of the operation. Audience participation is then solicited to generate discussion and suggestions about approaches and recommendations, with moderators polling the audience. 11:10 a.m. Cannabinoids in Treatment of Neurological and Psychiatric Disorders: Is There a Potential Role in Epilepsy? Nephi Stella, Ph.D. Tuberous Sclerosis: Thinking Outside the Tuber in TSC 11:40 a.m. Panel Discussion and Conclusions Amy Brooks-Kayal, M.D. This SIG will focus on the role of non-tuberal cortex and sub-cortical structures in epilepsy and neurobehavioral disabilities in TSC. Credit Designation Convention Center – Room 612, Level 6 Coordinator: Peter E. Crino, M.D., Ph.D. Speakers: Peter Crino M.D., Ph.D., Delia Talos Ph.D., Juurian Peters M.D. The American Epilepsy Society designates this live activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 2:15 p.m. – 3:00 p.m. Nurses may claim up to 3.0 contact hours for this session. Convention Center – Ballroom 6C, Level 6 Presentation: Karen Gale, Ph.D., Extraordinary Contributions Award Nurse Practitioners may claim 3.0 hours of pharmacology for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-035-L01-P. Initial Release Date: 12/8/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Merritt-Putnam Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Medical Knowledge, Practice-based Learning and Systems-based Practice Acknowledgment This program is supported in part by CURE. 62 9:00 a.m. – 10:30 a.m. u Lennox and Lombroso Lecture: Priorities in Pediatric Epilepsy Research Lecturer: Anne Berg, Ph.D. The past several decades of clinical and epidemiological research have provided a wealth of knowledge about the diversity within the pediatric epilepsies and greatly clarified the sometimes reassuring but still too often devastating prognosis of many of these disorders. The tremendous advances in neuroimaging, molecular cell biology, and therapeutics hold the promise of prevention, more effective targeted treatment, and even disease modification for these epilepsies with the possibility of ameliorating what can otherwise be moderate to severe lifelong disability. The challenge is to learn how -when and in whom- to utilize these techniques and therapies in an optimal manner to assure the best patient outcomes. Stakeholder identified and endorsed priorities can help develop a series of research priorities for accomplishing this goal. MONDAY December 8, 2014 3:00 p.m. – 4:30 p.m. Investigators’ Workshop This workshop is an AES Research Grant funded study Convention Center – Room 607, Level 6 Modeling Epilepsies with Patient-Derived Induced Pluripotent Stem Cells Moderator: Jack M. Parent, M.D. Speakers: Kevin Ess, M.D., Ph.D., Jack Parent, M.D., Lori Isom, Ph.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Town Hall FDA Update and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competency: Professionalism 3:00 p.m. – 5:00 p.m. FDA Town Hall Update: SUDEP and Clinical Trials (2.0 CME Credits) Convention Center – Room 612, Level 6 Overview In 2011, a meta-analysis published in Lancet Neurology suggested that patients randomized into placebo-controlled add-on studies of antiepileptic drugs had a higher likelihood of having SUDEP if they were randomized to the placebo arm compared to addition of an active drug. This analysis was recently repeated by the FDA using data requested from the companies performing the trials. This symposium will discuss the following issues: 1) How do the findings impact the design of add-on studies of antiepileptic drugs? 2) What do these findings mean for clinical practice? The session will include a long interactive audience discussion session, as specifically requested by the FDA, to provide community input to the regulatory process. Learning Objectives 3:00 p.m. – 5:15 p.m. Pediatric Epilepsy Highlights Session Convention Center – Ballroom 6E, Level 6 Note: Number below refers to poster assignment This session will showcase selected scientific abstracts focused on topics in clinical care and research in pediatric epilepsy. Authors will present a six-minute overview of their work. Presentations are chosen from all submitted abstracts. Participants will be able to view posters and meet the authors at the end of the program. 1.032 Diminished Antiepileptogenic Effects Of Neurosteroids In Mice Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/Bryan Clossen 1.052 Early-Life Clonazepam Exposure Leads To Persistent Alteration Of Seizure Susceptibility/Hana Kubova Define patient-specific risk/benefit ratios related to treatment interventions vs absence of intervention in treatment resistant patients 1.097 Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of Cognition?/Soyong Eom u Counsel patients regarding risks and benefits related to treatment interventions vs absence of intervention in treatment resistant patients 1.122 Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of 5HT1A and 5HT2A Receptos In Human Epileptogenesis/Kette Valente u Understand and counsel patients regarding risks and benefits related to treatment interventions vs absence of intervention in treatment resistant patients. Target Audience 1.365 Surgical Versus Medical Treatment For Children With Epileptic Encephalopathy In Infancy And Early Childhood – An Observational Cohort Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/ Taisuke Otsuki Program 2.023 Psychiatric Comorbidity In Children With Recent-Onset Epilepsy: A 2-Year Prospective Controlled Investigation/Jana Jones Intermediate and Advanced (see page 120 for details) Co-Chairs: Jacqueline A. French, M.D. and Billy Dunn, M.D. 3:00 p.m. 3:05 p.m. Introduction Billy Dunn, M.D. Review of 2011 Analysis Philippe Ryvlin, M.D., Ph.D. 3:20 p.m. Presentation of FDA Analysis Mary Doi, M.D., M.S. 3:40 p.m. Potential Impact on Clinical Trial Design and Practice Jacqueline A. French, M.D. 4:00 p.m. Interactive Panel/Audience Discussion Eric Bastings, M.D. Norman Hershkowitz, M.D., Ph.D. Mary Doi, M.D., M.S. Alice Hughes, M.D. Billy Dunn, M.D. Sally Jo Yasuda, Pharm.D., M.S. 4:55 p.m. Conclusions Jacqueline A. French, M.D. MONDAY u 2.169 Familial Ring Chromosome 20 Syndrome – A Case Report/ Iris Unterberger 2.179 Left Temporal Lobe Epilepsy Presenting As Apparent Life-Threatening Events In Infants/Richard Tang-Wai 3.013 Inflammatory Mechanisms Of Epileptogenesis In The Genetic Epilepsy, Tuberous Sclerosis Complex/Bo Zhang 3.202 A Brain-Machine Interface For Burst Suppression Control in Pediatric Status Epilepticus/Christos Papadelis 63 MONDAY December 8, 2014 3:00 p.m. – 5:15 p.m. Platform Sessions: 3 Concurrent Sessions See page 120 for locations There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a 10-minute overview of their work followed by a five-minute Q & A. 5:30 p.m. – 8:00 p.m. Pediatric State of the Art Symposium: Long-term Outcomes of Neonatal Seizures (2.5 CME Credits) Convention Center – Ballroom 6C, Level 6 Overview Seizures occur in a significant number of neonates, yet many critical questions remain regarding their diagnosis, treatment, and long-term prognosis. Modern neurophysiological monitoring indicates that the scope of the neonatal seizure problem may be more extensive than previously appreciated. Although contemporary neuroprotective strategies have led to improved short-term outcomes, the impact of both seizures and the medications used to treat them are now being explored more rigorously in both animal models and humans. There is a need for clinicians who treat infants, children, adolescents, and even adults to become familiar with the long-term sequelae of neonatal seizures. Importantly, these sequelae include not only seizures — cognitive, neuropsychological and social outcomes are affected, as well. This State of the Art Symposium will address the long-term outcomes of neonatal seizures, with a focus on both epilepsy and non-epilepsy factors. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-036-L01-P. Initial Release Date: 12/8/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Pediatric State of the Art Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care and Systems-based Practice Acknowledgment This program is supported in part by an educational grant from Mallinckrodt Pharmaceuticals. Learning Objectives u Recognize long-term sequelae of neonatal seizures from information provided by outcome studies u Choose appropriate medications used to treat neonatal seizures based on information from follow up studies regarding long-term sequelae u Utilizing information provided regarding long-term sequelae of neonatal seizures and medications used to treat them, counsel families about seizure- and development related outcomes after neonatal seizures. Target Audience Intermediate and Advanced (see page 120 for details) Program Co-Chairs: Adam Hartman, M.D. and Renée A. Shellhaas, M.D., M.S. 64 5:30 p.m. Introduction and Case Presentation Adam Hartman, M.D. 5:45 p.m. Introduction to Neonatal Seizures Geraldine Boylan, Ph.D. 6:10 p.m. Clinical and EEG Predictors of Prognosis Renée A. Shellhaas, M.D., M.S. 6:35 p.m. Are Neonatal Seizures So Bad? Rodney Scott, M.D. 7:00 p.m. Are Seizure Medicines So Bad? Timothy Benke, M.D., Ph.D. 7:25 p.m. Neonatal Seizure Management 2014 Janet Soul, M.D. 7:50 p.m. Conclusions Renée A. Shellhaas, M.D., M.S. Get Your Annual Meeting CME / CE Credit Online Go to www.AESnet.org See page 120 for details Monday December 8, 2014 A. Clinical Platform Sessions 3:00 p.m. - 5:15 p.m. B. Treatment / Imaging C. Translational Convention Center – Room 608, Level 6 Convention Center – Room 609, Level 6 Convention Center – Room 603, Level 6 Moderators: Amy Crepeau, M.D., Nicholas Abend, M.D. Moderators: Jacquelyn Bainbridge, Pharm.D., Jeffrey Ojemann, M.D. Moderators: Suzanne Bausch, Ph.D., Lori Isom, Ph.D. B.01 Neural Mechanism Of Impaired Consciousness In Typical Childhood Absence Seizures/J. Guo, R. Kim, W. R. Xiao, E. Feeney, X. Bai, M. Negishi, M. J. Crowley, L. C. Mayes, T. Constable, H. Blumenfeld C.01 Synaptic Impairment Of Frontal Cortical FastSpiking Basket Cells Induces Cognitive And Behavioural Deficits In Mice With A Cacna1a Loss-Of-Function Mutation./A. Lupien-Meilleur, I. Riebe, L. Damaj, C. Vanasse, G. Louise, A. M. Van den Maagdenberg, J. Lacaille, E. Rossignol 3:15 p.m. A.02 Factors Influencing Driving Impairment In B.02 Safety And Pharmacokinetics Of IV Loading Dose Of Lacosamide In The ICU/R. E. Ramsay, V. Sabharwal, F. Khan, H. Dave C.02 Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes Have Increased Sodium Current Density And Increased Beating Rate/C. R. Frasier, H. Zhang, K. Collon, J. Parent, L. L. Isom 3:30 p.m. A.03 Terminal Seizure Remission 45 Years After B.03 Field Potential Imaging: A New Paradigm For Focal Epilepsy/G. P. Kalamangalam, R. E. Gabr, P. A. Narayana C.03 Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy/ E. Krook-Magnuson, C. Armstrong, G. G. Szabo, M. Oijala, I. Soltesz 3:45 p.m. A.04 Children With Epilepsy And Mild B.04 Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy: Class II Diagnostic Evidence/ S. Hong, B. Bernhardt, D. Schrader, N. Bernasconi, A. Bernasconi C.04 (1-3)Insulin-Like Growth Factor 1 Suppresses Seizures And Hypsarrhythmia In An Animal Model Of Infantile Spasms./C. L. Lee, J. D. Frost, Jr., J. T. Le, R. A. Hrachovy, J. W. Swann 4:00 p.m. A.05 Management Of Children With Refractory B.05 Increased Cerebral Oxygenation Precedes Generalized Tonic Clonic Seizures/B. D. Moseley, J. Britton, E. So C.05 Development Of Glutamatergic Transmission Onto Transplanted MGE Interneurons/M. Howard, S. Baraban 4:15 p.m. A.06 Pulmonary Edema Occurs In Nearly B.06 Continuous Infusions In Refractory Convulsive Status Epilepticus. Results From The Pediatric Status Epilepticus Research Group (pSERG)./T. Loddenkemper, I. Sánchez Fernández, N. Abend, R. Arya, R. Basu, N. Brenton, J. Carpenter, K. Chapman, J. Condie, N. Dean, W. Gaillard, T. Glauser, J. Goldstein, H. Goodkin, A. J. Hani, M. Jackson, K. Kapur, T. Kebede, J. Klehm, M. Mikati, K. Peariso, M. Sacco, K. Schmidt, A. Topjian, D. Turner, A. Wilfong, K. Williams, M. Wainwright, R. Tasker C.06 A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy And Cortical Circuit Dysfunction/E. M. Goldberg, J. Zhou, C. Yue, P. Wang, D. Coulter 4:30 p.m. A.07 Temporal Lobe Epilepsy In Patients With B.07 The Johns Hopkins Hospital Adult Epilepsy Diet Center: Results And Experience In Four Years/ M. Cervenka, E. Kossoff, B. Henry, J. Barnett, R. Fisher C.07 Neuron Subset-Specific-PTEN Deletion Induces Abnormal Skeletal Activity In Mice/J. Lugo, M. Thompson, P. Huber, G. Smith, A. Holley, S. Bain, E. Gardiner, R. Kwon 4:45 p.m. A.08 A Diagnostic Blood Test For Epilepsy: B.08 Long-Term Memory And Language Outcomes With Responsive Cortical Stimulation Do Not Differ By Stimulation Localization/D. W. Loring, R. Kapur, K. J. Meador, M. Morrell C.08 Hippocampal DBS Affects Disease Development In The KA Rat Model For TLE/B. Van Nieuwenhuyse, R. Raedt, J. Delbeke, M. Sprengers, I. Dauwe, S. Gadeyne, W. Wadman, P. Boon, K. Vonck Epilepsies/A. Berg, K. Rychlik Persons With Refractory Epilepsy/V. Punia, P. Farooque, W. Chen, L. Hirsch, A. Berg, H. Blumenfeld selected for the Fritz Dreifuss Honor Onset Of Absence Epilepsies/M. Holtkamp, A. Kirschbaum, A. Kowski, D. Janz Intellectual Disability Do Not Have A High Risk Of Long-Term Resistant Epilepsy; However, Moderate Or Severe/Profound Intellectual Disability Is Ominous: A Population-Based Study With >20 Years Of Follow-Up/P. Camfield, C. Camfield Epilepsy. A Decision Analysis Comparing Medical Versus Surgical Treatment/I. Sánchez Fernández, S. An, T. Loddenkemper One-Third Of Monitored Patients With Convulsive Seizures And Is Directly Associated With The Duration Of The Preceding Seizure/J. Kennedy, P. Parikh, K. Hardin, M. Seyal Nonlesional MRI And Normal Memory: An SEEG Study/J. Miller, J. Sweet, S. Suresh, P. Landazuri, H. Lüders A Soluble ICAM-5-Based Panel/J. R. Pollard, P. B. Crino, G. P. Mueller, O. Eidelman, C. Dalgard, E. Brand, C. T. Anderson, P. Cai, M. Wamil, M. C. Strauman, E. Burakgazi-Dalkilic, K. A. Davis, H. B. Pollard 5:00 p.m. A.09 Predictive Model For Early Posttraumatic Seizures In The PICU/R. Rajaraman, J. Lerner, D. Arndt, D. McArthur, J. Fischer, M. Zeiger, M. Choe, C. Giza MONDAY 3:00 p.m. A.01 The Not So Simple Course Of Childhood selected for Goldberg Kaufman Honor B.09 Structural Connectivity Of Limbic Brain Regions In Patients With Psychogenic Non-Epileptic Seizures (PNES)/K. Hernando, J. Allendorfer, S. Lee, L. Ver Hoef, J. Szaflarski C.09 Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy/J. Wagnon, M. Korn, R. Parent, J. Jones, G. Murphy, J. Parent, M. Meisler The Fritz Dreifuss Honor is awarded to the highest ranking abstract in the outstanding patient care topic category and is sessioned as Platform A.02. The abstract honored is selected by the Scientific Program Committee from all submitted abstracts. The Rebecca Goldberg Kaufman Honor is awarded to the highest ranking abstract in the psychiatric topic category and is sessioned as Platform B.08. The abstract honored is selected by the Scientific Program Committee from all submitted abstracts. 65 Monday December 8, 2014 Poster Session 3 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 Authors Present: Noon – 2:00 p.m. Poster Walking Tours (see page 15 for details) Translational Research Mechanisms 3.001 Increase In Dendritic Spines Correlates With Increased Synapses In Hippocampal CA1 Following HypoxiaInduced Neonatal Seizures/ J. Lippman-Bell, S. Francomacaro, F. Jensen 3.002 Using CRISPR In Utero Electroporation To Study The Function Of PCDH19/Y. Wang, F. Chen, J. loturco, J. Parent 3.003 Targeting The JAK/STAT Pathway For Disease Modification In Epilepsy/A. J. Carrel, H. L. Grabenstatter, J. Carlsen, Y. Cruz Del Angel, S. Russek, M. F. Wempe, A. Brooks-Kayal 3.004 Topology Of Network Synchronization During Early Epileptogenesis/K. Lillis, Z. Wang, G. Q. Zhao, B. Bacskai, K. Staley 3.005 Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. Adult-Born Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/X. Du, A. L. Althaus, H. Zhang, E. G. Wolf, J. Parent 3.006 Disabled 1-Deficient Mice Exhibit Hippocampal Structural Abnormalities And A Reduced Seizure Threshold/M. J. Korn, J. Parent 3.007 Hippocampal Metaplasticity Induced By Early Life Hypoxic Seizures In Rats/H. Sun, F. E. Jensen 3.008 Extracellular And Intracellular K+ Accumulation And Buffering During Focal Cortical Epilepsy: A Spatiotemporal Study In Vivo/ S. Dufour, P. Bazzigaluppi, O. Levi, P. Carlen 3.009 Ceftriaxone Treatment In A Rat Posttraumatic Epilepsy Model Preserves Cortical Inhibitory Interneuron Function And Parvalbumin Expression/M. Q. Hameed, T. Hsieh, J. Morales-Quezada, G. S. Goodrich, A. Rotenberg 3.010 Mifepristone Treatment PostStatus Epilepticus Normalizes Basal Corticosterone Levels, Increases Calretinin Positive Cell Number In The Dentate Gyrus And Reduces Hilar Cell Proliferation In Mice/A. C. Wulsin, J. P. Herman, S. Danzer 3.011 ProBDNF Levels Increase Rapidly After Seizures In The Mouse/ A. X. Thomas, Y. Cruz Del Angel, S. J. Russek, B. L. Hempstead, A. R. Brooks-Kayal 3.012 Preventive Effect Of Levetiracetam Against The Pathological Changes In Hippocampus Of Temporal Lobe Epilepsy Model Mice/T. Higo, H. Sugano, M. Nakajima, Y. Iimura, H. Arai 3.013 Inflammatory Mechanisms Of Epileptogenesis In The Genetic Epilepsy, Tuberous Sclerosis Complex/B. Zhang, N. Rensing, J. Zou, M. Yang, M. Wong 66 3.014 Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep Syndrome/H. Yuan, A. Tankovic, S. F. Traynelis 3.015 A Juvenile Myoclonic Epilepsy GABAA Receptor Mutation Causes The Developmentally-Dependent Expression Of Seizures And Cortical Disinhibition/M. Gallagher, F. Arain, C. Zhou, L. Ding, S. Zaidi 3.016 Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To KCNT1 Mutations/I. H. Quraishi, G. E. Kim, J. K. Kronengold, R. L. Couture, M. L. Schwartz, G. Barcia, R. Nabbout, L. K. Kaczmarek 3.017 A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel Targeting To The Axon Initial Segment/B. Tran, M. Xu, E. C. Cooper 3.018 Prenatal Valproic Acid Exposure Impairs Interneuron Proliferation And Migration/ R. F. Martin, E. Powell 3.019 The Effects Of TRPV1 Ligands On Blood Brain Barrier Permeability In A Rodent Model Of Experimental Febrile Seizures/L. Scott, K. B. Rivard, K. Barrett, S. Nakanishi, M. Scantlebury 3.020 5-HT6 Receptor Ligands Modulate Seizure Thresholds And Inhibitory Synaptic Transmission In The Dentate Gyrus/G. J. Remigio, G. W. Saunders, P. J. West 3.021 The Effect Of Vitamin D On The Pentylenetetrazol-Kindling And The Seizure-Induced Neuronal Damage In The Mouse Hippocampus/S. Lim, Y. Shon, W. Kim 3.022 Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of Drug-Resistant Seizures/V. Dzhala, Y. Saponjian, Y. De Koninck, K. Staley 3.023 Time Course Of The Neuronal Sodium Concentration In PosttTraumatic Epileptogenesis In Vitro/T. Balena, K. Staley 3.024 A Novel Therapy For Status Epilepticus Using Biodegradable Immune-Modifying Nanoparticles/ D. Xu, S. Miller, S. Koh 3.025 Hypothalamus On The Horizon Of The Seizure Control/T. Chachua, C. Chern, I. Lilja, J. Veliskova, L. Velisek Models 3.026 Use Of Ethosuximide To Improve Outcome In The Kainic Acid Model Of Temporal Lobe Epilepsy/ S. S. Iyengar, J. J. LaFrancois, H. E. Scharfman 3.027 Unravelling The EEG Footprints That Develop Into Spontaneous Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse Model Of Temporal Lobe Epilepsy (TLE)/S. Puttachary, S. Sharma, T. Thippeswamy 3.028 The Piriform Cortex In The Intrahippocampal Kainic Acid Model: Effects Of Lesions And Deep Brain Stimulation On Spontaneous Seizures/M. Sprengers, R. Raedt, R. Siugzdaite, B. Descamps, B. Van Nieuwenhuyse, I. Dauwe, J. Delbeke, W. Wadman, P. Boon, K. Vonck 3.029 Effect Of A Conventional Antiepileptic Strategy On Seizure Activity And Neuroprotection In A Rat Model Of Human Cortical Dysplasia: Data From A Pilot Study/G. Battaglia, P. Nobili, A. Finardi, F. Colciaghi 3.030 New Model Of Focal Cortical Dysplasia Associated Epilepsy/ L. S. Hsieh, J. H. Wen, G. Buchanan, K. Claycomb, H. Zhan, A. Bordey 3.031 Electrographic Spiking And Frequency Power Analysis In Mouse CCI Models Of TBI Compared With Memory And Motor Deficits/J. Carlsen, D. Raible, L. Frey, A. Brooks-Kayal 3.032 Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe Epilepsy/J. Pearson, S. Rowley, L. Liang, B. Day, M. Patel 3.033 Aberrant Diurnal And Circadian Rhythms In Epileptic Mouse Model/ R. Maganti, E. Wallace, J. Williams 3.034 Microelectrode Array Neuronal Recordings From Intact Larval Zebrafish/ M. Meyer, A. Poduri, A. Rotenberg 3.035 Enhancing KCC2 By Acute TrkB Inhibition Rescues PhenobarbitalResistant Seizures In A Model Of Neonatal Ischemia/S. Kadam, S. Kang, M. Johnston 3.036 Cardiac Consequences Of Repeated Brief Seizures In Chronic Experimental Temporal Lobe Epilepsy/ J. Jefferys, A. Ashby-Lumsden, T. Lovick, K. Qing, S. Lee, P. Irazoqui 3.037 Spike-Wave Discharges Before And After The Induction Of Epilepsy In Rats/ J. LaFrancois, K. Bermudez-Hernandez, H. E. Scharfman 3.038 Pattern Recognition And Quantification Of Spike-And-Wave Discharge In Normal And Brain-Injured Sprague-Dawley Rats/D. Barth, F. Dudek, K. Rodgers 3.039 Flupirtine Is More Efficacious Than Phenobarbital In The Treatment Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/ D. Sampath, A. White, Y. Raol 3.040 EEG Analysis After Ketamine Induction – Mechanistic Similarities To Anti-NMDA Receptor Encephalitis/ C. N. Braun, L. UnCheol, S. Glynn, M. George 3.041 Increased Neuroinflammation In A Mouse Model Of Tuberous Sclerosis/A. A. Coley, H. Sun, S. S. Soldan, F. E. Jensen, D. M. Talos Monday December 8, 2014 Human Studies 3.053 Does Valproate Increase Levels Of Folate Receptor Autoantibodies In Women?/C. Lau, C. Harden, A. Palacios, R. Finnell 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.054 Characteristics Of Seizure Termination In Focal And Generalized Seizures/M. Borzello, A. Maheshwari, C. Chu, M. Westover, M. Kramer, S. Cash 3.055 Looking For Complexity In Quantitative Semiology Of Frontal And Temporal Lobe Seizures Using Neuroethology And Graph Theory/ N. Garcia-Cairasco, P. Bertti, J. Tejada, A. Pinheiro Martins, M. Cleto Dal-Cól, V. Terra, J. Cortes de Oliveira, T. Rodrigues Velasco, A. Ceiki Sakamotob 3.056 Quantitative Proteomic Profiling Reveals Repression Of Epilepsy Risk Genes Due To Aberrant MicroRNA Activity In Epileptogenic TSC Tubers/A. A. Dombkowski, D. Cukovic, N. J. Carruthers, P. M. Stemmer, H. T. Chugani, D. C. Chugani 3.057 The North American SUDEP Registry/B. Kaufman, D. Hesdorffer, E. Donner, G. Lapham, J. Buchhalter, D. Friedman, O. Devinsky 3.058 Deep Brain Stimulation For Focal Epilepsy – How Do Changes Of Interictal Epileptic Discharges Correspond To Outcome?/H. Lee, C. Kluge, F. Marquardt, J. Voges, L. Buentjen, S. Rampp, A. Kowski, M. Holtkamp, H. Heinze, F. Schmitt 3.059 The Safety, Efficacy And Dosing Of Barbiturate Coma In Pediatric Sustained Refractory Status Epilepticus/E. Payne, C. Griffiths, H. Frndova, A. Trope, C. Hahn 3.060 Whole Brain Networks Of Visual Object Recognition/ C. Kadipasaoglu, C. Conner, V. Baboyan, N. Tandon 3.061 Ventricular Repolarization Instability In Children With Epilepsy/ W. Ali, B. Bubolz, A. Anderson, Y. Lai 3.062 Multiple Functions Of The PreCentral Frontal Eye Field/E. C. Brown, O. Muzik, R. Rothermel, C. Juhasz, A. Shah, D. Fuerst, S. Mittal, S. Sood, E. Asano Biomarkers 3.063 Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By Nanoparticles/S. Eyal, E. Portnoy, B. Polyak, D. Inbar, A. Mann, A. Rai, A. Bishara, M. Shmuel, S. Magdassi, T. Ben Hur, D. Ekstein 3.064 High Frequency Oscillations Deviate From Neuronal Avalanche Dynamics In The Ictal Onset Zone/ E. Gireesh, C. Jouny, N. Crone 3.065 The Role Of Physiologic Biomarkers During A Taurine Trial For Succinic Semialdehyde Dehydrogenase Deficiency/J. Schreiber, P. Pearl, I. Dustin, E. Wiggs, E. Barrios, E. Wassermann, K. M. Gibson, W. Theodore 3.066 Mass Spectrometry-Based Metabolomics Approach For Uncovering Epileptogenic Mechanisms And Biomarker Discovery/ S. Heischmann, L. B. Gano, K. Quinn, C. Cruickshank-Quinn, N. Reisdorph, M. Patel 3.067 Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone/S. Gliske, W. Stacey 3.068 Occurence Of Ictal High Frequency Oscillations Mirrows Seizure Strength In Rats/N. Birk, K. Somerlik-Fuchs, T. Stieglitz, A. Schulze-Bonhage, J. Jacobs 3.069 How Reliable Are The HighFrequency Oscillations And Delayed Responses As Epileptogenicity Biomarkers? A Study Based On Intracranial Stimulation/A. Barborica, C. Donos, M. Maliia, J. Ciurea, A. Rasina, I. Mindruta 3.070 Early Seizure Detection Using Relative Gamma And Ripple Band Phase Decoherence/Z. Nadasdy, D. Benites, J. Shen, D. Briggs, D. F. Clarke, R. Buchanan, M. Lee, D. Nelson, P. Modur 3.071 High Frequency Oscillations In Patients With Nonlesional Class I Outcomes In Seizure Onset Channels Versus Non Seizure Onset Channels In Temporal And Neocortical Structures/N. D. Child, J. Cimbalnik, V. M. Vasoli, V. Svehlik, B. H. Brinkmann, M. Stead, G. Worrell 3.072 Spectroscopic Imaging In Early Post-Status Epilepticus In A Rodent Model/P. S. Pearce, N. de Lanerolle, A. Rapuano, T. Hitchens, J. W. Pan 3.073 Automated High-Frequency Oscillation Detection From Tripolar Concentric Ring Electrode Scalp Recordings/M. Abtahi, I. E. Martínez-Juárez, O. Makeyev, A. Medvedev, J. Gaitanis, R. Fisher, W. Besio 3.074 Modulating Epileptogenesis In The Glutamine-Synthetase Deficient Model Of MTLE/E. Perez, H. Zaveri, R. Joshi, H. Wang, E. Damisah, R. Dhaher, T. Eid MONDAY 3.042 In Vivo Modulation Of Synaptic Noise: A Novel Model Of Ictogenesis/ H. Luna-Munguia, P. Starski, W. Stacey 3.043 Lithium-Pilocarpine And DFPInduced Status Epilepticus In Immature Rats: Behavioral, Electrographic, And Neuropathological Characteristics/E. A. Scholl, N. Simon, M. Lehmkuhle, J. Ekstrand, F. E. Dudek 3.044 Epilepsy In A Novel Tuberous Sclerosis Mouse Model/S. C. Dhamne, E. Chadwick, S. Lammers, M. Q. Hameed, D. Kwiatkowski, A. Rotenberg, M. Sahin 3.045 First In-Vivo Model For Electrically Induced Seizures – An Electroclinical Characterization/ A. Y. Kitay, M. Brosch, F. Marquardt, L. Buentjen, C. Kluge, J. Mylius, E. Selezneva, K. Kopitzki, J. Voges, H. Heinze, H. Scheich, F. Schmitt 3.046 Identifying Gene Pathways Activated After Audiogenic Atimulus In Wistar Audiogenic Rats/A. Matos, A. S. Schwambach Vieira, V. Pascoal, C. S. Rocha, D. Nascimento, S. Martins, C. Maurer Morelli, A. Martins, A. Godard, I. Lopes-Cendes 3.047 Comparison Of Spike-Wave Discharges And Other Oscillatory Activity In Normal Animals With Spontaneous Recurrent Seizures Across Several Animal Models Of Acquired Epilepsy/F. Dudek, K. M. Rodgers, W. A. Pouliot, S. Kadam, E. H. Bertram, D. S. Barth 3.048 Rapamycin Normalizes Total EEG Power In Neuron Subset-Specific PTEN Knock-Out Mice/ A. Regnier-Golanov, L. Nguyen, A. Brewster, V. Patil, A. Anderson 3.049 Early EKG Changes And Cardiac Activation Of Intracellular Signaling Cascades In A Model Of Acquired Epilepsy/A. Brewster, A. Anderson, Y. Lai 3.050 Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia/L. Nguyen, A. Brewster, M. Clark, A. Regnier-Golanov, C. Sunnen, V. Patil, A. Anderson 3.051 Neonatal Stroke And Phenobarbital Treatment: Improved T-Maze Function And Impact On PostStroke Hilar Neurogenesis/A. Comi, M. Mateo, S. George, A. Garson, K. Fisk, H. Miao 3.052 Gender Differences In Cerebrospinal Fluid Levels Of Monamine Metabolites In The Baboon/M. Patel, J. Rogers, C. Szabo, M. Leland, M. A. Javors Poster Session 3 Behavior/Neuropsychology/ Language Adult 3.075 Development And Field-Testing Of An Epilepsy Self-Management Instrument For Adults With Epilepsy/C. Escoffery, Y. Bamps, W. LaFrance, S. Stoll, R. Shegog, J. Buelow, P. Shafer, N. Thompson 3.076 Distinct Domains Of Impulsivity Are Impaired In Juvenile Myoclonic Epilepsy, But Not In Temporal Lobe Epilepsy/P. Rzezak, S. Moschetta, E. Lima, C. X. Castro, A. Coan, C. Guerreiro, G. Busatto, K. Valente 3.077 Stability And Variability Of Cognitive Performance In Patients With Epilepsy/M. T. Lutz, T. Mayer 67 Monday December 8, 2014 3.078 Depression And Isolation In People With Epilepsy/N. Thompson, Y. A. Bamps, L. Selwa, S. Stoll, C. Begley, E. K. Johnson, R. Fraser 3.079 PHQ-9 And GAD-7 As Reliable Screening Tools For Mood Disorders In People With Epilepsy (PWE)/ I. Ahmed, S. Nair, A. Riaz, I. Ali 3.080 The Impact Of Disease Variables And Standard Cognitive Measures On Social Cognition In Epilepsy/K. Bujarski, L. Flashman, R. M. Roth 3.081 Felt Stigma In Families Containing Multiple Individuals With Epilepsy/M. Sabatello, S. T. Sorge, J. O. Okeke, V. Tangel, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman 3.082 Depression And Seizure Frequency Predicts Worse Social Functioning In Patients With Juvenile Myoclonic Epilepsy (JME)/ S. C. Moschetta, C. A. Guerreiro, C. Lima Castro, A. Coan, P. Rzezak, K. Valente 3.083 Unique Characteristics Of Patients With Comorbid Epileptic And Psychogenic Nonepileptic Seizures/ J. J. Konikkara, J. Pacheco, P. Van Ness, M. Agostini, R. Hays, L. Howe-Martin, C. B. Culver, J. Munoz, K. Ding, P. Modur, P. Gupta 3.084 Preoperative Hippocampal Volume And Neuropsychological Outcomes/S. C. Germeyan, E. Wiggs, L. Sepeta, E. Emery, I. Dustin, K. zaghloul, S. Inati, W. Theodore 3.085 Comparison Of Common Data Elements From The Managing Epilepsy Well (MEW) Integrated Database And A Well Characterized Sample With Nonepileptic Seizures/W. LaFrance, Jr, Y. Bamps, S. Stoll, S. S. Sahoo, E. Welter, J. Sams, C. Tatsuoka, M. Sajatovic Genetics Human Studies 3.086 Screen For Somatic Mosaic Mutations In Unexplained Dravet Syndrome Patients/C. Myers, J. McMahon, I. Scheffer, H. Mefford 3.087 The Phenotypic Spectrum Of SCN2A Encephalopathy: A Diagnosis With Treatment Implications/ K. Howell, J. McMahon, G. L. Carvill, A. Poduri, M. T. Mackay, M. V. Rodriguez Casero, R. Webster, D. Clark, J. L. Freeman, S. Calvert, S. Mandelstam, H. Mefford, A. S. Harvey, I. Scheffer 3.088 Are Mutations Of The Respiratory Control Gene PHOX2B Associated With Sudden Unexpected Death In Epilepsy (SUDEP)?/ B. M. Regan, R. D. Bagnall, D. E. Crompton, C. Cutmore, S. Berkovic, I. E. Scheffer, C. Semsarian 68 Poster Session 3 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.089 Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive Myoclonus Epilepsy/M. Muona, S. Berkovic, L. M. Dibbens, K. L. Oliver, S. Maljevic, T. Joensuu, M. A. Bayly, S. Petrou, H. Lerche, A. Palotie, A. Lehesjoki 3.090 Familial Adult Myoclonic Epilepsy: A New Family Consistent With Linkage To Chromosome 2/ K. Klein, M. Pendziwiat, R. Straussberg, I. Blatt, C. E. Kim, P. S. Reif, S. von Spiczak, A. Korczyn, H. Muhle, F. Rosenow, H. Hakonarson, G. Kuhlenbäumer, H. Goldberg-Stern, U. Stephani, Z. Afawi, I. Helbig 3.091 Genetic Determinants Of Common Epilepsies: A Meta-Analysis Of Genome-Wide Association Studies/G. Na 3.092 CHD2 Myoclonic Encephalopathy: Self-Induced Seizures, Photosensitivity And Variable Cognitive Outcome/ R. Thomas, L. Zhang, G. L. Carvill, J. Archer, S. Mandelstam, D. Craiu, S. Berkovic, D. Gill, H. Mefford, I. Scheffer 3.093 Whole-Exome Sequencing And Targeted Re-Sequencing In Pediatric Epileptic Encephalopathies/ J. L. Michaud, M. Lachance, F. F. Hamdan, S. Dobrzeniecka, H. Mefford, R. G. Lafrenière, B. Minassian, P. Cossette, E. Rossignol 3.094 CACNA1A-Related Hemiplegic Migraine Mimicking Psychogenic Non-Epileptic Seizures (PNES)/ M. Chadehumbe, M. Mintz, R. Boles 3.095 Epilepsy Genetics Initiative (EGI)/D. Goldstein, E. Heinzen, D. Lowenstein, S. Berkovic, T. Dixon-Salazar, J. Milder, H. White, O. Devinsky, D. Dlugos, W. Gallentine, M. Mikati, A. Poduri, I. Scheffer, J. Sullivan 3.096 Copy Number Variants Are An Important Cause Of Unexplained Epilepsy Plus Other Neurological Abnormalities/S. E. Buerki, E. Sade, P. Eydoux, M. Connolly, M. Demos 3.097 Severe Multi-Organ Involvement Including Pancreatic Neuroendocrine Tumor In A 51-YearOld Female With Tuberous Sclerosis Complex/F. Andermann, D. Amrom, M. Heshmati Moghaddam, P. Zanelli, E. Andermann 3.098 Regional Variation Of SLC7A11 Expression In Glioblastoma Associated Seizures/J. Lee, J. Snyder, T. Mikkelsen, P. Wen 3.099 Uncovering New Genetic Loci For Infantile Spasms Syndrome/ E. D. Marsh, J. Glessner, X. Bozarth, W. Dobyns, H. Hakonarson, I. Helbig 3.100 Utilizing Brain Expression Networks To Prioritize Candidate Epileptic Encephalopathy Genes/ K. L. Oliver, V. Lukic, N. P. Thorne, S. F. Berkovic, I. E. Scheffer, M. Bahlo 3.101 Association Between Polymorphisms In Genes Involved In P-Glycoprotein Regulation And Pharmacoresistance In ChildhoodOnset Epilepsy/J. Montalvo, M. Rios-Motta, S. Gonzalez-Crespo, L. Gonzalez-Sepulveda, K. Acevedo, M. Vazquez, I. Pita 3.102 Whole Exome Sequencing In Intractable Paediatric Epilepsy Patients In Calgary/L. Bello-Espinosa 3.103 Copy Number Variants In Children With Epilepsy/ S. J. Mackenzie, Y. Eksioglu 3.104 Natural History Of Seizures In Rett Syndrome And MECP2-Related Disorders/D. Tarquinio, J. B. Lane, W. Hou, W. Kaufmann, S. A. Skinner, K. J. Motil, J. L. Neul, D. Glaze, A. K. Percy Animal Studies 3.105 Superimposing Status Epilepticus On NS-PTEN Haploinsufficient And Wild Type Mice Results In Long-Term Changes In Behavior/G. Smith, J. White, J. Nicoletti, A. Pandian, J. Lugo 3.106 Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models Of Refractory Epilepsy/J. Wong, C. Makinson, H. Zafar, A. Escayg 3.107 Scn2a-null Heterozygosity Improves Survival And Modifies Neurocardiac Interaction In The Kcna1-Null Mouse Model Of SUDEP/ E. Glasscock, N. Gautier, B. Karumuri, R. Liu, I. Vlachos, L. Iasemidis Neuropathology of Epilepsy Human Studies 3.108 Oligodenderoglia-Like Cells In White Matter Recruiting The Extensive Epileptogenic Zones In Pediatric Intractable Focal Epilepsy/ S. Sakuma, W. Halliday, K. Okanari, S. Baba, M. Nakajima, Y. Sato, A. Ochi, H. Otsubo 3.109 Hippocampal Changes In Refractory Status Epilepticus: Autopsy Findings/K. M. Ikeda, L. Ang, G. Young 3.110 Neuroinflammatory Processes, Acute Neuronal Injury And Blood Brain Barrier In SUDEP/Z. Michalak, D. Obari, M. Thom, S. Sisodiya 3.111 Cerebral Glucose Hypometabolism Is Associated With Mitochondrial Dysfunction In Patients With Intractable Epilepsy And Cortical Dysplasia/J. Tenney, L. Rozhkov, P. Horn, L. Miles, M. Miles 3.112 The Serum Levels Of Sodium And Uric Acid In Children With Benign Convulsion With Mild Gastroenteritis/ S. Kim, J. Kang, H. Bang, T. Kim, H. Kim, J. Kang, J. Kim, Y. Kim Monday December 8, 2014 3.113 Gene Expression Profiling In Dentate Granule Cells Of Mesial Temporal Lobe Epilepsy Patients With And Without Hippocampal Sclerosis/ N. G. Griffin, Y. Wang, L. Hong, C. Hulette, M. Haglund, R. Radtke, P. Skene, S. Sinha, E. Heinzen 3.114 A Case Of Glioneuronal Tumor With Focal Cortical Dysplasia Type IIb/T. Saito, S. Sukigara, S. Hanai, A. Takahashi, M. Sasaki, T. Otsuki, M. Itoh In Vitro Studies 3.125 Laser Scanning Photostimulation Reveals Altered Astrocyte Maturation In A Model Of Developmental Cortical Malformation/ M. Armbruster, C. Dulla 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.126 Real-World Assessment Of The Burden Of Epilepsy In Tuberous Sclerosis Complex (TSC) Patients In The United Kingdom (UK)/P. Crawford, C. Shepherd, D. Demuth, P. Nasuti, L. Lucchese, Z. Haider, E. Gray, M. Magestro 3.127 Managing Information Well: Towards An Ontology-Driven Informatics Platform For Data Sharing And Secondary Use In Epilepsy Self-Management Research Centers/S. D. Lhatoo, S. S. Sahoo, G. Zhang, Y. Bamps, R. Fraser, S. Stoll, C. Tatsuoka, E. Welter, M. Sajatovic 3.128 Sudden Unexpected Death In Epilepsy. A Population-Based Study/ A. Einarsdottir, O. Sveinsson, E. Olafsson 3.129 Using Routine Data To Investigate Secular Trends In Hospital Admission Amongst Children With Epilepsy: A Nationwide Study/ O. Ajetunmobi, C. Weir, R. Wood, R. Chin 3.130 A Study Of Epilepsy Prevalence And Incidence In The U.S. Using Administrative Claims Data/ S. Helmers, D. Thurman, T. Durgin, A. Kalsanka Pai, A. Patel, E. Faught 3.131 Epidemiology Study Of Association Between Onset Of Chronic Headache And Epilepsy/ T. Chen 3.132 Long QT Mutations And QT Prolongation Are Linked With An Increased Risk Of Seizures/ D. S. Auerbach, M. Ruwald, M. Andrews, A. Moss 3.133 Retrospective Review Of Seizures Associated With Posterior Reversible Encephalopathy Syndrome (PRES)/N. Dike, S. Rana 3.134 Trajectories Of Emotional Well-Being In Children With Newly Diagnosed Epilepsy/S. W. Goodwin, P. Wilk, M. Campbell, K. N. Speechley 3.135 Fertility In Epilepsy: Effects Of Estimated Offspring Risk And Genetic Attribution/V. Tangel, S. T. Sorge, J. O. Okeke, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman 3.136 Defining The Prevalence And Characteristics Of Seizure Clusters/ T. Choezom, S. Zhang, S. Radhakrishna, J. Bonito, H. Zaveri, R. Joshi, L. Hirsch, K. Detyniecki 3.137 Sudden Unexpected Death In Dravet Syndrome: A Case-Control Study/E. Donner, D. Friedman, B. Kaufman, D. Hesdorffer, G. Lapham, J. Buchhalter, J. Thaler, S. Rai, A. Thaler, O. Devinsky 3.138 Predictors Of Seizure Clusters/B. Chen, H. Choi, L. Hirsch, R. Buchsbaum, K. Kato, A. Legge, K. Detyniecki 3.139 The Clinical And Social Impact Of The Post-Ictal State/C. Josephson, N. Jette, Y. Aghakhani, P. Federico, A. Hanson, W. Murphy, N. Pillay, S. Wiebe 3.140 The Elixhauser Index In Incident Epilepsy And First Unprovoked Seizure: Means And Reliability Of Patient Or Parent Report And Hospital Medical Record/E. Leaffer, A. Hauser, A. Pack, E. Baldin, C. I. Akman, D. Hesdorffer 3.141 How Do Caregivers Determine Seizure Severity In Their Child With Epilepsy?/S. Shih, M. Ardini, B. Kroner, W. Gaillard, S. Cushner-Weinstein, J. Salpekar, K. Havens, A. Kao, T. Zelleke, D. Depositario-Cabacar 3.142 Patterns Of Comorbidity In Pregnant Women with Epilepsy/ A. M. Malek, D. A. Wilson, B. Wannamaker, R. B. Newman, J. E. Vena, A. Selassie 3.143 Tuberous Sclerosis – Does Regional Differences In Clinical Features Exist?/E. V. Caetano, P. B. Cerqueira, M. G. Manreza, U. C. Reed, L. B. Sampaio, E. C. Miotto, F. A. Costa, P. S. Mendes, B. J. Correa 3.144 Parental Worry About Nocturnal Seizures And Utilization Of Methods For Monitoring/B. Kroner, S. Shih, M. A. Ardini, W. Gaillard 3.145 Etiologies And Yield Of Investigations For Infantile Spasms: Results Of A U.S. Multicenter, Prospective Study/E. Wirrell, C. Joshi, R. Shellhaas, C. Keator, S. Kumar, W. Mitchell Neurophysiology Other Clinical EEG 3.146 Pharmacologically Induced Burst Suppression In Pediatric And Adult Patients – Varying But Predictable Pattern?/L. M. Sorin, B. Jabo, T. Losey 3.147 Completely Lateralized Vertex Waves Of Sleep Are A Normal Phenomenon: A Retrospective, Blinded, Case Control Study/ J. N. Brenton, J. R. Mytinger 3.148 Posterior Rhythmic Delta Activity In Patients With Absence Epilepsy/R. Fabris, L. Wong-Kisiel, K. Nickels 3.149 Multifocal Electrographic Seizures Recorded By 128 Channel Dense Array High-Resolution EEG In Outpatient EEG LAB/H. Hasegawa 3.150 EEG Focal Interictal Epileptiform Transients (FIET) & Their Correlation With Clinical Diagnosis/ F. Matsuo 3.151 How Much Does Sleep Deprivation EEG Useful For Detecting Epileptiform Abnormalities?/D. Ozbek, I. Midi, K. Agan MONDAY Animal Studies 3.115 NMDA Receptor Activation Contributes To Benzodiazepine Refractoriness By Enhancing Ampa Receptor Mediated Transmission During Status Epilepticus/S. Joshi, K. Rajasekaran, J. Williamson, J. Kapur 3.116 Circulating Ccr2+ Monocytes Display Delayed Brain Infiltration After Chemoconvulsant-Induced Status Epilepticus/N. Varvel, J. J. Neher, R. J. Miller, M. Jucker, R. Dingledine 3.117 Deletion Of Micro-RNA-146a Leads To Fewer Animals Developing Acute Behavioral Seizures Following Viral Encephalitis/M. F. Cusick, J. E. Libbey, R. M. O’Connell, R. S. Fujinami 3.118 Effects Of Neuronal Nitric Oxide Synthase Inhibition In A Neonatal Mouse Model Of Acute Hypoxic Seizures/S. A. Zanelli, P. Wagley, J. Kapur 3.119 Regulation Of Hippocampal Glutamate Transporter-1 (GLT1) Expression In The Intrahippocampal Kainic Acid Model Of Epileptogenesis/ J. A. Hubbard, J. Szu, D. Binder 3.120 Impact Of Targeted Ablation Of Developing Dentate Granule Cells On Temporal Lobe Epileptogenesis/ B. Hosford, J. Liska, S. Danzer 3.121 Do Ripples Change After Pilocarpine-Induced Status Epilepticus?/C. Behr, M. Lévesque, C. Pack, J. Gotman, M. Avoli 3.122 Sex- And Brain Region-Specific Regulation Of Brd2 In GABAergic Neurons In A Juvenile Myoclonic Epilepsy Mouse Model/J. A. Miller, F. Mohammad, D. S. Chandler, J. Veliskova, L. Velisek, D. A. Greenberg 3.123 Evaluation Of The Inflammatory Process In Focal Cortical Dysplasia Model By Freeze Lesion/A. Donatti, A. Fernandes, N. Garcia-Cairasco 3.124 Effects Of Postnatal Inflammation On Brain Excitability In A Mouse Model Of Autism Spectrum Disorder/M. L. Lewis, L. Qulu, S. A. Candy, J. M. Rho, Q. J. Pittman Epidemiology Poster Session 3 69 Monday December 8, 2014 3.152 Generalized Onset Seizures With Focal Evolution Should Be Recognized As A Seizure Type/ A. Linane, B. Abou-Khalil, A. Lagrange 3.153 Preictal Failure Of Post-Spike Slow Waves To Control Spike-Related High-Frequency Oscillations Is Associated With Seizure Initiation In Focal Cortical Dysplasia Type II/ Y. Sato, S. M. Doesburg, S. M. Wong, A. Ochi, H. Otsubo 3.154 Correlation Between Bispectral Index And Electrocorticography During Epilepsy Surgery/D. San Juan Orta, M. Gómez Ramírez, L. R. Rodríguez Arias, A. Osorio Santiago, A. López Pizano, R. Llerenas Zamora, R. Vázquez Gregorio, A. Espinoza López, C. Trenado, A. Hernandez Ruiz, J. Delgado-delaMora, M. Alonso-Vanegas, D. Anschel 3.155 Diagnostic Utility And Yield Of Routine Electroencephalogram Study In Patients Referred By Epileptologists And Carrying A Diagnosis Of Epilepsy/A. Gudlavalleti, B. B. Allen, N. K. Sethi, G. Solomon 3.156 Diagnosis Of Electrical Status Epilepticus In Sleep Made By A Clinician Versus Computerized Spike Detection Software: A Comparison/ T. Bryant, M. Guess, L. Wenzel, D. Tadlock, C. Joshi 3.157 Validation Of The M-Score, An EEG Grading Scale For Infantile Spasms/J. R. Mytinger, S. A. Hussain, J. J. Millichap, N. Ryan, G. L. Heyer 3.158 30 Minute Versus Extended Outpatient Eeg For The Detection Of Epileptiform Abnormalities In New Referrals/D. Burkholder, J. Britton, V. Rajasekaran, R. Fabris, J. C. Perumpillichira, K. Kelly, E. So, K. Nickels, L. Wong-Kisiel, T. Lagerlund, G. Cascino, G. Worrell, E. Wirrell 3.159 High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity/ R. Sakuraba, M. Iwasaki, E. Okumura, K. Jin, Y. Kakisaka, K. Kato, T. Tominaga, N. Nakasato 3.160 The Dynamic Changes Of Ictal High Frequency Oscillations During Temporal Lobe Seizures Recorded By Stereo-Electroencephalography/ S. Wu, J. Tao, S. Rose, S. Lhatoo, H. Lüders 3.161 Detectability Of Fast Ripples On The Scalp EEG: A Preliminary Study With Subdermal Electrodes/ F. Pizzo, B. Frauscher, T. Ferrari-Marinho, F. Dubeau, J. Gotman 3.162 Fixation-Off Sensitivity (FOS)Like Phenomenon After Embolic Strokes Of The Parietal And Occipital Regions/F. Tirol, A. Foroughi, P. Foreman 70 Poster Session 3 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.163 The Intracerebral EEG Pattern Of Focal Cortical Dysplasia Changes During The Different Stages Of Sleep/I. Menezes Cordeiro, N. von Ellenrieder, F. Dubeau, J. Gotman, B. Frauscher 3.164 Changes In Scalp EEG Spectral Content During Deep Temporal Lobe Seizures Lacking A Scalp Ictal Correlate/A. D. Lam, S. S. Cash 3.165 Quantitative Analysis Of Interictal Discharges In Mesial Temporal Lobe Epilepsy/L. A. Oliveira, A. D. Borges, S. Yamashita, L. Betting 3.166 The Epileptiform Abnormalities In Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus (PANDAS) Patients/X. Zhou, A. Buckley, S. Swedo, S. Inati 3.167 How High Is High Enough? Do Faster EEG Sampling Rates Lead To Improved Seizure Onset Localization?/ S. P. DeVries, K. A. Davis, J. B. Wagenaar, W. C. Stacey 3.168 Changes In Intracranial Electroencephalography (iEEG) In Five Patients During WADA/S. Le, K. J. Meador 3.169 Increased Left Hemisphere Interictal Epileptiform Discharges Are Associated With Language Based Knowledge And Learning In Benign Rolandic Epilepsy/M. Takeoka, J. Girard, C. Harini, C. Vega, K. Boyer 3.170 EEG Photic Driving: Clinical Significance Of Asymmetric Responses/M. T. Kendirli, H. Tekeli, E. Togrol, F. Ozdag 3.171 The Utility Of Ambulatory Electroencephalography (aEEG)/ K. AbdeleRahman, R. Mahajan, M. Grigg-Damberger 3.172 Prevalence Of Epileptiform Activity In Children Less Than 1 Year Of Age Referred For Polysomnography/ A. W. Ho, A. Adeleye, A. Nettel-Aguirre, V. Kirk, J. Buchhalter 3.173 Differences In The Yield Of Routine EEG Studies In Patients 60 Years Or Older As Compared To Patients Less Than 60-Years-Old Presenting With Transient Loss Of Consciousness/N. Gupta, C. Christodoulou, J. Miller-Horn 3.174 Broadband Intracranial Ictal EEG Analysis In Lesional And NonLesional Pharmacoresistant Epilepsy/M. Dhakar, A. Shah 3.175 Characteristic Electrographic Findings In Fraternal Twins With Sialidosis/A. Sheikh, J. Menon, V. Ramsey-Williams, D. Cameron, H. Li 3.176 Fun Finding Artifacts This Is An Interactive Poster Showing Some Common And Uncommon Artifacts. The Goal Is To Challenge All Levels Of EEG Knowledge. See The Artifact And You Guess What You Think That It Is, Once You Have An Idea You Can Check Your Answer/C. L. Riley 3.177 Intracranial Recording: A Glimpse On White – Grey Matter Differences/M. Mercier, S. Bickel, P. Megevand, D. Groppe, A. Mehta, F. Lado 3.178 Visual-Evoked Responses As A Biomarker For Neural HyperExcitability In Childhood Absence Epilepsy/R. Holt, F. Pei, B. Porter, J. Tsai, A. Norcia 3.179 Eletroencephalographic Profile Of Outpatients Presenting Seizures During Routine EEG on a Tertiary Teaching Hospital/R. Alessi, C. N. Alencar, P. B. Lima, M. R. Silveira, J. Q. Andrade, E. Garzon 3.180 Photic Stimulation: Get More Information From An Old Test; Can We Do Better? Utility Of Change In SPR As A Marker Of Chronc Efficacy/ P. Timmings Computational Analysis & Modeling Of EEG 3.181 Accuracy Of EEG Interpretation Without A Reference Standard/J. Slater, A. C. Grant, A. Omurtag 3.182 On Seizure Dynamics And Propagation/C. Bernard, V. Jirsa, W. Stacey, F. Bartolomei, T. Proix 3.183 Spectral Analysis Of Intracranial Interictal Bursts May Localize Seizure Onset/H. Ung, K. Davis, D. Wulsin, B. Litt 3.184 Epileptic Spikes And High Frequency Oscillations Are More Frequent During Generalized Slow Oscillations Than During The Rest Of NREM Sleep/B. Frauscher, N. von Ellenrieder, T. Ferrari-Marinho, F. Dubeau, M. Avoli, J. Gotman 3.185 Ripple (80-250Hz) Characterization In Nonepileptic Brain Regions/N. von Ellenrieder, B. Frauscher, T. Ferrari-Marinho, F. Dubeau, J. Gotman 3.186 Interictal Localization Of The Seizure Onset Zone Using High Frequency Oscillations And Visibility Graphs/A. M. Spring, R. A. Bessemer, D. J. Pittman, Y. Aghakhani, P. Federico 3.187 Interictal Phase Clustering Of High Frequency Oscillations Derived From 256-Channel Scalp EEG Correlates With The Epileptogenic Zone/M. D. Holmes, C. Ramon 3.188 MRI And Electrical Source Analysis In Patients With Temporal Lobe Encephaloceles: Localization And Clinical Correlation/M. Quach 3.189 Index Of HFO Cross-Frequency Coupling For Assessing The Seizure Onset Zone/C. Jouny, U. Malinowska, M. Cervenka, G. Bergey 3.190 Investigation Of HFO In Human Intracranial EEG With A Semi-Supervised X-means Clustering/S. Liu, N. Ince, A. Abosch, T. Henry, Z. Sha Monday December 8, 2014 3.191 Co-Occurrence Of High Frequency Oscillations For Identification Of The Seizure Onset Zone/U. Malinowska, G. Bergey, M. Cervenka, C. Jouny 3.192 Integrating 3D Source Localization And Connectivity Maps For Guiding Pre-Surgical Subdural Grid Placement/A. Pinzon-Ardila, M. Cabrerizo, N. Rojas, P. Jayakar, G. Sergio, M. Adjouadi 3.193 Validating Individual Head Models In Electrical Source Imaging Of Spikes And Seizures/K. Jenson, D. Tucker, P. Luu, M. D. Holmes 3.194 Source Localization Techniques Are Essential In More Accurate Determination Of Target Tuber Conglomerates For MRI-Guided LaserInduced Thermal Ablation For Treatment Of Intractable Epilepsy And Neurocognitive Comorbidities In Pediatric Tuberous Sclerosis/ Y. Eksioglu, Z. Tovar-Spinoza, F. Duffy 3.195 Frequency-Frequency Coupling Of Brain Oscillations In Studying Ictal EEG Activity/Y. Hsin Clinical Epilepsy 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.202 A Brain-Machine Interface For Burst Suppression Control In Pediatric Status Epilepticus/ C. Papadelis, C. Doshi, S. Thome-Souza, E. Grant, R. Tasker, T. Loddenkemper 3.203 New-Onset Refractory Status Epilepticus: Etiology And Outcome In A Retrospective Series Of 121 Cases/N. Gaspard, B. Foreman, V. Alvarez, C. M. Cabrera Kang, J. Probasco, A. Jongeling, E. Meyers, K. Haas, A. Espinera, S. Schmitt, E. Gerard, T. Gofton, P. Kaplan, J. Lee, B. Legros, J. Szaflarski, M. Westover, S. Laroche, L. Hirsch 3.204 Clinical Correlates And Outcome Of Cyclic Seizures In Critically Ill Patients: A Case-Control Study/L. F. Pinto, E. Gilmore, O. Petroff, N. Rampal, L. Hirsch, N. Gaspard 3.205 Eyewitnesses Of Seizures Are More Accurate Historians Than The Patients/M. Spitz, S. Moreland, K. Horiuchi, K. Lervik, P. Korb, C. Drees, R. DeBello, L. Strom, L. Frey, A. Shrestha, C. O’Brien 3.206 Automated EMG Based Seizure Detection And Quantification For The Home And The EMU, A Prospective Multicenter Study/ J. Cavazos, M. Girouard, L. Whitmire 3.207 Jeavons Syndrome: Seizing The Light – A Compulsive Epilepsy Disorder?/A. Yadav, I. Tuxhorn 3.208 The Proportion Of Time Spent In The Tonic Phase Of A Convulsive Seizure Predicts Postictal Hypopnea/E. Acton, A. Thaler, A. Krause, C. Anderson, A. Esfahanizadeh, J. Pollard 3.209 Associated Cardiac Findings In Children With Down Syndrome And Infantile Spasms/D. Daniels, K. Knupp, T. Benke, F. Hickey, K. Wolter-Warmerdam, D. L. Cohen 3.210 KCNQ2-Deficiency: Clinical Spectrum Of Epilepsy, Encephalopathy, And Response To Ezogabine/K. Park, J. Millichap, E. C. Cooper 3.211 Temporal IEDs In Extratemporal Lobe Epilepsy Are Associated With Temporal Hypometabolism On PET Imaging/ E. Hartl, J. Rémi, A. Loesch, C. Vollmar, S. Noachtar 3.212 Co-Oscillation Of Spikes, Spindles And K Complexes: A Useful Biomarker Of Epileptogenicity And Outcome In Children With Epilepsy?/ A. Zrik, I. Tuxhorn, A. Yadav, P. Rai 3.213 Clinical And Intracranial EEG Features After Secondarily Generalized Seizures/L. M. Bateman, C. Schevon 3.214 Characteristics Of Other Seizure Types Associated With Infantile Spasms/J. Millichap, L. Wong-Kisiel, E. Yozawitz, J. Sullivan 3.215 Electrographic And Hemodynamic Changes In Patients With Focal Seizures/K. Hecox, J. Zemblis, C. Sauer, H. Whalen, P. Monrad 3.216 Clinical Course of Seizures In Ring Chromosome 20 Syndrome/ H. Ikeda, H. Ikeda, T. Hiyoshi, E. Yamazaki, K. Yoshimura, Y. Inoue Clinical Treatments 3.217 The Application Of An Explanatory Model Of Treatment Decision- Making In A Patient With Medically Refractory Focal Epilepsy/ S. Dewar, H. Pieters 3.218 Protective Effects Of Vagus Nerve Stimulation On Cardiac Electrical Instability In Patients With Drug-Resistant Epilepsy/A. Schomer, B. D. Nearing, S. Schachter, E. Bachman, P. Shafer, D. Sundstrom, R. L. Verrier 3.219 Pyridoxine Deficiency In Adult Status Epilepticus Patients/H. Dave, R. Ramsay, F. Khan, V. Sabharwal, I. Iwuchukwu 3.220 Outpatient Initiation Of The Ketogenic Diet: The BC Children’s Hospital Experience/A. Michoulas, M. Connolly, K. Selby, E. Anghelina, A. Ferguson, C. Simonson, F. Zanotto, K. Farrell 3.221 Electrical Stimulation Of The Hippocampus For Medically Refractory Mesial Temporal Lobe Epilepsy: A Long-Term Follow-Up Study/S. N. Lim, C. Y. Lee, S. T. Lee, P. H. Tu, B. L. Chang, C. H. Lee, C. W. Chang, W. E. Tseng, T. Wu 3.222 A Lack Of Clinically Significant Vision Loss Among Vigabatrin-Treated Patients With Infantile Spasms: The UCLA Experience/M. Schwarz, M. Li, J. Tsao, R. Zhou, Y. W. Wu, S. A. Hussain 3.223 The National Infantile Spasms Consortium (NISC): Moving Towards Standardization Of Care And Improved Treatment And Outcomes In Infantile Spasms/N. Ryan, J. Coryell, J. R. Mytinger, K. Nickels, K. Knupp 3.224 Improving Efficiency In Management Of Status Epilepticus Using A Specific EMR Order Set/ J. Boggs, R. Bolen, L. Bishop, M. Bailey, M. Bennett 3.225 Management Of Super Refractory Status Epilepticus With Ketamine And/Or Propofol/V. Sabharwal, H. Dave, R. Lancaster, M. Almualim, F. Khan, H. McGrade, E. Ramsay 3.226 New-Onset Refractory Status Epilepticus: Immune Modulatory Therapy And Outcome/C. M. Cabrera Kang, S. M. Laroche, B. Foreman, V. Alvarez, J. Probasco, A. Jongeling, E. Meyers, K. Haas, S. E. Schmitt, E. Gerard, T. Gofton, P. W. Kaplan, J. Lee, B. Legros, J. P. Szaflarski, M. Westover, L. J. Hirsch, N. Gaspard MONDAY Clinical Diagnosis 3.196 Clinical Manifestations Of The Patients With Caspr2 Encephalitis/ J. Sunwoo, J. Byun, J. Moon, J. Shin, J. Jun, S. Lee, K. Jung, K. Jung, K. Chu, S. Lee 3.197 Asystole In The Epilepsy Unit/A. Honig, S. Chen, F. Benninger, R. Bar Yossef, R. Eichel, S. Kipervasser, I. Blatt, M. Neufeld, D. Ekstein 3.198 Electroclinical Features Of Ring Chromosome 20 Syndrome In Children/H. Ikeda, H. Ikeda, K. Imai, Y. Takahashi, Y. Inoue 3.199 Referral Delay For Epilepsy Surgery Centers In Patients With Temporal Lobe Epilepsy And Hippocampal Sclerosis: Why We Should Educate Neurologists In First And Secondary Care Centers/ S. de Vincentiis, K. Rodrigues Ximenes Goldberg, S. E. de Melo-Souza, F. J. Arruda, P. C. Ragazzo, H. van der Linden J.r., K. Dualibi Ramos Valente 3.200 Increased Cerebrovascular Reactivity In The Epileptogenic Temporal Lobe In Mesial Temporal Lobe Epilepsy Patients/K. Alhadid, O. Sobczyk, G. Montandon, J. Poublanc, L. Venkatraghavan, A. Crawley, J. Fisher, D. Mikulis, T. Valiante 3.201 Ictal EEG Yield In NewlyTreated Focal Epilepsy: Interim Findings From The Human Epilepsy Project (HEP)/R. Singh, M. Hegde, V. Mays, D. Dlugos, on behalf of the HEP EEG Core and HEP Investigators Poster Session 3 71 Monday December 8, 2014 3.227 Lightning Strike Induced Vagus Nerve Stimulator Malfunction/P. Shah, G. Ghearing 3.228 Ketamine In Refractory Status Epilepticus – A Two Year Retrospective Study On 26 Patients/J. Höfler, A. Zerbs, J. Dobesberger, G. Pilz, M. Leitinger, H. Novak, E. Trinka 3.229 Frequency And Predictors Of Rescue Medication Use In Children Admitted To The Epilepsy Monitoring Unit/L. AHMADI, K. Nickels, L. Wong-Kisiel, E. Wirrell 3.230 Use Of Clobazam In Pediatric Epilepsy At A Tertiary Care Center/ N. McNamara, S. Joshi 3.231 Clinical Characterization Of The Pre-Ictal State In The Pediatric Population: A Caretaker’s Perspective On Seizure Prediction/P. Patel, R. Jehle, D. Gold, S. Haut 3.232 Spectrum Of Autoimmune Epilepsy With Glutamic Acid Decarboxylase Antibody/A. Shah, M. Dhakar 3.233 Early Complications Of Subdural Electrode Placement In Pediatric Epilepsy Surgery/ P. Pojomovsky, A. Mandel, D. McBrian, M. Giordano, L. Goldenstein, N. Feldstein, G. McKhann, C. Akman 3.234 Efficacy Of Ketogenic Diet: An Experience Of King Fahd Specialist Hospital-Dammam (KFSH-D)/ R. S. Al-Baradie Prognosis 3.235 Electrodermal Sleep Storm Activity As A Biomarker In Epilepsy Patient/K. Kapur, S. Thome-Souza, J. Klehm, R. Sarkis, E. Nagarajan, M. Jackson, R. Picard, C. Doshi, C. Papadelis, B. Dworetzky, C. Reinsberger, T. Loddenkemper 3.236 Mortality In Children Evaluated For Epileptic Spasms At A Tertiary Care Center/C. Harini, E. Nagarajan, A. Bergin, K. Kapur, C. Marti, M. Takeoka, T. Loddenkemper, M. Libenson 3.237 Predictors Of Refractory Status Epilepticus/M. Gonzalez, E. Santamarina, M. Toledo, S. Sarria, M. Sueiras, L. Guzman, J. Salas Puig 3.238 Ictal Vital Signs In Epilepsy/ W. O. Tatum, M. L. Langston, E. Acton, K. H. Yelvington, C. Bowman, J. J. Shih, W. Cheshire 3.239 EEG Prior To Weaning Antiepileptic Therapy In Seizure-Free Children: A Cost-Effectiveness Analysis/B. McCoy, E. Donner 3.240 Correlation Of EEG Findings And Prognosis In Patients On Therapeutic Hypothermia After Cardiac Arrest/Y. Krutoshinskaya, S. Manganaro, R. Krel, L. Bello 3.241 Outcome Of Early Successful Seizure Control Or Aggressive Seizure Management In Presumed Childhood Encephalitis/N. Rismanchi, J. Gold, S. Sattar, C. Glaser, H. Sheriff, A. Mower, J. Crawford, M. Nespeca, S. Wang 72 Poster Session 3 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.242 Clinical Phenotypes Within Patients With Non-Lesional Temporal Lobe Epilepsy Based On Response To Antiepileptic Drugs/J. Kim 3.243 Epilepsy With Onset Within 3 Years Of Age: Electro-Clinical Characterization And Long-Term Outcome/A. Vignoli, G. F. Scornavacca, F. La Briola, K. Turner, V. Chiesa, E. Zambrelli, V. Fergnani, M. Canevini 3.244 Adaptive Function In Dravet Syndrome/S. Kim, D. Nordli, L. Laux 3.245 Diagnosis, Treatment, And Outcomes Of Infantile Spasms In The Trisomy 21 Population/C. Beatty, J. Wrede, H. Blume 3.246 Clinical And Electroencephalographic Characteristics Of Neonates Who Underwent Continuous Electroencephalographic Monitoring/ A. J. Sansevere, I. Sánchez Fernández, J. Klehm, E. Nagarajan, L. St. Louis, P. Pearl, J. Neil, T. Loddenkemper 3.247 Long-Term Seizure Outcome In Response To Carbamazepine In Children With Newly Diagnosed Partial Onset Epilepsy/G. Aungaroon, S. Standridge, K. Holland 3.248 Sudden Unexpected Death In Epilepsy, Peri-ictal Physiology And The SUDEP-7 Inventory/N. Odom 3.249 Interictal Background Is Associated With Survival And Neurodevelopmental Outcome In Term Infants Undergoing Hypothermia For Hypoxic-Ischemic Encephalopathy/ L. Rao, J. Wu, T. Chanlaw, H. Wang, M. Garg 3.250 EEG Monitoring In Patients With Hypothermia Post Cardiac Arrest – A Comparison Of ‘Evolving’ Patterns And Outcomes/K. Suchdev, S. Rao, L. Avedian, S. Thadur, D. Zutshi 3.251 Praxis Induction In Juvenile Myoclonic Epilepsy. Significance In Prognosis/C. P. Uchida, K. Carvalho, M. B. Guaranha, L. M. Guilhoto, E. Yacubian 3.252 Sudden Unexpected Death In Epilepsy (SUDEP) – Vanderbilt University Experience/ S. Bandyopadhyay, N. Azar, A. Arain 3.253 Seizure Outcomes After Glioma Resection/A. C. Jongeling, P. D. Canoll, C. Schevon, S. Srinivasan Neuroimaging Structural Imaging 3.254 Relationship Between Cortical Thickness And Sulcal Depth In Pediatric Focal Epilepsy/S. Gurbani, P. Siddarth, D. Tosun, J. Levitt, R. Caplan 3.255 MRI Characterization Of Cerebellar Tubers In Tuberous Sclerosis Complex: Longitudinal Follow Up And Associations With Clinical Manifestations/A. Yogi, Y. Hirata, J. Wu, P. Pan, G. Mathern, N. Salamon 3.256 Brain Morphometry On MultiModal Imaging For The Detection Of Epileptogenic Cortical Dysplasias/ L. Kini, S. Das, K. Davis, B. Litt 3.257 Transient Focal Lesion In Corpus Callosum After First Episode Of Generalized Seizure: A Case Report/R. Vakili, M. M. Donohue, T. Emch 3.258 Are There Neuroanatomical Differences In New Onset Focal Epilepsy? Preliminary Results From The Human Epilepsy Project/ H. R. Pardoe, R. Kuzniecky, A. HEP MRI Core 3.259 Disrupted Modular Architecture Of Brain Structural Network In Temporal Lobe Epilepsy/ Z. Chen, C. Yasuda, G. C. Beltramini, T. M. Lopes, M. Morita, A. Coan, F. Bergo, F. Cendes, C. Beaulieu, D. Gross 3.260 Disrupted Brain Volumetric Network In Temporal Lobe Epilepsy/ C. Yasuda, C. Zhang, G. C. Beltramini, M. Morita, A. Coan, P. Araujo, F. Bergo, C. Beaulieu, F. Cendes, D. Gross 3.261 Contralateral Hippocampal Atrophy Following Temporal Lobe Surgery For Temporal Lobe Epilepsy/ C. A. Elliott, C. Yasuda, L. Concha, M. Liu, D. Gross, T. Sankar, M. Wheatley, C. Beaulieu 3.262 Correlation Between Brainstem Rotation After Hemispherectomy And The Occurrence Of Clinical Symptoms In Hemimegalencephaly Patients/A. Yogi, Y. Hirata, J. Wu, P. Pan, G. Mathern, N. Salamon 3.263 Volumetric And Shape Analyses Of Hippocampal Subfields In Temporal Lobe Epilepsy With Hippocampal Sclerosis/J. Kim 3.264 Reduced Right Hippocampal Volume In Patients With Left Hippocampal Atrophy Is Associated With Anxiety And Depression/ T. Stoub, C. L. Grote, A. Kanner 3.265 Biometric Correlations With Diffusion Tensor Data Of Temporal Lobe Epilepsy Mcd Patients At 3.0T/S. Nikolova, R. Nikolov, R. Bartha, J. G. Burneo 3.266 Reversible Brain MRI Changes Associated With Periodic Lateralized Epileptiform Discharges (PLEDs)/ A. B. Memon, A. Shah, M. Basha 3.267 Cortical Thickness And Cognition In Children With ECTS: A Longitudinal Study/D. Jackson, C. Garcia-Ramos, K. Dabbs, J. Jones, D. Hsu, C. Stafstrom, L. Zawadzki, M. Koehn, M. Seidenberg, B. Hermann 3.268 Hippocampal Subregion Analysis In Adults With Mesial Temporal Lobe Epilepsy/L. Sepeta, S. C. Germeyan, M. Berl, J. Ostuni, W. Gaillard, W. Theodore Monday December 8, 2014 3.269 Magnetic Resonance Imaging Abnormalities Associated With Status Epilepticus: A Case Report And Literature Review/A. M. Feyissa, L. Ponce Mejia, T. Masel 3.270 Disrupted Brain Network Topology In New-Onset Pediatric Epilepsy: A Controlled Prospective Study/J. Lin, R. Rajyaguru, J. Riley, G. Gulsen, K. Dabbs, J. Jones, D. Jackson, D. Hsu, C. Stafstrom, M. Seidenberg, L. Bonilha, B. Hermann 3.271 To Evaluate Original Diffusion Properties Of Neural Pathways Of Patients With Partial Seizures And Secondary Generalization By Individual Anatomic Reference Atlases/S. Peng, T. Harnod, C. Huang, Y. Hsin 3.272 Increased Fractional Anisotropy In Children With Epilepsy/M. Berl, V. Terwilliger, L. Sepeta, W. Gaillard 3.273 Quantitative Analysis Of Fiber Density From Diffusion Tensor Imaging Identifies Structural Changes In Cryptogenic Focal Epilepsy/J. Joc, N. Khalilieh, E. Hartl, S. Noachtar, C. Vollmar 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.281 Identification Of A Pre-Spike Network In Mesial Temporal Lobe Epilepsy/N. L. Faizo, H. Burianová, M. Gray, J. Hocking, G. Galloway, D. Reutens 3.282 FMRI Mesial Temporal Activation Paradigm For Children With Epilepsy/H. Shurtleff, J. Nixon, M. Warner, A. V. Poliakov, D. W. Shaw, E. Novotny, J. Ojemann 3.283 Altered Functional Connectome For Fearful Face Processing In Temporal Lobe Epilepsy/J. Riley, R. Rajyaguru, G. Gulsen, J. Lin 3.284 Resting State fMRI Lateralizes Seizure Onset But Fails To Predict Cognitive Change After Anterior Temporal Lobectomy In Temporal Lobe Epilepsy/M. Gelfand, K. Davis 3.285 Altered Resting-State Networks In Psychogenic Nonepileptic Seizures And Idiopathic Generalized Epilepsy/D. An, C. Luo, S. Chen, B. Yan, D. yao, D. Zhou 3.286 Ictal Perfusion Pattern With And Without Secondarily Generalized Tonic-Clonic Seizure: A Voxel-Based ECD-SPECT Analysis In Temporal Lobe Epilepsy/X. Chen, C. H. Wong, R. McCredie, M. L. Bartley, D. C. Farlow, Z. Zhao, E. Somerville, A. Bleasel 3.287 Abnormal Functional Organisation Of Default-Mode And Task-Positive Networks In LennoxGastaut Syndrome/A. Warren, J. Archer, D. Abbott, G. Jackson Antiepileptic Drugs Clinical Trials 3.288 FDA OGD’s Post-Marketing Studies To Ensure Therapeutic Equivalence Of Generic Antiepileptic Drugs In Epilepsy Patients/X. Jiang, N. Zheng, T. Ting, J. Polli, M. Privitera, M. Berg, W. Jiang 3.289 Open Label Trial Of Add-On Lacosamide Versus High Dose Monotherapy In Patients With Breakthrough Seizures/J. Alam, N. Llewellyn, B. Dworetzky, R. Sarkis, P. Pennell, E. Bubrick, J. Lee 3.290 Immediate Steady State Concentrations In Plasma After Oral Or Intravenous Lacosamide Loading Dose/W. Cawello, J. Andreas, C. Schaefer 3.291 Focal Seizure Frequency By Study Phase And Seizure Type In Conversion To Lacosamide Monotherapy Study: A Post-Hoc Analysis/J. Stern, M. Sperling, S. S. Chung, P. Ryvlin, R. Wechsler, S. Dimova, M. De Backer, T. Story, M. Brock, C. McShea, K. J. Werhahn 3.292 Conversion To Lacosamide Monotherapy: Post-Hoc Analysis On Responder And Seizure Freedom Rates/P. Ryvlin, M. Sperling, S. S. Chung, J. Stern, R. Wechsler, S. Dimova, M. De Backer, T. Story, M. Brock, C. McShea, K. J. Werhahn 3.293 Lacosamide Added To A Baseline Monotherapy In Patients With Partial-Onset Seizures (POS): Efficacy And Safety Across Center Types In The VITOBA Study/C. Brandt, M. Noack-Rink, T. Mayer, U. Runge, F. Ramirez, T. Lauterbach, P. Dedeken 3.294 Safety And Tolerability Of Lacosamide Monotherapy In Elderly: A Subgroup Analysis From Lacosamide Trials In Diabetic Neuropathic Pain/ J. Sirven, E. Faught, M. De Backer, K. Eckhardt, F. Tennigkeit, S. Bongardt, D. Rudd, D. Sen, K. Werhahn 3.295 Efficacy and Safety Of Lacosamide As Adjunctive Treatment For Partial-Onset Seizures In Hispanic/Latino Patients From Mexico: Post Hoc Analysis Of An Open-Label Trial/H. Ceja Moreno, P. Tzvetanov, W. Waldman Zadeh, A. Escartin, I. Wild, W. Byrnes, F. Tennigkeit, S. Borghs, C. McShea, P. Dedeken, M. De Backer 3.296 WITHDRAWN 3.297 Lacosamide Added To An Existing Monotherapy In Epilepsy Patients With Partial-Onset Seizures: A Subgroup Analysis Of The Elderly Population In The VITOBA Study (VImpat Added To One Baseline AED)/U. Runge, T. Mayer, M. Noack - Rink, F. Ramirez, M. De Backer, F. Tennigkeit, K. Werhahn 3.298 An Open-Label Trial Evaluating The Efficacy And Safety Of Lacosamide As First Add-On Treatment Of Partial-Onset Seizures/P. Tzvetanov, W. Waldman, A. Escartin, W. Byrnes, F. Tennigkeit, P. Dedeken, M. De Backer, S. Borghs, T. Li 3.299 Tolerability Of Lacosamide 200 Mg/Day Starting Dose: Post-Hoc Analysis Of Conversion To Lacosamide Monotherapy Study/K. J. Werhahn, S. Dimova, C. McShea, M. Brock, W. Byrnes, M. De Backer, E. Faught 3.300 Reduction Of TreatmentLimiting Non-Psychotic Behavioral Adverse Events Associated With Levetiracetam: An Open-Label, Prospective Study Of Patients With Epilepsy Switching From Levetiracetam To Brivaracetam Treatment/S. Yates, T. Fakhoury, W. Liang, K. Eckhardt, J. D’Souza 3.301 Impact Of Adding Perampanel To Existing Anti-Epileptic Drug (AED) Therapy On Health-Related Quality Of Life (HRQL) As Measured By The Quality Of Life In Epilepsy Inventory (QOLIE-31-P) In A Pooled Population Of Patients With Partial-Onset Seizures (POS) f/W. Tsong, S. Hudgens, A. Forsythe, R. Muniz 3.302 Vigabatrin For Treatment Of Complex Partial-Onset Seizures In Patients With Tuberous Sclerosis: Prospective Trial And Retrospective Case Series/B. Oommen, E. Brand, A. Volpe, A. Krause, P. Crino, J. Pollard MONDAY Functional Imaging 3.274 EEG-fMRI Study Of OperculoInsular Epilepsy/P. Pouliot, T. Tran, M. robert, A. Bouthillier, D. Nguyen 3.275 Decreased Functional Interactivity In Patients With Temporal Lobe Epilepsy And Normal MRI/ A. Coan, B. M. Campos, F. Cendes 3.276 Additive Potential Of Real-Time Functional Mapping (RTFM) To Electrical Stimulation Mapping (ESM) Results For Epilepsy Surgery Candidates/M. Elsayed, M. Korostenskaja, E. Castillo, P. Chen, A. Schaal, B. Edmonds, C. M. Salinas, M. Westerveld, J. Seo, G. Schalk, P. Brunner, J. Baumgartner, K. Lee 3.277 7T Mrs In Medically Refractory Temporal Lobe Epilepsy Patients With Normal 1.5T/M. jones, S. Nikolova, J. G. Burneo, R. Bartha 3.278 Language fMRI And PostOperative Language Decline/E. Emery, S. C. Germeyan, L. Sepeta, E. Wiggs, M. Berl, I. Dustin, D. Goldenholz, W. Gaillard, W. Theodore 3.279 Significance Of FDG-PET Hypermetabolism In Focal Cortical Dysplasia (FCD)/P. Laoprasert, R. W. Dudley, S. Koh, M. Handler, N. Stence, D. Mirsky, A. White 3.280 Voxel-Mirrored Homotopic Connectivity Analysis Of Pediatric Epilepsy Patients With Mesial Temporal Sclerosis/A. V. Poliakov, E. J. Novotny, S. L. Poliachik, S. D. Friedman, G. E. Ishak, J. N. Nixon, D. W. Shaw, J. G. Ojemann Poster Session 3 73 Monday December 8, 2014 3.303 Efficacy And Safety Of Epidiolex (Cannabidiol) In Children And Young Adults With TreatmentResistant Epilepsy: Initial Data From An Expanded Access Program/ O. Devinsky, J. Sullivan, D. Friedman, E. Thiele, E. Marsh, L. Laux, J. Hedlund, N. Tilton, J. Bluvstein, M. Cilio 3.304 Retrospective Study Of Lacosamide In The Elderly (> 60 years Of Age)/J. Bainbridge, P. Wong, M. Spitz, L. Frey, C. Drees, C. O’Brien, L. Strom, A. Shrestha, J. Sirven, S. Benbadis, E. Maa, S. S. Chung, B. Phillips 3.305 The Initial Results Of Adjunctive Lacosamide For Uncontrolled Partial-Onset Seizures in Eskisehir, Turkey/O. O. Erdinc, G. Akdag, G. Uzuner, D. Ilhan Algin 3.306 Vigabatrin In The First Line Treatment Of Infantile Spasms/ K. Jones, J. Boyd, C. Go, A. Ochi, B. McCoy, K. Puka, O. Snead 3.307 Prospective, Controlled Trial Of Cannabadiol In A Case Of FIRES/ C. Lopez, A. Wilfong, T. P. Ngo, M. R. Jenner 3.308 Initial Therapy Outcomes In Absence Epilepsy : Ethosuximide, Valproic Acid, Lamotrigine And The Combination Of Valproic Acid And Lamotrigine/B. Eun Other 3.309 Efficacy And Tolerability Of Lacosamide As An Adjunctive Treatment In Vascular Epilepsy: 3 Months Study/F. L. Gonzalez, X. Rodriguez Osorio, M. Toledo, M. Saavedra Piñeiro, E. Santamarina, I. Lopez Dequit, A. Pato, D. Campos Blance, P. Bellas, J. Salas Puig, J. Poza Aldea 3.310 Classification Of Phenytoin As A Narrow Therapeutic Index Drug/ N. Zheng, L. Fang, W. Jiang 3.311 A Preliminary Analysis Of The Effect Of Lacosamide On Seizure Control And Neuropsychological Performance: Anxiety, Depression And Quality Of Life/M. Romero Acebal, C. Sánchez Ortiz, F. Villalobos Chávez, G. Rubio Esteban, L. Redondo Verge, J. Romero-Godoy, E. Calzado Rivas, P. Quiroga Subirana, R. Hervas Navidad, P. Martínez Agredano, C. Pedraza Benitez 3.312 Efficacy And Tolerability Of Lacosamide In The Treatment Of Children With Refractory Generalized Epilepsy/C. Miskin, D. Khurana, I. Valencia, A. Legido, D. Hasbani, K. Carvalho 3.313 Therapeutic Use Of Lacosamide Does Not Alter Its Distribution Between Serum And Cerebrospinal Fluid/A. Shah, S. Michelhaugh, S. Mittal 74 Poster Session 3 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.314 VPA Retains Suppressive Ppr Effect At Steady-State With Less Variability Than CBZ: Retrospective Analysis Of 239 Photosensitive Clinic Patients/D. G. Kasteleijn-Nolst Trenite’, R. Reed 3.315 Efficacy Of Clobazam On Patients With Failed Resective Surgery Aparna Sarma DO, Carolina Restrepo, Janice Jordan, C. Akos Szabo M.D./A. Sarma, C. Restrepo, J. Jordan, C. Szabo 3.316 Resistance To Rectal Diazepam In Dravet’s Syndrome/P. McGoldrick, S. Wolf 3.317 Commonly Prescribed Antiepilepsy Drugs In Nursing Home Residents/A. Birnbaum, S. Bathena, I. Leppik Non-AED / Non-Surgical Treatments (Hormonal, Ketogenic, Alternative, Etc.) Adult 3.318 An Evaluation Of Catamenial Seizure Patterns And The Relationship Between The Menstrual Cycle, Seizures, And Ketosis In Women On The Modified Atkins Diet For Treatment For Epilepsy/E. Felton, E. Kossoff, B. Henry, M. Cervenka 3.319 Auricular Acupuncture For The Treatment Of Nonepileptic Seizures: NADA4NES Pilot Study/E. Maa 3.320 LORETA z-Score Neurofeedback Training In Patients With DrugRefractory Epilepsy/L. Frey, C. O’Brien 3.321 The Impact Of An Art Therapy Program On Self-Esteem And Quality Of Life In People With Epilepsy/ J. M. Buelow, L. R. Vitko, J. M. Gattone, J. R. Kakacek Pediatrics 3.322 Predictors Of Ketogenic Diet Efficacy In Children Based On The Electroencephalogram/I. M. Walker, R. Said 3.323 Intravenous Methylprednisolone For Intractable Childhood Epilepsy/M. M. Jan 3.324 Therapeutic Plasma Exchange (TPE) In Children With AntibodyMediated Neurologic Disease/ M. Oldham, M. Sweeney, P. Horn, L. Peglar, E. Rompies, K. Wesselkamper, B. Hallinan, S. Goldstein 3.325 Preliminary Overview Of Social Stressors And Social Work Support Of Patients And Caregivers In The Ketogenic Diet Program At Boston Children’s Hospital/C. Ryan, F. Chris, K. Costas, S. Tarrant, P. Lora, P. Pearl, A. Bergin 3.326 Ketogenic Diet Initiation: Step By Step For Sweet Success/L. Pixley, S. Tarrant, K. Costas, K. Kapur, A. Bergin 3.327 Blood Beta-Hydroxybutyrate Levels Correlate With Seizure Frequency In Epileptic Patients Treated With The Ketogenic Diet/ J. Buchhalter, J. D. Smith, S. D’Alfonso, R. Singer, M. Connolly, A. Michoulas, E. Fung, D. Sinasac, J. M. Rho 3.328 Evaluation Of Patients’ Right And Left Ventricular Functions Who Treated With Ketogenic Diet/ O. Dokgoz, K. celegen, O. Guzel, U. Yilmaz, R. Isgüder, M. Celegen, T. Mese 3.329 A Chef Educator’s Role In The Ketogenic Diet Program At Children’s Mercy Hospital/R. Finn 3.330 Lack Of Efficacy Of The Ketogenic Diet In The Treatment Of Highly Refractory Infantile Spasms/ J. Shin, K. Murata, J. Matsumoto, S. A. Hussain 3.331 Complications Of Vagus Nerve Stimulation For Epilepsy In Children: How Can We Do Better?/B. Sitwat, S. Williams, C. Patterson, S. Gedela, E. Tyler-Kabara, M. Tamber, Y. Sogawa 3.332 New Onset Super-Refractory Tonic Status Epilepticus In Child With Down Syndrome: Successful Treatment With Ketogenic Diet/ L. P. Sampaio, C. L. Moreira, L. Caboclo 3.333 Clinical Characteristics Of Children Less Than 3 Years Of Age Who Elected Vns As An Adjunctive Therapy For Medically Intractable Epilepsy/L. D. Fernandez, S. Gedela, Y. Sogawa 3.334 Pentobarbital, Propylene Glycol, And Ketosis In Refractory Status Epilepticus/K. Costas, R. Tasker, J. Soul, N. Lamb, L. Li, A. Bergin 3.335 Use Of The Ketogenic Diet In The Neonatal Intensive Care Unit – Safety and Tolerability/A. Hall, M. Gustafson, L. Thompson All Ages 3.336 Benefits Of Exercise in Patients With Epilepsy: A Literature Review/F. Gilliam, R. Hogan, G. Gilmet 3.337 Safety And Tolerability Of 1 Hz Deep Repetitive Transcranial Magnetic Stimulation (rTMS) For Treatment Of Temporal Lobe Epilepsy/L. Oberman, R. Gersner, A. Zangen, A. Rotenberg Animal 3.338 Antidepressants Have Different Effects On The Vesicular Glutamate Transporter 1 And EEG Spectrum In The Rat Hippocampus/ D. Shin, H. Song 3.339 Non-Invasive Low Frequency Sensory Stimulation Suppresses Seizures In Two Rodent Models Of Epilepsy/N. Couturier Monday December 8, 2014 3.340 Beta-hydroxybutyrate And Docosahexaenic Acid Suppress Seizures And Hippocampal Network Hyperexcitability In A Mouse Model Of Dravet Syndrome/Y. Abdulkadir, T. Scheuer, W. Catterall, F. Kalume 3.341 Regulation Of Brain PPARγ Mediates Ketogenic Diet Anti-Seizure Efficacy/T. A. Simeone, S. A. Matthews, K. K. Samson, K. Simeone 3.342 A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures in Pilocarpine-Induced Epileptic Mice/A. Fernandez, J. Stoll Surgery Pediatrics 3.350 Pediatric Epilepsy Surgery Techniques Specific Issues: InterCenter Worldwide Variability/ W. Harkness, B. Rydenhag, A. Cukiert, I. Panel 3.351 Epilepsy Related Characteristics Of Children Less Than Five Years Of Age Who Underwent Epilepsy Surgery/E. Thompson, J. Walker, W. Chlon, S. LeSure, D. F. Clarke 8:00 a.m. – 3:00 p.m. Convention Center – Hall 4B, Level 4 3.352 Surgical Treatment Of Patients With Rasmussen Encephalitis (34 Cases)/Y. Guan, G. Luan 3.353 SEEG-Based Tailored Laser Ablation For Lesional Epilepsy/ T. P. Ngo, C. Lopez, D. Curry, A. Wilfong 3.354 Review Of Extended Multi-lobar Epilepsy Surgery In Pediatric Patients/R. Yu, H. Kang, J. Lee, D. Kim, H. Kim 3.355 Follow Up EEG, MRI And Frequency Of Relapse In Children Status Post Resection Of Focal Cortical Dysplasia/K. Havens, C. Oluigbo, S. Magge, W. Gaillard, G. Vezina, D. Depositario-Cabacar 3.356 Special Needs Of Autistic Patients Undergoing Epilepsy Surgery: Review Of Inpatient Management In 57 Cases/S. Ghatan, M. Kokoszka, P. McGoldrick, M. La Vega-Talbott, H. Raynes, R. Prince, J. Kim, H. Kang, S. Wolf 3.357 Acute, Mid-And Long-Term Outcomes Of Medically Refractory Epilepsy And Neurocognitive Difficulties Following Staged MRIGuided Thermal Laser Ablation In Pediatric Patients With Tuberous Sclerosis Complex/Y. Eksioglu, Z. Tovar-Spinoza 3.358 Outcomes Of Stereotactic Laser Ablation For TreatmentResistant Epilepsy In The Pediatric Population With 1-Year Follow-Up/ D. Curry, A. Shetty, A. Wilfong 3.359 MEG In Pediatric Presurgical Evaluation: Comparative Study With Intracranial EEG Recordings In Children With Focal Cortical Dysplasia/U. Thome, N. Agarwal, Z. I. Wang, H. Murakami, B. Krishnan, R. Burgess, A. Alexopoulos, A. Gupta 3.360 Acute Intralesional Recording In Hypothalamic Hamartoma: Description Of 4 Cases/N. Specchio, M. Rizzi, M. Trivisano, L. Fusco, E. Rebessi, S. Cappelletti, F. Villani, A. Savioli, A. De Benedictis, C. Marras, O. Delalande, F. Vigevano 3.361 PET And SPECT Concordance With EEG And MRI In Pre-Surgical Evaluation For Pediatric Epilepsy/ C. Moufawad El Achkar, M. Takeoka 3.362 Surgical Management Of Patients With CSWS: The Detroit Experience/R. Agarwal, A. Kumar, E. Asano, R. Rothermel, S. Sood, H. Chugani 3.363 MRI-Guided Laser-Induced Thermal Ablation: A Promising Tool With Favorable Acute, Mid And LongTerm Outcomes For Intractable Seizures And Neurocognitive Comorbidities In Cortical Dysplasias/ Y. Eksioglu, K. Ogden, S. Huckins, Z. Tovar-Spinoza 3.364 Deep Focal Cortical Dysplasia And Surgical Outcomes In Children/ D. Depositario-Cabacar, K. Havens, C. Oluigbo, S. Magge, G. Vezina, W. Gaillard All Ages 3.365 VNS (Vagus Nerve Stimulation) Is A Useful Tool To Promote The Epilepsy Surgery/I. Takumi, T. Nozaki, Y. Kishi, A. Morita 3.366 Epilepsy Surgery In Or Close To Eloquent Cortex – New Methods Open For Surgery In More Patients/A. Egge, M. Stanisic, P. Larsson 3.367 Spontaneous Improvement In Seizure Control After Intracranial Electrode Implantation/C. Morris, J. Boggs, V. Woodard, C. O’Donovan, G. Popli 3.368 Radiographic Changes Following Laser Interstitial Thermal Therapy For Medically Intractable Epilepsy/R. Buckley, J. Ojemann 3.369 Temporopolar Grey/White Matter Abnormalities In Temporal Lobe Epilepsy With Hippocampal Sclerosis And Long-Term Prognosis After Epilepsy Surgery/P. V. Naves, L. Caboclo, H. Carrete. Jr., R. Centeno, B. V. Kelmann, E. Yacubian 3.370 Magnetoencephalography Localization Can Guide Reoperation After Unsuccessful Neocortical Epilepsy Surgery/I. Mohamed, A. Pooladian, Y. T. Tran, M. Robert, A. Bouthillier, D. Nguyen 3.371 Stereotactic Laser Ablation For Epilepsy: An Analysis Of The Safety Profile From Peer-Reviewed Reports/A. Wilfong, A. Shetty, D. Curry 3.372 Seizure Outcome After Battery Depletion In Patients Submitted To Deep Brain Stimulation For Epilepsy./J. A. Burattini, A. M. Lima, C. M. Cukiert, A. Cukiert 3.373 Epilepsy Surgical Outcomes 2004-2013: The USC Experience With Standard Temporal Lobectomy And Selective Amygdalohippocampectomy/ Y. Marquez, M. N. Zubair, B. Lee, D. Millett, L. Kalayjian, D. Ko, S. Shaw, C. Heck, C. Liu 3.374 Results Of A Drug Withdrawal Protocol After Temporal Lobe Epilepsy Surgery/R. S. Centeno, M. D. Guimaraes, L. Caboclo 3.375 Speed And Precision Of Robotic Depth Electrode Placement For Stereotactic EEG/N. Tandon, G. Kalamangalam, B. Seignot MONDAY Adult 3.343 Super-Selective Amygdalohippocampotomy Using RealTime Magnetic Resonance Guided Laser Ablation In Patients With Mesial Temporal Lobe Epilepsy/ J. W. Yoon, W. Tatum, J. J. Shih, V. Gupta, P. Vibhute, R. Wharen 3.344 Cognitive Outcome Of Patients Undergoing Stereotactic Laser Ablation Of Cavernous Malformations To Control Chronic Seizures/ D. L. Drane, J. Willie, D. W. Loring, N. Voets, A. M. Saindane, M. Ivanisevic, R. Brewster, R. Jayakar, R. Faught, K. J. Meador, R. Gross 3.345 A Case Report Of A Patient With Refractory Temporal Lobe Epilepsy Suffered Ischemic Stroke After The Wada Test Had Good Outcome/H. Gong, M. Kim-Tenser, D. Ko 3.346 Modulating Cortico-Cortical Evoked Potentials And Their Connectivity Maps With Differing Stimulation Parameters/S. Bickel, M. Mercier, P. Megevand, D. Groppe, A. Mehta, F. Lado 3.347 Frontal Topectomy May Be Palliative In Difficult To Localize Intractable And Disabling Frontal Epilepsy/J. Oster 3.348 Assessment Of Driving Outcomes After Epilepsy Surgery/ R. Dawkins, N. Omar, B. Agee, B. Walters, K. Riley 3.349 Stimulation Of Ncl. Accumbens In Intractable Partial Epilepsy – Possible Candidates/F. C. Schmitt, A. Kowski, L. Buentjen, H. Stefan, H. B. Straub, T. Mayer, T. Zaehle, F. Oltmanns, H. Heinze, M. Holtkamp, J. Voges Poster Session 3 75 THE EPILEPSY RESEARCH BENCHMARKS 2014 NINDS Benchmarks for Epilepsy Research Beginning in 2000, the National Institute of Neurological Disorders and Stroke (NINDS) has hosted a series of Curing the Epilepsies conferences in partnership with epilepsy advocacy and professional organizations to assess progress in epilepsy research and help set an agenda for future years. As an outcome, these conferences have led to the development of Benchmarks for Epilepsy Research, which reflect shared priorities across the epilepsy community. The current 2014 Benchmarks are: I. Understand the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic conditions A. Identify new genes and pathways associated with epilepsies and epilepsy-related conditions. B. Identify new infectious, immune, age-related, environmental, or other causes and risk factors associated with the epilepsies and epilepsy-related conditions. C. Determine whether factors related to age, gender, race / ethnicity, socioeconomic status, and other features of specific populations affect risk and mechanisms of epilepsy and epilepsy-related conditions. D. Determine whether the bi-directional relationships that exist between the epilepsies and several co-occurring conditions (e.g., neuropsychiatric or neurodevelopmental disorders) result from the same underlying causal mechanisms, interacting mechanisms, or are a consequence of the first presenting condition. II. Prevent epilepsy and its progression A. Understand epileptogenic processes involved in epilepsies with neurodevelopmental origins, including those due to genetic or presumed genetic causes. B. Understand epileptogenic processes involved in the development of epilepsy following traumatic brain injury, stroke, brain tumor, infections, neurodegeneration, or other insults to the brain. C. Identify biomarkers that will aid in identifying, predicting, and monitoring epileptogenesis and disease progression, including markers early after injury / insult that identify those people at risk for epilepsy. D. Develop or refine models aligned with the etiologies of human epilepsies to enable improved understanding of epileptogenesis and rigorous preclinical therapy development for epilepsy prevention or disease modification. E. Identify new targets and develop interventions to prevent or modify epileptogenesis and the progression of epilepsy and epilepsy-related conditions. III. Improve treatment options for controlling seizures and epilepsy-related conditions without side effects A. Understand the initiation, propagation, and termination of seizures at the network level in different forms of epilepsy. B. Identify biomarkers for assessing or predicting treatment response, including markers that may identify specific populations that are likely to have good outcomes or develop adverse responses. C. Develop or refine models that are aligned with etiologies and clinical features of human epilepsies, especially treatment resistant forms, to enable improved understanding of ictogenesis and preclinical development to improve seizure control with fewer side effects. Establish the sensitivity and specificity of these models with regard to current therapies. D. Identify, develop, and improve interventions to detect, predict, prevent, or terminate seizures, including approaches suitable for use in the home and other non-medical settings. E. Identify, develop, and improve anti-seizure therapies that target (either alone, or in combination) novel or multiple seizure mechanisms. F. Develop, improve, and implement interventions for effective self-management, including treatment adherence. G.Develop and validate objective patient-centered outcome metrics for clinical studies. IV. Limit or prevent adverse consequences of seizures and their treatment across the lifespan A. Understand and limit adverse impacts of seizures on quality of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and non-neurological functions. B. Understand and limit adverse impacts of anti-seizure treatments (medical, surgical, or other interventions) on quality of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and non-neurological functions. C. Understand risk factors and mechanisms involved in non-epileptic seizures (NES). Develop effective approaches for earlier and accurate diagnosis and treatment. D. Identify causes, risk factors, and potential preventive strategies for sudden unexpected death in epilepsy (SUDEP) and other epilepsy-related mortality (for example, suicide) in people with epilepsy. E. Identify the impact of pharmacological treatment of the epilepsies on fetal and neonatal development. Develop strategies to control seizures in pregnancy without causing harm to either the mother or child. Walter Koroshetz, M.D. Acting Director, NINDS Daniel H. Lowenstein, M.D. Chair, Benchmarks Stewards University of California, San Francisco Raymond J. Dingledine, Ph.D. Vice-Chair, Benchmarks Stewards Emory University Brandy Fureman, Ph.D. Co-Chair, Benchmark Stewards NINDS For more information about the Benchmarks and to view Steward’s previous reports, please visit: http://www.ninds.nih.gov/research/epilepsyweb/2014benchmarks.htm 76 • AES 68TH ANNUAL MEETING Seattle, WA • TUESDAY December 9, 2014 www.AESnet.org 7:00 a.m. – 8:30 a.m. Special Interest Group Meetings Location listed under each session Critical Care (ICU EEG Monitoring) – Controversies in ICU EEG Interpretation and Management Convention Center – Room 612, Level 6 Coordinators: Suzette M. LaRoche, M.D., Cecil Hahn, M.D. Speakers: Tammy Tsuchida, M.D., Ph.D., Courtney Wusthoff, M.D., William Gallentine, D.O., Eric Payne, M.D., M.P.H., FRCPC, Sarah Schmitt, M.D., Lawrence J. Hirsch, M.D. We will present three controversial cases (one neonatal, one pediatric, one adult) that demonstrate controversial EEG patterns and approach to management. Speakers will utilize a pro / con format, debating the merits of aggressive vs. non-aggressive treatment. Genetics: Personalized Epilepsy Diagnosis and Treatment Convention Center – Room 613, Level 6 Coordinators: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D. Speakers: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D., Stephen Traynelis, Ph.D., Elizabeth K. Ruzzo, Ph.D. This SIG will discuss the use of genome sequencing for individual diagnosis and its implication for treatment. The speakers will review exome application on an individual level, present cases that highlight the possibilities and limitations of personalized genetic medicine, and then discuss how to apply genetic data for individualized therapeutics. NEW – Global Health in Epilepsy: How Can You Get Involved? Convention Center – Room 603, Level 6 Coordinator: Sheryl Haut, M.D. Speakers: Jose Cavazos., M.D., Ph.D., Lionel Carmant, M.D. Practice Management Convention Center – Room 618, Level 6 Coordinator: Gregory Barkley, M.D. Annual update on ICD and CPT coding plus an open forum to discuss Electronic Health Record (EHR) issues, tips, and tricks. Participants are encouraged to submit suggestions of problems or tips from their own practices ahead of time. Submit to [email protected]. Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We Missing a Diagnostic / Therapeutic Opportunity? Temporal Lobe Club: The Thalamus in Epilepsy – Player or Bystander? Convention Center – Room 620, Level 6 Coordinators: John Huguenard, Ph.D., Robert S. Fisher, M.D., Ph.D. Speakers: Robert S. Fisher, M.D., Ph.D., John Huguenard, Ph.D., Hal Blumenfeld, M.D., Ph.D. The thalamus has been called “the gateway to the cortex.” Do seizures travel through the gate, and if so, in which direction? The role of the thalamus in seizures has been debated for decades. In this temporal lobe club session, we will consider whether the thalamus is a player or bystander in epilepsy. Time is set aside for a lively group discussion. Tumor Induced Epilepsy – Meningiomas Convention Center – Room 604, Level 6 Coordinators: Jeffrey Politsky, M.D., FRCP(C), Theodore Schwartz, M.D., FACS Speakers: Sandeep Mittal, M.D., Jeffrey Politsky, M.D., FRCP(C), Jeffrey G. Ojemann, M.D. The focus of the 2014 Tumor-Related Epilepsy SIG will be meningiomas. Dr. Sandeep Mittal and Dr. Jeffrey Politsky will be present clinical data. There will be a third presenter to discuss pathologic basis of meningioma-related epilepsy. We will also invite members to submit cases in advance and will reserve the final 20-30 minutes of the SIG for an open forum discussion. Women’s Issues: Controversies in Caring for Women with Epilepsy Convention Center – Room 615, Level 6 Coordinators: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D. Speakers: Samuel F. Berkovic, M.D., Terence J. O'Brien, M.D., FRACP, Andrew G. Herzog, M.D., M.Sc., Sanjeev V. Thomas, M.D., D.M. Caring for women with epilepsy poses significant challenges to healthcare professionals. Despite a growing wealth of knowledge, many issues remain controversial and we lack evidence-based guidelines and consensus for many difficult management issues in this field. This SIG targets four major controversial issues in counseling and caring for women with epilepsy and intends to bring together expert opinion and best available evidence in addressing these difficult areas. 1. Controversies about inheritance of epilepsy 2. Controversies about teratogenicity of new AEDs and prenatal counseling 3. Controversies regarding contraception and epilepsy 4. Controversies in hormonal and non-hormonal treatment of catamenial epilepsy. TUESDAY Participation in epilepsy-related global health projects is exciting, productive and important! Many people are still unaware of the possible avenues to pursue global health. This SIG will focus on opportunities for international collaborations, professorships and partnerships around the world, both in person and via telemedicine. The speakers will discuss challenges across different regions, successes and lessons learned. Areas to be highlighted as examples include ILAE supported activities such as the PECA (Partnering Epilepsy Centers in the Americas) program of the North American Commission of the ILAE and visiting professorship programs in Africa, and the ILAE/WFN supported epilepsy demonstration project in Haiti. diagnosing and treating sleep comorbidities in epilepsy patients. Approximately 15-40% of patients with refractory epilepsy have comorbid sleep apnea, and treatment of sleep apnea in epilepsy patients may improve seizure burden, in addition to improving alertness and well-being and modifying future health risk. However, identification of sleep apnea remains challenging, and most epilepsy centers have separate clinical infrastructures for the evaluation of epilepsy and sleep disorders, despite obvious intuitive, practical, and logistical advantages of employing sleep polygraphy techniques directly in the epilepsy monitoring setting. This year’s Sleep and Epilepsy SIG will feature three expert epileptologists addressing the timely issue of utilizing polysomnography in the differential diagnosis of epilepsy and spells, and the importance of identifying sleep apnea in epilepsy monitoring inpatients. Convention Center – Room 606, Level 6 Coordinators: Mark S. Quigg, M.D., Erik K. St. Louis, M.D. Speakers: Milena Pavlova, Terence J. O’Brien, M.D., FRACP, Erik K. St. Louis, M.D. Comorbid sleep disturbances such as obstructive sleep apnea, insomnia, and restless legs syndrome are frequent in persons with epilepsy, and epileptologists are increasingly recognizing the importance and value of 77 TUESDAY December 9, 2014 8:45 a.m. – 10:45 a.m. Hot Topics Symposium: Epilepsy Updates (2.0 CME Credits) Convention Center – Ballroom 6C, Level 6 ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Hot Topics Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competency: Medical Knowledge Overview The Hot Topics symposium will present information about newly developed approaches to epilepsy diagnosis and management. Faculty will discuss how MRI can be used to facilitate understanding the pathophysiology of epilepsy and interictal functional disturbances through study of the default mode network. In addition, new MRI analyses evaluate disease progression with important implications for both diagnosis and treatment. How generic drug use impacts seizure control will be discussed, presenting data from a new study. Lastly, a new less invasive surgical treatment for epilepsy, thermal ablation, will be discussed. This potpourri of topics covers the most recent advances in epilepsy, and should be valuable to both clinicians and basic scientists. Learning Objectives u Recognize when to use generic anticonvulsant drugs when appropriate, based on the potential impact on treatment efficacy and tolerability and assists patients in understanding the pros and cons of utilizing generic medications u Utilizing current understanding of the pathophysiology of epilepsy, including progression of disease, learner utilizes new diagnostic and treatment approaches u Educate patients on how new diagnostic and treatment approaches can be used to manage refractory epilepsy. 8:45 a.m. – 10:45 a.m. Scientific Symposium: The Epidemiology, Pathophysiology & Prevention of SUDEP (2.0 CME Credits) Convention Center – Ballroom 6E, Level 6 Overview This symposium will review the basic and clinical science of Sudden Unexpected Death in Epilepsy (SUDEP). Specific areas that will be addressed include epidemiology, clinical risk factors, potential role of preventive strategies, gaps in how physicians educate patients and families, current biomarkers of SUDEP and the evidence for the role of devices in seizure detection and their potential role in preventing SUDEP. In addition, two leading models used to understand the mechanisms underlying SUDEP in animals and humans will be discussed: the role of the serotonergic system and respiration and insights into human SUDEP from a mouse model of Dravet syndrome. Learning Objectives u Apply understanding of the clinical risk factors, epidemiology, educational gaps, and basic mechanisms of SUDEP, to developing treatment plans focused on potential role of preventive strategies u Counsel patients and families regarding utility of devices to detect seizures u Counsel patients / families regarding clinical risk factors, epidemiology, educational gaps, and potential role of preventive strategies underlying SUDEP u Understand and advice practitioners and patients / families regarding issues of medication adherence and therapeutic levels as prevention strategy for SUDEP prevention Assist patients / families to develop cognitive skills and strategies to improve medication adherence that could be life saving for some patients. Target Audience Intermediate (see page 120 for details) Program Co-Chairs: R. Edward Hogan, M.D. and Michael R. Sperling, M.D. 8:45 – 8:50 a.m. Introduction Michael R. Sperling, M.D. 8:50 – 9:15 a.m. The Default Mode and Networks in Epilepsy Jean Gotman, Ph.D. 9:15 – 9:40 a.m. Progression of Disease in Epilepsy Andrea Bernasconi, M.D. u 9:40 – 10:05 a.m. Generic Drug Update Michael D. Privitera, M.D. Target Audience 10:05 – 10:30 a.m. Thermal Ablation Robert Gross, M.D., Ph.D. Program 10:30 – 10:45 a.m. Conclusions R. Edward Hogan, M.D. 8:45 a.m. Introduction Orrin Devinsky, M.D. 8:55 a.m. The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Risk Factors and Prevention of SUDEP Dale C. Hesdorffer, Ph.D. 9:15 a.m. Serotonin, Adeonsine and Respiration George B. Richerson, M.D., Ph.D. Nurses may claim up to 2.0 contact hours for this session. 9:35 a.m. Insights from Dravet Syndrome William A. Catterall, Ph.D. 9:55 a.m. Biomarkers of SUDEP and the Role of Devices Daniel Friedman, M.D. Credit Designation Basic, Intermediate, and Advanced (see page 120 for details) Chair: Orrin Devinsky, M.D. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-038-L01-P. Initial Release Date: 12/9/2014. 78 TUESDAY December 9, 2014 10:15 a.m. Pediatric SUDEP and Patient / Family Education Elizabeth J. Donner, M.D. 10:35 a.m. Conclusions Orrin Devinsky, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-037-L01-P. Initial Release Date: 12/9/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Scientific Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Practice-based Learning, Interpersonal and Communication Skills Seven on-demand audio webinars introducing the core Audio Webinars include: l Basics of Epilepsy l Recognition and Care of Seizures and Emergencies: Parts 1-2 l Overview of Treatment Options: Parts 1-2 l Patient and Family Education and Self-Management Approaches TUESDAY elements of seizures, epilepsy, and epilepsy care. This program will assist nurses and other health care professionals to provide appropriate care and support to patients and families in any health care setting. https://www.AESnet.org/epilepsy_101 79 See you in Philadelphia! 2015 ANNUAL MEETING December 4 - 8 PHILADELPHIA, PA Pennsylvania Convention Center • • • • • FUTURE ANNUAL MEETING DATES 2016 2018 2017 2019 Houston, TX George R. Brown Convention Center December 2 - 6 Washington, D.C. Washington Convention Center December 1 - 5 80 CME Symposia and Lectures Platform Sessions Informative Exhibitors Special Interest Group Meetings Skills Workshops New Orleans, LA Ernest N. Morial Convention Center November 30 - December 4 Baltimore, MD Baltimore Convention Center December 6 - 10 SOUTH GALLERIA Coat Check ESCALATOR DOWN TO LEVEL 3 PE 1 ESCALATOR UP TO LEVEL 6 PE 2 Elevators CYBER CAFE 6 7 PE PE Poster Session Entrance When Exhibits are Closed WF Poster Information Table* OFFICE #2 OFFICE #1 216 220 316 205 217 219 223 PAVILION C 400 305 606 501 600 505 511 610 513 612 519 PAVILION D 724 726 605 617 625 FOOD & BEVERAGE SOUTH LOBBY - LEVEL 4 REGISTRATION BAG DISTRIBUTION MAIN ENTRANCE 405 EPILEPSY RESOURCE CENTER 333 233 332 337 339 335 336 101 200 202 201 300 301 105 117 119 AES 125 133 232 237 135 234 PAVILION B 235 334 239 137 236 PAVILION A MEDIA WALL Elevators Exhibit Manager Office POSTER BOARDS 816 818 805 811 817 823 932 905 909 911 913 915 917 919 921 925 927 FOOD & BEVERAGE EXIT EXIT 800 801 900 902 901 WF 705 713 717 721 820 723 822 725 824 833 733 832 727 835 837 936 735 834 737 836 EXHIBITOR FLOOR PLAN EXHIBITOR LOUNGE GES *Poster Walking Tours begin at the Poster Information Table Exhibit Hall Hours: Saturday, December 6 ..................................................Noon - 6:00 p.m. Sunday, December 7 ........................................10:00 a.m. - 6:00 p.m. Monday, December 8 ......................................10:00 a.m. - 3:00 p.m. 81 EXHIBITOR LOCATIONS Booth ABRET Neurodiagnostic Credentialing & Accreditation* .....3 Ad-Tech Medical Instrument Corp.................................505 AED Pregnancy Registry .............................................733 Ambry Genetics .........................................................233 Ambu Inc. ..................................................................911 American Board of Clinical Neurophysiology, Inc. (ABCN)* ..2 American Board of Psychiatry and Neurology ................837 American Clinical Magnetoencephalography Society* (ACMEGS) ...................................................................5 American Clinical Neurophysiology Society (ACNS)* ...........4 American Epilepsy Society ..........................................125 Angel Wings Foundation* ..............................................16 Anita Kaufmann Foundation, The* ...................................1 ANT North America ....................................................236 Ark Diagnostics, Inc. ..................................................820 ASET – The Neurodiagnostic Society* ............................15 Athena Diagnostics, Inc. .............................................612 Aurora Health Care ....................................................235 B. Braun CeGat, LLC ..................................................915 BIOPAC Systems, Inc..................................................836 Blackrock NeuroMed...................................................817 Brain Vision LLC.........................................................835 Cadwell Laboratories, Inc. ...........................................811 captureproof..............................................................919 Charlie Foundation, The and Ice Epilepsy* ......................19 Child Neurology Foundation .........................................832 Clever Sys, Inc. ..........................................................927 Compumedics Limited .................................................805 Courtagen Diagnostics Lab .........................................936 CorTechs Lab, Inc .......................................................334 CURE (Citizens United for Research in Epilepsy)*..............6 Cyberonics, Inc. .........................................................223 Department of Veterans Affairs, Epilepsy Centers of Excellence*..................................................................9 DigiTrace EEG Services ...............................................727 Dravet Syndrome Foundation* .......................................11 Eisai Inc. ...................................................................305 Electrical Geodesics, Inc.....................................717, 816 ELEKTA......................................................................519 Elsevier, Inc. ..............................................................901 Emfit Corp. ................................................................909 emka TECHNOLOGIES Inc............................................701 Emory Genetics Laboratory.........................................202 Epilepsy Foundation*...............................................8, 513 GeneDx .....................................................................822 GlaxoSmithKline .........................................................336 GW Pharmaceuticals ..................................................133 IEEG.org* ....................................................................17 International Epilepsy Congress...................................234 INSYS Therapeutics....................................................200 Jack Pribaz Foundation, The .......................................332 John Libbey EUROTEXT ...............................................301 82 Booth LGS (Lennox-Gastaut Syndrome) Foundation*.................10 Lifelines Neurodiagnostic Systems, Inc. .......................921 Lundbeck ...........................................................405, 511 Mallinckrodt Pharmaceuticals..............................217, 316 Medical Neurogenetics, LLC........................................216 MediKidz....................................................................232 Medtech Surgical .......................................................800 Medtronic..................................................................932 Moberg Research.......................................................239 Monteris Medical .......................................................905 Multi Channel Systems ...............................................300 National Association of Epilepsy Centers......................723 National Institute of Neurological Disorders & Stroke (NINDS)........................................................725 Natus Neurology Incorporated.....................................705 Neuralynx, Inc ............................................................713 Neurology Reviews .....................................................101 NeuroPace, Inc...........................................................824 NeuroQuest LLC ........................................................834 Neurotech .................................................................610 Nexstim ....................................................................119 Nihon Kohden America, Inc. .........................................617 Novartis Pharmaceuticals ...........................................137 Optima Neuroscience, Inc. ..........................................833 Oxford University Press ..............................................219 PCDH19 Alliance*...........................................................7 Persyst Development Corporation ...............................925 Physicians Insurance ..................................................220 Pinnacle Technology, Inc...............................................737 PMT Corporation ........................................................606 PreventionGenetics ....................................................902 Rhythmlink International, LLC ......................................721 Ring14 USA Outreach*.................................................12 Ripple LLC .................................................................724 Rogue Research Inc....................................................900 RosmanSearch, Inc. ...................................................726 SeizureTracker.com* .....................................................21 Smart Monitor Corp. ..................................................917 SUDEP Aware* ............................................................20 Sunovion Pharmaceuticals Inc. ....................................105 Supernus Pharmaceuticals, Inc. ..................................605 Texas Children’s Hospital.............................................201 Transgenomic, Inc.......................................................801 Triangle BioSystems, Inc. ............................................735 Tuberous Sclerosis Alliance* ..........................................22 UCB, Inc............................................................135, 205 UCSF Medical Center .................................................913 Upsher-Smith Laboratories, Inc ..........................625, 823 Vitaflo USA ................................................................117 Wiley .........................................................................818 Wolters Kluwer Health................................................400 *Please see Epilepsy Resource Center Participants on page 83 Stop by the EPILEPSY RESOURCE CENTER at the Entrance of the Exhibit Hall 2014 Epilepsy Resource Center — Participants — Table # ERC Participants: Presentation Area ENTRANCE ENTRANCE ENTRANCE ENTRANCE 1 The Anita Kaufmann Foundation 2 American Board of Clinical Neurophysiology, Inc. (ABCN) 3 The American Board of Registration of EEG and EP Technologies (ABRET) 4 American Clinical Neurophysiology Society (ACNS) 5 American Clinical MEG Society (ACMEGS) 6 CURE (Citizen’s United for Research in Epilepsy) 7 PCDH19 Alliance 8 Epilepsy Foundation 9 Epilepsy Centers of Excellence, Department of Veterans Affairs 10 LGS Foundation 11 Dravet Syndrome Foundation 12 Ring14 USA Outreach 14 North American SUDEP Registry 15 ASET – The Neurodiagnostic Society 16 Angel Wings Foundation 17 IEEG.org 18 British Paediatric Neurology Association 19 The Charlie Foundation and ICE Epilepsy 20 SUDEP Aware 21 SeizureTracker.com 22 Tuberous Sclerosis Alliance Many of the ERC participants will be offering mini-workshops dedicated to the education, awareness and research for people with epilepsy worldwide. All participants of AES, including exhibitors, are invited to attend the mini-workshops. The schedule will be posted daily outside the ERC. The Epilepsy Resource Center is a comprehensive one-stop resource for patients, researchers and clinicians specializing in the area of epilepsy. 83 EXHIBITORS as of October 21, 2014 Exhibit Schedule Saturday, December 6: Noon-6:00 p.m. Lunch: Noon-1:00 p.m. Symposia Break: 5:00 p.m.-6:00 p.m. Prize Drawing: 5:30 p.m. ABRET Neurodiagnostic Credentialing & Accreditation Booth #3 2908 Greenbriar Dr - Ste A Springfield IL 62704 Phone: 217-726-7980 Fax: 217-726-7989 Email: [email protected] Website: www.abret.org Contact: Ms. Janice Walbert ABRET Neurodiagnostic Credentialing & Accreditation offers five credentials (R. EEG T.®, R. EP T.®, CNIM®, CLTM, CAP) and manages three laboratory accreditation programs, LAB-EEG, LAB-NIOM, and LABLTM. Learn more about laboratory accreditation, view resources for technologists and receive assistance in recruiting neurodiagnostic technologists. Ad-Tech Medical Instrument Corp. Booth #505 1901 William St Racine WI 53404 Phone: 262-634-1555 Fax: 262-634-5668 Email: [email protected] Website: www.adtechmedical.com Contact: Ms. Angie Bouwma Sunday, December 7:10:00 a.m.-6:00 p.m. Lunch: Noon-1:00 p.m. Suds for Science: 5:00 p.m.-6:00 p.m. Prize Drawing: 5:30 p.m. Ambry Genetics Booth #233 15 Argonaught Aliso Viejo CA 92656 Website: www.ambrygen.com Contact: Colleen Garcia Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)certified commercial clinical laboratory with headquarters in Orange County, California. Ambry is a leader in providing genetic services focused on clinical diagnostics and genomic services, and has established a reputation for unparalleled customer satisfaction. Ambu Inc. Booth #911 6740 Baymeadow Dr Glen Burnie MD 21060 Phone: 800-262-8462 Email: [email protected] Website: www.ambuusa.com Contact: Megan Hasson Ambu is dedicated to the development of innovative products that help save lives and simplify workflow of the anesthetists to the benefit of the patients.Within the field of anesthesia Ambu offers a wide range of products from resuscitators, face masks and laryngeal masks to the highly innovative single use flexible intubation scope. Monday, December 8: 10:00 a.m.-3:00 p.m. Lunch: Noon-1:00 p.m. Prize Drawing & Grand Prize Drawing: 2:30 p.m. American Board of Psychiatry and Neurology Booth #837 2150 E Lake Cook Rd - #900 Buffalo Grove IL 60089 Phone: 847-229-6500 Fax: 847-229-6600 Email: [email protected] Website: www.abpn.com Contact: Ms. Karen Back The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes. ABPN also oversees the certification process for physicians seeking certification in child and adolescent psychiatry. American Clinical Magnetoencephalography Society (ACMEGS) Booth #5 555 E. Wells Street Ste 1100 Milwaukee WI 53202 Phone: 414-918-9804 Email: [email protected] Website: www.acmegs.org Contact: Ms. Megan Kelley ACMEGS is a non-profit association whose membership includes clinical MEG facilities in For over 25 years, Epilepsy Centers have the U.S. Founded by physicians committed to made Ad-Tech their choice for invasive high-quality care of patients with epilepsy, electrodes for brain mapping and epilepsy ACMEGS now advocates for patients with monitoring. We offer a large variety of neurological conditions who may benefit from electrodes and accessories to meet you and MEG by educating policymakers about your patient’s needs. Visit our Booth to American Board of Clinical Neurophysiology, recommended standards of care, discover why Ad-Tech is your best choice. reimbursement, and provider regulations. Inc. (ABCN) Booth #2 AED Pregnancy Registry American Clinical Neurophysiology Society 2908 Greenbriar Dr Ste A Booth #733 (ACNS) Springfield IL 62704 121 Innerbelt Rd - Ste 220 Booth #4 Phone: 217-726-7980 Massachusetts General Hospital 555 E. Wells Street Ste 1100 Fax: 217-726-7989 Somerville MA 02143 Milwaukee WI 53202 Email: [email protected] Phone: 888-233-2334 Phone: 414-918-9803 Website: www.abcn.org Fax: 617-724-8307 Fax: 414-276-3349 Contact: Ms. Janice Walbert Email: [email protected] Email: [email protected] The ABCN has a 65 year history of promoting Website: www.acns.org Website: www.aedpregnancyregistry.org excellence in Clinical Neurophysiology and Contact: Ms. Caitlin Smith Contact: Ms. Megan Kelley offers examinations with added competency The North American AED Pregnancy Registry in Epilepsy Monitoring or Neurophysiologic The American Clinical Neurophysiology Society is dedicated to determine the safety of Intraoperative Monitoring. A General Clinical (ACNS) is a professional association dedicated anticonvulsant medications that can be taken Neurophysiology Track is also available. A to fostering excellence in clinical by women during pregnancy. The primary goal Critical Care EEG Track will be offered in fall neurophysiology and furthering the is to determine the frequency of major understanding of central and peripheral 2015. International testing is available. malformations in the infants exposed during nervous system function in health and disease pregnancy to anticonvulsant drugs. Please through education, research, and the provision visit our booth to learn more about our of a forum for discussion and interaction. findings, and to obtain materials for use in your office. 84 EXHIBITORS American Epilepsy Society Booth #125 342 N Main St West Hartford CT 06117-2507 Phone: 860-586-7505 Fax: 860-586-7550 Email: [email protected] Website: www.AESnet.org Contact: Ms. Cheryl-Ann Tubby Ark Diagnostics, Inc. Booth #820 48089 Fremont Blvd Fremont CA 94538 Phone: 510-270-6270 Fax: 510-270-6298 Email: [email protected] Website: www.ark-tdm.com Contact: Mr. Ryan Olandria Visit the AES booth for information on membership, publications, and research funding opportunities. Stop by to watch interviews being taped with member experts on some of the hottest topics at the meeting. Recognize a mentor or colleague by purchasing a Community of Caring pin, and support AES research and awareness programs. Get a personal tour of AES online resources including the Epilepsy Learning Institute, EMU Caring, and the AES website. AES logo scarves, ties and bowties will also be available for purchase. Ark Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK’s proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. Anti-epileptic drug assays (FDA 510k Cleared): Levetiracetam, Lamotrigine, Topiramate, Gabapentin, and Zonisamide. Angel Wings Foundation Booth #16 2134 Baldwin Ct Hanover Park IL 60133 Phone: 630-550-1049 Email: [email protected] Website: www.angelwingsfoundation.net Contact: Ms. Debbie Flader Angel Wings Foundation is dedicated to enhancing the lives of adults with epilepsy, allowing them to reach their full potential through independent living in the community. Angel Wings will create home where adults with epilepsy can lead person-centered lives, with supports in place. Angel Wings will offer recreational, vocational and educational opportunities for adults with epilepsy. Anita Kaufmann Foundation, The Booth #1 PO Box 751 Livingston NJ 07039 Phone: 201-655-0420 Email: [email protected] Website: www.akfus.org Contact: Ms. Debra Josephs ANT North America Booth #236 437 S. Yellowstone Dr #216 Madison WI 53719 Phone: 608-204-0878 Email: [email protected] Website: www.ant-neuro.com Contact: Moshe Yuchtman ASET – The Neurodiagnostic Society represents more than 4,500 allied health professionals who perform neurodiagnostic procedures. ASET provides education and advocacy, creates greater awareness of the profession, and establishes standards and best practices to ensure quality patient care. Stop by the ASET booth to see our newest publications and educational offerings. Athena Diagnostics, Inc. Booth #612 Ms. Lorri Harrell 200 Forest Street 2nd Floor Marlborough MA 01752 Phone: 800-394-4493 Email: [email protected] Website: www.athenadiagnostics.com Athena Diagnostics is a leader in diagnostics testing for neurological diseases. Our comprehensive test menu includes over 400 tests for epilepsy, muscular dystrophy, peripheral neuropathy, stroke, and other neuromuscular and developmental disorders. Aurora Health Care Booth #235 3305 West Forest Home Ave Milwaukee WI 53215 Phone: 414-389-2696 Email: [email protected] Website: www.aurora.org/doctor Contact: Christine McCarrier Aurora Health Care is the largest healthcare system in eastern Wisconsin and extends into northern Illinois. Our integrated delivery model helps us coordinate and simplify quality care, minimize costs and improve our patients’ overall health care experience. Our 15 hospitals and 90+ clinics support neurologists who believe that better health care leads to stronger communities. B. Braun CeGaT is a genetic diagnostic laboratory that offers an extensive menu of single-gene sequencing tests and over 150 multi-gene diagnostic panels for a wide variety of genetic diseases, including 19 panels that analyze 400+ genes associated with epilepsies, migraines, and related disorders. BIOPAC Systems, Inc. Booth #836 42 Aero Camino Goleta CA 93117 Phone: 805-685-0066 Fax: 805-685-0067 Email: [email protected] Website: www.biopac.com Human and animal wireless EEG systems with AcqKnowledge analysis automation & scoring: small animal seizure detection, EPOCH 2-ch long-term wireless EEG/neural signals, B-Alert X10 wireless EEG & Cognitive State Metrics, Mobita 32-ch wireless EEG system with water electrodes, BioNomadix Wireless Physiology amplifiers, Stellar telemetry interface for multiple animals, Developer Scripting, and more! Blackrock NeuroMed Booth #817 630 Komas Dr - Ste 200 Salt Lake City UT 84108 Phone: 801-994-5661 Fax: 801-582-1509 Email: [email protected] Website: www.blackrockneuromed.com Contact: Ms. Shanna Ryan Blackrock NeuroMed’s Cervello® EEG/LTM systems provide physicians and clinicians an advanced EEG monitoring system with up to 256 channels, remote monitoring capabilities, Bluetooth wireless connectivity and a full HD 1080 PTZ video camera. All systems include comprehensive service and support with start to finish integration and IT consultation. Brain Vision LLC Booth #835 2500 Gateway Centre Blvd Ste 100 Morrisville NC 27560 Phone: 919-460-2510 Fax: 214-224-0829 Email: [email protected] Website: www.brainvision.com Brain Vision LLC offers full service solutions for customized neurophysiological related research including epilepsy related on infants and adults that include EEG/ERP as well as fNIRS software and hardware, fMRI 85 EXHIBITORS AKF, global sponsor of Purple Day®, is a 501(c)(3) public charity with a grassroots mission to educate the public not to fear people with epilepsy. Visit purpledayeveryday.org and akfus.org to learn about our Heads Up For Vets and Lace Up For Epilepsy Programs, or to register for our Purple Day Mall of America Walk for Epilepsy in conjunction with the CNF Brain Carnival on 3/21/15. ASET – The Neurodiagnostic Society Booth #15 402 E Bannister Rd Ste A Kansas City MO 64131-3019 Phone: 816-931-1120 Fax: 816-931-1145 Email: [email protected] Website: www.aset.org Contact: Ms. Sarah Ecker B. Braun CeGat, LLC Booth #915 824 Twelfth Ave Bethlehem PA 18018 Phone: 844-692-3428 Email: [email protected] Website: www.bbrauncegat.com Contact: Mitch Nemcek EXHIBITORS compatible equipment, stimulation devices (TMS, tDCS, tACS), wireless system applications for passive, active, dry electrodes and accessories. Cadwell Laboratories, Inc. Booth #811 909 N Kellogg St Kennewick WA 99336 Phone: 509-735-6481 Fax: 509-783-6503 Email: [email protected] Website: www.cadwell.com Contact: Ms. Lori Kaufman Cadwell introduces a new concept in Ambulatory and Clinical EEG. Come byBooth 811 to see the new ARC Alterna EEG system. Completely new software designed with the EEG specialist in mind, you will appreciate the clean, simple look and feel of this new system. The addition of an all new Photic Stimulator allows for clinical EEGs with the Ambulatory hardware while still providing Ambulatory EEGs. captureproof Booth #919 190 7th St. Ste 4 San Francisco CA 94103 Phone: 415-770-2020 Email: [email protected] Website: www.captureproof.com Do your patients send you videos? CaptureProof is the HIPAA secure photo and video solution that organizes events chronologically. Videos are uploaded by the patient and shown at the next appointment or shared online. You can also share images with peers for consults. See-and-know what your patients are talking about. Sign-up free at captureproof.com using invite code: AES2014. Charlie Foundation, The and Ice Epilepsy Booth #19 1325 Victoria Circle S Elm Grove WI 53122 Phone: 262-271-3479 Fax: 262-754-1369 Email: [email protected] Website: www.charliefoundation.org Contact: Ms. Beth Zupec-Kania The Charlie Foundation advocates ketogenic diet therapies through education programs and offers KetoCalculator, a web-based diet tool designed to manage ketogenic therapies. ICE Alliance provides drug information, advocacy support for appropriate medical treatment and education, a patient registry and funding of research for intractable childhood epilepsies:ice-epilepsy.org Child Neurology Foundation Booth #832 201 Chicago Ave - Ste 200 Minneapolis MN 55431 Phone: 612-928-6326 Fax: 612-454-2744 Email: [email protected] Website: www.childneurologyfoundation.org Contact: Ms. Amy Brin Miller 86 CNF improves lives of families battling one or more of the 450+ childhood neurologic disorders through our web resources, by supporting affiliate organizations, public policy initiatives, and the hope derived from our annual scholarships and awards. Clever Sys, Inc. Booth #927 11425 Isaac Newton Sq - Ste 202 Reston VA 20190 Phone: 703-787-6946 Fax: 703-757-7467 Email: [email protected] Website: www.cleversysinc.com Contact: Ms. Naili Zhang Headquartered in the metropolitan D.C. area, Clever Sys. Inc. sells products and services for lab animal behavior analysis including rodents, drosophila, zebra fish, primates, etc.. Our products utilize information of animal full body as well as animal body parts, providing measurements of novel behavioral paradigms and new parameters, which are more revealing of the intrinsic of animal behaviors. Compumedics Limited Booth #805 6605 W WT Harris Blvd - Ste F Charlotte NC 28269 Phone: 704-749-3200 Fax: 704-749-3299 Email: [email protected] Website: www.compumedics.com.au Contact: Ms. Marjie Cummings Compumedics provides solutions for Epilepsy monitoring. NEUVO LTM and Grael EEG Systems with CURRY 7 Neuroimaging Suite meet requirements for routine and ambulatory recordings as well as LTM / Neuro-ICU monitoring. Compumedics addresses ultra-high density recordings, source localization and source imaging. See more and do more with Compumedics. CorTechs Labs, Inc. Booth # 334 4690 Executive Dr - Ste 250 San Diego CA 92121 Phone: 858-459-9700 Fax: 858-459-9705 Email: [email protected] Website: www.cortechslabs.com Contact: Ms. Shelly Adams Courtagen Diagnostics Lab Booth #936 12 Gill St - Ste 3700 Woburn MA 01801 Phone: 617-999-4122 Fax: 617-892-7191 Email: [email protected] Website: www.courtagen.com Contact: Mr. John Geanacopoulos Courtagen is a diagnostic sequencing and molecular information company that converts NGS sequencing data into actionable clinical information for neurological and metabolic disorders such as mitochondrial disorders (mtSEEK® and nucSEEK®), epilepsy (epiSEEK®), and intellectual disability, including autism spectrum disorders (devACT™ and devSEEK™). CURE (Citizens United for Research in Epilepsy) Booth #6 430 W Erie Ste 210 Chicago IL 60654 Phone: 312-255-1801 Fax: 312-255-1809 Email: [email protected] Website: www.cureepilepsy.org Contact: Ms. Tracy Dixon-Salazar CURE (Citizens United for Research in Epilepsy) is a nonprofit organization dedicated to finding a cure for epilepsy by raising funds for research and by increasing awareness of the prevalence and devastation of the disease. Since its inception in 1998, CURE has raised over $28 million to fund epilepsy research and other initiatives that will lead the way to a cure. Cyberonics, Inc. Booth #223 100 Cyberonics Blvd Houston TX 77058 Phone: 281-228-7200 Fax: 281-218-9332 Email: [email protected] Website: www.vnstherapy.com Contact: Ms. Renee Adams Cyberonics, Inc. is the leader in device solutions for epilepsy and is committed to consistently delivering innovative and effective solutions for physicians, caregivers and people with epilepsy. Cyberonics’ VNS Therapy® is available in more than 70 countries for the treatment of drugresistant epilepsy, with more than 80,000 patients implanted worldwide. Department of Veterans Affairs, Epilepsy Centers of Excellence Booth #9 4150 Clement St (127E) San Francisco CA 94121 Phone: 415-221-4810 Fax: 415-379-5666 Email: [email protected] Website: www.epilepsy.va.gov Contact: Mr. Ryan Rieger The Department of Veterans Affairs, Epilepsy Centers of Excellence's mission is to improve the health and well-being of Veteran patients with epilepsy and other seizure disorders through the integration of clinical care, outreach, research, and education. EXHIBITORS DigiTrace EEG Services Booth #727 200 Corporate Pl - Ste 5B Peabody MA 01960 Phone: 978-536-7400 Fax: 978-535-9778 Email: [email protected] Website: www.sleepmed.md Contact: Mr. Dan Martin ELEKTA Booth #519 400 Perimeter Center Terrace Suite 50 Atlanta GA 30346 Phone: 770-670-2592 Fax: 770-448-6338 Email: [email protected] Contact: Doris AuBuchon DigiTrace EEG products and services are used by dozens of comprehensive epilepsy centers throughout the U.S. In addition, there are over 40 SleepMed Service Centers around the country where physicians can refer their patients for ambulatory EEG testing. We are noted for unique capabilities including our lightweight head-mounted preamplifier that minimizes motion artifact. Elekta is the global leader in advanced magnetoencephalography (MEG) instrumentation. MEG is a highly sensitive and completely non-invasive technology increasingly used for localizing the epileptogenic zone(s) and adjacent eloquent cortex in pre-surgical evaluation of epileptic patients. Dravet Syndrome Foundation Booth #11 PO Box 16536 West Haven CT 06516 Phone: 203-392-1950 Fax: 203-907-1940 Email: [email protected] Website: www.dravetfoundation.org Contact: Ms. Mary Anne Meskis The mission of Dravet Syndrome Foundation (DSF) is to aggressively raise research funds for Dravet syndrome and related epilepsies; to increase awareness of these catastrophic conditions; and to provide support to affected individuals and families. Eisai Inc. Booth #305 100 Tice Blvd Woodcliff Lake NJ 07677 Phone: 201-692-1100 Fax: 201-692-1804 Email: [email protected] Website: www.eisai.com/US Contact: Ms. Shirley Hunt As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). EGI brings next-generation clinical EEG systems, tools, and workflows to hospitals and clinics worldwide. EEG Systems feature EGI’s Geodesic Sensor Net for rapid application and unprecedented comfort. Your choice of routine EEG systems or dense array systems for source estimation. Visit EGI’s booth to see this in action! Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries, that advance the boundaries of knowledge and human progress. Visit our booth to find out about our Neurology journals. Emfit Corp. Booth #909 PO Box 342394 Austin TX 78734 Phone: 512-266-6950 Fax: 512-266-7203 Email: [email protected] Website: www.emfit.com Contact: Ms. Christine Ocean Emfit is a pioneer and world-leading manufacturer of movement activity and discreet vitals monitoring systems. We will be demonstrating the Emfit Movement Monitor for monitoring and detecting abnormal, nighttime movements, along with the newly released Emfit QS Sleep Monitor for tracking and recording essential sleep statistics, including heart rate, respiration rate, and movement activity. emka TECHNOLOGIES Inc. Booth #701 307 Annandale Rd - Ste 203 Falls Church VA 22042 Phone: 703-237-9001 Fax: 703-237-9006 Email: [email protected] Website: www.emkatech.com Contact: Ms. Virginie Brechet Stop by booth#701 to discover the all new non-invasive and tether-less monitoring system: rodentPACK v2. An affordable, head- Emory Genetics Laboratory Booth #202 2165 N Decatur Rd Decatur GA 30033 Phone: 404-778-8500 Fax: 404-778-8559 Email: [email protected] Website: www.genetics.emory.edu Contact: Mr. Derek Stevens Emory Genetics Laboratory (EGL) features fully integrated molecular genetics, cytogenetics, and biochemical genetics laboratories, making it a "one-stop shop" for genetic testing. EGL benefits from its affiliation with Emory University, but EGL is not the typical, highly specialized academic laboratory. EGL offers a full range of test options, with more than 900 tests available. Epilepsy Foundation Booths #8, 513 8301 Professional Pl Ardmore MD 20785 Phone: 301-918-3739 Email: [email protected] Website: www.epilepsy.com Contact: Ms. Temi Aregbesola The Epilepsy Foundation is a communitybased, family-led organization dedicated to improving the lives of people impacted by seizures. We provide programs, services, support, and encourage innovation in accelerating new treatments and therapies.We educate about proper seizure awareness, recognition and first aid.We advocate for improved rights and regulations involving people living with epilepsy. GeneDx Booth #822 481 Edward H Ross Dr Elmwood Park NJ 07407 Phone: 301-519-2100 Fax: 301-519-2892 Email: [email protected] Website: www.genedx.com Contact: Ms. Marianne Sansing GeneDx is highly respected laboratory, specializing in genetic testing for rare Mendelian disorders. GeneDx offers sequencing and deletion/duplication testing for inherited cardiac disorders, mitochondrial disorders, neurological disorders, inherited cancer disorders, prenatal disorders and other rare genetic disorders. GeneDx also offers whole exome sequencing, next-generation and microarray-based testing. 87 EXHIBITORS Electrical Geodesics, Inc. Booth #717, 816 500 East 4th Ave Ste 200 Eugene OR 97401 Phone: 541-687-7962 Fax: 541-687-7963 Email: [email protected] Website: www.egi.com Contact: Ms. Diana Aguilar Elsevier, Inc. Booth #901 1600 JKF Blvd - Ste 1800 Philadelphia PA 19103 Phone: 215-239-3491 Fax: 215-239-3494 Email: [email protected] Website: www.elsevierhealth.com Contact: Mr. Jeffrey Francis mounted, radio-telemetry device for recording EEG, EMG, ECG, temperature, and/or activity from up to 32 subjects simultaneously! Weighs only 4.5g with batteries, 5 meters transmission range, 150 hours continuous recording, no refurbishment, just replace batteries. EXHIBITORS GlaxoSmithKline Booth #336 Ms. Laura Byrne Five Moore Dr Research Triangle Park NC 27709 Phone: 800-366-8900 Email: [email protected] Website: www.gsk.com GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of program resources to support effective health management strategies and improve patient care. Please visit our exhibit to learn more about our products and resources. GW Pharmaceuticals Booth #133 1 Cavendish Pl London W1G 0QF United Kingdom Phone: 917-280-2424 Email: [email protected] Website: www.gwpharm.com Contact: Kelly Simontacchi With 15 years of cannabinoid research experience, GW is the world leader in development of novel cannabinoid prescription medicines to address unmet patient needs across a range of therapeutic areas. Our portfolio includes the world’s first plantderived cannabinoid prescription drug, Sativex®, as well as Epidiolex®, currently in development for treatment of Dravet and Lennox-Gastaut syndromes. IEEG.org Booth #17 Room 301 Hayden Hall, 240 S. 33rd St Philadelphia PA 19104 Phone: 215-746-4850 Email: [email protected] Website: eeg.org Contact: Carolyn Wilkinson IEEG.org: A Scientific Platform for collaborative science. The International Epilepsy Electrophysiology Portal is a collaborative initiative funded by the NIH/NINDS. This initiative seeks to advance research towards the understanding of epilepsy by providing a platform for sharing data, tools and expertise between researchers. ( NIH Grant #1 U24 NS063930-01) International Epilepsy Congress Booth #234 7 Priory Office Park, Stillorgan Rd Co. Dublin 18 Ireland Phone: 353-1-2056720 Fax: 353-1-2123576 Website: www.epilepsycongress.org Contact: Mr. Fergus Egan The ILAE is the world's preeminent association of physicians and other health professionals working towards a world where no person’s life is limited by epilepsy. The IBE 88 exists to improve the quality of life of people with epilepsy and their families and carers through national epilepsy organizations around the world. INSYS Therapeutics Booth #200 1333 S Spectrum #100 Chandler AZ 85286 Phone: 602-910-2617 Email: [email protected] Website: www.insysrx.com Contact: Anna Marzahl INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules, including its proprietary sublingual spray technology, to help improve patient quality of life. Focused on pharmaceutical cannabinoids development, the company is evaluating its pharmaceutical cannabidiol (CBD) for epilepsy treatment. Jack Pribaz Foundation, The Booth #332 PO Box 813 Wheaton IL 60187 Phone: 630-485-9986 Email: [email protected] Website: www.jacksarmy.org Contact: Angela Cherry The Jack Pribaz Foundation is a 501(c)(3) charity established in Illinois in 2011. Named for a boy diagnosed with one of the first known cases of KCNQ2 epileptic encephalopathy in North America, its mission is to support research for this condition by raising funds and awareness. To learn more visit www.kcnq2.org and. John Libbey EUROTEXT Booth #301 127 Avenue de la Republique 92120 Montrouge France Phone: 330-146-7306-79 Fax: 330-140-8409-99 Email: [email protected] Website: www.jle.com Contact: Mr. Gilles Cahn For decades, JOHN LIBBEY EUROTEXT has been THE Publisher of both worldrenowned specialists and new authors in Epilepsy. Through Epileptic Disorders, the Educational Journal of the ILAE, and moreover through our huge book series, we provide first-class knowledge in the field of Epilepsy. Visit www.epilepticdisorders.com, The Real Forum for The Worldwide Epilepsy Community. LGS (Lennox-Gastaut Syndrome) Foundation Booth #10 192 Lexington Ave Ste 216 New York NY 10150 Phone: 718-374-3800 Email: [email protected] Website: www.lgsfoundation.org Contact: Ms. Christina San Inocencio The LGS Foundation is a non-profit organization dedicated to providing information about Lennox-Gastaut Syndrome while raising funds for research, programs and services for individuals living with LGS, and their families. Lifelines Neurodiagnostic Systems, Inc. Booth #921 411 Edwardsville Rd Ste A Troy IL 62294 Phone: 618-667-6445 Fax: 618-667-1982 Email: [email protected] Website: www.lifelinesneuro.com Cloud-based technology is the next step in the evolution of EEG, and LifeLines Neurodiagnostic Systems is leading the industry with innovative, new products. iEEG Cloud is a complete, home video solution. Record and upload the EEG/video data to the Cloud for review over the Internet in nearreal time. We maintain servers with our hosted solution. Stop by booth #921 to see how EEG is evolving! Lundbeck Booth #405, 511 Four Parkway North Deerfield IL 60015 Phone: 847-282-1000 Fax: 847-282-1001 Email: [email protected] Website: www.lundbeck.com/us Contact: Ms. Lisa Berry Headquartered in Deerfield, Illinois, with a portfolio specialty central nervous system (CNS) therapies and a robust pipeline of promising CNS compounds, Lundbeck is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders, including rare diseases, for which few, if any, effective treatments are available. Mallinckrodt Pharmaceuticals Booth #217, 316 26118 Research Rd Hayward CA 94545 Phone: 510-400-0721 Fax: 510-400-0710 Email: [email protected] Website: www.mallinckrodt.com/ard Contact: J.T. Thomas Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and a Global Medical Imaging segment. EXHIBITORS Medical Neurogenetics, LLC Booth #216 5424 Glenridge Dr NE Atlanta GA 30342 Phone: 678-225-0222 Fax: 678-225-0212 Website: www.mnglab.com Contact: Juliann Kowalski soft tissue, including for use in neurosurgical procedures. More than 45 U.S. centers have performed more than 900 neurosurgical cases. National Institute of Neurological Disorders & Stroke (NINDS) Booth #725 31 Center Dr - Bldg 31 - Rm 8A07 Bethesda MD 20892-2540 Phone: 301-496-5751 Fax: 301-402-2186 Email: [email protected] Website: www.ninds.nih.gov Contact: Ms. Natalie Frazin The National Institute of Neurological Disorders and Stroke (NINDS) supports basic, translational, and patient-oriented research on epilepsy prevention, diagnosis and treatment, including mechanisms underlying seizures and epileptogenesis, gene discovery and targeted therapeutics, epidemiology, psychosocial and behavioral consequences, and development of new therapies. Free patient information. Natus Neurology Incorporated Booth #705 3150 Pleasant View Road Middleton WI 53562 Phone: 608-829-8500 Fax: 847-949-8615 Email: [email protected] Website: www.natus.com Neuralynx, Inc Booth #713 105 Commercial Dr Bozeman MT 59715 Phone: 406-585-4542 Fax: 406-585-9034 Email: [email protected] Website: www.neuralynx.com Contact: Ms. Kathy Walsh Neuralynx ATLAS systems record the entire range of human electrophysiology from surface EEG to single units via micro-wires. Features include DC capability, flexible referencing, and 40 KHz acquisition across all channels. ATLAS provides complete integration with Nihon Kohden EEG systems for a seamless clinical workflow. This functionality makes ATLAS the logical choice for clinical research. Neurology Reviews Booth #101 7 Century Dr - Ste 302 Parsippany NJ 07054 Phone: 973-290-8228 Fax: 973-206-9178 Email: [email protected] Website: www.frontlinemedcom.com Contact: Ms. Lynne Kalish EXHIBITORS Moberg Research Booth #239 224 S Maple Way Ambler PA 19002 MNG provides expert diagnostics through Phone: 215-283-0860 clinical services, biochemical testing and Next Fax: 215-283-0859 Generation Sequencing. Our panels are the Email: [email protected] most cost effective and comprehensive Website: www.moberg.com available, particularly for cellular energetics, Contact: Ms. Kathleen Fitzgerald muscular dystrophies, and epilepsy. A major focus is to provide rapid sequencing The Moberg CNS Monitor continuously /metabolic diagnostics. Now available is an records EEG and processed EEG trends, Anticonvulsant-Resistant Epilepsy Rapid time-synchronized with other physiology. Evaluation Kit. Multimodal monitoring with integrated video, EEG trends and physiology helps you evaluate MediKidz patients' neurological statuses. View Booth #232 correlations between EEG and parameters 21 West 46th St from other devices including vital signs, ICP, New York City NY 10036 brain oxygen, cerebral blood flow, and more. Phone: 718-808-5144 Email: [email protected] Monteris Medical Website: www.medikidz.com Booth #905 Contact: Ryan Mulcock 16305 36th Ave N - Ste 200 Plymouth MN 55446 Medikidz is an exciting initiative in children’s Phone: 719-487-9558 health education, which aims to provide Fax: 763-746-0084 accurate and relevant medical information for Email: [email protected] young people. Medikidz believes that every Website: www.monteris.com child deserves access to medical information Contact: Ms. Lisa Bichsel they can understand. We are creating a global community of young people that are Monteris Medical manufactures minimallyinformed, empowered and health-aware. invasive devices for MR-guided neurosurgery including: The NeuroBlate System for precise Medtech Surgical controlled laser ablation therapy of epilepsy Booth #800 and brain lesion targets; AxiiiS Stereotactic 211 Warren St - Ste 306 Miniframe skull-mounted platform for imageNewark NJ 07103 guided trajectory alignment; AtamA System, Phone: 612-251-6698 an MR-compatible transport and head Fax: 855-329-7672 stabilization system. Email: [email protected] Website: www.medtechsurgical.com Multi Channel Systems Contact: Mr. Eric Caille Booth #300 60 Marine St ROSA™ is a FDA approved Neurosurgery Farmingdale NY 11763 robot to offer a touchless Laser Registration Phone: 631-393-6401 that has been in use for several years in Fax: 631-393-6407 leading Epilepsy programs in North America Email: [email protected] and abroad. With over 1600 procedures to Website: www.multichannelsystems.com date ROSA™ is on the forefront of SEEG Contact: Ms. Margaret Badon Invasive monitoring. We offer a complete program including training, case observations, Multi Channel Systems develop precision consultation and innovative webinars and scientific measuring instrumentation & referral programs. equipment for research groups at universities & the pharmaceutical industry, in the field of Medtronic electrophysiology. We provide solutions for Booth #932 extracellular recordings with microelectrode 8058 El Rio St arrays in vitro & in vivo with the MEA-System Houston TX 77054 & the ME-System as well as for electrical Phone: 713-275-2063 stimulation with the STG series. Fax: 713-741-0122 Email: [email protected] National Association of Epilepsy Centers Website: www.visualaseinc.com Booth #723 Contact: Mr. Andre Marquette 600 Maryland Ave SW - Ste 835W Washington DC 20024 The Visualase Thermal Therapy System is an Phone: 202-524-6767 MRI-guided, minimally invasive laser ablation Email: [email protected] system which allows for continuous Website: www.naec-epilepsy.org monitoring of an ablation in real-time. The Contact: Ms. Johanna Gray system is FDA-cleared for the ablation of The National Association of Epilepsy Centers is a non-profit 501(c)(6) trade association with a membership of more than 210 specialized epilepsy centers in the United States. With the goal of no seizures and no side effects, NAEC strives to make high quality healthcare available to and affordable for epilepsy patients across the country. 89 EXHIBITORS NEUROLOGY REVIEWS is a clinical news publication with articles and timely department features that keep neurologists, primary care physicians, and other healthcare professionals informed of the latest news affecting their practice. NEUROLOGY REVIEWS covers major medical conferences and monitors the peer review literature to report the latest research findings. NeuroPace, Inc. Booth #824 455 N. Bernardo Ave Mountain View CA 94043 Phone: 650-237-2700 Fax: 650-237-2701 Email: [email protected] Website: www.neuropace.com Contact: Ms. Kathy Miller NeuroPace, Inc. develops and produces medical device solutions for the treatment of neurological disorders. NeuroPace, Inc. has FDA approval for the RNS® System, the world’s first and only neurostimulator that provides targeted, responsive therapy for patients with medically refractory epilepsy. NeuroQuest LLC Booth #834 S75 W17317 Janesville Rd Muskego WI 53150 Phone: 262-679-7100 Fax: 855-777-8378 Email: [email protected] Website: www.neuroquestllc.com Contact: Ms. Mindy Gersonde There's no place like home to have your EEG(SM), especially since we make house calls. NeuroQuest LLC is the premiere provider of extended ambulatory video EEGs. Our technologists travel into your patient's home, a clinic, office or institution to meet the goal of providing the highest quality, most convenient, cost-effective EEGs. Nexstim Booth #119 1360 Union Hill Rd Ste 5B Alpharetta GA 30004 Phone: 770-664-1000 Website: www.nexstim.com Contact: Sydney Bridger Nexstim’s Navigated Brain Stimulation (NBS) System integrates TMS, EMG, & MRI guided navigation to noninvasively map the motor cortex with the accuracy of DCS. Nexstim holds FDA clearances for (NBS) PreProcedural Planning and (NexSpeech) for Mapping Language Function. Future FDA applications: Stroke Rehabilitation*, Depression, and TBI. *currently in clinical trials. PCDH19 Alliance Booth #7 6 Wisteria Ct Novato CA 94945 Phone: 415-892-5794 Email: [email protected] Website: www.pcdh19info.org Contact: Ms. Julie Walters Nihon Kohden America, Inc. Booth #617 15353 Barranca Pkwy Irvine CA 92618 Phone: 949-580-1555 Fax: 949-580-1550 Email: [email protected] Website: www.nkusa.com Contact: Ms. Jeannie Callahan The PCDH19 Alliance focuses on raising and directing funds to scientific research with the goal of finding better, more effective treatments and, ultimately, a cure; providing information and support to affected families; and assisting the efforts of the medical community, so that no family suffers without a diagnosis and the most appropriate medical treatment. For over 60 years Nihon Kohden has been the trusted Neurology solution for Epilepsy Monitoring, Electroencephalography, EEG & PSG Wireless & Ambulatory Recording, Polysomnography, Out of Center Sleep Testing/PSG, Electromyography, Evoked Potentials, Intra-operative and cEEG ICU monitoring. Serving the Best Minds in Neurology for Over Sixty Years. Persyst Development Corporation Booth #925 12625 High Bluff Dr - Ste 213 San Diego CA 92130 Phone: 858-461-4542 Fax: 858-461-4531 Email: [email protected] Website: www.persyst.com Novartis Pharmaceuticals Booth #137 One Health Plaza East Hanover NJ 07936 Phone: 862-778-2159 Website: www.novartisoncology.com Contact: Marianne LaRosa Neurotech Booth #610 15285 Watertown Plank Rd Ste 2 Elm Grove WI 53122 Phone: 262-754-0895 Email: [email protected] Website: www.neurotecheeg.com Contact: Vickie Wolfe Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. Neurotech EEG Telemedicine – In Home Tests, 24/7 Remote Monitoring – Neurotech provides 24+ hour EEG tests to diagnose seizures. With prompt scheduling, technologists hookup patients in their homes. R EEG T remotely monitors patients continuously, any problems resolved by technologist returning to patient if necessary; ensuring quality test results. Physicians have live online access to data. Optima Neuroscience, Inc. Booth #833 11930 Research Circle Alachua FL 32615 Phone: 386-462-9622 Fax: 386-462-5365 Email: [email protected] Website: www.optimaneuro.com 90 Oxford University Press Booth #219 198 Madison Ave New York NY 10016 Phone: 212-726-6000 Fax: 212-726-6494 Email: [email protected] Website: www.oup.com/us Contact: Ms. Meagan Burnett Optima Neuroscience is a medical device company developing innovative technologies for the diagnosis and treatment of neurological disorders. Optima's initial product lines feature neurological status monitoring technologies designed to directly address these needs. For more than twenty years Persyst has produced the most trusted and innovative EEG analysis products. Today, Persyst is the world’s leading supplier of artifact reduction, seizure detection, spike detection, and quantitative analysis software to every leading EEG manufacturer for continuous EEG monitoring, LTM and ambulatory EEG. Physicians Insurance Booth #220 1301 Second Ave Ste 2700 Seattle WA 98101 Phone: 206-343-7300 Fax: 206-343-7100 Email: [email protected] Website: www.phyins.com Contact: Catherine Kunkel Physicians Insurance A Mutual Company is the largest medical professional liability insurance company in the Northwest, with 7,000 members in Oregon, Washington, Idaho, and Wyoming. Owned and operated by its insured physicians and clinics, Physicians Insurance offers broad protection at a reasonable cost, focusing on patient safety and claims management. EXHIBITORS Pinnacle Technology, Inc. Booth #737 2721 Oregon St Lawrence KS 66046 Phone: 785-832-8866 Fax: 785-749-9214 Email: [email protected] Website: www.pinnaclet.com Contact: Ms. Linda Lane Pinnacle provides preclinical research tools. New this year is optogenetics technology integrated into our seizure monitoring systems. Biosensors can be added to the core EEG/EMG units to measure neurotransmitters along with seizure activity. Our analysis software finds, identifies, marks and analyzes seizure events. Synchronized video and precision timing can be added to any system. PMT Corporation Booth #606 1500 Park Rd Chanhassen MN 55317 Phone: 952-470-0866 Fax: 952-470-0865 Email: [email protected] Website: www.pmtcorp.com Contact: Ms. Amanda Bammert Rhythmlink offers an array of monitoring devices including the first and only FDA cleared disposable MR Conditional EEG products on the market. Ring14 USA Outreach Booth #12 4313 Wood Dr. Midland TX 79707 Phone: 765-491-6910 Email: [email protected] Website: www.ring14usa.org Contact: Yssa DeWoody Ripple LLC Booth #724 2015 S 1100 E Salt Lake City UT 84106 Phone: 801-413-0139 Fax: 801-413-2874 Email: [email protected] Website: www.rppl.com Contact: Mr. Mitch Frankel Ripple provides high performance electrophysiology data acquisition systems for neuromuscular recording and stimulation. Our systems are compact, portable, and heavily optimized for real-time, closed-loop control applications with up to 512 channels of EMG, EEG and microelectrode data. Our PMT Corporation is the premier supplier of an software is cross platform, and can be run extensive line of neurosurgical products, on Windows, Mac OS X, and Linux. offering Cortac, cortical surface electrodes, Depthalon, depth electrodes and sEEG depth Rogue Research Inc. electrodes for epilepsy monitoring and Booth #900 microsurgical instruments. PMT also offers 4398 St-Laurent Ste 206 high-end neck braces, including halo systems Montreal QC H2W 1Z5 Canada and orthotic vests for cervical, thoracic and Phone: 514-284-3888 lumbar spinal immobilization. Fax: 514-284-6750 PreventionGenetics Booth #902 3800 South Business Park Ave Marshfield WI 54449 Phone: 715-387-0484 Email: [email protected] Website: www.preventiongenetics.com Contact: Danielle Krohn Rhythmlink International, LLC Booth #721 1140 First St S Columbia SC 29202 Phone: 816-429-5931 Fax: 803-252-1111 Email: [email protected] Website: www.rhythmlink.com Contact: Mr. Garrett Butler Rhythmlink International is a medical device manufacturing company specializing in devices that help connect patients to machines to record or elicit physiologic information. Seizure Tracker provides free tools to help patients and doctors better understand seizure activity and surrounding treatments. The site provides patients with resources to log their seizures along with medication, diet, VNS settings and much more. Reports generated on SeizureTracker.com include graphs that illustrate trending in treatment efficacy and can be easily shared with care providers. Smart Monitor Corp. Booth #917 6203 San Ignacio Ave #112 San Jose CA 95119 Phone: 408-505-1976 Fax: 408-351-0154 Email: [email protected] Website: www.smart-monitor.com Contact: Ms. Sheri Becker Smart Monitor provides monitoring solutions for people with chronic health conditions. Founded in 2009 and headquartered in San Jose, CA, Smart Monitor fuses together sensor, mobile and cloud technologies with big-data analytics in a seamless environment. Our patent protected solutions foster autonomy and enhance safety,while offering significant peace-of mind to their families and care providers. SUDEP Aware Booth #20 Rogue Research develops the Brainsight® 283 Danforth Ave Ste 350 Toronto ON M4K 1N2 Canada family of neuronavigation products, including Phone: 416-556-8770 Brainsight TMS, the first and most popular Email: [email protected] neuronavigation system designed specifically Website: www.sudepaware.org for TMS. Brainsight NIRS is a unique fNIRS system designed specifically for multimodality Contact: Ms. Tamzin Jeffs applications, allowing fNIRS acquisition during TMS and simultaneous fNIRS acquisition along SUDEP Aware is a not-for-profit organization that has worked since 2007 to bring more with EEG, fMRI or MEG. awareness and better understanding to Sudden Unexpected Death in EPilepsy RosmanSearch, Inc. (SUDEP). It provides support to families and Booth #726 researchers through its co-founder 30799 Pinetree Rd Ste 250 partnership between Dr Elizabeth Donner Pepper Pike OH 44124 (Pediatric Neurologist at Sick Kids Hospital, Phone: 216-287-2302 Toronto) & Tamzin Jeffs (who has epilepsy Fax: 216-803-6672 and lost her sister to SUDEP). Email: [email protected] Website: www.rosmansearch.com Contact: Mrs. Beth Dery RosmanSearch is a dual-specialty, truly expert, high integrity neurosurgical and neurology recruiting service you can trust. We specialize exclusively in neurosciences permanent placement, and our recruitment methodology is data driven and unique in the industry. Sunovion Pharmaceuticals Inc. Booth #105 84 Waterford Dr Marlborough MA 01752 Phone: 508-481-6700 Fax: 508-357-7490 Email: [email protected] Website: www.sunovion.com Contact: Ms. Susan Mahoney EXHIBITORS PreventionGenetics is a leader in providing comprehensive clinical DNA testing offering NextGen Sequencing, Sanger sequencing and deletion/duplication testing via array CGH for over 1000 genes. Our highly experienced team of geneticists provide fast turnaround times, outstanding personalized service, and the highest quality testing at the lowest prices possible. We are CLIA/CAP accredited. Email: [email protected] Website: www.rogue-research.com Contact: Mrs. Diane Gariepy SeizureTracker.com Booth #21 PO Box 10738 Alexandria VA 22310 Phone: 703-339-8448 Fax: 703-339-8430 Email: [email protected] Website: www.seizuretracker.com Contact: Mr. Robert Moss 91 EXHIBITORS Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry, Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion is a subsidiary of Sumitomo Dianippon Pharma Co., Ltd. Triangle BioSystems, Inc. Booth #735 2224 Page Rd Ste 108 Durham NC 27703 Phone: 919-361-2663 Fax: 919-544-3061 Email: [email protected] Website: www.trianglebiosystems.com Contact: Mr. James Morizio Upsher-Smith Laboratories, Inc Booth #625, 823 6701 Evenstad Dr Maple Grove MN 55369 Phone: 763-315-2000 Fax: 763-315-2244 Email: [email protected] Website: www.upsher-smith.com Contact: Ms. Becky Bouley Supernus Pharmaceuticals, Inc. Booth #605 1550 E Gude Dr Rockville MD 20850 Phone: 301-838-2500 Email: [email protected] Website: www.supernuspharma.com Contact: Mr. Tilton Conner Miniaturized stimulation and recording solutions for rodent and other animal models. Wireless Stim headstage (2-16ch). Recording headstages for single unit, EEG and other signals: tethered, multiplexed or signature wireless headstages (5–128Ch). Software: Neuroware™ acquisition, Optimap™ video tracking, StimWare™. Custom electrophysiology engineering solutions. Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life™. With capabilities ranging from early-stage research to delivering on-market products, UpsherSmith is committed to developing quality products that enable people to live life to its greatest potential. Tuberous Sclerosis Alliance Booth #22 801 Roeder Rd Ste 750 Silver Spring MD 20910-4467 Phone: 301-562-9890 Fax: 301-562-9870 Email: [email protected] Website: www.tsalliance.org Contact: Ms. Katie Smith Vitaflo USA Booth #117 316 Montgomery St Alexandria VA 22314 Phone: 631-897-6939 Email: [email protected] Website: www.vitaflousa.com Contact: Ms. Katrina Bellan Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases. The company has two marketed products for epilepsy, Oxtellar XR® (oxcarbazepine) extendedrelease tablets and Trokendi XR® (topiramate) extended-release capsules. Texas Children’s Hospital Booth #201 1919 S Braeswood Ste 6226 Houston TX 77030 Phone: 832-824-2143 Fax: 832-825-2624 Email: [email protected] Website: www.texaschildrens.org Contact: Ms. Karen Wilkinson The Neuroscience Center at Texas Children’s Hospital, located in Houston, Texas is committed to creating a healthier future for children and women by leading in patient care, education and research. Utilizing Neurology, Neurosurgery and the Jan and Dan Duncan Neurological Research Institute, we are able to identify, monitor and surgically correct the full continuum of neurological conditions. Transgenomic, Inc. Booth #801 12325 Emmet St Omaha NE 68164 Phone: 402-452-5400 Fax: 402-452-5401 Email: [email protected] Website: www.transgenomic.com Contact: Mr. Scott Stremick Transgenomic, Inc. specializes in genetic testing for cardiology (FAMILION), neurology, mitochondrial disorders and oncology. Transgenomic develops assays and offers testing with the goal to overall improve medical diagnosis and outcomes for patients. Founded in 1974, the TS Alliance is the only national voluntary health agency dedicated to finding a cure for TSC, while improving the lives of those affected. TSC is a genetic disorder characterized by seizures and tumor growth in vital organs such as the brain, heart, kidneys, lungs and skin. UCB, Inc. Booth #135, 205 1950 Lake Park Dr Smyrna GA 30080 Phone: 770-970-7500 Fax: 770-970-8917 Email: [email protected] Website: www.ucb-group.com Contact: Mr. Dave Tappan Wiley Booth #818 111 River Street Hoboken NJ 07030 Phone: 201-748-6000 Fax: 201-748-6617 Email: [email protected] Website: www.wiley.com At UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 8,500 employees in 40 countries, we invest more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. Wiley is the leading society publisher. We publish on behalf of more societies and membership associations than anybody else, and offer libraries and individuals 1,250 online journals, thousands of books and e-books, reviews, reference works, databases, and more. For more information, or our online resource: onlinelibrary.wiley.com. UCSF Medical Center Booth #913 3360 Geary Blvd Ste 301 San Francisco CA 94118 Phone: 415-353-7703 Email: [email protected] Website: jobs.ucsfmedicalcenter.org Contact: Cheryl Hardin Wolters Kluwer Health Booth #400 Two Commerce Sq 2001 Market St Philadelphia PA 19103 Phone: 215-521-8300 Fax: 215-521-8493 Email: [email protected] Website: www.lww.com Contact: Ms. Joey-Rose Jester If you are looking to take your career in the END field to the next level then UCSF Medical Center Neurodiagnostics Program is for you! UCSF has one of the largest, most comprehensive epilepsy surgery programs in the western United States. 92 Vitaflo® is at the forefront of developing innovative specialized medical foods for Metabolic Disorders, Nutrition Support and other areas of disease specific nutrition. Our aim is to create nutritional products that combine the best of cutting edge research with the lifestyle demands of modern living, ensuring the most acceptable products are available for the patient. Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. ABSTRACT AUTHOR INDEX A Alegre, M. 2.153 Alencar, C.N. 3.179 Alessi, R. 2.259, 2.260, 3.179 Alexandre, F.P. 1.086 Alexandre, V. 2.226 Alexopoulos, A. 1.040, 1.144, 1.149, 1.240, 2.249, 3.359 Alhadid, K. 3.200 Alhashem, A. 1.104 Alhusaini, S. 1.248 Ali, A. 2.095 Ali, I. 1.321, 3.079 Ali, N. 1.239, 2.106 Ali, W. 3.061 Alio Saenz, A. 2.318, 2.324 Alkawadri, R. 1.156 Allard, L. 2.239 Allen, A. 2.095 Allen, B.B. 3.155 Allen, V. 1.267 Allendorfer, J. 1.236, 1.257, B.09 Almane, D. 2.023 Almualim, M. 3.225 Almutairi, F. 1.104 Alonso-Vanegas, M. 2.186, 2.334, 3.154 Alqadi, K. 2.172 Alsaadi, T. 2.086 Alshafai, L. 1.189 Althaus, A.L. 3.005 Altura, C. 1.285 Alvarez, V. 3.203, 3.226 Aly, R. 2.066 Amador, A. 2.222 Amaro, P. 2.153 Amina, S. 2.126 Amiri, M. 1.171 Amrom, D. 1.121, 3.097 An, D. 3.285 An, S. 2.035, A.05 Anastassopoulos, K.P. 1.273, 1.287 Andermann, E. 1.121, 1.317, 1.319, 3.097 Andermann, F. 1.121, 3.097 Anders, B. 1.307, 1.308, 2.280, 2.281, 2.284 Anderson, A. 1.139, 3.048, 3.049, 3.050, 3.061 Anderson, C. 3.208 Anderson, C.T. A.08 Anderson, M. 1.290 Anderson, W. 1.045, 1.061, 2.025 Anderson, W.S. 1.064 Ando, N. 1.224, 1.243 Ando, T. 1.079 Andrade, D. 1.112, 2.095 Andrade, E. 2.261 Andrade, J.Q. 3.179 Andreas, J. 2.283, 3.290 Andrews, J. 1.164 Andrews, M. 3.132 Andriola, M. 1.132, 1.142, 2.162 Ang, L. 3.109 Anghelina, E. 3.220 Anschel, D. 3.154 Antony, A. 1.073 Aoki, M. 2.149 Appavu, B. 2.127 Appleton, R. 1.109 Aracri, P. 1.108 Arai, H. 1.116, 1.363, 1.370, 2.132, 3.012 Arain, A. 1.327, 2.117, 3.252 Arain, F. 3.015 Arakawa, Y. 1.350, 2.335 Araujo, P. 3.260 Archer, J. 3.092, 3.287 Ardini, M. 3.141, 3.144 Arican, N. 1.053 Arita, K. 1.265, 2.002 Arkilo, D. 1.123 Armbruster, M. 3.125 Armstrong, C. C.03 Arndt, D. 1.182, A.09 Arnedo, V. 1.085 Arnett, A. 1.090, 1.091 Arnold, S.T. 2.088 Arrigoni, E. 1.162 Arruda, F.J. 2.274, 3.199 Arya, R. 1.353, B.06 Arzimanoglou, A. 2.263, 2.277 Asadi-Pooya, A. 1.311 Asano, E. 1.251, 2.345, 3.062, 3.362 Ashby-Lumsden, A. 3.036 Asratyan, S. 2.076 Assaad, B. 1.151, 2.215 Ates, N. 1.053 Atherton, D. 2.070 Athing, U. 2.121 Atsumi, S. 2.202 Auerbach, D.S. 3.132 Auguste, K.I. 1.369 Aung, T. 2.109, 2.140 Aungaroon, G. 3.247 Auvin, S. 1.055, 1.056, 2.263 Avallone, J. 1.133 Avedian, L. 3.250 Avoli, M. 1.301, 3.121, 3.184 Ayasoufi, K. 1.008 Azar, N. 1.187, 1.327, 2.160, 3.252 Azarion, A. 2.301 Azuma, J. 1.116 Azuma, Y. 1.224, 1.235, 1.243 Azzam, R. 1.280, 2.117 B Baba, H. 1.359, 1.361, 1.365 Baba, K. 1.365 Baba, S. 1.127, 1.145, 2.353, 3.108 Babiarz, K. 2.085 Baboyan, V. 3.060 Babtain, F. 1.223 Bachman, E. 1.188, 3.218 Backofen-Wehrhahn, B. 1.069 Bacskai, B. 1.021, 3.004 Badesch, B. 1.267 Bagliella, E. 2.233 Bagnall, R.D. 3.088 Bahlo, M. 3.100 Bai, X. B.01 Bailey, L. 2.022, 2.250 Bailey, M. 3.224 Bain, S. C.07 Bainbridge, J. 3.304 Bakaki, P. 2.052, 2.090 Baker, D. 1.140 Baker, E. 1.184 Baker, M. 1.327 Baker, S. 1.043 Bakken, I. 2.072 Bal, C. 2.365 Balabanov, A. 2.037, 2.205 Balaguera, P. 2.241 Baldeweg, T. 1.190 Baldin, E. 3.140 Balena, T. 1.021, 3.023 Balestri, M. 2.146 Ball, T. 1.167 Ballaban-Gil, K. 2.061 Bamps, Y. 3.075, 3.078, 3.085, 3.127 Bandt, S. 1.376 Bandyopadhyay, S. 3.252 Bang, H. 3.112 Banks, G. 1.057 Bar Yossef, R. 2.175, 3.197 Baraban, S. C.05 Baram, T. 1.009, Barba, C. 1.348 Barber, A. 2.301 Barber, J. 2.039 Barborica, A. 1.191, 3.069 Barbosa-Nunez, C. 1.294 Barcia, G. 3.016 Barisic, N. 1.107, 1.118 Barker-Haliski, M. 1.050 Barkley, G.L. 1.151, 2.212, 2.215 Barnard, M.E. 1.154 Barnes, D. 2.058 Barnett, J. B.07 Barnett, P. 1.255, 2.237 Barrett, K. 1.025, 3.019 Barrios, E. 3.065 Barritt, S.E. 1.278 Barth, D. 3.038, 3.047 Bartha, R. 3.265, 3.277 Bartley, M.L. 3.286 Bartolomei, F. 1.377, 2.226, 3.182 Basha, M. 2.214, 3.266 Baslet, G. 2.236 Bastar, J. 1.161 Basu, I. 1.064 Basu, R. B.06 Bateman, L. 1.057, 3.213 Bates, J. 2.059 Bathena, S. 3.317 Battaglia, G. 3.029 Baudry, M. 1.039 Bauer, G. 2.068 Baulac, M. 3.296 Baumer, F. 2.124 Baumgartner, J. 1.179, 2.014, 2.248, 2.253, 2.255, 2.348, 2.364, 3.276 Bautista, J. 2.273 Baxter, R. 1.194 Baykan, B. 1.128, 2.183 Baykan, B. 2.224 Baykara, Y. 1.076 Bayly, M.A. 3.089 Baysal Kirac, L. 1.128 Bazil, C. 2.209, 2.212 ABSTRACT AUTHOR INDEX Aaberg, K. 2.072 Abbott, D. 3.287 Abdel-Latief, O. 1.066 AbdeleRahman, K. 3.171 Abdulkadir, Y. 3.340 Abel, T.J. 1.079 Abela, E. 2.244 Abend, N. 1.136, 1.182, B.06 Abibullaev, B. 1.130 Abisogun, A. 2.246 Abosch, A. 3.190 Abou-Khalil, B. 1.186, 1.280, 1.321, 1.327, 1.338, 2.117, 2.242, 3.152 Abramovici, S. 2.157 Abramson, E.L. 2.043 Abtahi, M. 3.073 Abu Abthan, M. 1.223 Abubakr, A. 1.183 Acevedo, K. 3.101 Aceves, J. 1.341 Ackley, M. 1.296, 1.303 Acton, E. 3.208, 3.238 Adams, E. 1.094, 2.021, 2.270 Adeleye, A. 3.172 Adhami, S. 2.196 Adjouadi, M. 3.192 Adkins, A. 1.066 Afawi, Z. 3.090 Afra, P. 1.068 Agadi, S. 1.215, 1.341 Agan, K. 3.151 Agarwal, M. 1.275 Agarwal, N. 1.144, 3.359 Agarwal, R. 3.362 Agee, B. 2.338, 3.348 Agha, C. 2.066 Agha-Khani, Y. 2.198 Aghakhani, Y. 1.264, 2.067, 2.150, 3.139, 3.186 Agostini, M. 2.038, 2.189, 2.193, 3.083 Agostini, S. 2.166 Agrawal, S. 2.041 Aguado Valcárcel, M. 2.300 Ahishali, B. 1.053 Ahmadi, L. 3.229 Ahmed, I. 3.079 Ahmed, O.J. 1.018 Ajetunmobi, O. 3.129 Akasaka, N. 1.116 Akdag, G. 3.305 Akiyama, M. 1.172 Akiyama, T. 1.172 Akman, C. 3.233 Akman, C.I. 3.140 Al Ghamdi, S. 1.223 Al Jarrah, S.A. 2.001 Al Matrooshi, N.O. 2.086 Al matrooshi, N.O. 2.106 Al-Baradie, R.S. 3.234 Alagapan, S. 1.159 Alam, J. 3.289 Alareddy, A. 1.062 Albert, J. 2.052 Alberts, G. 2.016 Aldenkamp, A. 2.018 93 ABSTRACT AUTHOR INDEX Bazzigaluppi, P. 1.016, 3.008 Beal, J.C. 2.061 Beatty, C. 3.245 Beaulieu, C. 3.259, 3.260, 3.261 Bebek, N. 1.128, 2.183, 2.224 Becchetti, A. 1.108 Bechstedt, S. 1.121 Becker, D. 2.007 Beers, C. 1.264 Begley, C. 2.009, 2.047, 3.078 Behr, C. 1.301, 3.121 Beimer, N.J. 2.030 Belfort, G. 1.296, 1.303 Bell, A.J. 2.144 Bellas, P. 3.309 Bello, L. 1.132, 1.142, 3.240 Bello-Espinosa, L. 1.360, 3.102 Belousova, E. 2.187 Beltramini, G.C. 3.259, 3.260 Ben Hur, T. 2.175, 3.063 Ben Salem, Z. 1.051 Ben-Menachem, E. 2.278 Benbadis, S. 1.101, 1.315, 1.317, 1.322, 1.340, 2.360, 2.361, 3.304 Bendrups, N. 1.279 Benedik, M. 2.187 Beniczky, S. 1.118 Benifla, M. 2.175 Benites, D. 3.070 Benke, T. 3.209 Bennett, M. 3.224 Bennett, O. 2.175 Benninger, F. 3.197 Bensalem-Owen, M. 1.323, 2.136 Bentz, J. 2.277 Berberi, N. 2.170 Berdichevsky, Y. 2.328 Berg, A. 1.097, 1.206, 2.035, A.01, A.02 Berg, K. 2.021, 2.270 Berg, M. 1.324, 2.285, 2.286, 2.287, 3.288 Berg, R. 1.182 Bergey, G. 1.174, 1.216, 2.209, 3.189, 3.191 Bergin, A. 3.236, 3.325, 3.326, 3.334 Bergo, F. 3.259, 3.260 Berkeley, J. 2.200 Berkovic, S. 1.120, 3.088, 3.089, 3.092, 3.095, 3.100 Berl, M. 2.019, 3.268, 3.272, 3.278 Bermudez-Hernandez, K. 3.037 Bernard, C. 3.182 Bernardo,, D. 1.159 Bernasconi, A. 1.237, 1.244, B.04 Bernasconi, N. 1.237, 1.244, B.04 Bernhardt, B. 1.237, 1.244, B.04 Berquin, P. 2.263, 2.277 Berrios-Siervo, G. 2.012 Bertram, E.H. 3.047 Bertti, P. 3.055 Besag, F. 2.018 Besio, W. 3.073 Bessemer, R.A. 3.186 Betting, L. 3.165 Betts, K. 1.342 Bevot, A. 1.118 Bhatia, H. 1.223 94 Bhatia, P. 2.092 Bickel, S. 1.157, 2.246, 3.177, 3.346 Bienes, G. 2.327 Bilir, E. 1.207 Binder, D. 2.238, 3.119 Bingaman, W. 1.058, 1.093, 1.099, 1.240, 1.347, 1.362, 1.377 Biraben, A. 1.317, 2.226 Birk, N. 3.068 Birnbaum, A. 1.272, 3.317 Birney, K.A. 2.042 Bishara, A. 3.063 Bishop, L. 3.224 Biton, V. 2.278, 2.292 Blatt, I. 1.307, 1.308, 2.280, 2.281, 3.090, 3.197 Bleasel, A. 3.286 Blezin, F. 2.064 Block, S.C. 1.186 Blum, D. 1.273, 1.287, 1.312, 1.314, 1.315, 1.316, 1.317, 1.318, 1.319, 1.320, 1.321, 1.322, 1.323, 1.342, 2.278, 2.290, 2.292 Blumberg, J. 2.180 Blumcke, I. 1.346 Blume, H. 3.245 Blumenfeld, H. 1.044, 1.062, 1.076, 1.164, A.02, B.01, Blumenfeld, J. 1.076 Blumenthal, H. 2.022 Bluvstein, J. 2.309, 3.303 Boada, R. 2.012 Boals, A. 2.022 Boelman, C. 1.145, 1.172 Bogaarts, G. 1.138 Boggs, J. 3.224, 3.367 Bolen, R. 3.224 Boles, R. 3.094 Bolger, P. 1.324, 2.285, 2.286, 2.287 Bollu, V. 1.342, 2.044 Bolton, J. 2.143 Bonanni, P. 2.122 Bond, T.C. 1.273, 1.287 Bonfert, M. 2.204 Bongardt, S. 3.294 Bonilha, L. 1.352, 2.004, 3.270 Bonito, J. 2.350, 3.136 Bonno, D.M. 1.125 Boon, P. 1.017, 1.067, 3.028, C.08 Bordey, A. 3.030 Borges, A.D. 3.165 Borggraefe, I. 2.204 Borghs, S. 2.219, 2.320, 3.295, 3.298 Bork, S.J. 2.333 Borlot, F. 1.112, 2.095 Borzello, M. 3.054 Bosler Walton, C. 2.006 Boudreau, E. 2.177, 2.269 Bouthillier, A. 2.123, 3.274, 3.370 Bowden, S.C. 1.279 Bower, M. 2.156 Bower Baca, C. 1.357 Bowman, C. 3.238 Bowyer, S. 1.151, 2.252 Boychuk, J. 1.027 Boyd, A. 2.320 Boyd, J. 3.306 Boyer, K. 2.017, 3.169 Boyle, M. 1.100 Bozarth, X. 3.099 Bozorg, A. 2.360, 2.361 Braesch, C.T. 1.278 Bragin, A. 1.177 Bramhall, M. 2.115 Brand, E. 3.302, A.08 Brandt, C. 2.059, 3.293 Braun, C.N. 3.040 Brazdil, M. 2.003 Brennan, G.P. 1.009 Brenton, J.N. 3.147 Brenton, N. B.06 Brewster, A. 3.048, 3.049, 3.050 Brewster, R. 3.344 Brickel, N. 2.318 Briggs, D. 2.131, 3.070 Brima, T. 1.305 Brinkmann, B. 1.175, 2.156, 3.071 Brittain, S.T. 1.337, 1.343, 2.329, 2.331 Britton, J. 1.374, 3.158, B.05 Brock, M. 3.291, 3.292, 3.299 Brodie, M. 1.331, 1.334, 1.335, 1.336 Brodtkorb, E. 2.282 Brooks, B. 2.271 Brooks-Kayal, A. 1.003, 3.003, 3.011, 3.031 Brosch, M. 3.045 Brouhard, G. 1.121 Brown, E.C. 3.062 Brown, M. 1.266 Brown, S. 1.209, 2.054 Brunner, P. 2.248, 2.255, 3.276 Brusco, S. 1.108 Bryant, T. 3.156 Bubolz, B. 3.061 Bubrick, E. 3.289 Buchanan, G. 1.049, 1.164, 3.030, Buchanan, R. 3.070 Buchfelder, M. 1.146, 1.346 Buchhalter, J. 1.276, 3.057, 3.137, 3.172, 3.327 Buchsbaum, R. 2.296, 2.312, 3.138 Buchtel, H. 2.030 Buckley, A. 3.166 Buckley, R. 3.368 Buckley, S. 1.228 Buckmaster, P. 1.014 Budech, C.B. 1.241 Buelow, J. 3.075, 3.321 Buentjen, L. 3.045, 3.058, 3.349 Buerki, S.E. 3.096 Bui, E. 2.232 Bujarski, K. 1.246, 1.286, 2.042, 3.080 Bukovskaya, Y. 2.322 Bulacio, J. 1.063, 2.249 Bulloch, A.G. 1.285, 2.071 Bunker, M.T. 1.375 Bunnenberg, A. 1.263 Burakgazi-Dalkilic, E. A.08 Burattini, J.A. 2.344, 3.372 Burch, E.A. 2.088 Burdette, D. 1.151 Burgess, G.G. 2.333 Burgess, R. 1.063, 1.144, 1.149, 1.240, 2.073, 3.359 Burgos, J. 1.333 Burianová, H. 3.281 Burkholder, D. 1.374, 3.158 Burn, S. 1.109 Burneo, J.G. 1.185, 2.032, 2.054, 2.313, 3.265, 3.277 Burns, M. 2.308 Burns, S. 1.061 Buroker, J. 1.353 Busatto, G. 3.076 Busch, R.M. 1.093, 1.099, 1.347 Butler, C. 1.027 Byars, A.W. 1.353 Byerman, B. 1.066 Byrne, R.W. 2.241 Byrnes, W. 2.320, 3.295, 3.296, 3.298, 3.299 Byun, J. 2.168, 3.196 Bzymek, K. 1.017 C Cabello, D. 2.360 Cabo López, I. 2.300 Caboclo, L. 3.332, 3.369, 3.374 Cabrera Kang, C.M. 3.203, 3.226 Cabrerizo, M. 3.192 Caetano, E.V. 2.119, 3.143 Cai, P. A.08 Cakmak, M. 2.129 Caller, T. 1.086, 1.286, 2.042 Calvert, S. 3.087 Calzado Rivas, E. 3.311 Cameron, D. 3.175 Cameron, J. 1.073 Camfield, C. 1.203, 2.223, A.04 Camfield, P. 1.203, A.04 Campbell, M. 3.134 Campos, B.M. 3.275 Campos Blance, D. 1.332, 3.309 Cances, C. 2.263 Candy, S.A. 3.124 Canevini, M. 2.184, 3.243 Canoll, P.D. 3.253 Caplan, R. 1.097, 1.252, 1.254, 2.018, 3.254 Cappelletti, S. 3.360 Cara, L. 1.168 Carbone, L. 1.096 Carlen, P. 1.010, 1.016, 3.008 Carlsen, J. 3.003, 3.031 Carlson, C. 2.148 Carlson, G. 1.075, 2.195 Carlson, H. 1.360 Carmona, H. 2.363 Carpenter, J. 1.182, B.06 Carrel, A.J. 3.003 Carrete Jr., H. 3.369 Carreño, M. 1.322, 2.278 CarrilloCarrillo, R. 2.186 Carruthers, N.J. 3.056 Carson, R.E. 2.332 Carvalho, K. 3.251 Carvalho, K. 3.312 Carver, C. 1.033 Carvill, G.L. 1.103, 3.087, 3.092 Cascino, G. 2.256, 2.337, 2.339, 3.158 ABSTRACT AUTHOR INDEX Chen, H. 1.013 Chen, J.J. 1.286, 2.042 Chen, P. 1.179, 2.014, 2.248, 2.253, 2.255, 3.276 Chen, S. 1.242, 2.135, 3.197, 3.285 Chen, T. 3.131 Chen, W. 1.062, 1.076, 1.164, A.02 Chen, X. 3.286 Chen, Y. 1.009 Chen, Z. 3.259 Cheng, H. 1.318, 1.322, 2.290, 2.292 Cheng, J. 2.216 Chern, C. 3.025 Cheshire, W. 3.238 Chevalier-Riffard, C. 1.190 Chez, M. 1.368 Chiang, S. 2.240, 2.247 Chiba, Y. 1.300 Chiesa, V. 2.184, 3.243 Chikako, O. 1.235 Child, N.D. 3.071 Chin, M. 2.080 Chin, R. 2.015, 2.072, 2.223, 3.129 Chin, R.F. 1.092 Chiti, L. 1.108 Chiyonobu, T. 1.116 Chlon, W. 3.351 Cho, K. 1.230 Cho, S. 1.087 Cho, Y. 1.202, 1.218, 1.230 Choe, M. A.09 Choezom, T. 3.136 Choi, H. 2.296, 2.312, 3.138 Choi, J. 1.195 Choi, S. 1.117 Choi, Y. 1.219 Chow, E. 1.066 Chrastina, J. 2.003 Chris, F. 3.325 Christensen, J. 2.266 Christian, E. 1.303 Christodoulou, C. 3.173 Christodoulou, J. 1.154 Chu, C. 3.054, Chu, J. 1.232 Chu, K. 2.168, 3.196 Chuang, S. 1.172 Chugani, D.C. 3.056 Chugani, H. 1.251, 2.167, 2.345, 3.056, 3.362 Chung, H. 1.234 Chung, J. 1.126, 2.227 Chung, J.M. 2.181 Chung, S. 1.111, 1.316, 1.319, 2.288 Chung, S.S. 1.198, 1.199, 1.200, 1.201, 1.307, 1.308, 1.334, 1.335, 1.336, 2.211, 2.280, 2.281, 3.291, 3.292, 3.304 Chung, W.K. 2.275, 3.081, 3.135 Ciechanowski, P. 2.039 Cieza, S. 2.153 Cilio, M. 2.146, 2.309, 3.303 Cimbalnik, J. 1.175, 2.156, 3.071 Cinar, N. 2.129 Ciricillo, S. 1.368 Ciurea, J. 1.191, 3.069 Clark, A.M. 1.307, 1.308, 2.280, 2.281, 2.284 Clark, C. 2.033, 2.047 Clark, D. 3.087 Clark, M. 3.050 Clark, S. 2.050 Clarke, D.F. 2.354, 3.070, 3.351 Claus, R. 1.315, 1.316, 1.317, 1.323, 2.278 Claycomb, K. 1.049, 3.030 Cleto Dal-Cól, M. 3.055 Clossen, B. 1.032 Coan, A. 3.076, 3.082, 3.259, 3.260, 3.275 Cobia, M. 2.115 Cohen, D.L. 2.012, 3.209 Cohen, G. 2.031 Cohen, J. 2.138 Cohen, J.W. 2.302 Cohen, M.S. 1.278 Cohen, N. 1.257, 2.286 Colciaghi, F. 3.029 Cole, A.J. 1.314 Coleman, M. 1.085 Coley, A.A. 3.041 Collon, K. C.02 Colón-Zimmermann, K. 1.084 Coman, D. 1.041 Comi, A. 3.051 Concha, L. 3.261 Condie, J. B.06 Congedo, B.A. 1.284 Conner, C. 3.060 Connolly, M. 2.040, 3.096, 3.220, 3.327 Connors, R. 1.057 Conry, J. 2.351 Constable, T. B.01 Constantinou, J. 1.151, 2.215 Conti, V. 1.108 Cook, M. 1.227, 1.232 Cooper, E.C. 3.017, 3.210 Corallo, K. 1.082 Cordeiro, M. 1.137 Cornett, K. 2.194 Correa, B.J. 2.119, 3.143 Corso, J.T. 2.327 Cortes de Oliveira, J. 3.055 Coryell, J. 3.223 Cossette, P. 3.093, Cossu, M. 2.184 Costa, F.A. 2.119, 3.143 Costas, K. 3.325, 3.326, 3.334 Costel, J. 2.313 Cothros, N. 2.054 Cotten, J. 1.023 Coulter, D. C.06 Couture, D. 2.256, 2.337, 2.339 Couture, R.L. 3.016 Couturier, N. 3.339 Covington, T.M. 2.074 Craddock, R.C. 2.246 Crail Melendez, D. 2.334 Craiu, D. 3.092 Cramer, J.A. 1.273, 1.287 Crawford, J. 3.241 Crawford, P. 3.126 Crawley, A. 3.200 Crespel, A. 2.226 Crino, P. 3.302, Crino, P.B. A.08 Cristofaro, S. 2.173 Crocker, C. 2.171 Crompton, D.E. 1.120, 3.088 Crone, N. 1.174, 1.353, 2.025, 3.064 Cross, J. 1.190 Crowder Skarpaas, T. 1.216, 2.212 Crowley, M.J. B.01 Cruickshank-Quinn, C. 3.066 Cruz, E. 1.132, 1.142, 2.162 Cruz Del Angel, Y. 1.003, 3.003, 3.011 Cukier, Y. 2.011, 2.029 Cukiert, A. 2.342, 2.343, 2.344, 2.363, 3.350, 3.372 Cukiert, C.M. 2.344, 2.363, 3.372 Cukovic, D. 3.056 Culver, C.B. 2.038, 3.083 Cummins, T.R. 1.294 Cunningham, C. 1.076 Cunningham, C.E. 1.100 Curatolo, P. 2.187 Curry, D. 2.347, 3.353, 3.358, 3.371 Cushner-Weinstein, S. 3.141 Cusick, M.F. 3.117 Cutmore, C. 3.088 Cutter, G. 2.161, 2.163 Czech, T. 1.137 D D’Alfonso, S. 1.276, 3.327 D’Ambrosio, R. 1.372 D’Souza, J. 2.219, 2.332, 3.300 D’Souza, W. 1.227, 1.232, 1.279 Da Rold, M. 2.122 Dabbs, K. 1.169, 3.267, 3.270 Dabscheck, G. 2.143 Dagam, J. 1.333 Dahlin, M. 2.187 Dalgard, C. A.08 Dalvi, N. 2.101, 2.120 Damaj, L. C.01 Damera, S. 2.010 Damiano, J.A. 1.120 Damisah, E. 3.074 Daniels, D. 3.209 Danny, L. 1.231 Danzer, S. 3.010, 3.120 Danzer, S.C. 1.048 Das, N. 2.221 Das, S. 3.256 Dauwe, I. 3.028, C.08 Dave, H. 2.107, 3.219, 3.225, B.02 Davis, A. 2.233, 2.234 Davis, A.M. 1.100 Davis, E.C. 1.278 Davis, G.G. 2.070 Davis, K. 1.242, 2.135, 3.183, 3.256, 3.284 Davis, K.A. 1.266, 3.167, A.08 Davis, R. 2.057, 2.311 Dawe, R. 1.074 Dawkins, R. 3.348 ABSTRACT AUTHOR INDEX Cash, S. 3.054 Cash, S.S. 1.018, 3.164 Castelnau, P. 2.263 Castillo, A. 1.332 Castillo, E. 1.179, 2.014, 2.248, 2.253, 2.255, 3.276 Castillo, R. 1.341 Castro, C. 1.295 Castro, C.X. 3.076 Catterall, W. 3.340 Cavalleri, G. 1.248 Cavaretta, J. 1.234 Cavazos, J. 3.206 Cavitt, J. 2.228 Cawello, W. 2.283, 3.290 Caylor, L. 2.039 Ceiki Sakamotob, A. 3.055 Ceja Moreno, H. 3.295 Celegen, K. 3.328 Celegen, M. 3.328 Cendejas, L. 1.074, 2.085 Cendes, F. 1.319, 1.377, 3.259, 3.260, 3.275 Centeno, R. 3.369, 3.374 Cerqueira, P.B. 2.119, 3.143 Cerven, S. 1.198, 1.199, 1.200, 1.201 Cervenka, M. 1.174, 3.189, 3.191, 3.318, B.07 Cha, B. 2.083 Chabardes, S. 1.191, 1.348 Chabrol, T. 1.039 Chachua, T. 3.025 Chadehumbe, M. 2.016, 3.094 Chadwick, E. 3.044 Chae, J. 1.119, 1.195 Chagin, K. 1.377 Chan, S. 1.190 Chan, V. 1.208 Chandler, D.S. 3.122 Chandra, S. 2.365 Chang, B.L. 3.221 Chang, B.S. 1.154 Chang, C.W. 3.221 Chang, E. 1.369 Chang, T. 1.136, 1.137 Chanlaw, T. 3.249 Chansard, M. 1.030 Chanteux, H. 2.310 Chapa Davila, J. 2.126 Chapman, B. 2.112 Chapman, K. 1.098, 1.182, 1.326, 1.345, B.06 Charpier, S. 1.039 Chassoux, F. 2.226 Chauvel, P. 1.377 Chavez, G. 1.155 Chavez-Hassan, F. 2.334 Chaytor, N. 2.039 Chea, K. 2.262 Chekhovtsov, I. 1.075 Chemali, Z. 2.008 Chen, B. 1.262, 2.312, 3.138 Chen, C. 2.297 Chen, D.K. 1.089 Chen, E. 1.076 Chen, F. 3.002 95 ABSTRACT AUTHOR INDEX Day, B. 3.032 Dayyoub, T. 2.215 Dazzo, E. 1.113 De, G. 1.342 De Backer, M. 2.320, 3.291, 3.292, 3.294, 3.295, 3.296, 3.297, 3.298, 3.299 De Benedictis, A. 3.360 de Grauw, A. 2.185 de Grauw, X. 2.185 De Jonghe, P. 1.115 de Kam, M.L. 2.307 De Koninck, Y. 3.022 de la Pena, C.B. 2.230 de Lanerolle, N. 3.072 de Melo-Souza, S.E. 2.274, 3.199 de Paula, V.D. 1.122 De Toffol, B. 2.226 de Vincentiis, S. 2.274, 3.199 de Vries, P. 2.187 Dean, N. B.06 DeBello, R. 2.053, 3.205 DeCoster, C. 2.051 Dedeken, P. 2.320, 3.293, 3.295, 3.296, 3.298 del Prete, A. 1.020 Delalande, O. 3.360 Delanty, N. 1.248 Delazer, M. 2.245 Delbeke, J. 3.028, C.08 Deleo, F. 2.184 Delgado-delaMora, J. 3.154 DeLorenzo, R. 1.026 Demos, M. 3.096 Demuth, D. 3.126 Denny, D. 1.198, 1.199, 1.200, 1.201 Deo, A.K. 2.332 Depaulis, A. 1.039 Depienne, C. 1.118 Depondt, C. 1.141 Depositario-Cabacar, D. 1.354, 2.351, 3.141, 3.355, 3.364 Derambure, P. 2.226 Dergalust, S. 2.322 Derry, R. 1.096 Descamps, B. 3.028 Deshpande, L. 1.026 Desnous, B. 1.055, 1.056 Desrochers, J.A. 2.160 DeStefino, V. 1.073 Detyniecki, K. 2.176, 2.296, 2.312, 3.136, 3.138, Devinsky, O. 1.123, 1.133, 1.262, 2.007, 2.033, 2.170, 2.309, 3.057, 3.095, 3.137, 3.303, DeVries, S.P. 3.167 Dewar, S. 2.336, 3.217 Dhaher, R. 1.041, 3.074 Dhakar, M. 3.174, 3.232 Dhamne, S.C. 3.044 Diaz, F. 1.324, 2.285, 2.286, 2.287 Diaz, M. 2.222 Diaz-Medina, G. 1.139 Dibbens, L.M. 3.089 DiCaccio, B. 2.155 Dickens, D. 2.235 Dickerson, B. 2.008 Dickstein, L. 1.002 96 Didato, G. 2.184 Diehl, B. 1.057 Dike, N. 3.133 Dilley, C. 2.033, 2.047 Dilley, D. 2.320 Dimova, S. 3.291, 3.292, 3.299 Ding, K. 2.038, 2.189, 2.193, 3.083 Ding, L. 3.015 Ding, Y.S. 1.262 Dingledine, R. 3.116 Dionisio, A. 1.058, 1.153 Divino, V. 2.044 Dixon-Salazar, T. 3.095 Dlugos, D. 1.182, 3.095, 3.201, Dobesberger, J. 3.228 Dobrinsky, C. 2.276, 2.279 Dobrzeniecka, S. 3.093 Dobyns, W. 1.043, 3.099 Doesburg, S. 1.145 Doesburg, S.M. 3.153 Doescher, J. 2.235 Doggett, K. 3.296 Doherty, C. 1.248 Doherty, J. 1.296, 1.303 Dokgoz, O. 1.229, 3.328 Dolce, A. 2.347 Dombkowski, A.A. 3.056 Donahue, D. 2.250 Donatti, A. 3.123 Donner, E. 2.353, 3.057, 3.137, 3.239 Donner, E.J. 1.208 Donohue, K.D. 1.071 Donohue, M.M. 3.257 Donos, C. 3.069 Dorland, N. 2.148 Doshi, C. 2.213, 3.202, 3.235 Doss, J. 1.094, 2.021 Doss, R. 1.080, 2.026, 2.046 Doucet, G. 1.255, 2.237 Dove, C. 1.185 Drake, J. 1.172, 2.353 Drane, D. 1.352, 3.344 Drazkowski, J. 2.139, 2.166 Drees, C. 2.053, 3.205, 3.304 Drouin, N. 2.239 Du, X. 3.005 du Plessis, D. 1.109 Dualibi Ramos Valente, K. 2.274, 3.199 Dubeau, F. 1.121, 1.259, 2.358, 3.161, 3.163, 3.184, 3.185 Dubey, D. 2.189 Dubroff, J.G. 1.266 Duchowny, M. 2.346 Duckrow, R. 1.062, 1.156, 1.216, 2.151, 2.212 Dudek, F. 1.161, 1.166, 3.038, 3.043, 3.047 Dudley, R.W. 1.267, 3.279 Duempelmann, M. 1.129, 1.167 Duffy, F. 3.194 Dufour, S. 1.016, 3.008 Dulla, C. 3.125, Dumpelmann, M. 2.180 Duncan, R. 1.109 Dunn, D. 2.018 Dunn, M. 2.235 Dupuis, N. 1.055, 1.056 Durand, D. 1.019, Durgin, T. 2.058, 2.297, 3.130 Dustin, I. 1.002, 3.065, 3.084, 3.278 Duveau, V. 1.039 Duwell, E. 2.192 Dworetzky, B. 1.281, 1.324, 2.213, 2.236, 2.285, 2.286, 2.287, 3.235, 3.289 Dykstra, H. 2.074 Dzhala, V. 1.021, 3.022 E Eb, A. 1.275 Eberle, M. 2.238 Eberly, L.E. 1.272 Ebril, M. 1.188 Eckhardt, K. 3.294, 3.300 Edagawa, K. 2.357 Edakawa, K. 1.060 Edmonds, B. 2.248, 2.255, 3.276 Egawa, K. 1.021, 2.174 Egge, A. 3.366 Eichel, R. 3.197 Eichstaedt, K.E. 2.361 Eid, T. 1.041, 3.074 Eidelman, O. A.08 Einarsdottir, A. 3.128 Eisenschenk, S. 2.212 Eksioglu, Y. 2.268, 3.103, 3.194, 3.357, 3.363 Ekstein, D. 1.302, 2.175, 3.063, 3.197 Ekstrand, J. 3.043 Ekstrom, A. 1.078 El Tahry, R. 1.067 El-Hagrassy, M. 2.268 Elder, E. 1.324, 2.285, 2.286, 2.287 Elger, C. 1.067, 1.316, 1.320 Eliashiv, D. 2.227, 2.321, 2.336 Eliassen, J.C. 1.257 Elledge, D. 2.299 Ellingson, B. 1.238, 1.245, 1.261 Elliott, C.A. 3.261 Elmenshawi, I. 2.272 Elmoufti, S. 2.219 Elsayed, M. 2.255, 3.276 Emch, T. 3.257 Emerson, R. 1.057, Emery, E. 3.084, 3.278 Enatsu, R. 1.063 Endres, J. 2.085 Engel, J. 1.278 Engel, M. 2.221 Englot, D.J. 1.369 Enoki, H. 1.371 Entz, L. 1.157 Eom, S. 1.097 Eom, T. 2.220 Epi4K/EPGP, C. 1.114 Epstein, J. 2.236 Erdinc, O.O. 3.305 Escalaya, L. 2.313 Escartin, A. 3.295, 3.298 Escayg, A. 1.046, 3.106 Escoffery, C. 3.075 Esfahanizadeh, A. 3.208 Eskandar, E.N. 1.018 Eslamy, H. 1.250 Espaillat Solano, L.M. 2.186 Espaillat Solano, L.M. 2.334 Espinera, A. 3.203 Espinoza López, D.A. 3.154 Ess, K. Ettinger, A.B. 2.276 Eun, B. 3.308 Euroepinomics-Res, C. 1.114 Evans, C. 2.324 Evans, J. 1.255 Evans, S. 2.318 Evrard, C. 2.269 Eyal, S. 3.063 Eydoux, P. 3.096 F Faber, A. 2.040 Fabo, D. 1.157 Fabris, R. 3.148, 3.158 Fain, R. 2.276, 2.288 Faingold, C. 1.023, 1.034, Faizo, N.L. 3.281 Fakhoury, T. 1.312, 3.300 Fallil, Z. 1.157, 2.246 Fang, L. 3.310 Fant, R.V. 2.279 Farah, J. 1.109 Faria, L. 1.299 Farlow, D.C. 3.286 Farmen, A. 2.231 Farooque, P. 2.350, A.02 Farrell, K. 3.220 Farwell Gonzalez, K.D. 1.194 Fasano, A. 1.112 Faught, E. 2.047, 2.219, 3.130, 3.294, 3.299 Faught, R. 2.339, 3.344 Faulkner, M. 2.041 Fauth, C. 2.169 Fayed, N. 1.100 Federico, P. 1.264, 2.067, 3.139, 3.186 Feeney, E. B.01 Fehr, K. 2.270 Feldstein, N. 3.233 Felton, E. 3.318 Feng, H. 1.023 Feoli, E. 1.131 Ferastraoaru, V. 2.180 Fergnani, V. 3.243 Ferguson, A. 3.220 Ferguson, L. 1.093, 1.099, 1.347 Ferguson, R.J. 1.086 Fernald, B. 2.256, 2.337 Fernandes, A. 3.123 Fernandez, A. 1.062, 3.342 Fernandez, G. 1.106 Fernandez, L.D. 3.333 Ferrari-Marinho, T. 3.161, 3.184, 3.185 Ferrazzano, P. 1.169 Ferreira, J. 1.101, 2.187 Ferro, M. 2.223 Ferrrari, L. 1.162 Ferry, J. 2.295 Fertig, E. 1.131, 1.140, 2.230 Fesler, J.R. 2.349 Fessler, A. 1.125 ABSTRACT AUTHOR INDEX Frost, Jr., J.D. C.04 Fu, A. 1.198, 1.199, 1.200, 1.201 Fuerst, D. 3.062 Fujikawa, M. 2.060, 2.132, 2.149 Fujimoto, A. 1.371 Fujinami, R.S. 3.117 Fujita, K. 1.220 Fujita, M. 1.002 Fujita, S. 1.014 Fujiwara, H. 1.152, 1.353 Fukasawa, T. 1.243 Fukumizu, M. 2.202 Fuller, P.M. 1.162 Funck, V. 1.295 Fung, E. 3.327 Fung, S.H. 2.254 Furman, M. 1.164 Fusco, L. 3.360 G Gabelia, D. 2.262 Gabr, R.E. B.03 Gabrieli, J.D. 1.154 Gaddam, A. 2.208 Gaddam, S. 2.215 Gadeyne, S. C.08 Gadhoumi, K. 1.178 Gaik-Siew, C. 1.105 Gaillard, W. 1.354, 2.142, 2.351, 3.141, 3.144, 3.268, 3.272, 3.278, 3.355, 3.364, B.06 Gaitanis, J. 3.073 Galanopoulou, A.S. 1.304, 1.305, Galimberti, C. 1.316 Gallagher, M. 3.015 Gallentine, W. 1.182, 2.194, 3.095 Galloway, G. 3.281 Gama, H. 1.315, 1.316, 1.317, 1.323, 2.278 Gandomi, S. 1.194 Gangisetty, O. 1.033 Gano, L.B. 3.066 Gao, J. 1.155 Garces, M. 1.332 Garcia, P. 1.369 Garcia, R. 1.295 Garcia Gracia, C. 2.073 Garcia-Cairasco, N. 3.055, 3.123 Garcia-Ramos, C. 3.267 Gardella, E. 1.118 Gardiner, E. C.07 Garg, A. 2.032, 2.365 Garg, K. 2.365 Garg, M. 3.249 Garrido, E. 1.295 Garrity, L. 2.229 Garson, A. 3.051 Garzon, E. 3.179 Gaspard, N. 1.135, 2.151, 3.203, 3.204, 3.226 Gaston, T. 1.236 Gaston, T.E. 1.247, 1.249 Gattaz, W.F. 1.122 Gattone, J.M. 3.321 Gautier, N. 3.107 Gavrilovici, C. 1.030 Gaxiola Valdez, I. 1.264 Gebre, R. 1.076 Gedela, S. 2.159, 3.331, 3.333 Gedzelman, E. 2.339 Gelfand, M. 3.284 Geller, E. 2.212 Geng, B. 1.062 Genov, R. 1.010 George, M. 3.040 George, S. 3.051 Gerard, E. 3.203, 3.226 Gerin, B. 2.310 Germeyan, S.C. 3.084, 3.268, 3.278 Gernert, M. 1.069, 1.070 Gerrard, J. 1.156, 2.151 Gersner, R. 1.158, 1.302, 3.337 Gerstl, L. 2.204 Gey, L. 1.070 Ghani, A. 1.255, 2.237 Ghassemi, A. 1.368 Ghatan, S. 3.356 Ghearing, G. 2.147, 2.157, 3.227 Gholipour, T. 2.113 Giarratano, M. 1.340 Gibson, K.M. 3.065 Gibson, M. 1.225 Gidal, B. 1.324, 2.284, 2.285, 2.286, 2.287 Gidal, B.E. 2.295 Gilbert, T. 1.263 Gilby, K. 1.047 Gill, D. 3.092 Gilliam, F. 3.336 Gilmet, G. 3.336 Gilmore, E. 1.135, 3.204 Giordano, M. 3.233 Girard, J. 2.017, 3.169 Gireesh, E. 3.064 Girouard, M. 3.206 Giza, C. 1.182, A.09 Gizewski, E. 2.245 Glaser, C. 3.241 Glass, H.C. 1.136 Glasscock, E. 3.107 Glauser, T. 2.024, B.06 Glaze, D. 3.104 Glessner, J. 3.099 Glielmi, C. 1.262 Gliske, S. 3.067 Glykys, J. 1.021 Glynn, S. 2.030, 3.040 Go, C. 1.127, 1.172, 1.189, 2.353, 3.306 Gobbi, G. 2.018 Godard, A. 3.046 Goel, M. 2.365 Gofton, T. 3.203, 3.226 Gokyigit, A. 1.128, 2.183, 2.224 Golby, A. 2.025 Gold, D. 3.231 Gold, J. 2.104, 3.241 Goldberg, E.M. C.06 Goldberg-Stern, H. 3.090 Goldenholz, D. 1.065, 3.278 Goldenholz, D.M. 2.356 Goldenstein, L. 3.233 Goldie, J. 1.158 Goldman, A. 2.222 Goldman, L. 2.301 Goldschmidt, Y. 2.033 Goldsmith, J. 2.275, 3.081, 3.135 Goldstein, D. 3.095 Goldstein, J. 1.182, B.06 Goldstein, S. 3.324 Gómez Ramírez, M. 3.154 Gommer, E. 1.138 Goncharova, I. 2.151 Gong, H. 3.345 Gonsalves, C. 2.110 Gonzales, E. 1.274, 1.356 Gonzalez, F.L. 3.309 Gonzalez, M. 3.237 Gonzalez-Crespo, S. 3.101 Gonzalez-Martinez, J. 1.058, 1.063, 1.153, 1.240, 1.347, 1.362, 1.377, 2.249 Gonzalez-Sepulveda, L. 3.101 González de la Aleja, J. 1.332 Good, L. 1.054 Goodkin, H. 1.028, B.06 Goodrich, G.S. 3.009 Goodwin, S.W. 3.134 Gordon, C.M. 1.375 Gorelik, D. 2.301 Gospe, S.M. 1.241 Goswami, S. 2.041, 2.098 Gotman, J. 1.171, 1.178, 1.259, 2.358, 3.121, 3.161, 3.163, 3.184, 3.185, Gowda, A. 2.256 Goy, E. 2.269 Goyal, A. 1.022 Gozzo, F. 2.184 Grabenstatter, H.L. 1.003, 3.003 Graf, S. 2.102 Graham, A. 2.058 Granbichler, C. 2.068 Grant, A.C. 1.085, 3.181 Grant, E. 3.202 Gray, E. 3.126 Gray, M. 3.281 Greenberg, D.A. 3.122 Grefe, A. 2.210 Greiner, H. 1.152, 1.353, 2.352 Griffin, N.G. 3.113 Griffiths, C. 3.059 Grigg-Damberger, M. 3.171 Grinspan, Z. 2.043, 2.055, 2.221 Groomes, L. 2.025 Groppe, D. 1.157, 2.246, 3.177, 3.346 Gross, D. 3.259, 3.260, 3.261 Gross, D.W. 1.253 Gross, R. 1.349, 2.212, 2.256, 2.337, 2.339, 3.344 Grote, C.L. 3.264 Grouiller, F. 2.244 Grova, C. 2.239, Gu, B. 1.006 Gu, F. 1.299 Guan, Y. 3.352 Guaranha, M.B. 3.251 Gubernale, M. 2.122 Gudbranson, E. 1.062, 1.076 Gudlavalleti, A. 3.155 ABSTRACT AUTHOR INDEX Feucht, M. 2.187 Feyissa, A.M. 3.269 Ficker, D. 2.285, 2.286, 2.287 Fiedler-Kelly, J. 1.312, 1.314, 1.319, 1.320, 1.321 Field, S.A. 2.298, 2.305 Fiest, K. 2.071 Fiest, K.M. 1.285 Filippi, C. 1.057 Finardi, A. 3.029 Fine, A. 2.203 Finger, L. 2.107 Finn, C. 1.286 Finn, R. 3.329 Finnell, R. 3.053 Fiol, M. 2.206 Fischer, J. A.09 Fisher, E. 2.019 Fisher, J. 3.200 Fisher, R. 1.068, 3.073, B.07 Fishman, J. 2.031 Fisk, K. 3.051 Fitzsimons, M. 1.248 Flanagan, P. 1.153 Flashman, L. 3.080 Fleming, M. 2.092, 2.230 Fletcher, L. 2.050 Fleury, A. 2.186 Flores, J. 1.332 Fonseca, N. 1.122 Ford, L. 1.309 Foreman, B. 3.203, 3.226 Foreman, P. 2.200, 3.162 Foreman, P.J. 2.257 Forgacs, P.B. 2.105 Forman, S. 1.023 Forman, S.D. 1.284 Foroughi, A. 2.200, 3.162 Forsythe, A. 3.301 Fountain, N. 1.209, 2.081 Fowles, K. 2.332 Franaszczuk, P. 1.174 Francois, D. 2.268 Francomacaro, S. 3.001 François, C. 1.334, 1.335, 1.336 Fraser, R. 3.078, 3.127 Fraser, R.T. 2.039 Frasier, C.R. C.02 Frauscher, B. 2.121, 2.262, 3.161, 3.163, 3.184, 3.185 Freedman, D. 2.250 Freeman, J.L. 3.087 French, C. 1.231 French, J. 1.318, 2.007, 2.176, 2.233 Frey, L. 2.053, 3.031, 3.205, 3.304, 3.320 Freyer, C. 2.173 Fried, I. 1.177 Friedman, D. 2.007, 2.142, 2.170, 2.309, 3.057, 3.137, 3.303 Friedman, K. 1.262 Friedman, S.D. 1.241, 3.280 Frigerio, F. 1.020 Fritz, P. 2.033, 2.047 Frndova, H. 3.059 Frohlich, F. 1.159 Frost, M. 2.235, 2.270 97 ABSTRACT AUTHOR INDEX Guekht, A. 2.076 Guenot, M. 1.348 Guerreiro, C. 3.076, 3.082 Guerrini, R. 1.108 Guess, M. 3.156 Gugler, K. 2.133, 2.137 Guilfoyle, S. 1.090, 1.091 Guilhoto, L.M. 3.251 Guimaraes, M.D. 3.374 Guiraud-Diawara, A. 1.334, 1.335, 1.336 Gulsen, G. 3.270, 3.283 Gulyaeva, N. 2.076 Gummadavelli, A. 1.044, 1.164 Gunasekara, R.C. 2.268 Guo, A. 1.213 Guo, D. 1.024 Guo, J. B.01 Gupta, A. 1.144, 1.362, 3.359 Gupta, N. 3.173 Gupta, P. 2.038, 2.189, 2.193, 3.083 Gupta, R.K. 2.125 Gupta, V. 3.343 Gupta, Y.K. 1.022 Gurbani, S. 1.252, 1.254, 3.254 Gurkoff, G. 1.078 Gurme, M. 2.321 Gurses, C. 1.053, 1.128, 2.183, 2.224 Gusev, E. 2.076 Gustafson, M. 2.133, 2.137, 3.335 Guttuso, T. 2.125 Guzel, O. 3.328 Guzman, L. 3.237 Gwinn, R. 2.212 H Haas, K. 1.327, 2.160, 3.203, 3.226 Hader, W. 1.360, 2.082 Haginoya, K. 1.367 Haglund, M. 3.113 Hahn, C. 1.182, 3.059 Haider, Z. 3.126 Hajek, M.A. 1.049 Hakami, T. 1.231 Hakimi, A. 2.034 Hakonarson, H. 3.090, 3.099 Halford, J.J. 2.160 Hall, A. 3.335 Hall, J. 2.239, 2.340 Halliday, W. 3.108 Hallinan, B. 3.324 Halvorsen, M.B. 1.307, 1.308 Hamano, S. 1.365 Hamberger, M.J. 2.027 Hamdan, F.F. 3.093 Hameed, M.Q. 3.009, 3.044 Hamer, H. 1.146, 1.346 Hamid, H. 2.059 Hammond, N. 2.111 Hammond, R. 1.296, 1.303 Han, H. 1.218 Han, J. 1.313 Han, R. 1.372 Han, S. 1.218 98 Hanai, S. 3.114 Hanaya, R. 1.265, 2.002 Handler, M. 1.267, 2.103, 3.279 Handreck, A. 1.069 Haneef, Z. 2.240, 2.247 Hani, A.J. 2.194, B.06 Hannestad, J. 2.332 Hanson, A. 2.067, 3.139 Hanson, M. 1.333 Hanson, R. 2.085 Hanusa, B.H. 1.284 Hanáková, H. 1.051 Haque, O. 1.355 Hara, K. 2.091, 2.093, 2.097 Hara, M. 2.091, 2.093, 2.097 Harada, Y. 1.370 Harden, C. 1.157, 2.011, 2.029, 2.092, 2.233, 2.246, 2.256, 2.339, 3.053 Hardin, K. A.06 Haridas, B. 2.055 Harini, C. 1.098, 2.196, 3.169, 3.236 Harkness, W. 2.342, 2.343, 3.350 Harnod, T. 3.271 Harrell, E. 2.131 Harrington, C. 2.318 Harrington, J. 1.086, 2.033, 2.042 Harris, D. 2.124 Harris, K. 1.137 Harris, R. 1.238, 1.261 Hart, S. 1.306 Hartl, E. 2.165, 3.211, 3.273 Hartman, A. Harvey, A.S. 3.087 Harvey, D.W. 2.152 Harvey, J. 1.068, 1.312, 1.319, 2.290 Harward, S.C. 1.269 Hasbani, D. 3.312 Hasegawa, H. 3.149 Hashizume, A. 1.265, 2.359 Hastings, W. 1.341 Hauser, A. 2.076, 3.140 Haut, J. 1.093, 1.099 Haut, S. 2.176, 3.231 Haut, S.R. 2.180 Havens, K. 2.351, 3.141, 3.355, 3.364 Hawasli, A.H. 1.376 Hawkins, C. 1.189 Hays, R. 2.038, 2.189, 2.193, 3.083 He, B. 1.268 Heath, J. 2.124 Heck, C. 1.216, 2.212, 3.373 Hecox, K. 1.173, 3.215 Hedlund, J. 2.309, 3.303 Hedrick, N.G. 1.269 Heers, M. 1.167 Hegde, M. 3.201 Heier, L.A. 2.221 Heinen, F. 2.204 Heinze, H. 3.045, 3.058, 3.349 Heinzen, E. 3.095, 3.113 Heischmann, S. 3.066 Heiss, J. 1.150 Helbig, I. 1.115, 3.090, 3.099 Helmers, S. 2.047, 2.339, 3.130 Helmstaedter, C. 1.283 Hempstead, B.L. 3.011 Hemza, J. 2.003 Henegan, P.L. 1.086 Hennessy, R. 2.176 Henning, O. 2.317, 2.326 Henry, B. 3.318, B.07 Henry, T. 3.190 Heo, K. 1.218, 1.230 HEP Investigators 2.173, 2.176, 3.201 HEP MRI Core 3.258 Herbillon, V. 2.263 Herekar, A. 1.216, 2.209 Herman, J.P. 3.010 Herman, S. 1.205 Hermann, B. 1.169, 2.004, 2.023, 2.218, 3.267, 3.270 Hernandez, A. 2.250 Hernandez Ronquillo, L. 1.228 Hernandez Ruiz, A. 3.154 Hernando, K. 1.236, B.09 Hertzberg, C. 2.187 Hervas Navidad, R. 3.311 Hesdorffer, D. 2.070, 2.275, 3.057, 3.081, 3.135, 3.137, 3.140 Heshmati Moghaddam, M. 3.097 Hevner, R. 1.250 Heyer, G.L. 3.157 Heyse, H. 1.257 Hibbard, K. 2.024 Hickey, F. 3.209 Higdon, L. 2.147 Higo, T. 1.363, 1.370, 3.012 Hildebrand, M.S. 1.120 Hilkman, D. 1.138 Hill, C. 2.135, Hines, D. 2.297 Hinn, A. 2.057 Hino-Fukuyo, N. 1.367 Hira, J. 2.246 Hirai, S. 1.116 Hirata, M. 1.060, 2.357 Hirata, Y. 1.238, 1.245, 1.261, 3.255, 3.262 Hirose, S. 1.365 Hirose, Y. 2.093 Hirsch, E. 2.226 Hirsch, L. 1.062, 1.135, 1.156, 2.151, 2.296, 2.312, 2.350, 3.136, 3.138, 3.203, 3.204, 3.226, A.02 Hirvonen, J. 1.002 Hitchens, T. 3.072 Hixson, J. 2.058, 2.176 Hiyoshi, T. 3.216 Hjalgrim, H. 1.118 Ho, A.W. 3.172 Hoang, K. 2.034 Hoch, D. 2.045 Hochberg, L.R. 1.018 Hocking, J. 3.281 Hoegl, B. 2.262 Hoerth, M. 1.082 Hofer, M. 2.262 Höfler, J. 3.228 Hoffmann, D. 1.191, 1.348 Hogan, R. 1.307, 1.308, 1.376, 2.280, 2.281, 3.336 Holden, D. 2.332 Holland, K. 1.353, 3.247 Hollen, C. 2.034 Holley, A. 1.292, C.07 Holmes, M.D. 1.180, 3.187, 3.193 Holt, R. 3.178 Holtkamp, M. 3.058, 3.349, A.03 Homa, K.A. 1.286 Honda, R. 1.147, 1.359, 1.361, 2.225, 2.341 Hong, J. 1.002 Hong, L. 3.113 Hong, S. 1.087 Hong, S. 1.130, 1.365, 2.207, B.04 Honig, A. 3.197 Hope, C. 1.111 Hope, O. 2.037 Hori, J.M. 1.278 Horiuchi, K. 3.205 Horn, P. 2.352, 3.111, 3.324 Hosain, S.A. 1.134 Hosford, B. 3.120 Hosny, H. 2.217 Hosoyama, H. 2.002 Hou, W. 3.104 Howard, M. 1.079, C.05 Howard, T. 2.215 Howe-Martin, L. 2.038, 3.083 Howell, K. 3.087 Hrachovy, R.A. C.04 Hsieh, C. 2.094 Hsieh, L.S. 3.030 Hsieh, T. 3.009 Hsin, Y. 3.195, 3.271 Hsu, D. 1.169, 2.023, 3.267, 3.270 Hsu, M. 1.169, 2.238 Hsu, S. 1.351 Huang, C. 2.094, 3.271 Huang, S. 2.289 Huang, Y. 1.006, 1.041, 1.253, 2.332 Hubbard, J.A. 3.119 Huber, P. C.07 Huckins, S. 3.363 Hudgens, S. 3.301 Huiskamp, F. 2.145 Hulette, C. 3.113 Hummelova, Z. 2.003 Hunt, M. 2.206 Hunter, M. 1.092, 2.015 Hur, E.E. 2.303 Husain, A. 2.036, 2.048, 2.077 Hussain, S.A. 2.108, 2.355, 3.157, 3.222, 3.330 Hussein, Z. 2.295 Huynh, J. 2.233 Hwang, D. 2.029 Hwang, E.S. 1.278 Hwang, H. 1.119, 1.195, 1.212 Hwang, K. 1.087, 2.207 Hwang, S. 1.157, 2.011, 2.246 Hwang, Y. 1.119, 1.195, 1.212 Hyder, F. 1.041 ABSTRACT AUTHOR INDEX I J Jabo, B. 3.146 Jack, S.M. 2.065 Jackson, D. 1.169, 2.023, 3.267, 3.270 Jackson, G. 2.243, 3.287 Jackson, G.D. 1.120 Jackson, M. 1.329, 2.213, 3.235, B.06 Jacobs, J. 1.129, 1.167, 2.358, 3.068 Jacobson, M. 1.318 Jaffe, D.B. 1.165 Jähn, J. 1.115 Jain, M. 2.085, 2.241 Jain, S. 2.352 Jaisani, Z. 1.240 Jalota, A. 2.241 Jan, M.M. 3.323 Jang, S. 1.163 Janio, E.A. 1.278 Janke, K. 2.011, 2.029 Janousek, J. 2.301 Jansen, A. 2.187 Janz, D. A.03 Jasinski, T. 2.197 Javors, M.A. 3.052 Jayabal, V. 1.148 Jayakar, P. 3.192 Jayakar, R. 3.344 Jefferys, J. 3.036 Jehi, L. 1.226, 1.347, 1.362, 1.377, 2.073 Jehle, R. 3.231 Jenko, K. 1.002 Jenner, M.R. 3.307 Jensen, F. 3.001, 3.007, 3.041 Jensen, J. 1.352 Jenson, K. 1.180, 3.193 Jeon, J. 1.202 Jeong, J. 1.251 Jepsen, B. 1.118 Jetté, N. 1.285, 2.051, 2.067, 2.071, 2.082, 3.139 Ji, K. 1.218 Jiang, W. 1.324, 2.285, 2.286, 2.287, 2.330, 3.288, 3.310 Jiang, X. 2.330, 3.288 Jiang, Y. 1.030 Jih, J. 1.306 Jimenez, X.F. 2.273 Jin, K. 1.367, 2.132, 2.149, 2.154, 3.159 Jin, X. 1.155 Jirsa, V. 3.182 Joachim, K.C. 2.056 Joaquim, H.P. 1.122 Job, A. 1.191 Jobst, B. 1.086, 1.209, 1.286, 2.042, 2.212 Joc, J. 3.273 Joensuu, T. 3.089 Johannessen, S. 2.282, 2.308, 2.317, 2.326 Johnson, E.K. 2.039, 3.078 Johnson, J.K. 1.337, 1.343 Johnson, M. 1.076 Johnston, L.A. 1.047 Johnston, M. 3.035 Jokeit, H. 2.245 Jones, A. 1.066 Jones, D. 1.334, 1.335, 1.336 Jones, J. 1.169, 2.023, 3.267, 3.270, C.09 Jones, K. 2.353, 3.306 Jones, M. 3.277 Jones, S.E. 1.240, 2.249 Jongeling, A. 3.226 Jongeling, A.C. 3.253 Jongeling, A. 3.203 Joo, E. 1.087, 1.130, 1.218, 2.207 Jordan, J. 3.315 Jordan, S. 2.050 Jorgensen, A. 1.109 Josan, V. 1.109 Josephson, C. 2.067, 3.139 Joshi, C. 1.206, 2.035, 3.145, 3.156 Joshi, R. 2.151, 3.074, 3.136 Joshi, S. 1.037, 2.050, 3.115, 3.230 Jouny, C. 1.174, 3.064, 3.189, 3.191 Jow, A. 2.356 Jozwiak, S. 2.187 Jucker, M. 3.116 Juhasz, C. 1.251, 2.345, 3.062 Jun, J. 2.168, 3.196 Jung, D. 1.222 Jung, H. 2.043 Jung, K. 2.168, 3.196 Jung, S. 1.170 Junger, K. 1.090, 1.091, 2.229, 2.316 Junna, M. 2.192 Jurasek, L. 2.089 Jurd, R. 2.007 K Kaczmarek, L.K. 3.016 Kadam, S. 3.035, 3.047 Kadipasaoglu, C. 3.060 Kadish, N.E. 1.329 Kadiwala, H. 2.254 Kagawa, K. 1.265, 2.359 Kahane, P. 1.191, 1.348, 2.226, Kahle, K.T. 1.021 Kaiboriboon, K. 2.052, 2.090 Kaido, T. 1.147, 1.365, 2.225, 2.341 Kaimovsky, I. 2.076 Kakacek, J.R. 3.321 Kakisaka, Y. 2.132, 2.149, 2.154, 3.159 Kalamangalam, G. 1.160, 1.168, 3.375, B.03 Kalayjian, L. 3.373 Kalsanka Pai, A. 3.130 Kalume, F. 1.043, 3.340 Kameyama, S. 1.365 Kaminski, R. 1.020 Kamson, D. 1.251 Kanaan, S. 2.349 Kandel, P. 2.319 Kaneko, Y. 1.147, 2.225, 2.341 Kang, H. 1.211, 3.354, 3.356 Kang, J. 2.315, 3.112 Kang, K. 1.219 Kang, S. 3.035 Kankirawatana, P. 1.268 Kanner, A. 2.191, 2.264, 2.265, 3.264 Kao, A. 2.351, 3.141 Kaplan, L.R. 1.106 Kaplan, P. 3.203 Kaplan, P.W. 3.226 Kapoor, S. 2.258 Kapur, J. 1.037, 3.115, 3.118 Kapur, K. 2.213, 3.235, 3.236, 3.326, B.06 Kapur, R. 2.209, 2.212, B.08 Karaarslan, U. 1.229 Karavaeva, E. 1.245, 1.261 Karkar, K. 2.028 Karkare, S. 2.101, 2.120, 2.128 Karsidag, S. 2.129 Kartagiri, M. 1.265, 2.359 Karumuri, B. 3.107 Kashambwa, R. 2.233 Kashida, Y. 2.002 Kassab, A. 1.072 Kassai, B. 2.263 Kassiri, J. 2.178, 2.179 Kasteleijn-Nolst Trenite’, D.G. 3.314 Kato, K. 2.132, 2.149, 2.154, 3.138, 3.159 Kato, M. 1.105, 1.116 Kattan, M. 1.377 Katus, L. 1.271 Kaufman, B. 2.233, 3.057, 3.137 Kaufman, K.R. 2.325 Kaufman, N.D. 2.325 Kaufmann, W. 3.104 Kaushal, R. 2.043 Kavak, K. 1.214 Kawasaki, H. 1.079 Kaya, M. 1.053 Kayani, S. 1.054 Keating, J. 2.016 Keating, R. 1.354 Keator, C. 2.250, 3.145 Kebede, T. B.06 Keller, C. 1.157 Kellermann, T. 2.004 Kelley, V. 2.360, 2.361 Kellogg, M.A. 2.118 Kelly, D. 1.054, 2.318 Kelly, K. 1.331, 3.158 Kelly, K.M. 2.160 Kelly, P. 2.036, 2.048, 2.077 Kelmann, B.V. 3.369 Kelten, B. 2.129 Kemmotsu, N. 2.005, 2.251 Kempapura, M. 1.341 Kendirli, M.T. 3.170 Kennedy, J. A.06 Keough, K.C. 2.354 Kern, L.M. 2.043 Kern, R.T. 2.160 Kerr, M.S. 2.010 Kerr, W.T. 1.278 Kerrick Walker, J. 2.298, 2.305 Kervyn, S. 2.310, 2.332 Kessler, S. 2.302 Khaddam, O. 2.086 Khalid, E. 2.188 Khalilieh, N. 3.273 Khan, F. 2.107, 3.219, 3.225, B.02 Khan, I. 1.181 Khan, O. 1.341 Khan, O.I. 2.356 Khawaja, A.M. 2.161, 2.163 Khaytin, I. 2.210 Khoo, H. 1.060, 2.357 Khurana, D. 3.312 Khusiwilai, K. 1.137 Kidokoro, H. 1.224, 1.235, 1.243, 2.158 Kikuchi, T. 1.350, 2.335 Kim, B. 1.218 ABSTRACT AUTHOR INDEX Iannotti, G. 2.244 Iasemidis, L. 3.107 Iida, K. 1.265, 2.002, 2.359 Iijima, K. 1.220 Iimura, Y. 1.363, 1.370, 3.012 Ikeda, A. 1.110, 1.350, 2.335 Ikeda, H. 3.198, 3.216 Ikeda, K.M. 3.109 Ikeda, T. 1.116 Ikegaya, N. 2.341 Ilhan Algin, D. 3.305 Imai, K. 3.198 Inaba, Y. 1.116 Inada, T. 2.335 Inaji, M. 2.091, 2.093, 2.097 Inano, R. 1.350, 2.335 Inati, S. 1.002, 1.150, 3.084, 3.166 Inati, S.K. 2.010 Inbar, D. 3.063 Ince, N. 3.190 Innis, R. 1.002 Inoue, N. 1.233 Inoue, Y. 1.060, 1.365, 2.357, 3.198, 3.216 International Pediatric Epilepsy Surgery Panel, T. 2.343 Iragui-Madoz, V. 2.251 Irazoqui, P. 3.036 Iriarte, J. 2.153 Isaacs Lebeau, K. 1.083 Iseki, H. 1.373 Isgüder, R. 3.328 Ishak, G. 1.250 Ishak, G.E. 1.241, 3.280 Ishihara, N. 1.224, 1.235, 1.243 Ishihara, Y. 1.300 Isnard, H. 2.263 Isnard, J. 1.348 Isojarvi, J. 1.334, 1.335, 1.336 Isom, L.L. C.02, Ito, T. 2.174 Ito, Y. 1.224, 1.235, 1.243 Itoh, K. 1.300 Itoh, M. 3.114 Ivanisevic, M. 3.344 Iwaki, T. 1.357 Iwasaki, K. 1.373 Iwasaki, M. 1.367, 2.132, 2.149, 2.154, 3.159 Iwasaki, T. 1.116 Iwuchukwu, I. 3.219 Iyengar, S.S. 3.026 Iyer, S. 1.133 Izadi, A. 1.078 99 ABSTRACT AUTHOR INDEX Kim, C.E. 3.090 Kim, D. 1.130, 1.204, 1.218, 3.354 Kim, E. 1.313, 1.328 Kim, G. 1.218, 2.348 Kim, G.E. 3.016 Kim, H. 1.119, 1.195, 1.211, 1.212, 1.244, 1.365, 2.164, 2.185, 2.315, 3.112, 3.354 Kim, J. 1.087 Kim, J. 1.211, 1.218, 2.164, 2.207, 2.315, 3.112, 3.242, 3.263, 3.356 Kim, K. 1.093, 1.119, 1.195, 1.212, 1.218 Kim, M. 1.117, 1.218, 1.219 Kim, R. B.01 Kim, S. 1.081, 1.218, 1.221, 2.164, 2.220, 2.315, 3.112, 3.244 Kim, T. 3.112 Kim, W. 1.218, 2.164, 2.315, 2.362, 3.021 Kim, Y. 1.117, 2.164, 2.315, 3.112 Kim-Tenser, M. 3.345 Kimura, S. 1.116 King, J. 2.034 King-Stephens, D. 1.216, 2.209 King-Stevens, D. 2.212 Kini, L. 3.256 Kinoshita, M. 1.110, 2.080 Kipervasser, S. 3.197 Kirk, V. 3.172 Kirkpatrick, M. 1.118 Kirmani, B. 1.341 Kirschbaum, A. A.03 Kishi, Y. 3.365 Kishima, H. 1.060, 2.357 Kitay, A.Y. 3.045 Kiura, Y. 1.265 Kjærvik, V. 2.317, 2.326 Klaas, P. 1.093, 1.099 Kleen, J. 1.086 Klehm, J. 1.098, 1.197, 1.329, 1.345, 2.213, 3.235, 3.246, B.06 Klein, K. 3.090 Klein, P. 1.315, 2.230, 2.301 Kleineschay, T. 2.253 Kleinfeld, K. 1.187 Klitgaard, H. 1.298, 2.332 Klooster, D. 1.154 Kloosterman, F. 1.017 Kluge, C. 3.045, 3.058 Kluger, D. 1.076 Klus, C. 1.129 Knopf, L. 1.188 Knoth, R.L. 2.298, 2.305 Knowlton, R.C. 1.236, 1.369 Knupp, K. 1.326, 2.035, 3.209, 3.223 Ko, D. 3.345, 3.373 Ko, T. 1.036, 1.328 Kobau, R. 2.074 Kobayashi, A. 1.233 Kobayashi, E. 2.239 Kobayashi, J. 1.208 Kobayashi, K. 1.172, 1.365 Kobayashi, M. 1.060 Kobylarz, E. 1.286, 2.042 Koehn, M. 3.267 Kogure, S. 1.233 100 Koh, E. 1.218 Koh, J. 2.314 Koh, S. 1.218, 1.222, 1.267, 3.024, 3.279 Kohler, C. 2.135 Kohli, S. 1.214 Kokoszka, M. 3.356 Kolls, B.J. 2.160 Kolodgie, M. 2.351 Komaki, H. 2.225 Kommajosyula, S.P. 1.034 Kondo, T. 1.110 Konikkara, J.J. 2.038, 3.083 Kopitzki, K. 3.045 Koppelstaetter, F. 2.245 Korb, P. 2.053, 3.205 Korczyn, A. 3.090 Korgaonkar, A.A. 1.007 Korn, M. 3.006, C.09 Koroma, M. 1.126 Korostenskaja, M. 1.179, 2.014, 2.248, 2.253, 2.255, 3.276 Koroukian, S. 2.052, 2.090 Korzeniewska, A. 1.174 Koscik, R. 2.218 Kossoff, E. 3.318, B.07 Kotagal, P. 2.172 Kothare, S. 2.170 Kotloski, R. 1.038 Kotzot, D. 2.169 Kowacs, P. 1.315 Kowski, A. 3.058, 3.349, A.03 Kozupsky, J. 2.265 Kraemer, D.L. 2.144 Kraemer, G. 2.099 Kramer, M. 3.054 Krause, A. 3.208, 3.302 Krauss, G. 1.316, 1.320, 2.292 Krebill, R. 1.324, 2.285, 2.286, 2.287 Kreiman, G. 2.025 Kreisl, W. 1.002 Krel, R. 3.240 Krishnan, B. 1.040, 1.144, 1.240, 3.359 Krishnan, V. 1.290 Kronengold, J.K. 3.016 Kroner, B. 3.141, 3.144 Krook-Magnuson, E. C.03 Krueger, A. 1.270 Krug, K. 2.241 Kruithof, A.C. 2.307 Krutoshinskaya, Y. 3.240 Krylov, V. 1.059, 2.076 Kuba, R. 2.003 Kubikova, R. 2.003 Kubota, M. 1.116 Kubota, T. 1.224, 1.243 Kubota, Y. 1.063 Kubova, H. 1.052 Kucewicz, M.T. 1.175, 2.156 Kuchibhotla, K. 1.021 Kuchukhidze, G. 2.068, 2.245 Kucuk, M. 1.053 Kucukboyaci, N. 2.005, 2.251 Kudela, P. 1.045 Kuhlenbäumer, G. 3.090 Kumada, S. 1.116 Kumada, T. 1.116 Kumar, A. 2.345, 3.362 Kumar, D. 2.293, 2.294, 2.295 Kumar, R. 1.022 Kumar, S. 3.145 Kumar, U. 1.289 Kumar, V. 2.365 Kunieda, T. 1.350, 2.335 Kunnakkat, S.D. 1.085 Kuo, C. 1.180 Kupsky, W. 2.345 Kuratani, J. 1.250 Kurisu, K. 1.265, 2.359 Kurlemann, G. 1.115 Kuruba, R. 1.029, 1.031 Kutluay, E.E. 2.160 Kuzniecky, R. 1.352, 3.258 Kwan, P. 1.231 Kwiatkowski, D. 3.044 Kwon, C. 2.082 Kwon, H. 1.130 Kwon, O. 1.081, 1.170 Kwon, R. C.07 L La Briola, F. 3.243 La Vega-Talbott, M. 3.356 Laban-Grant, O. 1.131, 2.230 Labiner, D. 1.349, 2.256, 2.337, 2.339 Lacaille, J. C.01 Lach, L. 1.100 Lachance, M. 3.093 Lachhwani, D. 1.093, 1.099, 1.192 Lackner, P. 2.121 Lacuey Lecumberri, N. 2.126 Ladino, L.D. 1.228 Lado, F. 3.177, 3.346 LaFrance, W. 3.075, 3.085 LaFrancois, J. 3.026, 3.037 Lafrenière, R.G. 3.093 Lagae, L. 2.294 Lagerlund, T. 3.158 Lagrange, A. 3.152 Lai, Y. 1.139, 3.049, 3.061 Lam, A.D. 3.164 Lamanna, I. 1.141 Lamar, T. 1.046 Lamartine Sabido Monteiro, M. 1.141 Lamb, N. 3.334 Lambrakis, C. 1.131 Lammers, S. 3.044 Lancaster, R. 3.225 Lancman, M. 1.083, 1.131, 2.020, 2.230 Lancman, M.E. 1.083, 2.020, 2.230 Landazuri, P. A.07 Landmark, C.J. 2.282, 2.308, 2.317, 2.326 Lane, J.B. 3.104 Lang, A.E. 1.112 Lang, N. 2.199 Langer, J. 2.267 Langston, M.L. 3.238 Lantz, G. 1.263 Lanyon, R. 1.082 Laoprasert, P. 1.267, 2.012, 2.103, 3.279 LaPalme-Remis, S. 1.225 Lapham, G. 3.057, 3.137 Lapointe, V. 1.017 Laroche, S. 2.339, 3.203 LaRoche, S.M. 2.160, 3.226 Larsen, J. 1.118 Larsson, P. 3.366 LaSarge, C.L. 1.048 Lashley, S. 2.039 Lasley, J.H. 2.298, 2.305 Latour, N. 2.310 Lau, C. 2.233, 3.053 Laura, W. 1.139 Laurenza, A. 1.325, 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, 2.295 Laureta, M. 2.128 Lauterbach, T. 3.293 Laux, L. 3.244, 3.303 Lavingia, J. 2.148 Lawson, J. 2.187 Laxton, A. 2.337, 2.339 Le, J.M. 1.278 Le, J.T. C.04 Le, N. 2.311 Le, S. 3.168 Leaffer, E. 3.140 Leanage, G. 1.035 Lebedeva, A. 2.076 Leclercq, K. 1.020 Lee, B. 1.230, 3.373 Lee, C. 2.210 Lee, C.H. 3.221 Lee, C.L. C.04 Lee, C.Y. 3.221 Lee, D. 1.078, 2.005 Lee, E. 1.211, 1.218 Lee, H. 3.058 Lee, I. 1.313, 2.220 Lee, J. 1.211, 1.218, 3.098, 3.203, 3.226, 3.289, 3.354 Lee, K. 1.179, 1.196, 1.234, 2.014, 2.110, 2.248, 2.253, 2.255, 2.348, 2.364, 3.276 Lee, M. 1.036, 3.070 Lee, M.R. 2.354 Lee, S. 1.218, 1.219, 1.236, 2.168, 2.314, 3.036, 3.196, B.09 Lee, S.T. 3.221 Lee, V. 2.159 Lee, W. 2.318 Lee, Y. 1.130, 1.230, 1.328 Lega, B. 1.058, 1.153 Legatt, A.D. 2.180 Legendre, A. 1.039 Legg, K. 2.171 Legge, A. 2.296, 3.138 Legido, A. 3.312 Legros, B. 1.141, 3.203, 3.226 Lehesjoki, A. 3.089 Lehmkuhle, M. 3.043 Leijten, F. 2.145 Leitinger, M. 3.228 Leland, M. 3.052 Lemesiou, A. 1.057 Lenz, F. 2.025 Leon, Y.C. 1.101 Leon-Vazquez, M. 2.186, 2.334 Leonard, S. 2.032 ABSTRACT AUTHOR INDEX Liu, R. 1.030, 3.107 Liu, S. 3.190 Liu, Y.C. 1.208 Liu, Z. 2.261 Llerenas Zamora, R. 3.154 Llewellyn, N. 2.233, 2.286, 3.289 Locke, D. 1.082 Loddenkemper, T. 1.098, 1.182, 1.197, 1.329, 1.345, 2.035, 2.213, 3.202, 3.235, 3.236, 3.246, A.05, B.06 Loeb, J. 1.004 Loesch, A. 2.165, 3.211 Loi, R.Q. 2.005 Long, X. 1.023 Longo, D. 2.146 Longo, F.M. 1.299 Lopes, T.M. 3.259 Lopes-Cendes, I. 3.046 Lopez, C. 2.299, 3.307, 3.353 Lopez, M. 2.191 Lopez Dequit, I. 3.309 López-Gomáriz, E. 1.332 López González, F. 1.332, 2.300 López Pizano, A. 3.154 Lopez-Trigo Picho, F. 1.332 Lora, P. 3.325 Loring, D.W. 2.320, 3.344, B.08 Lösch, C. 2.277 Loscher, W. 1.070 Losey, T. 3.146 Losher, C. 2.165 Lossius, M. 2.072, 2.231 Loturco, J. 3.002 Loughman, A. 1.279 Louise, G. C.01 Love, T.E. 1.347 Lovell, K. 2.131 Lovick, T. 3.036 Lowden, A. 1.210 Lowe, H. 1.208 Lowen, K. 1.338 Lowenstein, D. 3.095 Lozano, M. 2.286 Lu, Y. 1.268 Luan, G. 1.005, 1.365, 3.352 Lucchese, L. 3.126 Luczak, A. 1.017 Lüders, H. 2.126, 3.160, A.07 Ludmir, E.B. 1.006 Ludwig, E. 1.312, 1.314, 1.319, 1.320, 1.321 Luef, G. 2.121, 2.245, 2.262 Lugo, J. 1.292, 3.105, C.07 Lukic, V. 3.100 Luna-Munguia, H. 3.042 Lundstrom, B. 1.176 Luo, C. 3.285 Lupien-Meilleur, A. C.01 Lushbough, C. 1.085 Lutz, M.T. 3.077 Luu, P. 1.180, 1.263, 3.193 Ly, C. 1.009 Lyons, R. 1.288, 2.026 M Ma, Y. 1.299 Maa, E. 3.304, 3.319 Macaulay, D. 1.213 Macaya, A. 2.187 Machado, A. 2.239 Maciag, C. 1.303 Mackay, M.T. 3.087 Mackenzie, S.J. 3.103 Mackie, E.J. 1.291 Macrodimitris, S. 1.285, 2.071 Madakasira, P. 2.365 Mader, E. 2.114 Mader, M. 1.129, 2.358 Madhavan, D. 2.197 Madhavan, R. 2.025 Madsen, J. 2.025 Madsen, J.R. 1.366 Maehara, T. 2.091, 2.093, 2.097 Maertens, P. 2.115 Maganti, R. 3.033 Magdassi, S. 3.063 Magestro, M. 3.126 Magge, S. 1.354, 3.355, 3.364 Mah, S. 2.051 Mahajan, R. 3.171 Maher, D. 2.227 Maheshwari, A. 3.054 Mahmood, N. 2.215 Mai, R. 2.184 Maideniuc, C. 2.214 Maillard, L. 2.226 Mailo, J.A. 2.130 Majmudar, S. 1.089 Makeyev, O. 3.073 Makin, C. 2.044, 2.297 Makinson, C. 3.106 Malek, A.M. 3.142 Maliia, M. 3.069 Malik, A. 2.206 Malik, M. 2.230 Malik, S. 2.250 Malinowska, U. 3.189, 3.191 Maljevic, S. 3.089 Mall, E.M. 1.069 Maloney, T. 2.024 Malykhin, N.V. 1.253 Mamelak, A. 1.126, 2.181 Mandadi, S. 1.025 Mandel, A. 3.233 Mandelstam, S. 3.087, 3.092 Mandrekar, J. 1.374 Manganaro, S. 1.132, 1.142, 2.063, 2.162, 3.240 Manganas, L. 1.132, 1.135, 2.162 Mangano, F. 1.353 Manitpisitkul, P. 1.309 Mann, A. 3.063 Mann, K. 1.090 Manreza, M.G. 2.119, 3.143 Mapstone, T.B. 2.349 Marchal, C. 2.226 Marcotegui, I. 2.153 Mares, P. 1.051, 1.052 Mari, F. 1.108 Marin, A. 2.363 Marini, C. 1.108, 1.115 Marino, S.E. 2.329 Mariyappa, N. 1.143 Marquardt, F. 3.045, 3.058 Marquez, Y. 3.373 Marras, C. 3.360 Marsh, E. 3.303 Marsh, E.D. 3.099 Marsh, R. 1.175, 1.374, 2.156, 2.256, 2.337, 2.339 Marsh, S. 2.211 Marsh, S.T. 1.042 Marson, A. 1.109 Marti, C. 3.236 Martin, R.F. 3.018 Martinez, G. 1.296 Martinez, J. 1.295 Martinez, R.C. 2.114 Martinez-Juarez, I.E. 2.186, 2.334 Martinez-Perez, A. 2.186 Martins, A. 3.046 Martins, S. 3.046 Martz, G.U. 2.160 Martínez Agredano, P. 3.311 Martínez-Juárez, I.E. 3.073 Maruo, T. 1.060, 2.357 Maruyama, A. 1.220 Masel, T. 3.269 Mason, K. 1.151, 2.252 Mason, S. 1.288 Massaro, A. 1.137 Massey, S. 2.170 Massot-Tarrús, A. 1.185 Matagne, A. 1.298 Mateo, M. 3.051 Mathern, G. 1.245, 1.357, 2.355, 2.358, 3.255, 3.262 Matkovic, Z. 1.231 Matos, A. 3.046 Matosevic, B. 2.121 Matsui, T. 2.353 Matsumoto, H. 1.116 Matsumoto, J. 1.175, 1.182, 2.156, 3.330 Matsumoto, N. 1.105, 1.116 Matsumoto, R. 1.350, 2.335 Matsuo, F. 3.150 Matsuo, T. 1.177 Matsuura, M. 2.091, 2.093, 2.097 Matthews, S.A. 3.341 Mattson, R. 2.350 Matur, Z. 2.224 Maturu, S. 2.215 Maurer Morelli, C. 3.046 Mauri, J. 1.332 Mavroudakis, N. 1.141 Maxwell, C. 1.285 Mayer, T. 3.077, 3.293, 3.297, 3.349 Mayes, L.C. B.01 Mays, V. 2.173, 3.201 Maytal, J. 2.128 Mazarati, A. 1.055, 1.056, 1.289 Mbelwa, S. 2.089 McArthur, D. A.09 McAuley, J. 1.306 McBee, N. 1.324, 2.285, 2.286, 2.287 McBrian, D. 3.233 McCarthy, A. 1.203 McCarthy, D. 1.184 McCoy, B. 1.189, 3.239, 3.306 McCredie, R. 3.286 McDonald, C. 2.005, 2.251 ABSTRACT AUTHOR INDEX Leppik, I. 1.272, 1.325, 3.317 Lerche, H. 3.089 Lerner, J. 1.182, A.09 Lervik, K. 3.205 Lesage, F. 1.072, 1.260 LeSure, S. 3.351 Leung, L. 2.236 Leuthardt, E. 1.376 Leventer, R.J. 1.120 Lévesque, M. 1.301, 3.121 Levi, O. 3.008 Levin, H. 2.240, 2.247 Levin, S. 2.223 Levitt, J. 1.252, 1.254, 3.254 Levy, S. 2.350 Lewis, E. 1.225 Lewis, E.C. 2.141, 2.346 Lewis, M.L. 3.124 Leyden, K. 2.005, 2.251 Leymon-Porter, B. 2.031 Lhatoo, S. 2.090, 2.126, 3.127, 3.160 Li, B. 2.051 Li, H. 3.175 Li, L. 3.334 Li, M. 3.222 Li, N. 1.076 Li, P. 1.214, 2.125 Li, S. 1.231 Li, T. 1.005, 3.298 Li, W. 1.164 Li, Y. 1.007 Liang, L. 3.032 Liang, W. 3.300 Libbey, J.E. 3.117 Libenson, M. 3.236 Lie, O. 2.028 Liebenthal, J. 2.102 Ligot, N. 1.141 Lilja, I. 3.025 Lillis, K. 1.011, 3.004 Lim, B. 1.119, 1.195, 1.212 Lim, S. 2.362, 3.021 Lim, S.N. 3.221 Lima, A.M. 2.344, 3.372 Lima, E. 3.076 Lima, P.B. 3.179 Lima Castro, C. 3.082 Lin, C. 1.351 Lin, J. 1.352, 2.004, 2.013, 3.270, 3.283 Lina, J. 1.178, 2.239 Linane, A. 1.280, 3.152 Lindsay, K. 1.109 Lineweaver, T. 1.093, 1.099 Liow, J. 1.002 Lippman-Bell, J. 3.001 Lipski, W.J. 1.073 Lipton, R.B. 2.180 Liscano, A. 2.363 Lisicki, D. 1.101 Liska, J. 3.120 Lispi, M. 2.146 Litt, B. 3.183, 3.256 Liu, C. 3.373 Liu, G. 1.038 Liu, K. 2.032 Liu, M. 1.237, 2.081, 3.261 101 ABSTRACT AUTHOR INDEX McDonald, S. 2.318 McDonough, T. 2.221 McGoldrick, P. 3.316, 3.356 McGrade, H. 3.225 McGuire, R. 1.067 McIntosh, A. 1.231 McKee, H.R. 1.280 McKhann, II, G.M. 2.027, 3.233 McLachlan, R. 1.185 McLellan, A. 1.092, 2.015 McMahon, J. 1.103, 3.086, 3.087 McNamara, J. 1.006, 1.038, 1.269 McNamara, N. 3.230 McNaughton, B.L. 1.017 McPhillips, M. 1.092 McShea, C. 3.291, 3.292, 3.295, 3.299 Meador, K.J. 2.295, 2.320, 2.339, 3.168, 3.344, B.08, Mealey, R. 2.135 Mecchella, J.N. 1.286 Medvedev, A. 3.073 Mefford, H. 1.103, 3.086, 3.087, 3.092, 3.093 Megevand, P. 1.157, 3.177, 3.346 Mégevand, P. 2.246 Mehešová, S. 2.304 Mehrizi, M. 2.152 Mehrotra, K. 2.268 Mehta, A. 1.157, 2.011, 2.246, 2.256, 2.339, 3.177, 3.346 Mehta, D. 2.029 Meisler, M. C.09 Melaiki, B. 1.104 Melanson, D. 1.121 Memon, A.B. 3.266 Mendes, P.S. 2.119, 3.143 Mendes, S. 2.298, 2.305 Mendez, D. 2.045 Mendoza, L. 1.257, 1.310 Mendoza, M. 2.176 Menezes Cordeiro, I. 3.163 Menon, J. 3.175 Menon, U. 2.066 Mercan, M. 1.207 Mercedes, B. 2.226 Mercier, J. 2.332 Mercier, M. 3.177, 3.346 Mesad, S. 1.131 Mese, T. 1.229, 3.328 Messinger, M. 2.299, 2.333 Metcalfe, A. 2.082 Mevåg, M.A. 2.317, 2.326 Meyer, F. 1.175, 1.374, 2.156 Meyer, K. 1.344 Meyer, M. 3.034 Meyers, E. 3.203, 3.226 Miao, H. 3.051 Michalak, Z. 3.110 Michaud, J.L. 3.093 Michel, C. 2.244 Michelhaugh, S. 3.313 Michelucci, R. 1.113 Michoulas, A. 3.220, 3.327 Midi, I. 3.151 Midura, M. 1.062 Mikati, M. 3.095, B.06 Mikkelsen, T. 3.098 102 Mikulis, D. 3.200 Mikuni, N. 2.335 Milder, J. 3.095 Miles, L. 3.111 Miles, M. 3.111 Milh, M. 2.263 Milham, M. 2.246 Millan, C.M. 2.241 Millen, K.J. 1.043 Miller, I. 2.346 Miller, J. 1.372, 2.039, 2.126, A.07 Miller, J.A. 3.122 Miller, R.J. 3.116 Miller, S. 3.024 Miller-Horn, J. 3.173 Millett, D. 3.373 Millichap, J. 3.210, 3.157, 3.214 Milligan, C.J. 1.291 Minassian, B. 3.093 Mindruta, I. 1.191, 3.069 Minotti, L. 1.191, 1.348 Mintz, M. 2.016, 3.094 Mintzer, S. 2.291 Miotto, E.C. 2.119, 3.143 Miozzo, M. 2.027 Mirchandani, N. 1.181 Mirro, E. 1.209 Mirsattari, S. 1.185 Mirsky, D. 1.267, 3.279 Mirza, N. 1.109 Misajon, J. 1.133 Miskin, C. 3.312 Misra, S.N. 1.215 Mitchell, W. 3.145 Mittal, M. 2.111 Mittal, S. 3.062, 3.313 Miura, K. 1.224, 1.235, 1.243 Miyama, S. 1.116 Miyamoto, S. 1.350, 2.335 Mizrahi, E. 2.212 Modi, A. 1.090, 1.091, 2.316 Modur, P. 1.077, 2.038, 2.131, 2.193, 3.070, 3.083 Moeller, J. 2.296 Moffett, B.S. 2.333 Mohamadpour, M. 2.016 Mohamed, I. 2.123, 3.370 Mohamed, M.A. 2.272 Mohammad, F. 3.122 Mohammadi, M. 1.127 Mohan, C. 2.268 Mohanarangan, K. 2.208 Mohanraj, R. 1.109 Moheet, A. 2.227 Molins, A. 1.332 Møller, R.S. 1.115, 1.118 Monica, N. 2.085 Monrad, P. 3.215 Montalvo, J. 3.101 Montandon, G. 1.010, 3.200 Montoya, J. 1.332 Moon, C. 1.196 Moon, H. 1.202 Moon, J. 2.168, 3.196 Moore, J.L. 2.006 Moorley, N. 1.198, 1.199, 1.200, 1.201 Moraes, V. 2.306 Morales-Quezada, J. 3.009 Moran, J. 1.151 Morawo, A. 1.076 Moreira, C.L. 3.332 Moreland, S. 3.205 Morgan, L. 2.028 Morgan, V. 2.117 Morgan, V.L. 2.242 Morisada, N. 1.220 Morita, A. 3.365 Morita, D. 1.090, 2.024, 2.316 Morita, M. 1.377, 3.259, 3.260 Morrell, M. 1.216, 2.209, 2.212, B.08 Morris, C. 3.367 Morris, G. 1.333 Morse, C. 1.002 Moschetta, S. 3.076 Moschetta, S.C. 3.082 Moseley, B.D. 2.228, B.05 Moseley, M. 1.006 Mosher, J. 1.063, 1.149, 2.249 Moshé, S. 1.305 Moss, A. 3.132 Moss, R. 1.065 Motamedi, G. 1.202 Motelow, J. 1.044, 1.164 Motika, P. 1.277 Motil, K.J. 3.104 Moufawad El Achkar, C. 3.361 Moura, L.V. 2.045 Moussa, N.A. 2.001 Mower, A. 3.241 Mowrey, W. 1.304, 1.305 Mrelashvili, A. 1.364 Mucci, G. 2.013 Mudugal, D. 2.197 mueller, A. 2.195 Mueller, G.P. A.08 Mueller, M. 2.271 Muhle, H. 1.115, 3.090 Muhonen, M. 2.013 Mullatti, N. 1.067 Mullins, J.G. 1.111 Muma, E. 2.215 Muniz, R. 3.301 Munoz, J. 1.210, 3.083 Muona, M. 3.089 Murakami, H. 1.149, 3.359 Murata, K. 3.330 Murphy, G. C.09 Murphy, M. 1.232 Murphy, W. 2.067, 3.139 Murro, A.M. 2.212 Muzik, O. 3.062 Myers, C. 3.086 Myers, L. 1.083, 1.088 Mylius, J. 3.045 Myseros, J. 1.354 Mytinger, J.R. 3.147, 3.157, 3.223 N N Guyen The Tich, S. 2.263 Na, G. 3.091 Nabatame, S. 1.105 Nabbout, R. 2.187, 2.263, 3.016 Nabors, L.B. 1.330 Nabulsi, N. 2.332 Nachbauer, W. 2.121 Nadasdy, Z. 3.070 Naduvil Valappil, A. 1.149, 1.192, 1.362 Naeije, G. 1.141 Nagarajan, E. 1.197, 2.035, 2.213, 3.235, 3.236, 3.246 Nagasawa, T. 2.202 Nagase, H. 1.220 Naik, M. 2.159 Naik, P. 2.092 Nair, D. 1.063, 1.153, 1.216, 2.212, 2.249 Nair, S. 3.079 Najimipour, B. 1.068 Najm, I. 1.008, 1.012, 1.040, 1.058, 1.063, 1.240, 1.362, 1.377, 2.073, 2.249 Nakae, T. 1.350, 2.335 Nakagawa, E. 1.116, 1.147, 2.225, 2.341 Nakagawa, T. 1.220 Nakajima, M. 1.145, 1.363, 1.370, 2.174, 3.012, 3.108 Nakamura, K. 1.116 Nakane, S. 2.174 Nakanishi, S. 3.019 Nakano, H. 1.110 Nakasato, N. 1.367, 2.132, 2.149, 2.154, 3.159 Nakashima, M. 1.105, 1.116 Nakayama, T. 1.367 Nakhutina, L. 1.085 Nakken, K. 2.231 Nam, H. 1.218 Namihisa, Y. 2.060 Nampoothiri, S. 2.182 Napuri, S. 2.263 Narayana, P.A. B.03 Narayanan, M. 1.148 Narugami, M. 2.174 Nascimento, D. 3.046 Nash, K. 1.182 Nassar, M. 2.175 Nasuti, P. 3.126 Natsume, J. 1.224, 1.235, 1.243, 2.158 Navarro, V. 2.226 Naves, P. 2.327, 3.369 Navratilova, Z. 1.017 Ndayisaba, J. 2.068 Neal, J. 2.082 Nearing, B.D. 3.218 Negishi, M. B.01 Negoro, T. 1.224, 1.235, 1.243 Negrin, S. 2.122 Neher, J.J. 3.116 Neil, J. 2.059, 3.246 Neimat, J. 2.117 Nelson, D. 2.131, 3.070 Nelson, E.B. 1.257 Nelson, G.R. 2.134 Nemes, A. 1.008, 1.012, 1.040 Nemoto, M. 1.233 Neppe, V.M. 2.062 Nespeca, M. 2.104, 3.241 Nettel-Aguirre, A. 3.172 Neubauer, B. 1.115, 2.204 ABSTRACT AUTHOR INDEX O O’Brien, C. 2.053, 3.205, 3.304, 3.320 O’Brien, T. 1.231 O’Brien, T.J. 1.047, 1.291 O’Callaghan, F. 2.187 O’Connell, R.M. 3.117 O’Day, K. 1.344 O’Donovan, C. 3.367 O’Hara, B.F. 1.071 O’Neal, W. 2.303 O’Neill, B. 1.267 Oba, S. 2.353 Obari, D. 3.110 Obata, K. 2.080 Obeid, R. 2.159 Oberaigner, W. 2.068 Oberman, L. 3.337 Ochi, A. 1.127, 1.145, 1.172, 1.189, 2.353, 3.108, 3.153, 3.306 Odom, N. 2.057, 3.248 Ogawa, C. 1.243 Ogden, K. 3.363 Oguni, H. 1.365 Oh, A. 2.185 Oh, M. 1.221 Ohshima, M. 2.060 Ohta, K. 2.091, 2.093, 2.097 Oijala, M. C.03 Ojemann, J. 1.250, 3.280, 3.282, 3.368, Okanari, K. 1.127, 1.145, 2.353, 3.108 Okanishi, T. 1.127, 1.172, 1.371 Okeke, J.O. 2.275, 3.081, 3.135 Okoshi, Y. 2.202 Oktem, O. 2.224 Okumura, A. 1.224 Okumura, E. 3.159 Olafsson, E. 3.128 Oldham, M. 3.324 Oliveira, L.A. 3.165 Oliver, K.L. 3.089, 3.100 Olney, N. 2.108 Olson, A. 2.046 Olson, L. 1.339 Oltmanns, F. 3.349 Oluigbo, C. 1.354, 2.351, 3.355, 3.364 Omar, N. 3.348 Omurtag, A. 3.181 Ono, T. 1.359, 1.361 Onomura, A. 1.373 Oommen, B. 2.135, 3.302 Opperman, C. 2.021 Orhan, N. 1.053 Orii, K. 1.116 Orozco-Suarez, S. 1.001 Orton, K. 2.134 Osaka, H. 1.116 Osako, M. 2.060 Osawa, S. 1.367 Osborn, M. 1.338 Oshino, S. 1.060, 2.357 Osorio Santiago, A. 3.154 Oster, J. 3.347 Ostuni, J. 3.268 Otsubo, H. 1.127, 1.145, 1.172, 1.189, 2.353, 3.108, 3.153 Otsubo, T. 2.002 Otsuka, K. 2.174 Otsuki, T. 1.147, 1.365, 2.225, 2.341, 3.114 Ottman, R. 2.275, 3.081, 3.135 Otáhal, J. 1.051 Oya, H. 1.079 Ozbek, D. 3.151 Ozdag, F. 3.170 P Pacheco, J. 3.083 Pacheco, L. 1.295 Pacheco-Phillips, J. 2.049 Pack, A. 2.234, 3.140 Pack, C. 3.121 Paige, A. 1.324, 2.285, 2.286, 2.287 Painter, M. 2.159 Pakhomov, S.V. 2.329 Palacios, A. 3.053 Palao-Duarte, S. 2.078 Palat Chirakkara, S. 1.239 Palestrant, D. 2.227 Palmquist, M. 1.094 Palotie, A. 3.089 Pan, H. 2.236 Pan, J.W. 3.072 Pan, P. 3.255, 3.262 Pan, Y. 2.040 Pandey, R. 1.275 Pandian, A. 3.105 Panduranga, A. 2.177 Panel, I. 2.342, 3.350 Pang, T. 1.188, 1.205 Panigrahy, A. 2.159 Paolicchi, J. 2.221 Papadelis, C. 2.213, 3.202, 3.235 Papale, L. 1.046 Parada, I. 1.299 Pardoe, H.R. 3.258 Paredes Saenz, C.F. 1.158 Parent, J. 3.002, 3.005, 3.006, C.02, C.09, Parent, R. C.09 Parikh, P. A.06 Park, B. 2.238 Park, C. 1.130 Park, E. 1.366 Park, H. 2.315 Park, J.T. 2.167 Park, K. 1.110, 1.218, 3.210 Park, S. 1.030, 1.081, 1.218, 1.282, 1.313 Parker, P. 1.331 Parko, K. 2.058 Parra, M. 1.194 Parsons, K. 1.030 Parsons, T. 2.022 Parthasarathy, S. 1.148 Pascoal, V. 3.046 Pascual, F.T. 2.034 Pascual, J. 1.054 Pascual-Leone, A. 1.154, 1.205 Passarell, J. 1.312, 1.314, 1.319, 1.320 Passe, T. 2.235 Passen, N. 1.306 Passmore, C. 1.037 Patel, A. 2.055, 2.319, 3.130 Patel, A.B. 1.278 Patel, M. 3.032, 3.052, 3.066 Patel, P. 1.341, 3.231 Patel, R. 1.294 Pathmanathan, J. 1.184 Patil, V. 3.048, 3.050 Pato, A. 2.300, 3.309 Patten, S. 2.071 Patten, S.B. 1.285 Patterson, C. 3.331 Patterson, E. 1.372 Patterson, K.P. 1.009 Patwardhan, R. 2.256, 2.337, 2.339 Paudel, S. 2.319 Pavlova, M. 2.151 Payne, E. 1.182, 3.059 Pazarci, N. 2.183 Pazdera, L. 1.318 Pearce, P.S. 3.072 Peariso, K. B.06 Pearl, P. 1.197, 1.225, 3.065, 3.246, 3.325 Pearson, J. 3.032 Pedersen, M. 2.243 Pedersen, N.P. 1.162 Pedraza Benitez, C. 3.311 Peeters, P.A. 2.307 Peglar, L. 3.324 Pei, F. 3.178 Peinhof, S. 2.040 Pelayo, M. 2.126 Pella, R. 2.028 Pellegrino, G. 2.239 Pelliccia, V. 2.184 Peltier, A. 1.187 Pendziwiat, M. 1.115, 3.090 Peng, K. 1.260 Peng, S. 3.271 Pennell, P. 2.233, 3.289, Penovich, P. 1.288, 1.320, 2.046 Perchyonok, Y. 1.120 Percy, A.K. 3.104 Perez, D.L. 2.236 Perez, E. 3.074 Perez Velazquez, J. 1.010 Perez-Ruiz, J. 2.186 Perkins, F.F. 2.354 Perlman, J.M. 2.221 Pernot, F. 1.039 Perry, L. 1.247, 1.249 Perry, M. 2.022, 2.250 Perucca, P. 2.358 Perumpillichira, J.C. 3.158 Perven, G. 1.226 Perzynski, A.T. 1.084 Peters, J. 1.098 Peters, P.A. 1.175 Petersen, B. 1.069 Petersen, C. 2.266 Petit, J. 2.226 Petroff, O. 1.135, 3.204 Petrou, S. 1.291, 3.089 Petty, S.J. 1.291 Phelan, J.C. 2.275, 3.081, 3.135 Phillips, B. 3.304 Phillips, K. 1.026 Picard, R. 2.213, 3.235 Pickrell, W.O. 1.111 Pieters, H. 1.357, 3.217 Pike, V. 1.002 Pillai, A. 2.366 Pillay, N. 2.067, 2.150, 2.198, 3.139 Pilli, V. 1.251 Pilz, G. 3.228 Pina-Garza, J.E. 2.293 Ping, X. 1.155 ABSTRACT AUTHOR INDEX Neufeld, M. 3.197 Neul, J.L. 3.104 Neumann, A. 1.017 Neveux, M. 1.020 Newman, R.B. 3.142 Ng, E. 2.128 Ng, M. 2.113 Ng, Y. 2.201, 2.349 Ngo, T.P. 3.307, 3.353 Nguyen, D. 1.072, 3.274, 3.370 Nguyen, D.K. 1.260, 2.123 Nguyen, D.V. 2.123 Nguyen, L. 3.048, 3.050 Nguyen, M. 1.030, 2.123 Nguyen, V. 2.322 Ni, J. 1.043 Nick, S. 1.267 Nickels, K. 1.193, 1.355, 1.364, 2.079, 2.203, 3.148, 3.158, 3.223, 3.229 Nicolas, J. 2.310, 2.332 Nicoletti, J. 3.105 Niemann, H. 1.069 Nikanorova, M. 1.118 Nikolov, R. 3.265 Nikolova, S. 3.265, 3.277 Nishida, S. 1.350, 2.335 Nishioka, K. 2.353 Nishiyama, M. 1.220 Nita, D.A. 1.172 Nixon, J. 3.280, 3.282 Noachtar, S. 1.124, 2.165, 3.211, 3.273 Noack - Rink, M. 3.293, 3.297 Nobile, C. 1.113 Nobili, P. 3.029 Noe, K. 2.166 Noebels, J. Noh, G. 2.083 Nonoda, Y. 1.116 Norcia, A. 3.178 Nordli, D. 1.222, 3.244 Norman, J.L. 2.110 Nourski, K.V. 1.079 Novak, H. 3.228 Novak, Z. 2.003 Noviawaty, I. 1.192 Novotny, E. 1.250, 3.280, 3.282 Nowell, M. 1.057 Nozaki, T. 3.365 Nuno, M. 2.227 Nussbaum, N. 2.354 103 ABSTRACT AUTHOR INDEX Pinheiro Martins, A. 3.055 Pinto, L.F. 3.204 Pinzon-Ardila, A. 3.192 Pirmohamed, M. 1.109 Pirotte, B.D. 2.166 Pita, I. 3.101 Pittau, F. 2.244 Pittman, D.J. 1.264, 3.186 Pittman, Q.J. 3.124 Pixley, L. 3.326 Pizzo, F. 3.161 Plank, G. 2.136 Platel, J. 1.039 Plegue, M. 1.096 Plummer, C. 2.147 Poddar, K. 2.201 Poduri, A. 3.034, 3.087, 3.095 Pohlmann-Eden, B. 2.171 Pojomovsky, P. 3.233 Polack, P. 1.039 Poliachik, S. 1.241, 1.250, 3.280 Poliakov, A.V. 1.241, 1.250, 3.280, 3.282 Politsky, J. 1.131, 1.140 Pollard, H.B. A.08 Pollard, J. 1.324, 2.135, 2.285, 2.286, 2.287, 3.208, 3.302 Pollard, J.R. A.08 Polli, J. 2.330, 3.288 Polster, T. 1.115 Polyak, B. 3.063 Ponce Mejia, L. 3.269 Ponticello, L. 2.064 Pooladian, A. 3.370 Popli, G. 2.210, 2.256, 2.337, 2.339, 3.367 Porter, B. 3.178 Portnoy, E. 3.063 Poublanc, J. 3.200 Pouliot, P. 1.260, 3.274 Pouliot, W.A. 3.047 Powell, E. 3.018 Powell, K.L. 1.047 Poza Aldea, J. 1.332, 3.309 Prayson, R. 1.144, 1.240 Prescott, J.S. 2.324 Press, C. 1.326 Prieschl, M. 2.121, 2.262 Prince, D.A. 1.299 Prince, R. 3.356 Privitera, M. 1.324, 2.228, 2.285, 2.286, 2.287, 3.288, Pro, S. 2.146 Probasco, J. 3.226, 3.203 Probst, L. 2.268 Proix, T. 3.182 Prusa, C. 1.306 Pugh, M. 2.059, 2.257 Puka, K. 1.095, 3.306 Pullum, B. 2.110, 2.364 Punia, V. A.02 Pushchinska, G. 1.181 Pustina, D. 1.255, 2.237 Puthenveettil, V. 2.182 Puttachary, S. 3.027 Pylypyuk, V. 2.241 104 Q Qiang, J. 2.232 Qing, K. 3.036 Quach, M. 3.188 Que, G.T. 2.066 Quelen, C. 1.334, 1.335, 1.336 Quigg, M. 1.209 Quinn, H. 2.064 Quinn, K. 3.066 Quiroga Subirana, P. 3.311 Qulu, L. 3.124 Quraishi, I. 1.062 Quraishi, I.H. 3.016 Qureshi, M. 2.206 R Rabinovitz, B. 2.029 Rabinowicz, A.L. 1.213 Radhakrishna, S. 3.136 Radtke, R. 3.113 Raedt, R. 1.017, 3.028, C.08 Ragazzo, P.C. 2.274, 3.199 Raghavan, M. 2.148 Ragheb, J. 2.346 Rai, A. 3.063 Rai, P. 3.212 Rai, S. 3.137 Raible, D. 3.031 Rajaraman, R. 2.108, A.09 Rajasekaran, K. 1.054, 3.115 Rajasekaran, V. 1.374, 3.158 Rajyaguru, R. 3.270, 3.283 Rama Madhava, A. 2.065 RamachandranNair, R. 2.065 Raman, K.R. 1.278 Ramey, P. 1.338 Ramirez, C. 1.101 Ramirez, F. 3.293, 3.297 Ramon, C. 3.187 Rampal, N. 1.135, 3.204 Rampp, S. 1.146, 1.346, 3.058 Ramsay, E. 2.107, 3.225 Ramsay, R. 3.219 Ramsay, R.E. B.02 Ramsey, R.K. 1.084 Ramsey-Williams, V. 3.175 Rana, S. 3.133 Randall, M. 1.034 Rankin, S. 1.043 Ransom, C. 1.015 Rao, L. 3.249 Rao, S. 3.250 Raol, Y. 3.039 Rappoport, D.A. 1.049 Rapuano, A. 3.072 Rasina, A. 3.069 Rau, S. 1.096 Rawal, P. 1.281, 2.319 Rayer, K. 1.169 Raygor, K. 1.369 Raynes, H. 3.356 Raña Martínez, N. 2.300 Rebessi, E. 3.360 Reck-Peterson, S. 1.121 Reddy, D. 1.029, 1.031, 1.032, 1.033 Reddy, J. 1.239 Reddy, S. 2.299 Redondo Verge, L. 3.311 Reed, C.M. 2.181, 2.321, 2.336 Reed, R. 3.314 Reed, U.C. 2.119, 3.143 Rees, M.I. 1.111 Reese Jr, J. 2.142 Regan, B.M. 3.088 Regnier-Golanov, A. 3.048, 3.050 Rehman, R. 2.048, 2.077 Reid, C. Reif, P.S. 3.090 Reimers, A. 2.282 Reinsberger, C. 2.213, 3.235 Reisdorph, N. 3.066 Rektor, I. 2.003 Remi, J. 1.124, 2.165 Rémi, J. 3.211 Remigio, G.J. 3.020 Rener Primec, Z. 1.105 Renfroe, B. 2.294 Rensing, N. 1.024, 3.013 Resnick, T. 2.303 Restrepo, C. 3.315 Reutens, D. 1.035, 3.281 Rheims, S. 1.348, 2.226, 2.263 Rho, J.M. 1.030, 3.124, 3.327 Rhone, A.E. 1.079 Riaz, A. 3.079 Ribot, R. 2.063, 2.264 Richards, S. 2.040 Richardson, J. 2.064 Richardson, M. 1.073, 2.147 Richardson, Z. 1.281 Richeh, W. 2.114 Richerson, G. 1.164 Riebe, I. C.01 Riley, C.L. 3.176 Riley, J. 2.013, 3.270, 3.283 Riley, K. 2.338, 3.348 Rios-Motta, M. 2.096, 3.101 Rios-Motta, R. 2.096 Rismanchi, N. 3.241 Risse, G. 1.080, 2.026 Ritacco, D.G. 1.222 Ritchie, H. 2.057 Ritter, F. 2.021, 2.235 Rivard, K.B. 1.217, 3.019 Rizzi, M. 3.360 Robbins, E. 2.302 Robert, M. 3.274, 3.370 Roberts, H. 1.213 Roberts, J. 1.284 Robichaud, A. 1.303 Robichaud, A.J. 1.296 Robinson, L. 2.237 Robinson, S. 1.150 Rocha, C.S. 3.046 Rocha, F. 1.273, 1.287, 1.315, 1.316, 1.319, 1.320, 1.322, 2.278 Rocha, L. 1.001 Rodan, L. 2.124 Rodgers, K. 3.038 Rodgers, K.M. 3.047 Rodgers, P. 1.140 Rodrigues, L. 2.327 Rodrigues Velasco, T. 3.055 Rodrigues Ximenes Goldberg, K. 2.274, 3.199 Rodriguez, C. 2.238 Rodriguez, J. 1.295 Rodriguez Casero, M.V. 3.087 Rodriguez Osorio, X. 2.300, 3.309 Rodriguez Uranga, J. 1.332 Rodriguez-Osorio, X. 1.332 Rodríguez Arias, L.R. 3.154 Roehl, K. 2.205 Roers, E. 1.337 Roessler, K. 1.146, 1.346 Rogawski, M.A. 2.279 Rogers, B.P. 2.242 Rogers, J. 3.052 Rogin, J. 1.314, 2.290 Rojas, N. 3.192 Romain, J. 2.013 Romatoski, K. 1.154, 1.188 Romeo, A. 2.338 Romero Acebal, M. 3.311 Romero-Godoy, J. 3.311 Romigi, A. 1.108 Rompies, E. 3.324 Ronen, G. 1.100 Rosa, M. 2.310 Rose, D. 1.152, 1.353 Rose, K. 1.075, 2.195 Rose, S. 2.102, 3.160 Rosenbaum, P.L. 1.100 Rosenberg, E. 2.309 Rosenfeld, W. 1.315 Rosenow, F. 3.090 Rossi, M.A. 1.074, 2.085, 2.241 Rossignol, E. 3.093, C.01 Rotenberg, A. 1.158, 1.302, 3.009, 3.034, 3.044, 3.337 Roth, R.M. 1.086, 3.080 Rothermel, R. 3.062, 3.362 Rothman, S. 1.372 Roucard, C. 1.039 Rowley, S. 3.032 Roy, A. 1.043 Roy, A.G. 2.182 Rozen-Zvi, M. 2.033 Rozhkov, L. 3.111 Rubio Esteban, G. 3.311 Rubio-Nazábal, E. 2.300 Rudd, D. 3.294 Rudoinov, R. 1.057 Rueda, C.H. 1.050 Ruiz Chow, A. 2.334 Runge, U. 3.293, 3.297 Russek, S. 3.003, 3.011 Russo, G. 2.311 Rutecki, P. 2.209 Rutishauser, U. 1.126, 2.181 Rutka, J. 1.172, 1.189, 2.353 Ruttle-Soon, L. 1.360 Ruvalcaba, N. 1.295 Ruwald, M. 3.132 Ryan, B. 2.056 Ryan, C. 3.325 Ryan, E. 2.057 Ryan, N. 3.157, 3.223 Rychlik, K. A.01 Rydenhag, B. 2.342, 2.343, 3.350 Ryu, H. 1.195 ABSTRACT AUTHOR INDEX Ryvlin, P. 1.348, 2.226, 3.291, 3.292 Rzezak, P. 2.259, 3.076, 3.082 S 1.167, 2.180, 2.358, 3.068 Schwabe, M.J. 1.173 Schwalb, J. 2.208 Schwambach Vieira, A.S. 3.046 Schwartz, M.L. 3.016 Schwarz, M. 3.222 Schwieterman, D. 2.286 Schönherr, M. 1.146 Scornavacca, G.F. 3.243 Scott, J. 1.150 Scott, L. 1.025, 3.019 Scullion, K. 1.217 Secore, K. 2.042 Secore, K.L. 1.086 Seeck, M. 2.244 Seidenberg, M. 2.023, 3.267, 3.270 Seidl, S. 1.078 Seif Eddeine, H. 2.127 Seignot, B. 3.375 Selassie, A. 2.087, 3.142 Selby, K. 3.220 Selezneva, E. 3.045 Selwa, L. 3.078 Semah, F. 2.219 Semsarian, C. 3.088 Sen, D. 3.294 Sencer, S. 2.224 Seneviratne, U. 1.227 Seo, D. 1.130, 2.207 Seo, J. 1.130, 1.179, 2.014, 2.110, 2.253, 2.255, 2.348, 2.364, 3.276 Sepeta, L. 2.019, 3.084, 3.268, 3.272, 3.278 Seppi, K. 2.068 Serafini, A. 2.122 Serafini, R. 1.004 Seraphim, E.A. 2.327 Sergio, G. 3.192 Serioli, E. 1.113 Serout, F. 1.164 Sethi, N.K. 1.271, 3.155 Seyal, M. A.06 Sha, Z. 3.190 Shafer, P. 3.075, 3.218 Shafi, M. 1.154, 1.205 Shah, A. 1.317, 1.321, 3.062, 3.174, 3.232, 3.266, 3.313 Shah, P. 3.227 Shahlaie, K. 1.078 Shallcross, A. 2.007 Shandra, O. 1.304 Shapiro, J.S. 2.043 Shapiro, M.J. 2.065 Shapiro, M.S. 1.165 Sharan, A. 1.255, 1.349, 2.256, 2.337, 2.339 Shariff, S. 2.032 Sharma, A. 2.228 Sharma, B. 1.270 Sharma, P. 1.047 Sharma, R. 2.201 Sharma, S. 3.027 Shatila, A. 2.086 Shaw, D.W. 1.241, 3.280, 3.282 Shaw, E.C. 2.074 Shaw, S. 3.373 Shea, K. 2.073 Shegog, R. 2.009, 3.075 Sheikh, A. 3.175 Shellhaas, R. 1.096, 1.136, 3.145, Shen, A. 1.066 Shen, J. 2.131, 3.070 Shen, S.C. 1.208 Shen, V. 1.334, 1.335, 1.336 Shepherd, C. 3.126 Sheriff, H. 3.241 Sherman, E. 1.360 Shetty, A. 2.256, 2.337, 3.358, 3.371 Shetty, J. 1.092, 2.015 Shi, Y. 1.309 Shiau, D. 2.160 Shibata, S. 1.350, 2.335 Shields, D. 1.216 Shih, J.J. 1.349, 2.256, 2.337, 2.339, 3.238, 3.343 Shih, S. 3.141, 3.144 Shih, Y. 1.351 Shimoda, Y. 1.367 Shimono, M. 1.116 Shin, D. 1.218, 1.289, 3.338 Shin, H. 1.159, 2.057 Shin, J. 3.330, 2.168, 3.196 Shin, W. 1.218 Shindo, K. 2.080 Shinpoo, M. 1.116 Shiraishi, H. 2.174 Shmuel, M. 3.063 Shmuts, R. 2.135 Shneker, B. 1.306, 2.278 Shon, Y. 2.362, 3.021 Shostak, S. 2.275, 3.081, 3.135 Shrestha, A. 2.053, 3.205, 3.304 Shults, J. 1.182 Shurtleff, H. 3.282 Shutter, L.A. 1.310 Si, Y. 1.062, 1.076 Siddarth, P. 1.252, 1.254, 3.254 Siddiqui, K. 2.001, 2.188 Siddiqui, R.S. 2.188 Sidovar, M. 1.213 Siebert, R. 1.115 Siedentopf, C. 2.245 Sieren, J. 2.286 Silbersweig, D.A. 2.236 Sillanpaa, M. 2.018 Sills, G. 1.109 Silveira, M.R. 3.179 Silvia, M. 2.210 Simeone, K. 1.293, 3.341 Simeone, T. 1.293 Simeone, T.A. 3.341 Simon, N. 3.043 Simonson, C. 3.220 Sinasac, D. 3.327 Sinclair, D. 2.178 Singer, R. 3.327 Singh, A. 2.007 Singh, K. 2.196 Singh, M. 1.275 Singh, P. 2.117 Singh, R. 3.201 Singh, S. 2.150, 2.198 Singh, S.P. 2.041, 2.098 ABSTRACT AUTHOR INDEX Saadatmand, H. 2.234 Saavedra Piñeiro, M. 2.300, 3.309 Sabatello, M. 3.081 Sabau, D. 2.152 Sabesan, S. 1.075, 2.195 Sabharwal, V. 2.107, 3.219, 3.225, B.02 Sabri, J. 1.131 Sacco, M. B.06 Sackellares, J.C. 2.160 Sade, E. 3.096 Saenz, J. 1.281 Safi, D. 1.072 Sager, M. 2.218 Sahin, D. 1.053 Sahin, M. 3.044 Sahin, S. 2.129 Sahoo, S.S. 3.085, 3.127 Said, R. 1.210, 3.322 Said, R.R. 2.088 Saindane, A.M. 3.344 Sainju, R. 1.062, 1.135 Saito, T. 2.225, 3.114 Saito, Y. 1.147 Saitsu, H. 1.105, 1.116 Saiz-Diaz, R. 1.332 Sajatovic, M. 1.084, 3.085, 3.127 Sakaguchi, Y. 1.235, 1.243 Sakata, M. 2.060 Sakuma, S. 1.127, 1.145, 2.353, 3.108 Sakuraba, R. 3.159 Salam, M. 2.084 Salam, T. 1.010 Salamon, N. 1.238, 1.245, 1.261, 1.278, 3.255, 3.262 Salanova, V. 2.212 Salas Puig, J. 1.332, 3.237, 3.309 Salinas, C.M. 2.014, 2.248, 2.253, 2.255, 3.276 Salinsky, M. 2.177, 2.269 Salituro, F. 1.296 Salpekar, J. 3.141 Sampaio, L.B. 2.119, 3.143 Sampaio, L.P. 3.332 Sampath, D. 3.039 Sams, J. 3.085 Samson, K.K. 3.341 San Juan Orta, D. 3.154 Sanchez Barrera, W.S. 2.190 Sánchez Fernández, I. 1.098, 1.182, 1.197, 1.329, 2.035, 3.246, A.05, B.06 Sánchez Ortiz, C. 3.311 Sanchez-Ortiz, L. 2.096 Sander, T. 1.115 Sander, V. 2.187 Sandy, S. 2.150, 2.198 Saneto, R. 1.250 Sankar, R. 1.289, 2.108, 2.195, 2.355 Sankar, T. 3.261 Sankaraneni, R.R. 2.172 Sansevere, A. 1.197 Sansevere, A.J. 3.246 Santamarina, E. 3.237, 3.309 Santana-Gomez, C. 1.001 Santaniello, S. 1.061 Santhakumar, V. 1.007 Santos, V.R. 1.048 Saper, C.B. 1.162 Saponjian, Y. 1.021, 2.328, 3.022 Saposnik, G. 2.032 Sarkar, C. 2.365 Sarkis, R. 2.008, 2.213, 3.235, 3.289 Sarma, A. 3.315 Sarma, S.V. 1.061, 2.010 Sarode, A. 1.341 Sarria, S. 3.237 Sasaki, M. 1.147, 2.225, 2.341, 3.114 Satishchandra, P. 1.143 Sato, K. 2.080 Sato, S. 1.150 Sato, Y. 1.145, 3.108, 3.153 Sattar, S. 2.104, 3.241 Sauer, C. 3.215 Saunders, G.W. 3.020 Sauro, K. 2.051 Savioli, A. 3.360 Sawan, M. 1.072, 1.260 Sawchuk, T. 1.276 Sawer Jr, R. 2.125 Scantlebury, M. 1.025, 1.030, 1.217, 3.019 Schaal, A. 2.248, 2.255, 3.276 Schachter, S. 1.232, 1.302, 3.218 Schaefer, C. 2.283, 3.290 Schaffer, D. 2.029 Schaffer, S. 2.011 Schalk, G. 2.248, 2.255, 3.276 Scharfman, H.E. 3.026, 3.037 Scheffer, I. 1.103, 1.115, 1.120, 3.086, 3.087, 3.088, 3.092, 3.095, 3.100 Scheich, H. 3.045 Scheuer, T. 3.340 Schevon, C. 1.057, 3.213, 3.253, Schiemann, J. 2.219 Schiff, N. 1.044, 2.105 Schildt, C. 1.071 Schiltz, N. 2.090 Schmid, E. 2.245 Schmidt, K. B.06 Schmidt, M. 2.171 Schmidt, S. 1.159 Schmiedel, G. 1.118 Schmitt, F. 3.045, 3.058 Schmitt, F.C. 3.349 Schmitt, S. 1.242, 3.203 Schmitt, S.E. 3.226 Schneider, S. 2.128 Schober, H. 2.169 Schoedel, K.A. 1.323 Schoenberg, M. 2.360, 2.361 Scholl, E.A. 3.043 Schomer, A. 3.218 Schooley, D.E. 1.042 Schrader, D. B.04 Schreiber, J. 3.065 Schultz, L. 2.208, 2.215 Schulze-Bonhage, A. 1.067, 1.129, 105 ABSTRACT AUTHOR INDEX 106 Sinha, S. 1.143, 1.148, 1.239, 2.106, 2.188, 3.113 Sinha, S.R. 2.160 Sinisterra, N. 2.363 Sirsi, D. 2.088 Sirven, J. 3.294, 3.304 Sisodiya, S. 3.110 Sitwat, B. 3.331 Siugzdaite, R. 3.028 Sivaraju, A. 1.062 Skene, P. 3.113 Skibo, J. 1.043 Skidmore, C. 1.216, 1.255 Skinner, S.A. 3.104 Slansky, A. 2.063, 2.162 Slater, J. 1.160, 3.181 Slick, D. 1.360 Smith, B. 1.027, 2.194 Smith, D. 2.286 Smith, E. 1.057 Smith, G. 2.271, 3.105, C.07 Smith, J.D. 1.276, 3.327 Smith, M. 1.095, 2.212 Smith, N. 1.044 Smith, P.E. 1.111 Smyth, M. 1.372 Snead, C. 1.172 Snead, O. 1.189, 2.353, 3.306 Snead III, O.C. 1.127, 2.095 Snyder, J. 2.215, 3.098 So, E. 3.158, B.05 Sobczyk, O. 3.200 Sobrido, M. 2.300 Soderblom, E.J. 1.006 Sofat, P. 2.125 Sogawa, Y. 2.159, 3.331, 3.333 Sohn, Y. 1.218 Sohrabpour, A. 1.268 Soldan, S.S. 3.041 Solomon, G. 3.155 Solt, K. 1.023 Soltesz, I. C.03 Somerlik-Fuchs, K. 3.068 Somerville, E. 3.286 Sommer, B. 1.346 Song, H. 3.338 Soni, N. 1.085 Sonmezturk, H. 1.186, 1.327 Sood, S. 1.251, 2.345, 3.062, 3.362 Soraas, C. 2.072 Sorge, S.T. 2.275, 3.081, 3.135 Sorin, L.M. 3.146 Soucy, A. 1.270 Soul, J. 2.124, 3.334 Sousa, R. 1.273, 1.287, 1.317, 1.319, 1.320, 1.322, 1.323 Sozzani, S. 1.020 Spain, W. 1.015 Spampanato, J. 1.161, 1.166 Spanaki, M. 2.208, 2.215, 2.252 Specchio, L. 1.315 Specchio, N. 3.360 Speechley, K. 2.056, 2.069, 2.223, 3.134 Spencer, D. 1.156, 1.209, 1.216, 2.151, 2.350 Sperling, M. 1.255, 1.318, 1.320, 1.323, 1.349, 2.290, 2.256, 2.289, 2.337, 2.339, 3.291, 3.292, Spiciarich, M.C. 2.061 Spitz, A. 1.106 Spitz, M. 2.053, 3.205, 3.304 Spreafico, R. 2.184 Sprengers, M. 1.017, 3.028, C.08 Spring, A.M. 3.186 Spritzer, S.D. 2.166 Spruill, T. 2.007 Squillacote, D. 1.213 Srikanth Mysore, C. 2.197 Srinivasan, S. 3.253 St. Louis, E. 2.192 St. Louis, L. 1.197, 3.246 Staba, R. 1.177 Stacey, W. 3.042, 3.067, 3.167, 3.182 Stafstrom, C. 1.169, 2.023, 3.267, 3.270 Staley, K. 1.011, 1.021, 2.328, 3.004, 3.022, 3.023 Stamatoyannopoulos, J. 1.103 Stamboulian-Platel, S. 1.039 Standridge, S. 2.229, 3.247 Stanisic, M. 3.366 Stanslaski, S. 1.073 Stanton, P. 1.295 Starski, P. 3.042 Stead, M. 1.175, 2.156, 3.071 Steenland, H. 1.017 Stefan, H. 1.346, 3.349, 1.146 Steger, H. 2.165 Stemmer, P.M. 3.056 Stence, N. 2.103, 3.279 Stephani, U. 1.115, 2.199, 3.090 Stephen, L. 1.331 Stern, E. 2.236 Stern, J. 1.278, 3.291, 3.292 Steve, T.A. 1.253 Steven, D. 2.054 Stieglitz, T. 3.068 Stino, A. 2.214 Stockis, A. 2.307, 2.310 Stocks, J.D. 1.337, 1.343 Stoll, J. 3.342 Stoll, S. 3.075, 3.078, 3.085, 3.127 Stoltenberg, C. 2.072 Storrs, J.M. 1.257 Story, T. 2.320, 3.291, 3.292 Storzbach, D. 2.269 Stoub, T. 3.264 Straub, H.B. 3.349 Strauman, M.C. A.08 Straussberg, R. 3.090 Streiner, D.L. 1.100 Striano, P. 1.113, 1.115 Striano, S. 1.113, 1.320, 1.322 Stribling, J. 2.064 Stringer, K. 2.303 Strode, D. 1.003 Strom, L. 1.314, 2.053, 3.205, 3.304 Struck, P.J. 2.325 Stufflebeam, S. 1.256, 1.258 Suchdev, K. 3.250 Sudo, A. 1.116 Sueiras, M. 3.237 Sugai, K. 1.147, 1.365, 2.225, 2.341 Sugano, H. 1.358, 1.363, 1.370, 3.012 Sukigara, S. 3.114 Sulc, V. 2.156 Sullivan, J. 1.136, 2.309, 3.095, 3.214, 3.303 Suls, A. 1.115 Sumi, Y. 2.091, 2.093, 2.097 Sumpter, R. 2.015 Sun, F. 1.209, 2.209 Sun, H. 1.028, 3.007, 3.041 Sun, P.Y. 1.193 Sunderam, S. 1.071, 1.077 Sundstrom, D. 3.218 Sunkaraneni, S. 1.312, 1.314, 1.319, 1.320, 1.321 Sunnen, C. 3.050 Sunwoo, J. 2.168, 3.196 Suren, P. 2.072 Suresh, S. A.07 Sutton, S. 2.057 Suwanpakdee, P. 1.240, 1.362 Suzuki, H. 2.132 Suzuki, N. 1.256, 1.258, 2.154 Svehlik, V. 1.175, 3.071 Sveinsson, O. 3.128 Svendsen, K.H. 1.272 Svendsen, T. 2.282 Svenson, L. 2.051 Swaminathan, A. 2.258 Swann, J. 1.013, C.04 Swearingen, R. 2.034 Swedo, S. 3.166 Sweeney, M. 3.324 Sweet, J. A.07 Swenson, A. 2.100 Swiercz, W. 1.011, 2.328 Sylvester, C. 1.080 Szabo, C. 2.028, 3.052, 3.315 Szabo, G.G. C.03 Szaflarski, B.A. 1.257 Szaflarski, J. 1.236, 1.257, 1.281, 1.310, 1.324, 1.330, 2.024, 2.161, 2.163, 2.285, 2.286, 2.287, 3.203, 3.226, B.09 Szaflarski, M. 1.281, 1.310 Szklarski, L. 2.016 Szu, J. 2.238, 3.119 Sætre, E. 2.282 T Tabata, A. 2.091, 2.097 Taccone, F. 1.141 Tadlock, D. 3.156 Tailby, C. 2.243 Takada, S. 1.220 Takagi, Y. 1.350 Takahashi, A. 1.147, 1.365, 2.225, 2.341, 3.114 Takahashi, K. 2.174 Takahashi, R. 1.110, 1.350 Takahashi, Y. 2.335, 3.198 Takami, Y. 1.116 Takeoka, M. 1.098, 2.017, 3.169, 3.236, 3.361 Takeshita, S. 1.116 Takeuchi, T. 1.235, 1.243 Takumi, I. 3.365 Talib, L.L. 1.122 Talos, D.M. 3.041 Talypov, A. 1.059, 2.076 Tamber, M. 3.331 Tampieri, D. 1.121 Tan, M. 1.231 Tanaka, N. 1.256, 1.258 Tanaka, S. 2.091, 2.093, 2.097 Tanaka, T. 1.220 Tandon, N. 3.060, 3.375 Tang, H. 2.025 Tang-Wai, R. 2.179 Tangel, V. 2.275, 3.135, 3.081 Tani, N. 2.357 Tankovic, A. 3.014 Tanuma, N. 2.202 Tao, J. 2.102, 3.160 Tao, W. 1.015 Tapia, M. 2.037 Taplinger, D. 2.267 Tarquinio, D. 3.104 Tarrant, S. 3.325, 3.326 Tasker, R. 1.197, 3.202, 3.334, B.06 Tassi, L. 1.377, 2.184 Tatsuoka, C. 3.085, 3.127 Tatum, W. 1.349, 2.155, 2.256, 2.337, 2.339, 3.343 Tatum, W.O. 3.238 Tayah, T. 1.260 Taylor, C.T. 1.165 Taylor, D. 1.295 Tecoma, E. 2.005, 2.251 Tejada, J. 3.055 Tekeli, H. 3.170 Telecka, S. 2.003 Telesco, R. 2.159 Tellez-Zenteno, J. 1.228, 2.082, 2.095 Temkin, N. 2.039 Tenney, J. 1.152, 2.024, 3.111 Tennigkeit, F. 3.294, 3.295, 3.297, 3.298 Terashima, H. 1.116 Terhaerdt, J. 2.069 Terra, V. 3.055 Terrill, M. 1.263 Terry, D. 2.049 Terwilliger, V. 2.019, 3.272 Teskey, G. 1.030, 1.217, Testa, F. 2.350 Teter, B. 1.214 Tezer-Filik, F. 1.124 Thadani, V. 1.286, 2.042 Thadur, S. 3.250 Thaker, A.A. 1.266 Thakur, D.S. 1.286 Thaler, A. 3.137, 3.208 Thaler, J. 3.137 Thamattoor, A. 1.014 Theodore, W. 1.002, 1.065, 1.150, 1.225, 2.356, 3.065, 3.084, 3.268, 3.278 Thibert, R. 1.123 Thiele, E. 3.303 Thippeswamy, T. 3.027 Thom, M. 3.110 Thomas, A.X. 3.011 ABSTRACT AUTHOR INDEX Tripathi, M. 2.365 Trivisano, M. 3.360 Trobliger, R. 2.020 Troncoso, L. 1.118 Troncoso, M. 1.118 Trope, A. 3.059 Tropea, T. 1.271 Tsai, J. 3.178 Tsao, J. 3.222 Tseng, P. 2.081 Tseng, W.E. 3.221 Tsenov, G. 1.052 Tshionyi, M. 2.085 Tsimerinov, E. 2.227 Tsong, W. 3.301 Tsuchida, T. 1.136, 1.137, 2.351 Tsuchiya, K. 1.233 Tsuji, T. 1.224 Tu, P.H. 3.221 Tucker, D. 1.180, 1.263, 3.193 Turco, L. 2.041 Turnbull, J. 2.126 Turner, D. B.06 Turner, K. 3.243 Turner, M. 2.229 Tuxhorn, I. 3.207, 3.212 Tyler-Kabara, E. 3.331 Tyrlik, M. 2.003 Tyrlikova, I. 2.003, 2.301 Tzvetanov, P. 3.295, 3.298 U Uchida, C.P. 3.251 Uchio, H. 1.116 Ueda, Y. 1.297 Uematsu, M. 1.367 Ueno, M. 1.300, 2.353 Ugorec, I. 1.140 Ugur Yilmaz, C. 1.053 Ukitsu, S. 2.353 Ullmann, J. 1.035 Umezu, M. 1.373 Ünalp, A. 1.229 UnCheol, L. 3.040 Ung, H. 3.183 Unnwongse, K. 2.073 Unterberger, I. 2.121, 2.169, 2.245, 2.262 Upchurch, K. 1.184 Upreti, C. 1.295 Urrestarazu, E. 2.153 Uysal, U. 2.111 Uzun, M. 2.075 Uzuner, G. 3.305 V Vago, D.R. 2.236 Vajjala, V.S. 1.134 Vakili, R. 3.257 Vale, F. 2.360, 2.361 Valencia, I. 1.203, 2.035, 3.312 Valente, K. 1.122, 2.259, 2.260, 2.306, 3.076, 3.082 Valiante, T. 1.016, 3.200 Valle-Dorado, M. 1.001 Valton, L. 2.226 Valujskikh, A. 1.008 Van Bebber, S. 2.058 Van Cott, A.C. 1.284 Van den Maagdenberg, A.M. C.01 van der Linden, Jr., H. 2.274, 3.199 van Gerven, J.M. 2.307 Van Grunderbeek, W. 1.067 Van Kampen, A. 1.333 van Kranen-Mastenbroek, V. 1.138 Van Ness, P. 1.316, 2.038, 2.189, 2.193, 2.209, 3.083 Van Nieuwenhuyse, B. 3.028, C.08 Van Orman, C. 2.134 van Rijckevorsel, K. 1.067 Van Straten, A.F. 2.042 Vanasse, C. C.01 VanCott, A. 2.257 VanHaerents, S. 1.188, 1.205 Vanli- Yavuz, E. 2.224 Vannasing, P. 1.072, 1.260 Vannest, J. 1.353, 2.024 Vargas, L. 2.101, 2.120 Varni, J. 1.090 Varvel, N. 3.116 Vasoli, V. 1.175, 2.156, 3.071 Vater, I. 1.115 Vaughan, D. 2.243 Vaughn, B. 2.057 Vazquez, B. 1.213 Vazquez, M. 3.101 Vázquez Gregorio, R. 3.154 Veenstra, A. 2.013 Vega, C. 1.098, 3.169, 2.017 Velez, A. 2.028 Velez, F. 1.342, 1.344, 2.044 Velez, F.F. 1.273, 1.287 Velisek, L. 3.025, 3.122 Veliskova, J. 3.025, 3.122 Velmurugan, J. 1.143 Velmurugan, M. 1.223 Vena, J.E. 3.142 Venkatesan, C. 1.222 Venkatraghavan, L. 3.200 Venkatraman, K. 1.066 Ver Hoef, L. 1.236, 1.247, 1.249, 2.338, B.09 Verity, K. 2.015 Verma, A. 2.254 Vernet, M. 1.154 Vernier, E. 1.340 Vernino, S. 2.189 Verpillat, P. 1.334, 1.335, 1.336 Verrier, R.L. 3.218 Vestergaard, M. 2.266 Vezina, G. 3.355, 3.364 Vezzani, A. 1.020 Vibhute, P. 3.343 Vickrey, B. 1.357, 2.045 Vidaurre, J. 2.112 Vigevano, F. 2.146, 3.360 Vignoli, A. 3.243 Villagran, A. 2.317, 2.326 Villalobos, R. 1.274, 1.356 Villalobos Chávez, F. 3.311 Villani, F. 2.184, 3.360 Villanueva, V. 1.332 Villeda Hernandez, J. 2.334 Villega, F. 2.263 Vincent, J. 1.141 Vincentiis, S. 1.122, 2.259, 2.260, 2.306 Virta, J. 1.052 Viteri Torres, C. 2.153 Vitko, L.R. 3.321 Vitkovskiy, P. 1.062, 1.076, 1.164 Vlachos, I. 3.107 Voets, N. 3.344 Voges, J. 3.045, 3.058, 3.349 Vollaro, T. 2.311 Vollmar, C. 2.165, 3.211, 3.273 Volpe, A. 3.302 von Deimling, M. 1.115 von Ellenrieder, N. 3.163, 3.184, 3.185 von Spiczak, S. 1.115, 3.090 Vonck, K. 1.017, 1.067, 3.028, C.08 Vossler, D.G. 2.144 Vulliemoz, S. 2.244 Vyas, M. 2.313 W Waber, D.P. 2.017 Wada, T. 1.116 Wade, A.G. 1.334, 1.335, 1.336 Wade, R. 2.297 Wadhawan, A. 2.365 Wadman, W. 3.028, C.08 Wagenaar, J.B. 3.167 Wagley, P. 3.118 Wagner, G. 1.067 Wagner, J. 2.271 Wagnon, J. C.09 Wainwright, M. B.06 Waldman, W. 3.298 Waldman Zadeh, W. 3.295 Walker, I.M. 3.322 Walker, J. 3.351 Walker, M. 1.057 Wallace, E. 3.033 Waller, K. 1.194 Walsh, N. 2.318 Walters, B. 3.348 Wambacq, I. 1.183 Wamil, M. A.08 Wang, G. 2.161, 2.163 Wang, H. 1.041, 1.103, 3.074, 3.249 Wang, J.L. 1.162 Wang, L. 1.016 Wang, P. C.06 Wang, S. 2.104, 3.241 Wang, X. 1.167, 1.273, 1.287 Wang, Y. 3.002, 3.113 Wang, Z. 1.240, 3.004 Wang, Z.I. 1.040, 3.359 Wannamaker, B. 3.142 Ward-Mitchell, R. 2.136 Wark, J.D. 1.291 Warner, M. 3.282 Warren, A. 3.287 Warren, C. 1.066 Warren, P. 1.330 Wasade, V.S. 2.208, 2.215, 2.252 ABSTRACT AUTHOR INDEX Thomas, G.P. 1.246 Thomas, P. 2.226 Thomas, R. 3.092 Thome, U. 3.359 Thome Costa, U. 1.144, 2.172 Thome-Souza, S. 1.098, 1.329, 2.213, 3.202, 3.235 Thompson, A.L. 1.139 Thompson, D. 1.066 Thompson, D.M. 2.034 Thompson, E. 3.351 Thompson, L. 3.335 Thompson, M. 2.267, C.07 Thompson, N. 3.075, 3.078 Thomson, J. 1.076 Thomson, K. 1.050 Thorne, N.P. 3.100 Thurman, D. 2.047, 2.074, 3.130 Tian, N. 2.074 Tilton, N. 2.309, 3.303 Timarova, G. 2.304 Timmings, P. 3.180 Ting, T. 2.330, 3.288 Tippin Davis, B. 1.194 Tirol, F. 2.200, 3.162 Titus, J.B. 2.354 Toda, K. 1.359, 1.361 Todaro, M. 1.231, 1.291 Togrol, E. 3.170 Tohma, S. 2.091, 2.093, 2.097 Tohyama, J. 1.105, 1.116 Toledo, M. 1.332, 3.237, 3.309 Toler, J. 1.345 Tom, M. 2.046 Tominaga, K. 2.202 Tominaga, T. 1.367, 3.159 Tominaga, Y. 1.116 Tomson, T. 2.231 Topjian, A. 1.182, B.06 Torello, A. 1.020 Tornes, L. 2.063 Toropova, K. 1.121 Torres-Barba, D. 1.278 Torrez-Corzo, J. 1.356 Tosun, D. 1.252, 1.254, 3.254 Toth, E. 1.157 Tovar Quiroga, D.F. 2.138 Tovar-Spinoza, Z. 3.194, 3.357, 3.363 Toyoda, I. 1.014 Toyoshima, D. 1.220 Tracy, J. 1.255, 2.237 Tran, B. 3.017 Tran, H. 2.227 Tran, P.T. 2.123 Tran, T. 3.274 Tran, T.T. 2.036 Tran, Y.T. 3.370 Tranel, D. 1.079 Traynelis, S.F. 3.014 Treiman, D.M. 1.042 Treiman, L.J. 1.042 Tremblay, J. 1.072, 1.260 Trenado, C. 3.154 Trent, C. 1.054 Trifonov, I. 1.059, 2.076 Trinka, E. 1.317, 1.319, 2.068, 2.245, 3.228 107 ABSTRACT AUTHOR INDEX Waseem, H. 2.360, 2.361 Washington III, J. 1.289 Wassermann, E. 3.065 Watanabe, K. 1.224, 1.235, 1.243 Watanabe, S. 1.259, 2.239, 2.307 Watanabe, T. 1.116 Watson, R. 2.339 Weaver, K. Weber, Y. 1.115 Webster, E. 2.320, 3.296 Webster, R. 3.087 Wechsler, R. 3.291, 3.292 Wechsler, R.T. 1.312, 2.291 Weckhuysen, S. 1.114 Wedberg, E. 2.131 Wei, S.P. 2.042 Weinand, M. 1.349, 2.256, 2.337, 2.339 Weinstein, S. 2.351 Weinstock, A. 1.214 Weir, C. 3.129 Weiss, S. 2.353 Weiss, S.A. 1.057 Welter, E. 1.084, 3.085, 3.127 Welty, T. 1.324, 2.285, 2.286, 2.287 Wempe, M.F. 3.003 Wen, J.H. 3.030 Wen, M. 2.322 Wen, P. 3.098 Wenzel, L. 3.156 Werhahn, K. 3.294, 3.297 Werhahn, K.J. 3.291, 3.292, 3.299 Wesselkamper, K. 3.324 West, P.J. 3.020 Westerveld, M. 2.014, 2.248, 2.255, 3.276 Weston, M. 1.013 Westover, M. 1.154, 3.054, 3.203, 3.226 Wetjen, N. 1.355 Whalen, H. 3.215 Whalley, B.J. Wharen, R. 1.349, 2.212, 2.337, 2.339, 3.343 Whealy, M.A. 2.079 Wheatley, M. 2.178, 3.261 Whelan, P. 1.025 Wheless, J. 2.195 White, A. 1.267, 3.039, 3.279 White, H. 1.050, 3.095 White, J. 3.105 Whitehead, M. 1.354 Whitfield-Gabrieli, S. 1.154 Whitmire, L. 3.206 Wicks, P. 2.058 Widjaja, E. 1.127, 1.189, 2.353 Wiebe, S. 1.285, 2.051, 2.067, 2.071, 2.082, 2.150, 2.198, 2.223, 3.139 Wiggs, E. 3.065, 3.084, 3.278 Wild, I. 3.295 Wilfong, A. 2.299, 2.333, 2.347, 3.307, 3.353, 3.358, 3.371, B.06 Wilk, P. 2.056, 3.134 Wilkening, G. 1.098, 2.012, 2.103 Williams, B. 1.325, 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, 2.295 Williams, J. 3.033 108 Williams, K. 1.182, B.06 Williams, P. 3.296 Williams, S. 3.331 Williamson, J. 1.037, 3.115 Willie, J. 1.349, 2.256, 2.337, 2.339, 3.344 Willmore, L. 1.297 Wilman, A.H. 1.253 Wilner, A. 1.270 Wilson, D.A. 2.087, 3.142 Wilson, J.A. 1.353 Winawer, M. 2.275, 3.081, 3.135 Wirrell, E. 1.193, 1.206, 1.355, 1.364, 2.035, 2.079, 2.203, 3.145, 3.158, 3.229 Wise, C.A. 1.120 Wisnowski, J. 2.159 Wlodek, M.E. 1.047 Woldoff, S. 2.016 Wolf, E.G. 3.005 Wolf, S. 3.316, 3.356 Wolff, M. 1.118 Wollack, J.B. 1.134 Wolter-Warmerdam, K. 3.209 Wong, C.H. 3.286 Wong, J. 1.046, 3.106 Wong, M. 1.024, 3.013, Wong, P. 3.304 Wong, S. 1.145, 2.325 Wong, S.M. 3.153 Wong, V.S. 1.209, 1.277, 2.118 Wong-Kisiel, L. 1.193, 1.355, 1.364, 2.079, 2.203, 3.148, 3.158, 3.214, 3.229 Woo, D. 1.036 Woo, Y. 1.117 Wood, R. 3.129 Woodard, V. 3.367 Woodrum, D. 2.339 Woodward, R. 2.136 Works, K. 2.084 Worrell, G. 1.169, 1.175, 1.374, 1.377, 2.156, 2.212, 2.256, 2.337, 2.339, 3.071, 3.158 Wrede, J. 3.245 Wright, C. 2.070 Wu, C. 2.256 Wu, E. 1.213 Wu, J. 1.245, 2.355, 3.249, 3.255, 3.262 Wu, J.Y. 2.358 Wu, R. 1.062 Wu, S. 2.102, 3.160 Wu, T. 3.221 Wu, X. 1.029, 1.031, 1.033 Wu, Y.W. 3.222 Wulsin, A.C. 3.010 Wulsin, D. 3.183 Wusthoff, C. 1.136, 1.182 Wyatt, K. 1.193 Wyllie, E. 1.149, 1.362 X Xiao, W.R. B.01 Xie, J. 1.017 Xing, D. 1.325, 2.276, 2.279, 2.288, 2.291 Xiong, W. 1.155 Xu, D. 3.024 Xu, M. 3.017 Yue, C. C.06 Yum, M. 1.036, 1.328 Y Z Yacubian, E. 2.327, 3.251, 3.369 Yadav, A. 3.207, 3.212 Yaffe, R.B. 2.010 Yaghouby, F. 1.071, 1.077 Yagiri, E. 2.132 Yakovlev, A. 2.076 Yamada, M. 2.116 Yamagata, S. 2.080 Yamaguchi, T. 1.116 Yamamoto, H. 1.235, 1.243, 1.365, 2.158 Yamamoto, T. 1.371, 1.373 Yamao, Y. 1.350, 2.335 Yamashita, H. 1.110 Yamashita, S. 3.165 Yamauchi, K. 2.132 Yamazaki, E. 3.216 Yamazoe, T. 1.371 Yan, B. 3.285 Yan, C. 2.246 Yanagisawa, T. 1.060, 2.357 Yang, A. 1.182 Yang, G. 1.102 Yang, H. 1.325, 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, 2.295 Yang, M. 3.013 Yang, T. 1.170 Yang, X. 1.372 Yang Kao, Y. 2.094 Yao, D. 3.285 Yarbrough, C. 1.372 Yardi, R. 1.226 Yardi, R. 1.347, 1.377 Yasuda, C. 3.259, 3.260, 3.261 Yasuda, R. 1.269 Yates, S. 3.300 Yaun, A. 2.351 Ye, S. 1.126 Yelvington, K.H. 2.155, 3.238 Yeom, J. 1.170 Yerra, S. 1.231 Yildirim Capraz, I. 1.207 Yilmaz, C. 1.229 Yilmaz, U. 3.328 Ying, Z. 1.008, 1.012, 1.040 Yogi, A. 1.238, 1.245, 1.261, 3.255, 3.262 Yokoi, S. 1.235, 1.243 Yokota, T. 1.371 Yoon, J. 1.211 Yoon, J.W. 3.343 Yoong, M. 1.092, 2.015 Yoshimine, T. 1.060, 2.357 Yoshimura, K. 3.216 Young, G. 3.109 Youroukos, S. 2.187 Yozawitz, E. 3.214 Yu, H. 1.351 Yu, J. 2.314, 2.315 Yu, R. 3.354 Yu, W. 2.227 Yuan, H. 3.014 Yudovin, S. 1.245 Zack, M. 2.074 Zadeh, N. 1.106 Zaehle, T. 3.349 Zafar, H. 3.106 Zaghloul, K. 1.150 zaghloul, K. 3.084 Zaghloul, K.A. 2.010 Zaher, A. 2.272 Zaidi, S. 3.015 Zak, M. 1.208 Zamarian, L. 2.245 Zambrelli, E. 3.243 Zanelli, P. 3.097 Zanelli, S.A. 3.118 Zangen, A. 3.337 Zanotti-Fregonara, P. 1.002 Zanotto, F. 3.220 Zaveri, H. 1.041, 1.156, 2.151, 2.350, 3.074, 3.136 Zawadzki, L. 2.023, 3.267 Zeft, A. 1.192 Zeiger, M. A.09 Zelleke, T. 2.351, 3.141 Zelmann, R. 2.358 Zemblis, J. 3.215 Zeng, C. 1.023 Zeng, L. 2.323 Zeng, R. 1.088 Zerbs, A. 3.228 Zeuthen, T. 1.021 Zhan, H. 3.030 Zhan, Q. 1.044, 1.164 Zhang, B. 3.013 Zhang, C. 3.260 Zhang, G. 3.127 Zhang, H. 3.005, C.02 Zhang, L. 3.092 Zhang, M. 2.249 Zhang, S. 3.136 Zhang, W. 2.026, 2.235 Zhao, B. 1.057 Zhao, G.Q. 3.004 Zhao, J. 1.043 Zhao, Z. 3.286 Zheng, N. 3.288, 3.310 Zhou, C. 3.015 Zhou, D. 3.285 Zhou, J. C.06 Zhou, R. 3.222 Zhou, X. 3.166 Ziemba, K.S. 2.139 Zillgitt, A. 1.151, 2.215, 2.252 Zimmerman, A.M. 2.325 Ziobro, J. 2.351 Zoghbi, S. 1.002 Zohrevand, P. 2.222 Zou, J. 3.013 Zrik, A. 3.212 Zubair, M.N. 3.373 Zupanc, M. 2.013 Zutshi, D. 3.250 COMMERCIAL SUPPORTER RECOGNITION All as of October 21, 2014 Benefactor Level Special thanks to: Sunovion Pharmaceuticals Inc. for supporting: • Exhibit • Program Book Ad • Media Wall Spots (3 days) • Footprints • virtualTote Bag Banner Ad • virtualTote Bag Insert • Cell Phone Charging Station (3 days) • Networking Massage Lounge (3 days) • Airport Baggage Carousel Display AD • Passport to Prizes • Innovation Pavilion (Saturday / Sunday) • Cyber Café (3 days) Door Drops Scientific Exhibit Office Rental in Exhibit Hall Epilepsy Currents Ads Educational Grant Annual Fundamentals Symposium, AET Symposium • AES Fellows / EpiPORT • SIGs (2) SUPPORTER LEVELS • Suds for Science Reception • • Lunch in Exhibit Hall • (3 days) • • Poster Session Breakfast • (2 days) • • Coffee Break in Exhibit Hall (3 days) 109 Leader Level Special thanks to: Eisai, Inc. for supporting: • Exhibit • Program Book Ad • Innovation Pavilion (Monday) • virtualTote Bag Banner Ad • Passport to Prizes • Door Drops • Epilepsy Currents Ads • Named Fellowship (Sustained) • Nurse / Young Investigator Awards • AES Fellows / EpiPORT • Educational Grant – Epilepsy Specialist Symposium, Annual Fundamentals Symposium, AET Symposium, Professionals in Epilepsy Care Symposium 110 Leader Level Special thanks to: UCB, Inc. for supporting: • Exhibit • Program Book Ad • Scientific Exhibits • Educational Grant — Epilepsy Specialist Symposium, Annual Fundamentals Symposium, AET Symposium • AES Fellows / EpiPORT • Cyber Café (3 days) • Media Wall Spot (3 days) • Coffee Break in Exhibit Hall (2 days) SUPPORTER LEVELS 111 Partner Level Special thanks to: Lundbeck Pharmaceuticals, Inc. for supporting: • Exhibit • Program Book Ad • Media Wall spot (2 days) • Innovation Pavilion (Saturday / Sunday) • Passport to Prizes • Door Drops • Scientific Exhibit • Epilepsy Currents Ads • Educational Grant — AET Symposium, Annual Fundamentals Symposium 112 Partner Level Special thanks to: Upsher-Smith Laboratories, Inc. for supporting: • Exhibit • Hoyer Lecture • Program Book Ad • Passport to Prizes • Door Drops • Scientific Exhibits • Epilepsy Currents Ads • Seed Grant • AES Fellows / EpiPORT • Year Round Education SUPPORTER LEVELS 113 Supporter Level Special thanks to: for supporting: Cyberonics, Inc. • Exhibit • Innovation Pavilion (Saturday / Sunday) • Scientific Exhibit • Named Fellowship (Sustained) • Educational Grant — Annual Fundamentals Symposium Supporter Level 114 Special thanks to: for supporting: Natus Neurology Incorporated • Exhibit • Auction of XLTEK LTM System Supporter Level Special thanks to: Supernus Pharmaceuticals, Inc. for supporting: • • • • • • Exhibit Program Book Ad Passport to Prizes Door Drop AES Fellows / EpiPORT Educational Grant — Annual Fundamentals Symposium Supporter Level for supporting: Mallinckrodt Pharmaceuticals • Exhibit • Epilepsy Currents Ads • Educational Grant — Pediatric State of the Art Symposium SUPPORTER LEVELS Special thanks to: 115 Supporter Level Special thanks to: for supporting: Acorda Therapeutics • Investigator Workshop • SIGs (2) • Program Book Ad • virtualTotebag Banner Ad • Epilepsy Currents Ads • AES Fellows / EpiPORT 116 Contributor Level Contributor Level Special thanks to: Special thanks to: Nihon Kohden America, Inc. Cadwell Laboratories, Inc. for supporting: for supporting: • Exhibit • Exhibit • Media Wall Spot (2 days) • Auction of EEG-1200 • Footprints • Passport to Prizes • Epilepsy Currents Ads Contributor Level Contributor Level Special thanks to: Compumedics Limited • Exhibit • Epilepsy Currents Ad Pfizer Inc. for supporting: • General Conference Grant SUPPORTER LEVELS for supporting: Special thanks to: 117 Advocate Level Special thanks to these companies for supporting: NeuroPace, Inc. • Exhibit • Innovation Pavilion (Saturday/Sunday) ELEKTA • Exhibit • Epilepsy Currents Ad Electrical Geodesics, Inc. • Exhibit • Epilepsy Currents Ad • Educational Grant — Annual Course Medtronic, Inc. • Exhibit • Nurse/Young Investigator’s Awards 118 GW Pharmaceuticals • Exhibit • Investigator’s Workshop (1) • SIG (1) Blackrock Microsystems, LLC • Exhibit Patron Level Special thanks to these companies for supporting: Rhythm Link • Exhibit • Epilepsy Currents Ad PMT Corporation • Exhibit Ripple LLC Ad-Tech Medical Instrument Corp. • Exhibit Monteris Medical, Inc. • Exhibit Medical Neurogenetics, LLC • Exhibit • Exhibit Lifelines Neurodiagnostics Systems, Inc. • Exhibit The Jack Pribaz Foundation • Exhibit • Passport to Prizes • Media Wall Spot (3 days) Nexstim, Inc. • Exhibit Neurolynx, Inc. • Exhibit SUPPORTER LEVELS 119 GENERAL INFORMATION AES 2014 Annual Meeting The American Epilepsy Society (AES) is one of 108 Chapters of the International League Against Epilepsy (ILAE). The Annual Meeting of the American Epilepsy Society is the largest meeting and exhibition in the world for those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. The meeting attracts more than 4,000 attendees dedicated to improving the quality of life for those dealing with epilepsy. This meeting is the top forum to examine common concerns and to gain insight from leading authorities. Mission Statement The American Epilepsy Society advances research and education for professionals dedicated to the prevention, treatment and cure of epilepsy. Target Audiences Basic: Those new to epilepsy treatment or whose background is limited, e.g., students, residents, general physicians, general neurologists and neurosurgeons, other professionals in epilepsy care, administrators. Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, and other providers with experience in epilepsy care (e.g., advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers. Advanced: Symposia will address highly technical or complex topics (e.g., neurophysiology, advanced imaging techniques or advanced treatment modalities, including surgery). Policy on Commercial Support and Conflict of Interest The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. This information will also be made available through syllabus materials and faculty presentations. Disclosure of Unlabeled / Unapproved Uses This educational program may include references to the use of products for indications not approved by the FDA. These discussions are noted on the faculty’s disclosure forms as well as during their presentations. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals. Abstracts Abstracts from the 2014 Annual Meeting are available on the AES website and will also be available as an online supplement to Epilepsy Currents. Accreditation The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians. Credit Designation Physicians: The American Epilepsy Society designates this live activity for a maximum of 32.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physician Assistant: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 32.75 hours of Category 1 credit for completing this program. 120 Nursing: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity is awarded 30.75 contact hours. Nurse Practitioners: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: 030803. This program is accredited for 30.75 contact hours which includes 7.0 hours of pharmacology. Program ID #21424 This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. Pharmacy: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Select portions of this Annual Meeting are approved for pharmacy CE credit. Specific hours of credit for approved presentations and Universal Activity Numbers assigned to those presentations are found elsewhere in program materials. Criteria for success: Credit is based on documented program attendance and online completion of a program evaluation / assessment. If you have any questions about this CE activity, please contact AKH Inc. at [email protected]. International Credits: The American Medical Association has determined that non-U.S. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits TM. CME / CE Certificates The Medical Education Evaluator® is an online system that allows attendees to complete course evaluations, track educational credits and print out the appropriate certificate. Once you have accessed the Medical Education Evaluator®, you will be asked to enter your “myAES number” and password that you created. The certificate(s) are saved to your personal account page and are cumulative. You may print the certificate(s) at any time. The following fees apply for obtaining educational credits: Member Fees: $50 through January 16, 2015 $75 January 17 – February 27, 2015 Non-member Fees: $75 through January 16, 2015 $100 January 17 – February 27, 2015 The online Evaluator will be open through February 27, 2015. You must complete the evaluations and credit tracking by that date. Completing this information online also assists the Council on Education and Annual Meeting Committee with important needs assessment data so AES can further plan and address educational gaps to meet the needs of our learners. Attendance Certificate / International Attendees A meeting attendance certificate will be available at the registration desk for international meeting attendees on Tuesday, December 9. Handouts Handouts for the educational symposia will be available via the virtualTotebag. For instructions: please refer to the flyer provided in your meeting bag or go to the AES website for details at www.AESnet.org. Questions? Please contact virtualTotebag Support Desk at 410.402.1062 Email: [email protected] GENERAL INFORMATION Audience Response System Press Room Commercial Exhibits (page 82) AES offers meeting information and assistance for journalists reporting on epilepsy studies, educational presentations, and special reports at this meeting. The AES on-site Press Room staff works with journalists to develop stories, research facts and information, and connect with experts and presenters. The on-site Press Room is also available to sponsors and exhibitors for the display and distribution of relevant press releases and media kits. For more information, contact Ellen Cupo at (203) 314-6545 and [email protected], or Natalie Judd at (203) 605-9515 and [email protected]. AES will be utilizing the Audience Response System (ARS) in several of the symposia. Faculty will have ARS questions throughout their presentations with multiple choice answers. To participate, you will use your cell phone to text your reply. When a question appears in a presentation, simply text your answer (a 5 or 6 digit code) to “22333.” Standard text rates will apply. The ARS will allow for interactive audience participation as well as real time, immediate feedback to enhance the learning environment and ensure that we are meeting the learning objectives set forth by each symposium. The Exhibit Hall is an integral part of the learning experience. Meeting participants will have an ideal opportunity to learn about the latest in pharmaceuticals, publications, scientific equipment, and technology relevant to the fields of epilepsy and neurophysiology. Please check the AES website for an updated listing of exhibiting companies and organizations. To ensure safety and security, no children under 12 years of age, strollers, carriages, wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours. Saturday, December 6 Sunday, December 7 Monday, December 8 Noon - 6:00 p.m. 10:00 a.m. - 6:00 p.m. 10:00 a.m. - 3:00 p.m. Scientific Exhibits (page 23) AES has approved guidelines for industry-sponsored Scientific Exhibits at the Annual Meeting. Scientific Exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials, or a thematic presentation of one aspect of drug development. Scientific Exhibits will be displayed on Sunday, December 7 and Monday, December 8. An application to register for a Scientific Exhibit was emailed to interested companies in June. Reservations will be reviewed and accepted on a first-come, first-served basis until space is sold out. Send inquiries of interest to JoLynn Amsden at [email protected]. Cyber Café Convention Center – Exhibit Hall 4B, Level 4 Open during Exhibit Hall hours The Cyber Café will be available during Exhibit Hall hours at the Convention Center with email and Internet access. You will also be able to complete the course evaluations and obtain your CME certificate online. For your convenience, Wi-Fi will also be available in the Convention Center. Photography and Recording of Programs AES strictly prohibits all photography (flash, digital, or otherwise), audio and / or videotaping during the Annual Meeting. Equipment will be confiscated. Material presented at the AES Annual Meeting is not to be reproduced in any format without the express written consent of the AES. Attendees acknowledge and agree that commercial or promotional distribution, publishing or exploitation of speaker sessions, content, or materials from the AES Annual Meeting is strictly prohibited unless you have received the express prior written permission from AES or the otherwise applicable rights holder. Business Centers Two full-service FedEx Office business centers are conveniently located in Seattle for Annual Meeting attendees. Both offer a variety of services which include shipping, mailing, faxing and photocopying. Please contact the office directly for details. Washington State Convention Center, Level 1 (Suite 11-13) http://local.fedex.com/wa/seattle/office-5161/ Phone: 206.467.1767 Sheraton Seattle Hotel, Level 2 http://local.fedex.com/wa/seattle/office-5539/ Phone: 206.467.5885 Friday, December 5 .................................................. Saturday, December 6 .............................................. Sunday, December 7 ................................................ Monday, December 8 .............................................. Tuesday, December 9................................................ 11:00 a.m. - 6:30 p.m. 7:30 a.m. - 6:30 p.m. 7:30 a.m. - 6:30 p.m. 7:30 a.m. - 6:30 p.m. 7:30 a.m. - 1:00 p.m. A series of media briefings on a select number of topics will be held in the press room from Friday, December 5 through Monday, December 8. Details will be posted in Room 304, Level 3 at the Washington State Convention Center and in advance on the AES website Press Room after December 1. Hotel Information Early Departure Policy Guests who check out of the hotel prior to their scheduled departure date will be charged a penalty of one night’s room rate and tax. Sheraton Seattle Hotel (Headquarters Hotel) 1400 Sixth Avenue, Seattle, Washington 98101 Telephone: 206.621.9000 Crown Plaza Hotel Seattle 1113 Sixth Avenue, Seattle, WA 98101 Telephone: 206.464.1980 Grand Hyatt Seattle 721 Pine Street, Seattle, WA 98101 Telephone: 206.774.1234 Hyatt at Olive 8 Seattle 1635 8th Avenue, Seattle, WA 98101 Telephone: 206.695.1234 Hilton Seattle 1301 Sixth Avenue, Seattle, WA 98101 Telephone: 206.624.0500 Mayflower Park Hotel 405 Olive Way, Seattle, WA 98101 Telephone: 206.623.8700 Motif Seattle Hotel (formerly the Red Lion) 1415 Fifth Avenue, Seattle, WA 98101 Telephone: 206.971.8000 Renaissance Seattle Hotel 515 Madison Street, Seattle, WA 98101 Telephone: 206.583.0300 The Fairmont Olympic Seattle 411 University Street, Seattle, WA 98101 Telephone: 206.621.170 The Paramount Hotel 724 Pine Street, Seattle, WA 98101 Telephone: 206.292.9500 The Roosevelt Hotel 1531 7th Avenue, Seattle, WA 98101 Telephone: 206.621.1200 Warwick Seattle Hotel 401 Lenora Street, Seattle, WA 98121 Telephone: 206.443.4300 Meeting Location Washington State Convention Center 800 Convention Place, Seattle, WA 98101-2350 GENERAL INFORMATION When you attend an approved AES event or program, you enter an area where photography, audio, and video recording may occur. By entering the event premises, you consent to photography and its release, publication, exhibition, or reproduction to be used for news, newsletters, promotional purposes, advertising, inclusion on websites, or any other purpose by AES and representatives. You release AES, its officers and employees, and each and all persons involved from any liability connected with the taking, digitizing, or publication of photographs and computer images. You have been fully informed of your consent, waiver of liability, and release before entering the event. Convention Center – Room 304, Level 3 121 GENERAL INFORMATION Program Changes AES cannot assume liability for any changes in the program due to external or unforeseen circumstances. Language The official language of the Annual Meeting is English. Meeting Attire Dress for the Annual Meeting is business casual. Consider bringing a light jacket or sweater with you since meeting room temperatures and personal comfort levels vary. No Smoking Policy For the comfort and health of all attendees, smoking is not permitted at any AES function. This includes educational sessions, meetings and all food functions. Both the Convention Center and the Sheraton Seattle are smokefree facilities. Also, smoking is not permitted in public buildings, restaurants or bars. Gratuities Gratuities are not automatically added to the bill, except in some cases for large groups. Waiters and waitresses are usually given 15% to 20% of the bill. Taxi drivers usually receive 15% of the fare and doormen and $2 per night for hotel housekeeping. Skycaps and porters are normally tipped $1 per bag. Registration & Security AES is committed to providing a secure meeting environment. A formal security plan is developed in consultation with the Security Department at the Convention Center. All meeting attendees will be required to produce government-issued photo identification prior to receiving their badge and registration materials. Appropriate badges must be worn at all times while in attendance at the Annual Meeting and are required for admittance to all meeting activities. Security procedures will also be in place for exhibition materials and all deliveries to the Annual Meeting. Insurance / Liabilities AES cannot be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance. Contact Information Safety and Security Information The following security measures have been designed to further enhance your personal and professional safety. • Pick up any Convention Center house phone located in the facility and dial 5127 or 206.694.5127. Uniformed Convention Center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the Convention Center. We respectfully request that you do NOT call 911 directly. • An EMT will be on duty in the Convention Center throughout the meeting. • A government-issued photo identification is required to receive a badge and to replace a lost badge. • Convention Center Security may randomly check packages and bags at the Convention Center entrances, meeting rooms and in the Exhibit Hall. • You will be asked to always clearly display your name badge and to use only approved Convention Center entrances and exits. • Appropriate badges will be required to enter all educational sessions, Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity. • Throughout the meeting, you will notice security staff presence to monitor the safety of all participants. • Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the Convention Center or hotel. • Please report any suspicious activity to security staff or to the AES registration desk staff. General Safety Tips • Remove your badge once you leave the meeting facilities. • Carry important telephone numbers with you. • Do not display or carry large amounts of cash. • Walk in groups, especially at night. • Lock your hotel room door. • Always verify hotel room repair or service calls. • Do not disclose your room number to anyone. • Never give your personal information (credit card, room number, etc.) over the phone; instead, go to the front desk if the hotel calls with questions. American Epilepsy Society 342 North Main Street, Suite 301 West Hartford, CT 06117-2507 Phone: Meeting Fax: Email: Website: 860.586.7505, ext. 512 888.238.7428 [email protected] www.AESnet.org Faculty Ready Room and Photos Location: Convention Center – Room 303, Level 3 Faculty need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint presentations have already been uploaded through the AES Faculty Development Room. All faculty must stop by to reconfirm their presentation with an audiovisual technician. Thursday, December 4 Friday, December 5 .............................. .................................. 4:00 p.m. - 8:00 p.m. 8:00 a.m. - 6:00 p.m. Saturday, December 6 .............................. 8:00 a.m. - 6:00 p.m. Sunday, December 7 ................................ 8:00 a.m. - 6:00 p.m. Monday, December 8 ................................ 8:00 a.m. - 6:00 p.m. Tuesday, December 9.............................. 8:00 a.m. - 11:00 a.m. 122 MAP OF SEATTLE, WA 8th 8 t h Av ve e. N. N . St d oa Br . St St ia tS t. in ew ar Vi St . St no ra Bl Le el no rA . no rA . . e. rs S on ve ve Av f fe sS t. r f fe so nS t. Al de t. rS t. Yesle Y Ye es er W Way ay SW Washington a s h n g to n S t . S Main M a n St . S Jackson J a c k s o n St . on I st S Je s nA We ry a t tl e Je me St . n sla n ea t t CH IN ’L ATO SW We eller er SDt IS W TR N / I S Lane L a n e St . C T I S King K ng SN t T d a le W te r i Ta x Occidental O c c d e n t a Av ve e. S Se ash to V e r to 1st 1 s t Av ve e. S ry Fe r B re m Ja St . me re y to Bo Fe rr ER NE R E PIO UA SQ F e r r y to B a i n b r i d g e I s l a n d . ry . St . Ja PIER P R 52 52 WA S WA STA TAT ATE FERRIES F RR ES r Te C r he ve ia mb ve t. hA nS lu 5 . hA St . Co . ve e. M o a ri St on hA Av PI E R 5 5 ARGOS Y CRUISES/ TILLICUM VILL AGE on t. is ad 7t rn M is ad M gS 8t . ri n ri n 9t ve Sp t. gS St . Mi Sp 10 0 a St . 1 ec n Se ca . . S 3S e en Broadway Br o a d w ay ve . ve r Mi ve hA e niv y si t U on Unio Un n St . t. nTSE WA W A SHIN SH N GT TO ON STA TAT T A AT nio U CONV NVE V NTIO ON C CENTER R 6 ve . U dA te e. es Av T W t 1s KE Fe r P I E R 57 SE AT TLE GRE AT WHEEL V illag e ic u m r y to T ill St . 2n AR WATERFRONT PARK A S U n nio 4 ve M PIER 59 SE AT TLE AQUARIUM hA dA E AC E 4t K PI E R S 6 2 & 6 3 W 8 3r W ay 11 1 7 2 9 WE W E S TL LAKE AK t. St. PA PARK ke S e n Pi Pi PL N EI N PA BRU RK E C e. e. KE PI E R 6 6 BELL S T. CRUISE TERMINAL n Av e. e hA ST ka d e. 5t as Av Av 6t Al 1s t e.12 1 PI PIER 67 BELL HARBOR CONFERENCE CENTER 2n e. rg . St d ar ch an e. Av e. Av . Av Av Av Av h ve tt d h h . . St ll Be 3r lio h e. 9t 8t w . St y er tt 4t e. Ho . St t. W al lS ne e. Av Av re hA El Ba Av h ry lS rS t. ay rn 5t h 7t a B.C . P I E R 69 VIC TORIA CLIPPER te 7t 6t . c to r i e. Vi K es da Cl Av Ce oa Br R PA W e.. N ke Ave Wes ttllake DS d Ea St . gl AR W e ED St . E 1s t Bo Crowne Plaza Hotel Seat tle Grand Hyat t Seat tle Hilton Seat tle Motif Seat tle (formerly Red Lion) Renaissance Seat tle Hotel Sheraton Seat tle Hotel The Paramount Hotel May flower Park Hotel The Roosevelt The Fairmont Olympic Hotel Hyat t at Olive 8 War wick Seat tle Hotel C A L A N D E R SO N PARK A TL Denn D enn Te r Ya Y a YR SC O L U YM PALPT PIC RK UR E Ea E a M Denn D enny Wa Way ay LEGEND 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. JJohn ohn DENN Y PA ARK Po P o JJohn ohn S St. t Min M n Fairvi Fa r v e w Av ve e. N. N Boren Bor e n Av e e. Thoma Th homass St. Terry T e r r y Av ve e. N. N Westlake W es t ake Av ve e. N. N 6 t h Av e e. N N. EMP MUSEUM E.. M E Mercer e rc e r St . Harrison H arr son Stt.. Taylor T a y o r Av ve e. N . CHIHULY GARDEN & G L A SS PACIFIC SCI E N CE CENTER Rep epublican ub c an St. E . Ro E. oyy S Stt. 9th 9 t h Av ve e. N. N SEAT TLE CENTER W J o h n St . W.John W. M MOH AI A L AKE K UNION I PAR ARK Merce M ercer St. 5th 5 t h Av ve e. N. N W. Thomas T h o m a s St . D ex xtte err Av ve e. N . Aurora A u r o r a Av ve e. N . Ro oyy St. BILL B LL & MELIN MEL NDA GAT G ATE AT ES F FOUN OUN DAT AT ON ATION Queen Q ueen Anne A n n e Av ve e. N. N W. Harrison H a r r s o n St . to V i Va alley St. Merce M ercerr St. W. Rep publican u b c a n St . Fe rr y 4 t h Av ve e. N. N 2nd 2 n d Av ve e. N. N 1sstt Av ve e. W. W Warren W a r r e n Av e e. N. 1st 1 s t Av ve e. N. N 2nd 2 n d Av ve e. W. W W.Ro oyy St. Aloh A oha a St . CENTURYLINK FIELD S Dearborn D e a r b o r n St . S Charles C h a r e s St . SP Plumme ummer St. Pike Place Market to CenturyLink Event Center: 1 mi / 1.6 km Pike Place Market to Space Needle: 1 mi / 1.6 km Pike Place Market to Convention Center: ½ mi / 800 m S . L A K E U N I O N S T R E E TC A R PARK BUS/LIGHT R AIL TUNNEL BUS/LIGHT R AIL TUNNEL STAT TION SE AT TLE CENTER MONOR AIL CONVENTION HOTEL INFORMAT TION CENTER DR . JOSE R IZ AL PARK A Ro oyya al B Brougham ro u g h a m W Way ay S A F E CO F I E L D Edgar E dgar Martinez Ma r t n ez W Way ay 4 t h Av ve e. MA JOR AT TR AC TION CENTURYLINK EVENT CENTER 123 WASHINGTON STATE CONVENTION CENTER LEVEL 3 Faculty Ready Room (302) Faculty Photo Room (303) n Press Room (304) n n Poster entrance when exhibit hall is closed LEVEL 4 Registration Exhibit Hall n Poster Sessions n n 124 WASHINGTON STATE CONVENTION CENTER LEVEL 6 Ballrooms 6C and 6E n Session Rooms n Scientific Exhibits n 125 SHERATON SEATTLE HOTEL 126 Seattle Children’s Epilepsy Program Offers Unsurpassed Care Seattle Children’s Epilepsy Program is the largest on the West Coast dedicated to treating children and young adults up to age 21. As part of the University of Washington’s Regional Epilepsy Center and the Northwest Epilepsy Consortium, Seattle Children’s serves patients in Washington, Alaska, Idaho and Montana. Our six pediatric epileptologists collaborate with experts in neurosurgery, neuropsychology and neuroradiology to provide promising leading-edge options for children with epilepsy like laser ablation. We have special expertise in neurogenetics, participated in NIH sponsored EPGP and EPI-4K projects, and mitochondrial disorders. We are active in epilepsy research and offer clinical trial and study opportunities. Learn more at www.seattlechildrens.org/epilepsy 127 127 THE MOST WIDELY READ AND HIGHLY CITED PEER-REVIEWED NEUROLOGY JOURNAL The Official Journal of the American Academy of Neurology One subscription...four ways to access Neurology brings you: Ǧǂ Clinical/Scientific Notes Ǧʮǩ Medical Hypothesis papers) Ǧ Ǧ in Neurologic Practice ǦImages Ǧ Ǧ Ǧ® – Online Correspondence Ǧ Ǧ Ǧ Enjoy full-text online access, including expedited e-pub, presentation downloads, search functions, topic alerts, e-TOC service, RSS feeds of current issues and podcasts, mobile device downloads, and a Resident & Fellow subsite. Plus, access Neurology on your iPad® for a print-like reading experience enhanced with article-sharing features, links, and more! Neurology.org Visit Booth #400 for Meeting Discounts 4-R013 128 Neurology Clinical Practice An Official Journal of the American Academy of Neurology ǦAdditional Series Sections: Ǧ Ǧǂ ǦǒǓ Ǧʬǂ Ǧ Neurology® Clinical Practiceʬ ǀ ǂǀ lj AAN.com/Membership. Neurology.org/cp Visit Booth #400 for Meeting Discounts ȟǂțȜȟ 129 Indexed In: Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine, EMBASE, Excerpta Medica, Index Medicus, MEDLINE, Neuroscience Citation Index, Research Alert, Scopus and Scisearch Seminars in Neurology Editor-in-Chief: D. Greer 2015/Volume 35/6 issues p.a./ISSN 0271-8235 USA and Canada Individuals: $316 $253 Institutions: $1,054 Please contact [email protected] For institutional licenses, please contact [email protected] Mexico, Central and South America Individuals: $343 $274 Institutions: $1,081 Please contact [email protected] For institutional licenses, please contact [email protected] Europe, Africa, Asia, Australia, New Zealand Individuals: €336 €269 Institutions: €1,084 (Please add shipping charges: €57.00) Please contact [email protected] For institutional licenses, please contact [email protected] Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka For subscription rates in INR, please contact [email protected] SUBSCRIBE NOW AND STAY UP-TO-DATE IN 2015 Visit www.thieme.com/journals in order to subscribe or renew your subscription. Take full advantage of your individual subscription by registering online at www.thieme-connect.com/products: • Individual subscribers get free online access to current and back issues of their journal(s) • Advanced online access for select journals via the eFirst service • Up-to-date Alerts via email or RSS-Feed • Advanced search across our entire library of journals ORDER TODAY http://www.thieme.com Become a fan at www.facebook.com/thiemepublishers. 130 Follow us @ThiemeNY Exploring Critical Advances in Brain Connection Research Brain Connectivity is the premier peer-reviewed journal for cutting-edge research in the expanding area of systems neuroscience. Critical advancements in the diagnosis and treatment of neurodegenerative diseases and psychiatric disorders Vital information on brain mapping, new imaging modalities, and translating research discoveries from lab to clinic Accepted in MEDLINE® in its first year Founding and Co-Editors-in-Chief: Christopher P. Pawela, PhD and Bharat B. Biswal, PhD Subscribe Today! www.liebertpub.com/brain 131 Adjunctive therapy for patients ages 12 and up with partial-onset seizures1 NOVEL TARGET. NOVEL POTENTIAL. FYCOMPA®—the first and only non-competitive AMPA receptor antagonist1-3 GET ON TARGET AT AES Visit us at Booth #305 Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older. AES = American Epilepsy Society 132 Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older. Important Safety Information WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA • Closely monitor patients particularly during the titration period and at higher doses • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening Serious Psychiatric and Behavioral Reactions Hostility- and aggression-related adverse reactions occurred in 12% and 20% of clinical trial patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in FYCOMPA-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebotreated patients. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm, and/or any unusual changes in mood or behavior. Should suicidal thoughts or behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events. Somnolence was reported in 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and 15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 5% of placebo-treated patients. In the controlled Phase 3 epilepsy clinical trials, these adverse reactions occurred mostly during the titration phase. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known. Falls Falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients. Withdrawal of AEDs A gradual withdrawal is generally recommended with antiepileptic drugs to minimize the potential of increased seizure frequency. Most Common Adverse Reactions In clinical trials, the most frequently reported dose-related adverse reactions in patients receiving FYCOMPA 8 mg or 12 mg vs placebo (≥4% and at least 1% higher than the placebo group) included dizziness (36% vs 9%), somnolence (16% vs 7%), fatigue (10% vs 5%), irritability (9% vs 3%), falls (7% vs 3%), nausea (7% vs 5%), ataxia (5% vs 0%), balance disorder (4% vs 1%), gait disturbance (4% vs 1%), vertigo (4% vs 1%), and weight gain (4% vs 1%). Drug Interactions FYCOMPA may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with carbamazepine, phenytoin and oxcarbazepine. Concomitant use with strong CYP3A inducers such as St. John’s wort and rifampin should be avoided. Multiple dosing of FYCOMPA 12 mg/day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Pregnancy Category C and Lactation FYCOMPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when FYCOMPA is administered to a nursing woman. Hepatic and Renal Impairment Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment. Drug Abuse and Dependence FYCOMPA is a Schedule III controlled drug substance and has the potential to be abused or lead to drug dependence. Please see Brief Summary of full Prescribing Information on the next page for Boxed WARNING and additional Important Safety Information. References: 1. Fycompa Prescribing Information. Woodcliff Lake, NJ: Eisai Inc.; June 2014. 2. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56-63. 3. Hanada T, Hashizume Y, Tokuhara N, et al. Fycompa: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331-1340. FYCOMPA® is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc. Manufactured and marketed by Eisai Inc., Woodcliff Lake, NJ 07677 © 2014 Eisai Inc. All rights reserved. FYCO0788 September 2014 133 FYCOMPA® (perampanel) tablets, for oral use, CIII Initial U.S. Approval: 2012 BRIEF SUMMARY-see package insert for full Prescribing Information WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS • Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA (5.1) • These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression (5.1) • Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA (5.1) • Closely monitor patients particularly during the titration period and at higher doses (5.1) • FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening (5.1) INDICATIONS AND USAGE FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older. DOSAGE AND ADMINISTRATION Dosing Information In the Absence of Enzyme-Inducing AEDs The recommended starting dosage of FYCOMPA is 2 mg once daily taken orally at bedtime. Increase dosage by 2 mg per day increments no more frequently than every week to a dose of 4 mg to 8 mg once daily taken at bedtime. In elderly patients, dosage increases during titration are recommended no more frequently than every two weeks. The recommended dose range is 8 mg to 12 mg once daily. A dose of 12 mg once daily resulted in somewhat greater reductions in seizure rates than the dose of 8 mg once daily, but with a substantial increase in adverse reactions. Individual dosing should be adjusted based on clinical response and tolerability [see Clinical Studies (14)]. In the Presence of Enzyme-Inducing AEDs The recommended starting dosage of FYCOMPA in the presence of enzyme-inducing AEDs, including phenytoin, carbamazepine, and oxcarbazepine, is 4 mg and patients should be monitored closely for response. Clinical trials revealed a substantially reduced effect on seizure rates in these patients. The reduction in seizure frequency was somewhat greater at 12 mg than at 8 mg [see Clinical Studies (14)]. When these enzyme-inducing AEDs are introduced or withdrawn from a patient’s treatment regimen, patient should be closely monitored for clinical response and tolerability. Dose adjustment of FYCOMPA may be necessary. Dosage Adjustments in Patients with Hepatic Impairment Based on higher exposure and the longer half-life of perampanel in patients with mild and moderate hepatic impairment, dosage adjustment is recommended. Starting dose should be 2 mg per day with weekly increments of 2 mg per day every two weeks until target dose is achieved. The maximum recommended daily dose is 6 mg for patients with mild hepatic impairment and 4 mg for patients with moderate hepatic impairment. Dose increases in patients with mild and moderate hepatic impairment, as with all patients, should be based on clinical response and tolerability. Use in patients with severe hepatic impairment is not recommended [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. Patients with Renal Impairment FYCOMPA can be used in patients with moderate renal impairment with close monitoring. A slower titration may be considered based on clinical response and tolerability. Use in patients with severe renal impairment or patients undergoing hemodialysis is not recommended [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Serious Psychiatric and Behavioral Reactions In the controlled Phase 3 epilepsy clinical trials, hostility- and aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. FYCOMPA-treated patients experienced more hostility- and aggressionrelated adverse reactions that were serious, severe, and led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. In general, in placebo-controlled Phase 3 epilepsy trials, neuropsychiatric events were reported more frequently in patients being treated with FYCOMPA than in patients taking placebo. These events included irritability, aggression, anger, and anxiety which occurred in 2% or greater of perampanel treated patients and twice as frequently as in placebo-treated patients. Other symptoms that were observed with perampanel treatment and more commonly than with placebo, included belligerence, affect lability, agitation, and physical assault. Some of these events were reported as serious and life-threatening. Homicidal ideation and/or threat were exhibited in 0.1% of 4,368 perampanel treated patients in controlled and open label studies, including non-epilepsy studies. In the Phase 3 epilepsy trials these events occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression. Some patients experienced worsening of their pre-existing psychiatric conditions. Patients with active psychotic disorders and unstable recurrent affective disorders were excluded from the clinical trials. The combination of alcohol and perampanel significantly worsened mood and increased anger [see Drug Interactions (7.3)]. Patients taking FYCOMPA should avoid the use of alcohol. In healthy volunteers taking FYCOMPA, observed psychiatric events included paranoia, euphoric mood, agitation, anger, mental status changes, and disorientation/confusional state. In the non-epilepsy trials, psychiatric events that occurred in perampanel-treated subjects more often than placebo-treated subjects included disorientation, delusion, and paranoia. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Dose of FYCOMPA should be reduced if these symptoms occur. Permanently discontinue FYCOMPA for persistent severe or worsening psychiatric symptoms or behaviors and refer for psychiatric evaluation. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebotreated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs. 134 Table 1. Risk by indication for antiepileptic drugs in the pooled analysis Relative Risk: Risk Difference: Placebo Patients Drug Patients Incidence of Additional Drug Indication with Events Per with Events Per Events in Drug Patients/ Patients with Events 1000 Patients 1000 Patients Incidence in Placebo Per 1000 Patients Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. Neurologic Effects Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination [see Adverse Reactions (6.1)]. In the controlled Phase 3 epilepsy clinical trials, dizziness and vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated patients. The gait disturbance related events (including ataxia, gait disturbance, balance disorder, and coordination abnormal) were reported in 12% and 16% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase and led to discontinuation in 3% of perampanel-treated subjects compared to 1% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and adolescents. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events (including fatigue, asthenia, and lethargy). In the controlled Phase 3 epilepsy clinical trials, 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, reported somnolence compared to 7% of placebo patients. In the controlled Phase 3 epilepsy clinical trials, 12% and 15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, reported fatigue-related events compared to 5% of placebo patients. Somnolence or fatigue-related events led to discontinuation in 2% of perampanel-treated patients and 0.5% of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger adults and adolescents. Risk Amelioration Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known. In the controlled Phase 3 epilepsy clinical trials these adverse reactions occurred mostly during the titration phase. Falls An increased risk of falls, in some cases leading to serious injuries including head injuries and bone fracture, occurred in patients being treated with FYCOMPA (with and without concurrent seizures). In the controlled Phase 3 epilepsy clinical trials, falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients. Falls were reported as serious and led to discontinuation more frequently in FYCOMPA-treated patients than placebo-treated patients. Elderly patients had an increased risk of falls compared to younger adults and adolescents. Withdrawal of Antiepileptic Drugs There is the potential of increased seizure frequency in patients with seizure disorders when antiepileptic drugs are withdrawn abruptly. FYCOMPA has a half-life of approximately 105 hours so that even after abrupt cessation, blood levels fall gradually. In antiepileptic clinical trials FYCOMPA was withdrawn without down-titration. Although a small number of patients exhibited seizures following discontinuation, the data were not sufficient to allow any recommendations regarding appropriate withdrawal regimens. A gradual withdrawal is generally recommended with antiepileptic drugs, but if withdrawal is a response to adverse events, prompt withdrawal can be considered. ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the prescribing information: • Serious Psychiatric and Behavioral Reactions [see Warnings and Precautions (5.1)] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.2)] • Dizziness and Gait Disturbance [see Warnings and Precautions (5.3)] • Somnolence and Fatigue [see Warnings and Precautions (5.3)] • Falls [see Warnings and Precautions (5.4)] Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A total of 1,038 patients on perampanel (2, 4, 8, or 12 mg once daily) constituted the safety population in the pooled analysis of Phase 3 placebo controlled studies (Studies 1, 2, and 3) in patients with partial onset seizures. Approximately 51% of patients were female and the mean age was 35 years. Adverse Reactions Leading to Discontinuation In controlled Phase 3 clinical trials (Studies 1, 2, and 3), the rate of discontinuation as a result of an adverse reaction was 3%, 8% and 19% in patients randomized to receive FYCOMPA at the recommended doses of 4 mg, 8 mg and 12 mg/day, respectively, and 5% in patients randomized to receive placebo [see Clinical Studies (14)]. The adverse events most commonly leading to discontinuation (≥1% in the 8 mg or 12 mg FYCOMPA group and greater than placebo) were dizziness, somnolence, vertigo, aggression, anger, ataxia, blurred vision, irritability, and dysarthria [see Warnings and Precautions (5.1 and 5.3)]. Most Common Adverse Reactions Table 2 gives the incidence in the Phase 3 controlled trials (Studies 1, 2, and 3) of the adverse reactions that occurred in ≥2% of patients with partial-onset seizures in any FYCOMPA dose group. Overall, the most frequently reported dose-related adverse reactions in patients receiving FYCOMPA at doses of 8 mg or 12 mg (≥4% and occurring at least 1% higher than the placebo group) included dizziness (36%), somnolence (16%), fatigue (10%), irritability (9%), falls (7%), nausea (7%), ataxia (5%), balance disorder (4%), gait disturbance (4%), vertigo (4%), and weight gain (4%). For almost every adverse reaction, rates were higher on 12 mg and more often led to dose reduction or discontinuation. Table 2. Adverse Reactions in Pooled Double-blind Trials in Patients with Partial-Onset Seizures (Reactions ≥2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) Placebo Ear and Labyrinth Disorders Vertigo Eye Disorders Diplopia Blurred vision Gastrointestinal Disorders Constipation Nausea Vomiting Infections and Infestations Upper respiratory tract infection Injury, Poisoning and Procedural Complications FYCOMPA n=442 % 4 mg n=172 % 8 mg n=431 % 12 mg n=255 % 1 4 3 5 1 1 1 1 1 3 3 4 2 5 3 2 3 2 2 6 3 3 8 4 3 3 3 4 Table 2. Adverse Reactions in Pooled Double-blind Trials in Patients with Partial-Onset Seizures (Reactions ≥2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) (cont.) Contusion Falls Head injury Limb injury Skin laceration Investigations Weight gain Metabolism & Nutrition disorders Hyponatremia Musculoskeletal and Connective Tissue disorders Arthralgia Back pain Musculoskeletal pain Myalgia Pain in extremity Peripheral edema Nervous system disorders Asthenia Ataxia Balance disorder Coordination abnormal Dizziness Dysarthria Fatigue Gait disturbance Headache Hypersomnia Hypoaesthesia Memory impairment Paraesthesia Somnolence Psychiatric disorders Aggression Anger Anxiety Confusional state Euphoric mood Irritability Mood altered Respiratory, Thoracic and Mediastinal Disorders Cough Oropharyngeal pain 1 3 1 <1 1 0 2 1 1 0 2 5 1 1 2 2 10 3 2 2 1 4 4 4 <1 0 0 2 1 2 1 2 1 1 0 2 1 1 0 1 3 2 1 1 2 1 2 5 2 3 3 2 1 0 1 0 9 0 5 1 11 0 1 1 1 7 1 1 0 1 16 1 8 1 11 1 0 0 0 9 2 3 5 <1 32 3 8 4 11 2 0 1 1 16 2 8 3 2 43 4 12 4 13 3 3 2 2 18 1 <1 1 <1 0 3 <1 1 0 2 1 0 4 1 2 1 3 1 <1 7 <1 3 3 4 2 2 12 2 3 1 1 2 1 2 4 2 Weight gain Weight gain has been observed with FYCOMPA use in adults. In the controlled Phase 3 epilepsy clinical trials, FYCOMPA-treated adults gained an average of 1.1 kg (2.5 lbs) compared to an average of 0.3 kg (0.7 lbs) in placebo-treated adults with a median exposure of 19 weeks. The percentages of adults who gained at least 7% and 15% of their baseline body weight in FYCOMPA-treated patients were 9.1% and 0.9%, respectively, as compared to 4.5% and 0.2% of placebo-treated patients, respectively. Clinical monitoring of weight is recommended. Comparison of Sex and Race No significant sex differences were noted in the incidence of adverse reactions. Although there were few non-Caucasian patients, no differences in the incidences of adverse reactions compared to Caucasian patients were observed. DRUG INTERACTIONS Contraceptives With concomitant use, FYCOMPA at a dose of 12 mg/day reduced levonorgestrel exposure by approximately 40% [see Clinical Pharmacology (12.3)]. Use of FYCOMPA with oral or implant contraceptives containing levonorgestrel may render them less effective. Additional non-hormonal forms of contraception are recommended. Cytochrome P450 (CYP) Inducers The concomitant use of known CYP enzyme inducers including carbamazepine, phenytoin, or oxcarbazepine with FYCOMPA decreased the plasma levels of perampanel by approximately 50~67% [see Clinical Pharmacology (12.3)]. The starting doses for FYCOMPA should be increased in the presence of enzymeinducing AEDs [see Dosage and Administration (2.1)]. When these enzyme-inducing AEDs are introduced or withdrawn from a patient’s treatment regimen, patient should be closely monitored for clinical response and tolerability. Dose adjustment of FYCOMPA may be necessary. As noted, however, the decrease in the therapeutic effect seen in patients on concomitant treatment, was not affected by use of higher doses (8 mg to 12 mg) [see Dosage and Administration (2.1)]. Concomitant use of FYCOMPA with other strong CYP3A inducers (e.g., rifampin, St. John’s wort) should be avoided. Alcohol and Other CNS Depressants The concomitant use of FYCOMPA and CNS depressants including alcohol may increase CNS depression. A pharmacodynamic interaction study in healthy subjects found that the effects of FYCOMPA on complex tasks such as driving ability were additive or supra-additive to the impairment effects of alcohol [see Clinical Pharmacology (12.3)]. Multiple dosing of FYCOMPA 12 mg/day also enhanced the effects of alcohol to interfere with vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Care should be taken when administering FYCOMPA with these agents. Patients should limit activity until they have experience with concomitant use of CNS depressants (e.g. benzodiazepines, narcotics, barbiturates, sedating antihistamines). Advise patients not to drive or operate machinery until they have gained sufficient experience on FYCOMPA to gauge whether it adversely affects these activities. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. In animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses. FYCOMPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in an increase in visceral abnormalities (diverticulum of the intestine) at all doses tested. In a dose-ranging study at higher oral doses (10, 30, or 60 mg/kg/day), embryo lethality and reduced fetal body weight were observed at the mid and high doses tested. The lowest dose tested (1 mg/kg/day) is similar to a human dose of 8 mg/day based on body surface area (mg/m2). Upon oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rabbits throughout organogenesis, embryo lethality was observed at the mid and high doses tested; the no effect dose for embryo-fetal developmental toxicity in rabbit (1 mg/kg/day) is approximately 2 times a human dose of 8 mg/day based on body surface area (mg/m2). Oral administration of perampanel (1, 3, or 10 mg/kg/day) to rats throughout gestation and lactation resulted in fetal and pup deaths at the mid and high doses and delayed sexual maturation in males and females at the highest dose tested. No effects were observed on measures of neurobehavioral or reproductive function in the offspring. The no-effect dose for pre- and postnatal developmental toxicity in rat (1 mg/kg/day) is similar to a human dose of 8 mg/day based on body surface area (mg/m2). Pregnancy Registry To provide information regarding the effects of in utero exposure to FYCOMPA, physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website: http://www.aedpregnancyregistry.org. Nursing Mothers Perampanel and/or its metabolites are excreted in rat milk, and are detected at concentrations higher than that in maternal plasma. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FYCOMPA is administered to a nursing woman. Pediatric Use The safety and efficacy of FYCOMPA for the adjunctive therapy of partial-onset seizures was established by three randomized double blind, placebo-controlled, multicenter studies which included 72 pediatric patients between 12 and 16 years old exposed to perampanel [see Clinical Studies (14.1), Clinical Pharmacology (12.3)]. The safety and effectiveness of FYCOMPA in pediatric patients <12 years old have not been established. Juvenile Animal Data Oral administration of perampanel (1, 3, 3/10/30 mg/kg/day; high dose increased on postnatal days [PND] 28 and 56) to young rats for 12 weeks starting on PND 7 resulted in reduced body weight, reduced growth, neurobehavioral impairment (water maze performance and auditory startle habituation) at the mid and high doses, and delayed sexual maturation at the high doses. CNS signs (reduced activity, incoordination, excessive grooming/scratching), pup death, decreased hindlimb splay, and decreased hindlimb grip strength were observed at all doses. Effects on pup body weight, pup growth, hindlimb splay, impairment in the water maze performance and auditory startle persisted after dosing was stopped. A no-effect dose for postnatal developmental toxicity was not identified in this study. Oral administration of perampanel (1, 5, 5/10 mg/kg/day; high dose increased on PND 56) to juvenile dogs for 33 weeks, starting on PND 42, resulted in CNS signs (incoordination, excessive grooming/licking/scratching, spatial disorientation, and/or ataxic gait) at all doses tested. Geriatric Use Clinical studies of FYCOMPA did not include sufficient numbers of patients aged 65 and over to determine the safety and efficacy of FYCOMPA in the elderly population. Because of increased likelihood for adverse reactions in the elderly dosing titration should proceed slowly in patients aged 65 years and older [see Dosage and Administration (2.1)]. Patients with Hepatic Impairment Use of FYCOMPA in patients with severe hepatic impairment is not recommended and dosage adjustments are recommended in patients with mild or moderate hepatic impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)]. Patients with Renal Impairment Dose adjustment is not required in patients with mild renal impairment. FYCOMPA should be used with caution in patients with moderate renal impairment and slower titration may be considered. Use in patients with severe renal impairment or patients undergoing hemodialysis is not recommended [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. DRUG ABUSE AND DEPENDENCE Controlled Substance FYCOMPA contains perampanel and is listed as a Schedule III controlled substance. Abuse Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence (for example, abuse may not be accompanied by physical dependence) [see Drug Abuse and Dependence (9.3)]. Studies of human abuse potential were performed to evaluate the abuse potential of FYCOMPA (8 mg, 24 mg, and 36 mg) as compared to alprazolam C-IV (1.5 mg and 3 mg), and oral ketamine C-III (100 mg) in recreational polydrug users. Supra-therapeutic doses of FYCOMPA 24 and 36 mg produced responses for “Euphoria” that were similar to ketamine 100 mg and alprazolam 3 mg. For “High,” FYCOMPA 24 mg and 36 mg produced responses comparable to ketamine 100 mg and significantly higher than both doses of alprazolam on a visual analog scale (VAS). “Drug Liking”, “Overall Drug Liking”, and “Take Drug Again” for FYCOMPA were each statistically lower than ketamine 100 mg. In addition, for “Bad Drug Effects”, FYCOMPA 24 mg and 36 mg produced responses significantly higher than ketamine 100 mg. For “Sedation,” FYCOMPA 24 and 36 mg produced responses similar to alprazolam 3 mg and higher than ketamine 100 mg. Additionally, on VAS measures related to dissociative phenomena such as “Floating”, “Spaced Out” and “Detached,” FYCOMPA at supra-therapeutic doses produced responses similar to ketamine 100 mg and greater than both doses of alprazolam tested. Of note, due to somnolence a number of subjects had missing data around Tmax of FYCOMPA. The above described data might represent an underestimate of FYCOMPA’s effects. The duration of effects of higher doses of FYCOMPA on the majority of measures was much greater than alprazolam 3 mg and ketamine 100 mg. In this study, the incidence of euphoria following FYCOMPA administration 8 mg, 24 mg and 36 mg was 37%, 46%, 46%, respectively, which was higher than alprazolam 3 mg (13%) but lower than ketamine 100 mg (89%). Dependence Physical dependence is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. The potential for FYCOMPA to produce withdrawal symptoms has not been adequately evaluated. OVERDOSAGE Signs, Symptoms, and Laboratory Findings of Acute Overdose in Humans There is limited clinical experience with FYCOMPA overdose. The highest reported overdose (approximately 264 mg) was intentional. This patient experienced serious adverse reactions of altered mental status, agitation, and aggressive behavior and recovered without sequelae. In general, the adverse reactions associated with overdoses were similar to the reactions at therapeutic doses with dizziness reported most frequently. There were no reported sequelae. Treatment or Management of Overdose There is no available specific antidote to the overdose reactions of FYCOMPA. In the event of overdose, standard medical practice for the management of any overdose should be used. An adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital sign measurement is recommended. A certified poison control center should be contacted for updated information on the management of overdose with FYCOMPA. Due to its long half-life, the reactions caused by FYCOMPA could be prolonged. PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Medication Guide). Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking FYCOMPA. Instruct patients to take FYCOMPA only as prescribed. Serious Psychiatric and Behavioral Reactions Counsel patients, families and caregivers of patients of the need to monitor for the emergence of anger, aggression, hostility, unusual changes in mood, personality, or behavior, and other behavioral symptoms. Advise them to report any such symptoms immediately to their health care providers. Suicidal Thinking and Behavior Counsel patients, their caregivers, and families that AEDs, including FYCOMPA, may increase the risk of suicidal thinking and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers and families to report behaviors of concern immediately to healthcare providers. Neurologic Effects: Dizziness, Gait Disturbance, Somnolence, and Fatigue Counsel patients that FYCOMPA may cause dizziness, gait disturbance, somnolence, and fatigue. Advise patients taking FYCOMPA not to drive, operate complex machinery, or engage in other hazardous activities until they have become accustomed to any such effects associated with FYCOMPA. Falls Counsel patients that FYCOMPA may cause falls and injuries. Withdrawal of Antiepileptic Drugs Counsel patients that abrupt discontinuation of FYCOMPA may increase seizure frequency. Contraceptives Counsel patients that FYCOMPA may decrease efficacy of contraceptives containing levonorgestrel. Alcohol and Other CNS Depressants Counsel patients that FYCOMPA may enhance the impairment effects of alcohol. These effects may also be seen if FYCOMPA is taken with other CNS depressants. Missed Doses Counsel patients that if they miss a dose, they should resume dosing the following day at their prescribed daily dose. Instruct patients to contact their physician if more than one day of dosing is missed. Controlled Substance Counsel patients that FYCOMPA is a controlled substance that can be misused and abused. Pregnancy Registry To provide information regarding the effects of in utero exposure to FYCOMPA, recommend pregnant patients treated with FYCOMPA to enroll in the NAAED Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org. FYCOMPA® is a registered trademark owned by Eisai R&D Management Co., Ltd. Manufactured and Marketed by Eisai Inc., Woodcliff Lake, NJ 07677 ©2014 Eisai Inc. FYCOXXXX 135 NOTES 136 VISIT SUPERNUS PHARMACEUTICALS AT BOOTH #605 Get your Passport to Prizes stamped at booth #605 each day of the convention to be eligible for the daily prize drawing For more information visit www.TrokendiXR.com and www.OxtellarXR.com Proudly Supports the American Epilepsy Society (AES) 2014 Annual Meeting Trokendi XR and Oxtellar XR are registered trademarks of Supernus Pharmaceuticals, Inc. ©2014 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2014-0040 COME VISIT OUR BOOTH! Learn more about APTIOM at Booth 105 Under license from is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc., is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2014 Sunovion Pharmaceuticals Inc. All rights reserved. 09/14 APT435-14
Similar documents
KORB-Seizure - Hospitalist Presentation with Cases [31576].pptx
– Psychogenic
seizures,
pseudoseizures,
stress
induced
seizures